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Abstract 
Neuropathic pain (pain caused by nerve damage) is considered challenging to manage. 
One of the most common neuropathic pain conditions is believed to be the presence 
of sciatica in low back-related leg pain (LBLP). A systematic review of the literature 
highlighted a paucity of evidence on the prevalence, characteristics and prognosis of 
LBLP patients with neuropathic pain in primary care. Epidemiological analysis used an 
existing prospective cohort (n=609) of LBLP patients consulting in primary care, 
including items from routine clinical examination and self-report at baseline, plus 
general practice electronic medical and prescribing records of patients with 
neuropathic pain. Cases of neuropathic pain were identified using three definitions, 
two based on clinical examination (with or without MRI), and one using the self-report 
Leeds Assessment for Neurological Symptoms and Signs (s-LANSS). Prevalence 
estimates varied from 48% to 74% according to definition. At baseline, patients with 
neuropathic pain (across three definitions) had higher leg pain intensity, poorer pain 
self-efficacy, more had pain below the knee and sensory loss based on findings from 
routine neurological examination. The clinical course (pain intensity and LBLP-related 
disability) of patients with neuropathic pain rapidly improved up to four months after 
initial consultation; the extent of improvement depended on case definition. The 
presence of neuropathic pain changed over time, remaining persistent in 16% over 
three years. The clinical course of patients with persistent neuropathic pain was worse 
compared to those with non-persistent neuropathic pain; there was no evidence that 
neurological examination items were associated with persistent neuropathic pain at 
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four months. Pain medication was commonly prescribed to patients with neuropathic 
pain; 30% were prescribed neuropathic pain medication, patients improved with and 
without such medication. This thesis provides new evidence that challenges some 
commonly held perceptions about neuropathic pain, with clear implications for clinical 
practice and future research.  
  
  
v 
 
Acknowledgements 
There are many people to thank for support during my doctoral studies. I would 
especially like to thank my supervisors Kika Konstantinou, Kate Dunn, Reuben Ogollah 
and Nadine Foster for their committed supervision, invaluable advice and contribution 
to this thesis.  
I would like to thank the following people for their contribution to specific aspects of 
this thesis; Joanne Jordan, Opeyemi Babatunde and Siobhán Stynes (systematic 
review), Sarah Lawton, Jenny Titley and Julie Ashworth (prescribing patterns of pain 
medications). During this programme of work I visited the Chronic Pain Research 
Group at University of Dundee, thank you to Professor Blair Smith and Dr Nicola 
Torrance, this visit was made possible by a Society of Back Pain Research (SBPR) Travel 
Fellowship. The Chartered Society of Physiotherapists (CSP) Charitable Trust awarded 
me a Conference and Presentation to attend the 6th International Congress on 
Neuropathic pain in Gothenburg, Sweden to present work from this thesis. This 
Doctoral programme was supported by NIHR and work in this thesis relates to an 
award by MACP. I gratefully appreciate the investment and opportunities given to me 
by CSP Charitable Trust, SBPR, NIHR and MACP.  
I would also like to thank my family, friends and colleagues for their support and 
encouragement and finally, thank you to my husband Stuart for his support, 
encouragement and unfailing optimism and my children, Eliza and Campbell. 
 
  
vi 
 
 
  
  
vii 
 
Contents 
Declaration ............................................................................................................... i 
Abstract .................................................................................................................. iii 
Acknowledgements .................................................................................................. v 
List of Tables ......................................................................................................... xvii 
List of Figures ......................................................................................................... xxi 
List of Boxes ......................................................................................................... xxiii 
List of Abbreviations ............................................................................................. xxv 
Published and presented work associated with this thesis .................................... xxvi 
Awards associated with this thesis ..................................................................... xxviii 
Chapter One. Introduction ....................................................................................... 1 
1.1 Overview of pain ..................................................................................................... 1 
1.1.1 Definition of pain ...................................................................................... 1 
1.1.2 Nociceptive pain ....................................................................................... 2 
1.1.3 Neuropathic pain ...................................................................................... 3 
1.1.4 Pain from mixed mechanisms ................................................................... 6 
1.1.5 Pain referral .............................................................................................. 7 
1.2 Prognosis of pain in primary care ........................................................................... 8 
1.2.1 Primary care as a setting for research ...................................................... 9 
1.3 Neuropathic pain .................................................................................................. 10 
1.3.1 Assessment of neuropathic pain ............................................................ 10 
  
viii 
 
1.3.2 Management of neuropathic pain .......................................................... 20 
1.3.3 Epidemiology of neuropathic pain .......................................................... 21 
1.4 Low back pain ....................................................................................................... 24 
1.4.1 Overview ................................................................................................. 24 
1.4.2 Epidemiology of neuropathic pain in LBP patients ................................. 24 
1.5 Low back-related leg pain ..................................................................................... 32 
1.6 Summary ............................................................................................................... 34 
Chapter Two. Rationale, aims and objectives .......................................................... 35 
2.1 Thesis rationale ..................................................................................................... 35 
2.2 Aims and Objectives .............................................................................................. 37 
2.2.1 Objectives ............................................................................................... 37 
2.3 Outline .................................................................................................................. 38 
2.4 Summary ............................................................................................................... 42 
Chapter Three. Neuropathic pain in low back-related leg pain: prevalence, 
characteristics and prognosis. A systematic review of the literature. ...................... 43 
3.1 Introduction .......................................................................................................... 43 
3.2 Aims ...................................................................................................................... 43 
3.3 Methods ................................................................................................................ 44 
3.3.1 Protocol registration ............................................................................... 44 
3.3.2 Search strategy ....................................................................................... 44 
3.3.2 Study selection ........................................................................................ 46 
3.3.3 Data extraction ....................................................................................... 47 
3.3.4 Risk of bias (quality assessment) ............................................................ 48 
3.3.5 Data analysis ........................................................................................... 49 
  
ix 
 
3.4 Results ................................................................................................................... 50 
3.4.1 Studies identified .................................................................................... 50 
3.4.2 Prevalence ............................................................................................... 65 
3.4.3 Characteristics ......................................................................................... 70 
3.4.4 Prognosis ................................................................................................. 97 
3.5 Discussion ........................................................................................................... 102 
3.5.1 Prevalence ............................................................................................. 102 
3.5.2 Characteristics and prognosis ............................................................... 103 
3.5.3 Strengths and weaknesses .................................................................... 107 
3.5.4 Implications for research and clinical practice ..................................... 108 
3.6 Conclusions ......................................................................................................... 108 
Chapter Four. Study design and methods .............................................................. 112 
4.1 Introduction ........................................................................................................ 112 
4.2 Data source ......................................................................................................... 112 
4.3 Population of interest ......................................................................................... 112 
4.4 Recruitment procedure and data collection ....................................................... 113 
4.5 Clinical examination ............................................................................................ 116 
4.6 Care pathways..................................................................................................... 117 
4.7 Case definitions of neuropathic pain .................................................................. 118 
4.7.1 Definition based on a case ascertainment tool .................................... 118 
4.7.2 Definition based on clinical diagnosis ................................................... 119 
4.8 Data management .............................................................................................. 119 
4.9 Selected characteristics ...................................................................................... 120 
4.9.1 Sociodemographic ................................................................................ 121 
  
x 
 
4.9.2 Health status ......................................................................................... 122 
4.9.3 Pain characteristics ............................................................................... 123 
4.9.4 Limitations in activities, participation and risk of persistent disability 126 
4.9.5 Psychological characteristics and illness perceptions .......................... 128 
4.9.6 Neurological examination ..................................................................... 129 
4.9.7 Neuroimaging ....................................................................................... 132 
4.9.8 Health care use ..................................................................................... 134 
4.10 Study sample ..................................................................................................... 138 
4.10.1 Completion of baseline data and clinical examination....................... 138 
4.10.2 Response to follow-up ........................................................................ 139 
4.11 Missing data ...................................................................................................... 148 
4.11.1 Multiple imputation ............................................................................ 148 
4.12 Statistical software ........................................................................................... 149 
4.13 Summary ........................................................................................................... 150 
Chapter Five. Prevalence and characteristics of neuropathic pain in primary care 
patients with low back-related leg pain ................................................................. 151 
5.1 Introduction ........................................................................................................ 151 
5.2 Aims and objectives ............................................................................................ 151 
5.2.1 Overall aim ............................................................................................ 151 
5.2.2 Objectives ............................................................................................. 151 
5.3 Methods .............................................................................................................. 152 
5.3.1 Study design .......................................................................................... 152 
5.3.2 Neuropathic pain definitions ................................................................ 152 
5.3.3 Selected characteristics of interest ...................................................... 153 
  
xi 
 
5.4 Statistical analysis ............................................................................................... 158 
5.5 Results ................................................................................................................. 159 
5.5.1 Prevalence of neuropathic pain ............................................................ 159 
5.5.2 Characteristics of patients with neuropathic pain defined by s-LANSS 162 
5.5.3 Characteristics of patients with neuropathic pain based on a clinical 
diagnosis of sciatica ....................................................................................... 175 
5.5.4 Characteristics of patients with neuropathic pain based on a clinical 
diagnosis plus evidence of possible or clear nerve root compression on MRI185 
5.5.5 Characteristics of patients with neuropathic pain across three definitions
 ....................................................................................................................... 196 
5.6 Discussion ........................................................................................................... 201 
5.6.1 Prevalence ............................................................................................. 201 
5.6.2 Baseline characteristics......................................................................... 203 
5.6.3 Strengths and limitations ...................................................................... 209 
5.6.4 Implications for clinical practice and research ..................................... 210 
5.7 Conclusions ......................................................................................................... 212 
Chapter Six. Clinical course of patients with and without neuropathic pain consulting 
in primary care with low back-related leg pain ...................................................... 214 
6.1 Introduction ........................................................................................................ 214 
6.2 Aims and objectives ............................................................................................ 214 
6.2.1 Overall aim ............................................................................................ 214 
6.2.2 Objectives ............................................................................................. 214 
6.3 Methods .............................................................................................................. 215 
6.3.1 Study design .......................................................................................... 215 
6.3.2 Neuropathic pain definitions ................................................................ 215 
  
xii 
 
6.3.3 Measures of clinical course................................................................... 216 
6.4 Statistical analysis ............................................................................................... 216 
6.5 Results ................................................................................................................. 217 
6.5.1 Study population ................................................................................... 217 
6.5.2 Clinical course of pain intensity ............................................................ 219 
6.5.3 Clinical course of leg and back pain-related disability.......................... 223 
6.6 Discussion ........................................................................................................... 226 
6.6.1 Strengths and limitations ...................................................................... 229 
6.6.2 Implications for clinical practice and research ..................................... 230 
6.7 Conclusions ......................................................................................................... 231 
Chapter Seven. Change in the presence of neuropathic pain in patients consulting in 
primary care with low back-related leg pain .......................................................... 232 
7.1 Introduction ........................................................................................................ 232 
7.2 Aims and objectives ............................................................................................ 232 
7.2.1 Overall aim ............................................................................................ 232 
7.2.2 Objectives ............................................................................................. 233 
7.3 Methods .............................................................................................................. 233 
7.3.1 Study design .......................................................................................... 233 
7.3.2 Neuropathic pain definitions ................................................................ 234 
7.3.3 Baseline characteristics......................................................................... 234 
7.4 Statistical analysis ............................................................................................... 238 
7.4.1 Frequency of neuropathic pain in LBLP patients over baseline, short, 
intermediate and long-term time points ....................................................... 238 
7.4.2 Change in the presence of neuropathic pain in LBLP patients ............. 238 
  
xiii 
 
7.4.3 Missing data .......................................................................................... 239 
7.5 Results ................................................................................................................. 239 
7.5.1 Study population ................................................................................... 239 
7.5.2 Frequency of neuropathic pain at baseline, short, intermediate and long 
term time points ............................................................................................ 239 
7.5.3 Change in the presence of neuropathic pain in LBLP patients ............. 240 
7.5.4 Comparison of complete case analysis versus imputed data ............... 253 
7.6 Discussion ........................................................................................................... 254 
7.6.1 Strengths and limitations ...................................................................... 257 
7.6.2 Implications for clinical practice and research ..................................... 258 
7.7 Conclusions ......................................................................................................... 259 
Chapter Eight. Prognosis of LBLP patients with neuropathic pain: Characteristics, 
clinical course and prognostic factors .................................................................... 260 
8.1 Introduction ........................................................................................................ 260 
8.2 Aims and objectives ............................................................................................ 261 
8.2.1 Overall aim ............................................................................................ 261 
8.2.2 Objectives ............................................................................................. 261 
8.3 Methods .............................................................................................................. 261 
8.3.1 Study design .......................................................................................... 262 
8.3.2 Data collection ...................................................................................... 262 
8.3.3 Neuropathic pain definitions ................................................................ 262 
8.3.4 Measures .............................................................................................. 263 
8.4 Statistical analysis ............................................................................................... 266 
8.4.1 Baseline characteristics......................................................................... 266 
  
xiv 
 
8.4.2 Clinical course ....................................................................................... 266 
8.4.3 Exploratory prognostic factor research ................................................ 266 
8.5 Results ................................................................................................................. 271 
8.5.1 Baseline characteristics......................................................................... 271 
8.5.2 Clinical course ....................................................................................... 281 
8.5.3 Identification of potential prognostic factors ....................................... 287 
8.5.4 Prognostic value of selected factors ..................................................... 291 
8.6 Discussion ........................................................................................................... 294 
8.6.1 Baseline characteristics and clinical course .......................................... 294 
8.6.2 Exploratory prognostic factor research ................................................ 295 
8.6.3 Strengths and limitations ...................................................................... 301 
8.6.4 Implications for clinical practice and research ..................................... 302 
8.7 Conclusions ......................................................................................................... 303 
Chapter Nine. Prescribing patterns of pain medications in LBLP patients with 
neuropathic pain ................................................................................................... 305 
9.1 Introduction ........................................................................................................ 305 
9.2 Aims and objectives ............................................................................................ 306 
9.2.1 Overall aim ............................................................................................ 306 
9.2.2 Objectives ............................................................................................. 306 
9.3 Methods .............................................................................................................. 306 
9.3.1 Study design .......................................................................................... 306 
9.3.2 Data collection ...................................................................................... 307 
9.3.3 Definitions of neuropathic pain, refractory neuropathic pain and 
improvement ................................................................................................. 308 
  
xv 
 
9.3.4 Baseline characteristics and consultations in primary care ................. 309 
9.4 Statistical analysis ............................................................................................... 313 
9.4.1 Patterns of pain medication prescriptions ........................................... 313 
9.4.2 Baseline characteristics and consultations in primary care ................. 313 
9.4.3 Estimates of LBLP patients with refractory neuropathic pain .............. 314 
9.5 Results ................................................................................................................. 315 
9.5.1 Patterns of pain medication prescriptions ........................................... 315 
9.5.2 Baseline characteristics of patients with neuropathic pain prescribed 
neuropathic pain medication......................................................................... 321 
9.5.3 Prescribed medications and proportion of patients with neuropathic pain 
with improvement four months after index consultation at ATLAS research clinic
 ....................................................................................................................... 327 
9.5.5 Estimates of LBLP patients with refractory neuropathic pain .............. 330 
9.6 Discussion ........................................................................................................... 330 
9.6.1 Prescribing patterns of pain medications in LBLP patients with neuropathic 
pain ................................................................................................................ 331 
9.6.2 Characteristics of patients prescribed neuropathic pain medication .. 334 
9.6.3 Refractory neuropathic pain ................................................................. 337 
9.6.4 Strengths and limitations ...................................................................... 340 
9.6.5 Implications for clinical practice and research ..................................... 342 
9.7 Conclusions ......................................................................................................... 343 
Chapter Ten. Discussions and conclusions ............................................................. 345 
10.1 Key findings ....................................................................................................... 347 
10.3 Strengths and limitations of the thesis ............................................................. 356 
10.4 Implications for clinical practice ....................................................................... 360 
  
xvi 
 
10.5 Implications for future research ....................................................................... 362 
10.6 Conclusions ....................................................................................................... 364 
References ............................................................................................................ 366 
Appendix A Supplementary data for Chapter Three ............................................... 393 
Appendix A1 Full systematic search strategy ................................................ 393 
Appendix A2 Data extraction tool ................................................................. 408 
Appendix A3 Flow chart of the 2nd systematic search and study selection .. 416 
Appendix A4 Results of quality appraisal ...................................................... 417 
Appendix B Supplementary data for Chapter Seven: analysis based on imputed data
 ............................................................................................................................. 421 
Appendix C Supplementary data for Chapter Nine: analysis based on imputed data
 ............................................................................................................................. 431 
 
 
 
  
  
xvii 
 
List of Tables 
Chapter One 
Table 1.1 Comparison of methodology used in neuropathic pain case ascertainment 
tools…………………………………………………………………………………………16 
Table 1.2 Comparison of sensory descriptors, physical tests and scoring in 
neuropathic pain case ascertainment tools……………………………………………………..18 
Table 1.3 Characteristics of studies showing prevalence of neuropathic pain in low 
back pain, grouped by setting in primary care or mixed setting (primary and, or 
secondary and, or tertiary care)…………………………………………………………………..26 
Chapter Three  
Table 3.1 Details of electronic databases searched………………………………………….45 
Table 3.2 Eligibility criteria for study selection…………………………………………………46 
Table 3.3 Summary of all fifteen studies included in the systematic review…….56  
Table 3.4. Summary of quality assessment (described as risk of bias) of the ten 
included studies used to derive prevalence……………………………………………………..67 
Table 3.5 Studies showing prevalence of neuropathic pain, grouped by method of 
defining neuropathic pain…………………………………………………………………………...69 
Table 3.6. Summary of quality assessment (described as risk of bias) of the eleven 
included studies used to describe characteristics and prognosis…………..73 
Table 3.7 Studies showing characteristics of neuropathic pain…………………………82  
Table 3.8 Study by Morsø et al. (2011) showing overall prognosis of neuropathic pain 
in low back-related leg pain (n=145) ………………………………………………..……101 
Table 3.9 Study by Hüllemann et al. (2017) showing change in the presence of 
neuropathic pain in low back-related leg pain…………………………………………..…..103  
  
  
xviii 
 
Chapter Four 
Table 4.1 Differentiating signs and symptoms of sciatica and referred leg pain 
………………………………………………………………………………………………………………………117 
Table 4.2 Neuropathic pain definitions based on clinical diagnosis………………..119 
Table 4.3 Categorisation of pain medications in this thesis……………………….……137 
Table 4.4 Baseline characteristics of participants followed-up and lost to follow-
up………………………………………………………………………………………………………………….141 
Chapter Five   
Table 5.1 Summary of key characteristics used to describe patients with neuropathic 
pain medication in research in Chapter five…………………………….…154 
Table 5.2 Prevalence of neuropathic pain in patients based on three case 
definitions..……………………………………………………………………………………………………160 
Table 5.3 Baseline characteristics of patients with neuropathic pain based on s-
LANSS…………………………………………………………………………………………………………….166 
Table 5.4 Baseline characteristics of patients with neuropathic pain defined by 
clinical diagnosis of sciatica……………………………………………………………………………177 
Table 5.5 Baseline characteristics of patients with neuropathic pain based on a 
clinical diagnosis of sciatica and evidence of nerve root compression on MRI.187 
Chapter Six  
Table 6.1 Treatment (care pathway) received by patients across three definitions of 
neuropathic pain……………………………………………………………………..220  
Chapter Seven  
Table 7.1 Summary of key characteristics used to describe patients in research in 
Chapter seven………………………………………………………………………………………………..237 
  
xix 
 
Table 7.2 Change in the presence of neuropathic pain in patients over a three-year 
follow-up period………………………………………………………….…………………………244 
Table 7.3 Proportion of patients by neuropathic pain sub-group (n=199)………247 
Table 7.4 Baseline characteristics of patients by neuropathic pain sub-group over 
three-years (n=199) ………………………………………………………………………………249 
Table 7.5 Evidence of nerve root compression across neuropathic pain sub-groups 
comparing imputed data and data using complete cases……………………256 
Chapter Eight 
Table 8.1 Summary of key characteristics used to describe patients with persistent 
neuropathic pain in research in Chapter eight……………………………….267 
Table 8.2 Selected potential prognostic factors……………………………………………..273  
Table 8.3 Baseline characteristics of patients with and without persistent 
neuropathic pain (based on s-LANSS) ……………………………………………………………275  
Table 8.4 Baseline characteristics of patients with and without persistent 
neuropathic pain (based on a clinical diagnosis of sciatica) …………………………..279 
Table 8.5 Univariable associations between potential prognostic factors and 
persistent neuropathic pain at four months (based on s-LANSS) …………………..292 
Table 8.6. Univariable associations between potential prognostic factors and 
persistent neuropathic pain at four months (based on a clinical diagnosis of sciatica) 
…………………………………………………………………………………………………………294  
Table 8.7 Multivariable associations between potential prognostic factors and 
persistent neuropathic pain at four months (based on s-LANSS)……………………296  
Table 8.8 Multivariable associations between potential prognostic factors and 
persistent neuropathic pain at four months (based on a clinical diagnosis of sciatica) 
…………………………………………………………………………………………………………297  
  
  
xx 
 
Chapter Nine 
Table 9.1 Summary of groups of pain medication in research in Chapter nine.311 
Table 9.2 Summary of key characteristics used to describe patients with neuropathic 
pain medication in research in Chapter nine………………………………313 
Table 9.3 Pain medication prescribed in primary care for patients with neuropathic 
pain (for three definitions) up to four months before and after index 
consultation…………………………………………………………………………………………321 
Table 9.4 Pain medication prescribed in primary care for patients with neuropathic 
pain (based on s-LANSS) up to four months before and three years after index 
consultation…………………………………………………………………………………324 
Table 9.5 Baseline characteristics of patients with neuropathic pain (based on s-
LANSS) by neuropathic pain medication prescribed four months before and after 
index consultation.…………………………………………………………………………………………326 
Table 9.6 Proportion of patients with neuropathic pain (based on s-LANSS) who 
improved by the number of neuropathic pain medications prescribed, comparing 
imputed data and data using complete cases……………………………….332  
Chapter Ten 
Table 10.1 Symptoms of anxiety and depression for neuropathic pain sub-groups 
over three years…………………………………………………………………………………………….356 
xxi 
 
List of Figures 
Chapter One 
Figure 1.1 Key features of positive and negative signs of neuropathic pain…….…4 
Figure 1.2 Updated hierarchical classification system for patients with neuropathic 
pain. Reproduced with permission from Walters Kluwer Health (Finnerup et al. 
2016) ………………………………………………………………………………….….11 
Chapter Two 
Figure 2.1 Flow diagram summarising thesis structure…………………………………….39  
Figure 2.2 Outline of chapters in this thesis……………………………………………………..40  
Chapter Three 
Figure 3.1. Flow chart of systematic search and study selection (adapted from the 
PRISMA flow chart) (Moher et al., 2009) …………………………………………..………52 
Chapter Four 
Figure 4.1 ATLAS study flow diagram (adapted from Konstantinou et al. (2015)) 
………………………………………………………………………………………………………………………115 
Chapter Five 
Figure 5.1 Neuropathic pain definitions, grouped by certainty of definition.….152 
Figure 5.1 Venn diagram depicting the overlap between LBLP patients with and 
without neuropathic pain at baseline based on three definitions………….……….160 
Figure 5.2 Characteristic associated with only one definition of neuropathic pain.. 
…………………………………………………………………………………………………………….198 
Figure 5.3 Characteristic associated with two definitions of neuropathic pain.199  
  
xxii 
 
Figure 5.4 Characteristics consistently associated with neuropathic pain across three 
definitions and characteristics that were similar between the two groups. 
………………………………………………………………………………………………………………………200 
Figure 5.5 Summary of pain medication use in patients with and without 
neuropathic 
pain……………………………………………………………………………………………………………….201 
Chapter Seven  
Figure 7.1 Proportion of patients with neuropathic pain at baseline and at three 
subsequent follow-up time-points (shown as patients who responded to follow-up) 
………………………………………………………………………………………………………………..242  
Chapter Eight 
Figure 8.1 Summary of baseline characteristics for patients with and without 
persistent neuropathic pain across two definitions……………………….………….……284 
Chapter Nine 
Figure 9.1 Bar chart showing proportion of patients with a clinically important 
difference in leg pain intensity and/or leg and back pain-related disability by four 
months………………………………………………………………………………..…………………331 
Chapter Ten 
Figure 10.1 Key findings of the thesis……………………………………….……………………347 
xxiii 
 
List of Boxes 
Chapter Six 
Box 6.1 Three year clinical course (mean pain intensity) of patients with and without 
neuropathic pain (based on s-LANSS) at baseline……………………………..222 
Box 6.2 Three year clinical course (mean pain intensity) of patients with and without 
neuropathic pain (based on a clinical diagnosis of sciatica) at baseline. 
………………………………………………………………………………………………………………………223 
Box 6.3 Three year clinical course (mean pain intensity) of patients with and without 
neuropathic pain (based on a clinical diagnosis of sciatica with evidence of nerve 
root compression) at baseline………………………………………………………….224 
Box 6.4 Three year clinical course (leg and back pain-related disability) of patients 
with and without neuropathic pain (based on s-LANSS) at baseline…226 
Box 6.5 Three year clinical course (leg and back pain-related disability) of patients 
with and without neuropathic pain (clinical diagnosis of sciatica) at 
baseline…………………………………………………………………………………………………………227 
Box 6.6 Three year clinical course (leg and back pain-related disability) of patients 
with and without neuropathic pain (clinical diagnosis of sciatica with evidence of 
nerve root compression) at baseline…………………………………………..228 
Chapter Eight 
Box 8.1 Criteria for investigating prognostic factors………………………….……………272 
Box 8.2 Three year clinical course (pain intensity) of LBLP patients with and without 
persistent neuropathic pain (based on s-LANSS) at four months………286 
Box 8.3 Three year clinical course (leg and back pain-related disability) of LBLP 
patients with and without persistent neuropathic pain (based on s-LANSS) at four 
months………………………………………………………………………………………………..…287 
  
xxiv 
 
Box 8.4 Three year clinical course (pain intensity) of LBLP patients with and without 
persistent neuropathic pain (based on a clinical diagnosis of sciatica) at four 
months………………………………………………………………………………………………..…289 
Box 8.5 Three year clinical course (leg and back pain-related disability) of LBLP 
patients with and without persistent neuropathic pain (based on a clinical diagnosis 
of sciatica) at four months………………………………………………………………290 
 
xxv 
 
List of Abbreviations 
ATLAS  Assessment and Treatment of Leg pain Associated with the Spine Study 
CI  Confidence interval (95%) 
BMI  Body mass index (Kg/m2) 
GP   General Practitioner 
HADS  Hospital Anxiety and Depression Scale 
IASP  International Association for the Study of Pain 
IPQ-R  Musculoskeletal Illness Perceptions Questionnaire 
MRI  Magnetic Resonance Imaging 
MRR  Medical Records Review 
N  Number  
NeuPSIG  Neuropathic Pain Special interest Group of IASP 
NICE  The National Institute for Health and Care Excellence 
NSAID  Non-steroidal anti-inflammatory medication 
NHS  National Health Service 
NRS  Numerical rating scale 
OR   Odds ratio 
PSEQ  Pain Self-Efficacy Questionnaire 
RMDQ  Roland Morris Disability Questionnaire 
SD  Standard deviation 
s-LANSS Self-report version of Leeds Assessment of Neuropathic Symptoms and 
Signs  
xxvi 
 
Published and presented work associated with this thesis 
Research articles  
Harrisson, S. A. Stynes, S. Dunn, K. M. Foster, N. E. Konstantinou, K. Neuropathic Pain 
in Low Back-Related Leg Pain Patients: What Is the Evidence of Prevalence, 
Characteristics, and Prognosis in Primary Care? A Systematic Review of the Literature. J 
Pain. 2017 Nov; 18 (11):1295-1312  
Published protocols  
Harrisson, S. A. Stynes, S. Dunn, K. M. Foster, N. E. Konstantinou, K. Neuropathic pain 
in patients with low back pain and leg pain: prevalence, characteristics, clinical course 
and prognostic indicators: a systematic review of the literature. PROSPERO 2015 
CRD42015023388 Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015023388 
Published abstracts  
Harrisson, S. A. Ogollah R. Dunn, K. M. Foster, N. E. Konstantinou, K. Prevalence and 
characteristics of neuropathic pain in primary care patients with low back-related leg 
pain. Bone Joint Res. Feb 2018. 99-B (Supp 10):16 
Work presented  
Harrisson, S. A. Epidemiology of neuropathic pain in primary care patients consulting 
with low back-related leg pain. BritSpine, Leeds, March 2018. 
Harrisson, S. A. Ogollah R. Dunn, K. M. Foster, N. E. Konstantinou, K. Primary care 
patients with low back-related leg pain: identification of cases with persistent 
neuropathic pain. Society for Back Pain Research Annual Meeting, November 2017. 
  
xxvii 
 
Harrisson, S. A. Ogollah R. Dunn, K. M. Foster, N. E. Konstantinou, K. Low back-pain 
related leg pain patients in primary care: Identifying change in the presence of 
neuropathic pain. XV International Back and Neck Pain Forum, Oslo, September 2017. 
Harrisson, S. A. Ogollah R. Dunn, K. M. Foster, N. E. Konstantinou, K. Is the clinical 
course of patients with low back-related leg pain with neuropathic pain worse 
compared to those without? 6th International Congress on Neuropathic pain, 
Gothenburg, June 2017.  
Harrisson, S. A. Change in the presence of neuropathic pain over time in patients with 
low back related leg pain consulting in primary care. Keele University Research 
Institute of Primary care and Health Sciences Postgraduate Symposium, May 2017. 
Harrisson, S. A. Is the clinical course of patients with low back-related leg pain with 
neuropathic pain worse compared to those without? Keele University Institute for 
Liberal Arts and Sciences: Crossing paths conference, April 2017.  
Harrisson, S. A. Ogollah R. Dunn, K. M. Foster, N. E. Konstantinou, K. Prevalence and 
characteristics of neuropathic pain in primary care patients with low back-related leg 
pain. Society for Back Pain Research Annual Meeting, Preston, November 2016. 
Harrisson, S. A. Stynes, S. Dunn, K. M. Foster, N. E. Konstantinou, K. Neuropathic pain 
in primary care patients with low back and leg pain: prevalence, characteristics and 
prognosis. A systematic review of the literature. XIV International Back and Neck Pain 
Forum, Buxton, May 2016. 
Harrisson, S. A. Epidemiology of neuropathic pain in patients with low back-related leg 
pain: A systematic review of the literature and development of a doctoral study. Keele 
University Research Institute of Primary care and Health Sciences Postgraduate 
Symposium, May 2016. 
  
xxviii 
 
Awards associated with this thesis 
Winning presentation. Keele University Research Institute of Primary care and Health 
Sciences Postgraduate Symposium, May 2017 
Selected to work with the Marketing and Communication department to produce a 
short video presentation. Keele University Institute for Liberal Arts and Sciences: 
Crossing paths conference, April 2017. 
Early Career Researcher first place poster presentation. XIV International Back and 
Neck Pain Forum, Buxton, May 2016. 
  
1 
 
Chapter One. Introduction  
The research in this thesis is concerned with the epidemiological study of neuropathic 
pain in patients with low back-related leg pain (LBLP) consulting in primary care. In 
order to assist the reader in understanding the rationale for this focus, this first 
chapter outlines the current understanding of causal mechanisms underlying 
nociceptive and neuropathic pain. Methods of assessing and diagnosing neuropathic 
pain are briefly discussed and case ascertainment tools appropriate for use in both 
epidemiological research and primary care are presented and discussed. A section 
outlines the principles of epidemiology in primary care and the advantages of choosing 
primary care as a setting for prognostic research. The chapter summarises the 
literature on the frequency of neuropathic pain in the general population and 
heterogeneous populations of chronic pain. The penultimate section outlines the 
prevalence, characteristics and prognosis of neuropathic pain in low back pain (LBP) 
reported in the literature before the final section outlines the distinction between LBP 
and LBLP.  A discussion is presented in the final section on the clinical diagnoses and 
underlying pain mechanisms related to LBLP. 
1.1 Overview of pain 
1.1.1 Definition of pain 
The International Association for the Study of Pain (IASP) Task Force on Taxonomy, 
edited by Merskey and Bogduk (1994) define pain as:  
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An unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such 
damage. 
The perception of pain is entirely subjective. Pain is always an unpleasant experience 
and is considered a psychological state (Merskey and Bogduk 1994).   
1.1.2 Nociceptive pain  
The term nociceptive pain is used to describe pain in a normally functioning 
somatosensory nervous system (Merskey and Bogduk 1994) where somatosensory 
refers to sensation (such as pain, pressure or warmth) which can occur anywhere 
within the body including the visceral organs, but not external to the body (for 
example, vision, hearing, olfaction). Not all activity in the nociceptors and in the 
nociceptor pathway result in pain, because a noxious stimuli has to be perceived 
psychologically to be painful. The following section will present an overview of some of 
the mechanisms of nociceptive pain that are important for the purpose of this thesis.  
1.1.2.1. Mechanisms of nociceptive pain 
After an injury, both thin (pain) and thick (touch, pressure and vibration) nerve fibres 
carry impulse signals from the site of injury to the dorsal horn of the spinal cord. At the 
dorsal horn, the impulse is transmitted through ascending tracts in the spinal column 
to the brain where the pain is perceived in the thalamus; this may trigger a descending 
signal to the area of injury which in turn may result in modulation of cell activity and 
the experience of pain. The perception of pain at any one time depends in part on the 
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previous experiences of the individual, the context in which they received the injury, 
and the current state of the individual’s mood. Activity in both the thin and thick nerve 
fibres is important to consider because they have different roles in the transmission of 
pain signals. In a normal state, thin fibre activity tends to result in the transmission of 
signals to the brain whereas thick fibre activity tends to result in reduction of 
transmission, the more the thick (vibration, touch and pressure) fibre activity the less 
pain is perceived. 
1.1.3 Neuropathic pain 
Nociceptive pain is considered to be an adaptive process which differs from 
neuropathic pain which is considered maladaptive. Neuropathic pain is defined by the 
Neuropathic Pain Special Interest Group of the International Association for the Study 
of Pain (IASP) (Treede et al. 2008) as: 
Pain arising as a consequence of a lesion or disease of the 
somatosensory system.  
A lesion reflects abnormalities when there is trauma or injury (for example, spinal cord 
transection) and a disease is commonly used when the cause for the underlying lesion 
is known (for example, stroke, cancer or diabetes mellitus) (Merskey and Bogduk 
1994). Neuropathic pain is a sub-group of neurogenic pain (Merskey and Bogduk 1994) 
and the implication of this is that neuropathic pain is irreversible. Patients with clinical 
conditions characterised by neuropathic pain may report symptoms such as electrical 
attack-like pain which are particularly distressing. Unlike in nociceptive pain, 
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neuropathic pain is characterised by spontaneous (non-evoked) pain such as electrical 
attacks or pins and needles (this is an example of a positive sign of neuropathic pain) 
and also a loss of function (also known as negative signs) (Baron et al. 2010). Figure 1.1 
summarises the key features of both positive and negative signs. The pain system is 
not considered static and as such, the signs and symptoms of neuropathic pain may 
change during the course of the disease (Jensen and Baron 2003). 
Figure 1.1 Key features of positive and negative signs of neuropathic pain 
 
  Evoked pain 
• Allodynia: Pain response to non-noxious stimuli (often light touch) 
• Hyperalgesia: Increased pain sensitivity in response to nociceptive 
stimuli (for example response to pin prick) 
• Response to summation: Increasing pain sensitivity to repetitive 
application of a single noxious stimuli (wind up-like pain) 
Non-evoked pain (Spontaneous sensations and pain in response to 
weak or no stimuli) 
• Paroxysmal pain: Shooting electrical attacks 
• Paresthesia: Skin crawling or tingling, pins and needles  
• Superficial pain: Often burning 
Positive 
Signs 
Negative 
Signs 
Hypoalgesia 
• Reduced sensation to painful stimuli 
Hypoaesthesia 
• Reduced sensation to non-painful stimuli (for example cold or 
warm, or vibration) 
  
5 
 
1.1.3.1 Mechanisms of neuropathic pain 
In the event of an injury or lesion to the somatosensory system, a number of events 
occur both local to the site of injury and centrally in response to the injury. As with the 
mechanisms of nociceptive pain, an understanding of how mechanisms generate 
symptoms in neuropathic pain is important for the purpose of this thesis and an 
outline of mechanisms is provided in the discussion below.  Further details can be 
found in a review on Neuropathic pain by Cohen and Mao (2014). At the site of a 
lesion, demyelination and cell death can lead to both positive and negative signs of 
neuropathic pain. Positive signs such as spontaneous pain are generated in part by 
abnormal impulse generation and electrical hyperexcitability (called ectopic 
excitability) at the site of injury (Devor 2013), and negative signs can result from loss of 
function because of a reduction in impulse conduction (Woolf 2004). Ectopic 
excitability in peripheral nerves contributes to neuropathic pain in two ways, firstly, it 
directly drives pain pathways in the central nervous system and secondly, it can trigger 
and maintain increased sensitivity of neurons in the central nervous system to normal 
or subthreshold peripheral nerve activity (also called central sensitisation) (Devor 
2013). 
Central sensitisation is not exclusive to neuropathic pain; in both neuropathic and 
nociceptive pain conditions, changes in the spinal cord and in the higher centres of the 
brain are in part, characterised by an amplification of pain. Amplification arises when 
thick nerve fibres that normally do not produce pain undergo a change in cellular 
characteristics that results in normally non-noxious stimuli being perceived as noxious 
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(described as allodynia) (Devor 2013). This process by which the nerve changes its 
function is synonymous with alterations in gene expression and is described as a 
phenotypic switch. The phenotypic switch in this case brings about a change in cellular 
characteristics that increases the expression of inflammatory mediators (Cohen and 
Mao 2014). The following section (1.1.4) outlines the role of inflammatory mediators 
in both neuropathic and nociceptive pain mechanisms, and then section 1.1.5 outlines 
how sensitisation at the level of the spinal cord contributes to the phenomena of 
referred pain. 
1.1.4 Pain from mixed mechanisms 
The mechanisms underlying nociceptive and neuropathic pain involve inflammatory 
pain responses (Devor 2013). The role of inflammation in nociceptive pain is 
considered to be a necessary part of the healing process in the acute stages, and these 
mechanisms are well established (Bennett 2006). In neuropathic pain conditions, 
where nerve damage causes inflammation and also inflammation causes ongoing 
nerve damage, the underlying process is less clear (Bennett 2006). Conceptually and in 
terms of clinical application it is difficult to make a clear distinction between 
neuropathic and inflammatory pain (Bennett 2006). In fact, inflammatory pain, 
neuropathic pain and nociceptive pain often co-exist. A space occupying tumour can 
simultaneously apply noxious force on adjacent healthy tissue (nociceptive pain), 
directly injure nerves (neuropathic pain) and trigger an inflammatory response (Devor 
2013). The presence of one type of pain does not infer the absence of the other type of 
pain and the three clinically co-exist together.  
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1.1.5 Pain referral  
Referred pain is that perceived in a region topographically distinct from the region in 
which the actual pain source is located, is thought to be caused by amplification of 
neurons in the spinal cord and is assumed to be non-neuropathic in nature (Merskey 
and Bogduk 1994). Referred pain can occur in both somatic tissue and visceral tissue, a 
common example in somatic tissue is the self-report of buttock or leg pain arising from 
degenerative changes in the facet joints. In this example, pain referred to the buttock 
or leg may be caused by convergent inputs to spinal cord neurons receiving inputs 
from sensory neurons of the facet joints as well as the remote tissues of the leg or 
buttock (Treede et al. 1992). In the example given of facet joint degeneration, the 
location of the remote pain in the leg is associated with the intensity and duration of 
the activation of the sensory inputs from the facet joint.  
The classical view of the natural history of patients with nociceptive pain is that of a 
favourable prognosis whereas that of patients with neuropathic pain appears different, 
with many people with neuropathic pain often living with persisting pain (Ciaramitaro 
et al. 2010). This chapter now proceeds to discuss some of the key concepts of 
prognosis research in pain, and then the relevance of settings in pain research (Section 
1.2). This is before section 1.3 which provides an outline of the methods commonly 
used to assess neuropathic pain in clinical practice and in epidemiological research, 
and an outline of how neuropathic pain is currently managed in clinical practice before 
presenting the epidemiology of neuropathic pain in common clinical conditions.  
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1.2 Prognosis of pain in primary care 
The term “prognosis” refers to the risk of future health outcomes in people with a 
particular disease or health condition, in the context of this thesis the health condition 
is neuropathic pain. The prognosis of patients with neuropathic pain is thought to be 
worse than those with nociceptive pain. Overall prognosis research answers questions 
such as, “what is the most likely course of this patient with this health condition”. In 
patients who consult with health care professionals, overall prognosis describes the 
clinical course rather than natural history of a condition as it takes into consideration 
that a patient would have undergone some form of diagnostic assessment with a 
treatment plan. To improve the likely clinical course of patients with neuropathic pain, 
evidence is required on whether specific characteristics (prognostic factors) are 
associated with future endpoints such as neuropathic pain-related disability or 
persistence of pain (Hemingway et al. 2013). Information comes from prospective 
observational studies where the temporal relation between a prognostic factor and 
given endpoint can be investigated. A prognostic factor is defined as a biological, 
behavioural, symptomatic, psychological or environmental measure that can be 
modifiable (for example body mass index) or non-modifiable (for example family 
history) and is associated with a future outcome (Riley et al. 2013). Prognosis research 
informs clinicians and patients on an individual level and provides valuable information 
for public health policy (Hemingway et al. 2013).  
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1.2.1 Primary care as a setting for research 
The setting in which pain is studied is crucial to the questions posed and the 
interpretation of prognosis research findings. The first point of contact for an 
individual with pain entering the health care system in the UK is usually a primary care 
provider (Costa Lda et al. 2013) such as a general practitioner, or other clinicians such 
as practice nurses, physiotherapists or osteopaths. The majority of patients with pain 
are managed in primary care rather than in specialist pain centres (Breivik et al. 2006). 
In the current literature on pain, specialist pain services have been used extensively to 
provide access to large numbers of patients for research. It is likely that populations of 
patients drawn from specialist pain services are systematically different than patients 
consulting in primary care which limits the generalisability of research findings 
(Crombie and Davies 1998). Epidemiological studies that draw from primary care 
rather than specialist pain settings have key advantages. One advantage is that 
estimates of prevalence and characteristics of a condition of interest are likely to more 
accurately reflect the problem in the general population than studies in set in specialist 
pain centres (Tager 1998). The epidemiology of neuropathic pain in primary care is 
important for many reasons. It provides valuable information on the prevalence, 
characteristics in terms of symptom duration, and severity of neuropathic pain within a 
condition. Such evidence may be very useful in developing better management 
strategies in those patients with neuropathic pain.  
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1.3 Neuropathic pain 
1.3.1 Assessment of neuropathic pain 
Neuropathic pain is a clinical description (and not a diagnosis) (Merskey and Bogduk 
1994). Detecting neuropathic pain can present with difficulties. There is not one sign or 
symptom that is exclusively attributed to neuropathic pain, nor is there absolute 
consensus on how patients with neuropathic pain should be identified in clinical 
practice or epidemiological research. This section discusses how, in the absence of a 
gold standard, patients with neuropathic pain are commonly identified in both clinical 
practice and for the purposes of epidemiological research. A number of neuropathic 
pain case ascertainment tools that are commonly cited in the neuropathic pain 
literature are described in section 1.3.1.2 and are summarised in Tables 1.2 and 1.3.  
1.3.1.1 Assessment using clinical examination 
There is some consensus that in clinical practice, patients with neuropathic pain are 
identified by clinical history and examination (Treede et al. 2008). The Neuropathic 
Pain Special Interest Group of IASP proposed a hierarchical classification system with 
four criteria based on clinical examination and confirmatory tests (Treede et al. (2008) 
updated by Finnerup et al. (2016)). Figure 1.2 reproduces the updated grading system 
reported by Finnerup et al. (2016).  
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Figure 1.2 Updated hierarchical classification system for patients with neuropathic 
pain. Reproduced with permission from Walters Kluwer Health (Finnerup et al. 2016)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The area of sensory changes may extend beyond the innervation territory. Neurological examination 
may include sensory examination of touch, vibration, pin-prick, cold and/or warm. Sensory loss is 
generally required to be present for patients to meet criterion of “probable” neuropathic pain. 
 
In specialist pain settings, clinical history and an extensive neurological examination 
may identify patients at best as having “probable” neuropathic pain, additional 
confirmatory tests may identify patients with “definite” neuropathic pain but despite 
investigations the cause of the pain often remains unknown (Cruccu and Truini 2009). 
Pain 
History of relevant neurological lesion or disease and  
pain distribution neuro-anatomically plausible 
Pain is associated with sensory signs in the same 
neuro-anatomically plausible distribution*  
Diagnostic test confirming a lesion or disease of the 
somatosensory nervous system explaining the pain 
Possible 
neuropathic 
pain  
Probable 
neuropathic 
pain  
Definite 
neuropathic 
pain  
Unlikely to 
be 
neuropathic 
pain  
Leading complaint 
History 
Examination  
Confirmatory 
tests 
Yes 
Yes 
Yes 
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In primary care where clinicians are non-specialists, patients would be identified at 
best as having “possible” neuropathic pain. It is questionable whether forms of 
assessment that are offered in specialist pain settings are clinically useful in settings 
such as primary care where the majority of patients with neuropathic pain are 
managed (Breivik et al. 2006). In epidemiological research too, a more detailed 
assessment other than clinical examination is generally unattainable (Smith and 
Torrance 2010). Questionnaires or case ascertainment tools potentially provide benefit 
to the clinician by facilitating early diagnosis and decision-making about appropriate 
treatment.  Academically, questionnaires allow for population-based epidemiological 
studies and clinical trials (Smith and Torrance 2010). Simple tools have been developed 
for use in research and in clinical practice where complex and time consuming 
methods of assessment are not possible.  
1.3.1.2 Assessment using neuropathic pain case ascertainment tools 
This section provides a description of neuropathic pain case ascertainment tools 
commonly cited in the published literature. Case ascertainment tools for the purposes 
of epidemiological study in neuropathic pain need to detect features of pain that are 
characteristically neuropathic in an efficient, valid and reliable manner (Smith and 
Torrance 2010). One of the first tools to use sensory descriptors of neuropathic pain 
was the McGill Pain Questionnaire (Boureau et al. 1992). It identifies six sensory 
descriptors that are more commonly used by patients with neuropathic pain, these 
were: “electric shock”, “burning”, “cold”, “pricking”, “tingling” and “itching”. These six 
  
13 
 
descriptive words have been used in a number of subsequent tools that attempt to 
screen and identify cases of neuropathic pain.  
These tools include: the Leeds Assessment of Neuropathic Symptoms and Signs 
(LANSS) (Bennett 2001), the Douleur Neuropathique en 4 questions (DN4) (Bouhassira 
et al. 2005), painDETECT (Freynhagen et al., 2006), Neuropathic Pain Questionnaire 
(Krause and Backonja 2003) and ID Pain (Portenoy 2006).  All have been adapted for 
use in a number of languages, neuropathic pain disorders (i.e. diabetic neuropathy, 
radicular pain/sciatica, and trigeminal neuropathy) and health care settings and at best 
describe patients with “possible” neuropathic pain (Smith et al. 2012a). The LANSS, 
PainDETECT and DN4 have been used in populations relevant to low back pain (for 
example, Walsh et al. (2012) and Beith et al. (2011)). LANSS was subsequently 
developed into a self-report version, the s-LANSS (Bennett et al. 2005). Each of these 
tools are presented in more detail below, the methodology used in the development 
of each tool is considered in Table 1.1, and the reported sensory and physical items 
and scoring is reported and compared in Table 1.2.  
1.3.1.2.1 LANSS and s-LANSS 
LANSS (Bennett, 2001) was developed in two populations with chronic pain, and 
consists of a seven-item pain scale including five sensory descriptors and two items of 
clinical examination with a simple, weighted scoring system. Clinical diagnosis was 
classified by one clinician based on clinical features, known pathology, and radiological 
or electro-physical evidence. The tool was then validated in a second group of patients 
with nociceptive and neuropathic pain (known pathology of mixed origin) (n=40) 
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(Bennett, 2001).  A score of 12 or more (out of a possible 24) suggests neuropathic 
pain. Further research has led to the development of a self-report, self-examination of 
the LANSS (Bennett et al., 2005), known as s-LANSS. Individual items of s-LANSS 
reported the following changes: dysesthesia, autonomic (for example, red mottled 
changes to the skin), evoked, paroxysmal, thermal, allodynia and tenderness or 
numbness. S-LANSS has also been used in back pain populations within the UK (Walsh 
et al. 2012). 
1.3.1.2.2 DN4 
The DN4 was originally developed in France (Bouhassira et al., 2005) where a small 
number of items was found to be able to discriminate neuropathic pain. It consists of 
four questions sub-divided into seven items related to the history taken from the 
patient and three items taken from the physical examination.  It was initially tested in 
160 pain clinic patients and has been tested in a variety of chronic pain conditions 
including LBP (Attal et al. 2011). It has been translated into different languages using 
different pain populations, including LBLP (Walsh et al., 2012).   
1.3.1.2.3 PainDETECT 
PainDETECT (Freynhagen et al., 2006) was developed in a population of patients with 
LBP in Germany. It includes seven weighted sensory descriptor items and two items 
relating to the radiating and temporal characteristics of the pain pattern and is 
completed by self-report. Patients are classified by painDETECT scores as having “likely 
nociceptive pain”, “unclear pain” mechanism and “possible neuropathic” pain. The 
questionnaire has been used in LBLP populations (Beith et al. 2011) and validated 
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further in fibromyalgia (Gauffin et al. 2013) and neck and upper limb pain (Tampin et 
al. 2013).   
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Table 1.1 Comparison of methodology used in neuropathic pain case ascertainment tools 
Tool Format Methods Reference Standard Sensitivity (%)* Specificity (%)*  
LANSS 
 
5 pain descriptors +2 
physical tests 
Study 1: 30 neuropathic (mixed 
chronic pain) versus 30 
nociceptive pain patients. 
Study 2: 20 neuropathic versus 20 
nociceptive pain patients 
Clinical diagnosis taking into 
account clinical features, known 
pathology, radiological evidence 
and electrophysiological 
evidence if available. 
83 87 
s-LANSS 
 
7 self-report 
questions 
Study 1: Clinic study of 100 
patients with neuropathic pain 
versus 100 patients with 
nociceptive pain.  
Study 2: Postal study of 310 
patients 
Clinical diagnosis on the basis of 
history, clinical examination and 
investigations. 
74 (completion 
by self-report) 
74 (completion 
by interview) 
76 (completion 
by self-report) 
83 (completion 
by interview) 
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Tool Format Methods Reference Standard Sensitivity (%)* Specificity (%)*  
DN4 
 
7 pain descriptors +3 
physical tests 
Study of 89 patients with pain due 
to a nerve lesion and 71 patients 
with a non-neurological lesion 
Clinical diagnosis by medical 
history, physical examination, 
electromyography and imaging 
when indicated. 
80 92 
Pain- 
DETECT 
 
9 self-report 
questions 
Study 1. Validation study of 228 
neuropathic and 164 nociceptive 
patients. 
Study 2: Epidemiological survey of 
7,772 low back pain patients 
Clinical diagnosis with 
appropriate diagnostic methods 
including neurological and 
electrophysiological imaging. 
85 80 
Abbreviations: DN4, Douleur Neuropathique en 4 questions. LANSS, Leeds Assessment of Neuropathic Symptoms and Signs. S-LANSS, Self-report version of the Leeds 
Assessment of Neuropathic Symptoms and Signs. *Derived from development study  
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Table 1.2 Comparison of sensory descriptors, physical tests and scoring in neuropathic pain case ascertainment tools 
Item 
  
LANSS s-LANSS DN4 PainDETECT 
Patient interview  
Pain course pattern 
   
-1 to 1 
Pain radiation 
     
0 or 2 
Pain descriptor 
/quality  
Non-
painful 
sensations  
Pricking or tingling, like 
pins and needles 
0 or 5 0 or 5 0 or 1* 0-5§ 
Itching 
  
0 or 1 
 
Numbness 
  
0 or 1 0-5 § 
 
Pain 
quality 
Electric shock or shooting 0 or 2 0 or 2 0 or 1 0-5 § 
Burning 0 or 1 0 or 1 0 or 1 0-5 § 
Evoked 
pain 
Mild/blunt pressure 
   
0-5 § 
Warm or cold 
   
0-5 § 
Light touching 0 or 3 0 or 3 
 
0-5 § 
Brush   0 or 5   
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Item 
  
LANSS s-LANSS DN4 PainDETECT 
Altered 
threshold 
Pin-prick   0 or 3 ‡   
Changes in skin  
  
0 or 5 0 or 5 
  
Clinical examination  
 
Light touching 
  
0 or 1† 
 
Brush 
 
0 or 5 ‡ 
 
0 or 1‡ 
 
Pin-prick 
 
0 or 3 ‡ 
 
0 or 1† 
 
Scoring       
Score range   0 to 24 0 to 24 0 to 10 -1 to 38 
Score interpretation   ≥ 12 neuropathic 
< 12 non-
neuropathic 
≥ 12 neuropathic 
< 12 non-
neuropathic 
≥4 neuropathic, 
< 4 non- 
neuropathic 
≥ 19 likely neuropathic, 
13-18uncertain 
neuropathic. 
≤12 unlikely neuropathic 
Abbreviations: DN4, Douleur Neuropathique en 4 questions. LANSS, Leeds Assessment of Neuropathic Symptoms and Signs. S-LANSS, Self-report version of the Leeds 
Assessment of Neuropathic Symptoms and Signs. *Score of 1 given for tingling and score of 1 given to pins and needles. † Score given for decreased response. ‡ Score given 
for stimulus evoked pain.  § For each question: never, 0; hardly noticed, 1; slightly, 2; moderately, 3; strongly, 4; very strongly, 5.
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Use of each of the four tools reported in this section (1.3) is likely to result in some 
failure to identify patients with clinically diagnosed neuropathic pain, and it is possible 
they may also over-identify patients because the tools are too broad and imprecise 
(Smith and Torrance 2010). However, case ascertainment tools are easy to use by 
professionals and by patients alike, in clinic or via telephone or by mail and without a 
gold standard with which to compare an assessment tool for neuropathic pain, the 
questionnaires provide interesting interim estimates (Smith and Torrance 2010). 
PainDETECT, DN4 and s-LANSS have been used in cross-sectional epidemiological 
surveys in mixed populations of neuropathic pain, to report prevalence. (Bouhassira et 
al. 2008, Torrance et al. 2006, Nakamura et al. 2014).  
1.3.2 Management of neuropathic pain 
There are specific medications available in both primary care and specialist pain 
settings for patients with neuropathic pain conditions. Guidelines advocate the use of 
specific neuropathic pain medication, such as Duloxetine, Amitriptyline, Pregabalin 
and, or Gabapentin and in some instances Tramadol (NICE CG173 2013, Finnerup et al. 
2015), and non-pharmacological treatments such as physiotherapy or cognitive 
behavioural therapy (NICE CG173 2013). In primary care, of patients with chronic pain 
conditions and neuropathic pain, just less than half are treated with an adequate trial 
of a neuropathic drug and over half do not receive any targeted pharmacological 
treatment for neuropathic pain (Torrance et al. 2013). Of those patients treated with 
specific neuropathic medications a small proportion do not respond and are 
considered to have “refractory” neuropathic pain (Torrance et al. 2013). Failure to 
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treat patients with neuropathic pain using specific medication may be in part because 
these patients go undetected, especially in primary care (Torrance et al. 2013) and in 
part due to a differences in the response to both pharmacological and non-
pharmacological treatment (Baron et al. 2012, Martin et al. 2014). Despite current 
guidelines advocating the use of specific neuropathic pain medications, the condition 
itself is difficult for clinicians and in turn patients to manage. Prognosis research is 
likely to inform clinicians of the likely course of neuropathic pain, to assist clinicians to 
identify patients who will or will not have a favourable outcome and to use this 
information to better inform clinical decision-making about treatment. 
1.3.3 Epidemiology of neuropathic pain  
1.3.3.1 Frequency of neuropathic pain   
Current estimates of the frequency of neuropathic pain in primary care are derived 
from estimates in the general population (van Hecke et al. 2014) or from specialist pain 
settings. The prevalence of neuropathic pain in the general population, derived in part 
using neuropathic case ascertainment, was estimated to be between 6.9% and 10% 
(van Hecke et al. 2014). The frequency of neuropathic pain varies from condition to 
condition but for three commonly cited neuropathic conditions (post-herpetic 
neuralgia, trigeminal neuralgia and painful diabetic neuropathy) the incidence was less 
than one 1/1,000 person years for each condition (van Hecke et al. 2014). Prevalence 
estimates of neuropathic pain in patients with chronic pain, including chronic 
widespread pain and soft tissue syndromes (for example, tendinopathy, fibromyalgia 
and musculoskeletal pain) varied from 13% to 43.3% (Fishbain et al 2014). LBP is 
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among the most common presentations of neuropathic pain in UK primary care 
(46.4%) (Berger et al. 2012, Torrance et al. 2014). The variation in the estimates 
provided here highlights the importance of establishing best estimates within one 
neuropathic pain condition, but given the challenge in agreeing a case definition, an 
understanding of the key characteristics and prognosis of these patients with 
neuropathic pain may be more appropriate.  
1.3.3.2 Characteristics of neuropathic pain 
Previous research reports that individuals with chronic pain thought to be neuropathic 
may be more likely to be female, no longer married, with no educational qualifications 
and to be smokers (Torrance et al. 2013, Torrance et al. 2014) than those with chronic 
pain that was thought to be non-neuropathic. Those with chronic pain thought to be 
neuropathic in nature may be more likely to be living in council rented accommodation 
than those without (Torrance et al. 2013, Torrance et al. 2014); housing status was 
reported to be a proxy for social class (Stoate 1989). The incidence of neuropathic pain 
may increase with increasing age (Hall et al. 2013). In individuals with neuropathic 
pain, three-quarters report moderate to severe pain (Bouhassira et al. 2008) and 
increased pain severity was associated with increased disability and higher medication 
use compared to those with chronic pain without neuropathic features (Schaefer et al. 
2014). Most individuals with neuropathic pain reported pain in two or more locations 
(Bouhassira et al. 2008) and one quarter suffered with other health problems, in 
particular anxiety and depression (de Andres et al. 2014, Bouhassira et al. 2008). In the 
general population, 24% of individuals with neuropathic pain considered themselves 
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disabled (Schaefer et al. 2014) and individuals with neuropathic pain related to chronic 
pain were more likely to be unable to work than those without neuropathic pain 
(Torrance et al. 2006).  
1.3.3.3 Prognosis of neuropathic pain 
There is an assumption that neuropathic pain is irreversible (Merskey and Bogduk 
1994) but in clinical practice as an episode of pain improves the signs and symptoms of 
neuropathic pain often recede accordingly. The notion that the course of neuropathic 
pain can vary in individuals is supported by the literature (Baron et al. 2016) but 
empirical evidence from prospective cohort studies is scarce. There is some evidence 
from one systematic review for a number of potential prognostic factors associated 
with persistent neuropathic pain including male gender, older age, smoking, lower 
health status and higher pain severity (Boogaard et al. 2015). However, there was little 
consistency of the definition of persistent neuropathic pain itself and little consistency 
across different neuropathic pain definitions. In a Delphi consensus study of experts in 
neuropathic pain, Boogaard et al. (2011) reported that psychological characteristics 
were perceived to be the strongest prognostic factors associated with persistent 
neuropathic pain, this was perhaps a surprising finding since the first line treatment for 
neuropathic pain is generally considered to be pharmacological (NICE NG59 2016, NICE 
CG173 2013). Overall, the presentation of patients with neuropathic pain appeared 
worse in terms of pain severity and disability compared to patients without 
neuropathic pain. It is evident that there is a substantial variation in prevalence, 
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characteristics and prognostic factors across neuropathic pain conditions, across 
settings and definitions of neuropathic pain.  
1.4 Low back pain 
1.4.1 Overview  
LBP is the leading cause of disability globally (Buchbinder et al. 2013) and with an aging 
population this level of burden is likely to continue, LBP is therefore a major public 
health problem. Most people will experience an episode on LBP at some point in their 
lives (Hoy et al. 2012a). LBP is defined as pain typically between the lower rib margins 
and the buttock creases (Dionne et al. 2008) and can present with pain in one or both 
legs (Hartvigsen et al. 2018, Chou 2010). In LBP, nociceptive pain arises from activation 
of nociceptors of the innervated part of the intervertebral disc, ligaments, joints, 
fascia, and muscles of the spinal segment as a response to injury, biomechanical stress 
or inflammation. In the majority of cases, the source of pain cannot be identified and 
those patients are classified as having non-specific LBP (Maher et al. 2017). In some 
cases, patients with LBP present with leg pain and neurological symptoms in the legs as 
a result of injury to the spinal nerve root, the most common cause of injury is a disc 
herniation (Porchet et al. 2002). Pain arising from damage or compression to the nerve 
root is considered to be neuropathic (Baron et al. 2016).  
1.4.2 Epidemiology of neuropathic pain in LBP patients 
The following sections describes the epidemiology, in terms of prevalence 
characteristics and prognosis of neuropathic pain in LBP patients and Table 1.3 
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summarises studies that report prevalence, characteristics and prognosis of 
neuropathic pain in this patient population.   
1.4.2.1 Prevalence of neuropathic pain in LBP patients  
The prevalence of neuropathic pain in LBP at any one point in time and in any setting 
has been estimated to range from 2% in a sample of older patients with acute LBP 
(Enthoven et al. 2013) to 90%, in a study with a group of workers who regularly 
consulted with chronic LBP (Mehra et al. 2012). Variation in prevalence may not be 
only due to clinical setting but also due to patient selection. Low prevalence of 
neuropathic pain was reported in axial back pain symptoms (12%, Forster et al., 2013) 
and in LBP without evidence of sensory loss or severe motor deficits on neurological 
examination (15%, Hiyama et al. (2015)), whereas higher prevalence was reported in 
LBP populations with and without leg pain (average of 50% across studies; (El Sissi et 
al. 2010, Kaki et al. 2005, Hassan et al. 2004)). In the same patient population, Sakai et 
al (2015) used both PainDETECT and the Japanese neuropathic screening questionnaire 
(Matsubayashi et al. 2013) to estimate neuropathic pain prevalence, and reported it to 
be 16% and 44%, respectively. The difference in case ascertainment tools to derive 
neuropathic pain appear to generate significantly different prevalence estimates of 
neuropathic pain. Prevalence of neuropathic pain in samples derived from the general 
population was lower than that of settings that included specialist pain centres (19% 
versus 36% (Schmidt et al. 2009)).
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Table 1.3 Characteristics of studies showing prevalence of neuropathic pain in low back pain, grouped by setting in primary care or mixed 
setting (primary and, or secondary and, or tertiary care) 
Study Study design 
includes 
longitudinal 
data? 
Sample* Method for 
identifying 
neuropathic pain 
Setting Prevalence of 
neuropathic 
pain (% ) 
Cappelleri et al. 
(2017) 
No Diagnosis of CLBP 
associated with 
NeuP: n=103, 
(NR)%M, Age (NR) 
PainDETECT 33 Community based physician 
practices in United States 
(includes general practitioners, 
neurologists, pain specialists 
and endocrinologists) 
63 
Enthoven et al. 
(2013) 
No LBP† patients aged 
>55 years: n=250, 40 
%M, Age: 66 (8) 
DN4 plus physical 
examination 
GP consulters in Netherlands 2 
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Study Study design 
includes 
longitudinal 
data? 
Sample* Method for 
identifying 
neuropathic pain 
Setting Prevalence of 
neuropathic 
pain (% ) 
El Sissi et al. (2010) †† No LBP: n= 1134, 
60%M, Age: 45 (12) 
LANSS Outpatient medical setting 
(includes medical surgical, 
orthopaedics, general 
practitioners, neurologists and 
pain specialists) 
55 
Forster et al. (2013) †† No Axial§ LBP: n= 1083, 
42%M, Age: 58 (15) 
PainDETECT 450 outpatient centres in 
Germany (GPs, 
rheumatologists, orthopaedics 
and pain specialists) 
12 
Freynhagen et al. 
(2006b)†† 
No CLBP: n=7772, 
(NR)%M, Age: 57 
(NR) 
PainDETECT 158 GPs, 45 orthopaedics, 67 
neurologists, 202 pain clinics 
37 
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Study Study design 
includes 
longitudinal 
data? 
Sample* Method for 
identifying 
neuropathic pain 
Setting Prevalence of 
neuropathic 
pain (% ) 
Hassan et al. (2004) †† 
 
 
No CLBP: n=100, 69%M, 
Age: NocP 42 (11), 
NeuP 50 (13) 
LANSS 10 "centres" across the middle 
east region 
41 
Hiyama et al. (2015) No LBP||: n=331, 58%M, 
Age NocP 54 (17), 
NeuP 57 (15) 
Japanese version of 
PainDETECT 
Japanese suburban tertiary 
care centre  
15 
Kaki et al. (2005) †† No CLBP: n= 1125, 
60%M, Age 47 (13) 
LANSS Mixed outpatient setting: 
neurologist, neurosurgeons, 
pain specialists, 
rheumatologists, orthopaedic  
55 
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Study Study design 
includes 
longitudinal 
data? 
Sample* Method for 
identifying 
neuropathic pain 
Setting Prevalence of 
neuropathic 
pain (% ) 
Kew et al. (2017) No  LBP ≥ 1 month: 
n=210, 39%M, Age: 
58 (NR) 
PainDETECT Tertiary referral spine clinic in 
Malaysia 
12 
Mehra et al. (2012) ‡‡ 
 
 
No LBP: n=39425, 
36%M, Age: 51 (NR) 
ICD-9 codes for 
neuropathic pain 
US patient commercial 
insurance claims integrated 
database** 
90 
Sakai et al. (2015) 
 
 
Yes, follow-up 
data 
CLBP‡: n=30, 70%M, 
Age: 72 (6) 
PainDETECT and 
Neuropathic 
screening 
questionnaire 
(Japanese) 
National Centre for Geriatrics 
and Gerontology 
PainDETECT: 
16 
Neuropathic 
screening 
questionnaire: 
44 
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Study Study design 
includes 
longitudinal 
data? 
Sample* Method for 
identifying 
neuropathic pain 
Setting Prevalence of 
neuropathic 
pain (% ) 
Schmidt et al. (2009) 
†† 
No LBP (Sample 1): 
n=6920, 38%M, Age: 
51 (12) 
PainDETECT 500 general practices and 
specialist pain practices and in 
hospitals across Germany.  
36 
No LBP (Sample 2): 
n=1718, 44%M, Age: 
50 (14) 
PainDETECT German back pain research 
network study: population 
survey ** 
19 
Abbreviations: CLBP, chronic low back pain. DN4, doleur Neuropathique-4. ICD-9, International Classification of Diseases, 9th-Revision. LANSS, Leeds assessment of 
neuropathic symptoms and signs neuropathic pain scale. LBP, low back pain. M, male. NR, not reported. NocP, nociceptive pain. NeuP, neuropathic pain.  
* Age written as mean (standard deviation) years 
† Back pain includes whole region of spine from top of shoulder blades to first sacral vertebra 
‡ Chronic LBP (back pain > leg pain), whose condition was ineffective on NSAID 
Patients were excluded if they presented with pain radiating into the leg or other body sites§, or findings of sensory loss of severe motor deficits on neurological 
examination|| 
** Samples based on surveys rather than clinical settings 
†† Supported by Pfizer 
‡‡ Supported by Johnson & Johnson 
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1.4.2.2 Characteristics and prognosis of neuropathic pain in LBP patients 
Neuropathic LBP was not associated with either female or male sex (El Sissi et al. 2010, 
Enthoven et al. 2013, Freynhagen et al. 2006b, Hassan et al. 2004, Kaki et al. 2005, Kew 
et al. 2017). There was evidence of inconsistent findings about age in LBP patients with 
neuropathic pain. Three studies reported no difference in age between patients with 
and without neuropathic pain (Enthoven et al. 2013, Freynhagen et al. 2006b, Kew et 
al. 2017) whereas older age was associated with neuropathic pain in two studies (Kaki 
et al. 2005, Hassan et al. 2004). Smoking was not strongly associated with neuropathic 
pain in LBP (Hassan et al. 2004, Kaki et al. 2005, El Sissi et al. 2010).  
Patients with neuropathic LBP were more likely to report more severe pain 
(Freynhagen et al. 2006a, Kew et al. 2017), higher disability, higher levels of anxiety 
and depression (Freynhagen et al. 2006a, Schmidt et al. 2009, Kew et al. 2017) 
compared to those without. There was conflicting evidence that patients with 
neuropathic LBP present with more co-morbidities compared to those without (El Sissi 
et al. 2010, Hassan et al. 2004, Kew et al. 2017). Disc prolapse and spinal stenosis were 
associated with more features characteristic of neuropathic pain than nociceptive pain 
(Kaki et al. 2005, El Sissi et al. 2010), and degenerative disc disease was unlikely to be 
associated with neuropathic pain features in LBP (El Sissi et al. 2010). Neuropathic pain 
was associated with the presence of leg pain (Kew et al. 2017) in LBP patients 
compared to those without, and commonly, patients with neuropathic pain had below 
the knee pain (Enthoven et al. 2013, Kew et al. 2017).  
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One study of 30, elderly LBP patients with and without neuropathic pain (Sakai et al. 
2015) reported on the effectiveness of the neuropathic pain medication Pregabalin 
over a four week period. In this study, both patients with and without neuropathic 
pain improved over time in terms of back pain intensity. However, overall there was no 
evidence of prognostic factors research in LBP patients with neuropathic pain. 
1.5 Low back-related leg pain 
Section 1.4 highlights the low prevalence of neuropathic pain in patients with LBP 
alone and shows that LBP patients with neuropathic pain present with more severe 
pain and higher LBP-related disability, compared to those without. Neuropathic pain 
was reported to be associated with pain location and patients with neuropathic pain 
commonly presented with LBLP. Compared to LBLP, LBP without leg pain is most likely 
assumed to be nociceptive whereas LBLP may be neuropathic, and some patients 
present with neurological signs and symptoms in the legs (Hartvigsen et al. 2018).  
About two thirds of patients with LBP, in both primary and secondary care settings, 
present with leg pain (Hill et al. 2011a, Kongsted et al. 2012). Patients with LBLP suffer 
with higher pain, disability and poorer quality of life compared to those patients with 
LBP alone (Konstantinou et al. 2013). LBLP is considered an obstacle to recovery 
(Burton et al. 1995, Cherkin et al. 1996, Shaw et al. 2001) or a marker of severity (Hill 
et al. 2011a), the further the pain radiates down the leg, the greater the likelihood of 
increased disability and health care use (Selim et al. 1998, BenDebba et al. 2000, Hicks 
et al. 2008).  
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LBLP can be clinically diagnosed as either referred or radicular in nature, where 
radicular pain is understood to be caused by compression or irritation of a lumbar 
spinal nerve root for any reason, and referred leg pain may be due to pain from any 
other lumbar spinal tissue than the nerve root (Bogduk 2009) (the reader is referred to 
section 1.1.5 (page 7) for a report and an example of referred pain). Radicular pain 
refers to the symptom of pain that arises from one or more of the nerve roots. The 
terms “radicular pain” and “nerve root pain”, are not synonymous with 
“radiculopathy”. It is common for patients with radiculopathy to have radicular pain, 
but the term “radiculopathy” refers to a complex of symptoms of neurological deficit, 
pain and sensory characteristics that are concurrent with neuropathic pain (Wolff and 
Levine 2002). In LBLP, sciatica is the most common term used in the literature to 
denote lumbar radicular pain with or without evidence of radiculopathy (Konstantinou 
and Dunn 2008). Recent guidelines use the term sciatica for describing radicular pain 
(NICE NG59 2016) and for consistency the term sciatica will be used throughout this 
thesis.  
The mechanisms underlying sciatica are assumed to be neuropathic as the pain is 
arising from involvement of a nerve root, whereas the mechanisms underlying referred 
leg pain are assumed to be nociceptive in nature (Merskey and Bogduk 1994). Sciatica 
is classically described in textbooks as a narrow band of lancinating pain travelling 
down the back of the lower limb (Bogduk 2009) and referred leg pain as dull, aching 
pain in an ill-defined distribution (Cohen and Mao 2014) but without any features of 
neural involvement. Classification by dichotomising LBLP into either referred leg pain 
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or sciatica may provide simplicity but the clinical reality is that patients rarely present 
with clear presentation of either sciatica or referred leg pain (Murphy et al. 2009). It is 
likely that there is considerable overlap between both clinical features and 
mechanisms underpinning sciatica and referred leg pain.  
1.6 Summary 
This chapter has presented an overview of current knowledge about nociceptive and 
neuropathic pain mechanisms, including a discussion of the role of sensitisation and 
referred pain. The chapter highlights the complexity of identifying cases of neuropathic 
pain in clinical practice and in epidemiological research. An outline is provided on the 
role of prognosis research and the use of primary care as a setting in this thesis. 
Furthermore, this chapter has presented the epidemiology of neuropathic pain in its 
broadest context and more specifically in patients with LBP. As discussed in this 
chapter, previous research has shown that LBP patients with neuropathic pain present 
with more severe pain and LBP-related disability compared to those without but 
evidence on prognosis was limited. This chapter presented the distinct differences in 
the underlying pain mechanisms between LBP and LBLP. The following chapter 
presents the rationale, aims, objectives and outline of the research in this thesis. 
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Chapter Two. Rationale, aims and objectives 
This chapter provides the rationale, the aims and objectives of the research in this 
thesis and concludes with an outline of the contents of the subsequent chapters in this 
thesis.  
2.1 Thesis rationale 
The previous chapter highlighted that patients with neuropathic LBP seem to present 
with higher levels of pain severity and pain related disability than those LBP patients 
without. The chapter also highlighted inconsistencies in the literature and a large 
variation in prevalence estimates, in part this may be because the LBP population is 
broadly defined and heterogeneous in nature. This thesis focuses on a subgroup of 
LBP, those patients with LBLP because it is leg pain that is thought to be caused by 
neuropathic pain mechanisms, whereas the mechanisms underlying LBP alone (also 
called axial back pain) are more likely to be nociceptive. LBLP is common and is 
associated with increased pain, disability and poorer quality of life compared to LBP 
alone and for this reason there is an argument that LBLP patients should be considered 
as distinct for research purposes (Coggon et al. 2016). Not all LBLP is thought to be 
neuropathic, LBLP is clinically diagnosed as having sciatica or referred leg pain, where 
sciatica is thought to be neuropathic and referred leg pain to be nociceptive. There is 
evidence that in clinical practice, the mechanisms underlying LBLP are not clearly 
delineated, it is not clear what proportion of LBLP patients do have neuropathic pain 
and although it is not known with certainty, it is widely thought that these patients 
with neuropathic pain do worse over time compared to those without. Understanding 
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the pain mechanisms underlying back pain presentations such as LBLP is an 
internationally agreed research priority (Costa Lda et al. 2013). 
In some key areas of musculoskeletal pain research, there has been a move away from 
considering all pain patients as the same or a ‘one size fits all approach’ and towards 
stratified care that develops and tests ways to better match patients to treatment 
(Foster et al. 2013). There are specific treatments (principally medications) available to 
patients with neuropathic pain in primary care and neuropathic pain medications are 
advocated for patients with sciatica. In the background literature review presented in 
Chapter 1, published research reports that despite the availability of specific 
medications, patients with neuropathic pain are often under-treated. In part, under-
treatment may be because detecting neuropathic pain with reasonable certainty is 
difficult in clinical practice, the causal mechanisms are complex and there is no gold 
standard for identifying cases of neuropathic pain. Despite difficulties in identifying 
patients with neuropathic pain there is some agreement that cases can be identified 
by clinical history and examination and by using validated neuropathic case 
ascertainment tools. This agreement is important because identifying cases is a 
necessary starting point in the epidemiological research of patients with neuropathic 
pain. Understanding the prevalence, characteristics, clinical course, factors 
contributing to the prognosis of, and pain medication use in LBLP patients with 
neuropathic pain may help to inform patients and clinicians of the likely nature of the 
pain and inform future research leading to the provision of timely, targeted 
treatments.  
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2.2 Aims and Objectives 
The overall aim of the research in this thesis is to investigate the epidemiology, in 
terms of the prevalence, baseline characteristics, clinical course, factors contributing 
to the prognosis of, and the pain medication use in LBLP patients with neuropathic 
pain who consult with their general practitioner (GP) in primary care.  
2.2.1 Objectives  
The specific objectives of this thesis are: 
1. To systematically review the literature on the prevalence, clinical course and 
prognosis of LBLP patients with neuropathic pain in primary care.  
2. To provide point prevalence estimates of neuropathic pain in a primary care 
population. 
3. Describe the characteristics of LBLP primary care patients with neuropathic 
pain compared to those without. 
4. To compare the clinical course of LBLP patients with neuropathic pain at 
baseline compared to those without.  
5. To describe the change in neuropathic pain over time in LBLP patients with and 
without neuropathic pain at baseline. 
6. To investigate the overall prognosis of LBLP patients with neuropathic pain, in 
terms of clinical course and exploratory prognostic factor research. 
7. To describe the pain medications prescribed in primary care to LBLP patients 
with neuropathic pain, and to identify patients with refractory neuropathic 
pain. 
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2.3 Outline  
This thesis is divided into the following ten chapters: Introduction, rationale, aims and 
objectives, systematic review,  study design and methods, prevalence and baseline 
characteristics, clinical course, change in the presence of neuropathic pain, prognosis 
of LBLP patients with persistent neuropathic pain, pain medication use and discussion 
and conclusions (Figure 2.1 illustrates the structure of this thesis). Chapters 5 to 9 
provide a report of the epidemiological analysis carried out for this thesis, the research 
in Chapter 5 reports on findings from research using cross-sectional data and the 
research in Chapters 6 to 9 report on findings from research using longitudinal data. 
The series of analyses in Chapter 5 (prevalence and baseline characteristics), 6 (clinical 
course) and 8 (prognosis of LBLP patients with neuropathic pain) was linear, with the 
conclusions of the preceding chapter informing the next. The descriptive analysis in 
Chapter 7 (change in the presence of neuropathic pain) was completed concurrently to 
that in Chapters 5 and 6, the findings of Chapter 7 also informed the analysis in 
Chapter 8. Electronic prescribing records from participating general practices were 
prepared and coding was generated to identify pain medications in Chapter 9 
(prescribing patterns of pain medication) concurrent to research in preceding chapters, 
with findings of analyses in earlier chapters informing the analysis plan in this chapter. 
Finally, Chapter 10 presents the combined findings and implications of this series of 
analyses. Figure 2.2 below provides a brief outline of each chapter.  
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Figure 2.1 Flow diagram summarising thesis structure  
 
  
Chapter 10. Discussion and conclusions 
Chapter 9. Prescribing patterns of pain medication 
Chapter 8. Prognosis of patients with neuropathic pain 
Chapter 7. Change in the presence of neuropathic pain  
Chapter 6. Clinical course 
Chapter 5. Prevalence and characteristics 
Chapter 4: Design and methods 
  
Chapter 3: Systematic review 
Chapter 2: Rationale, aims and objectives 
Chapter 1: Introduction 
Shaded boxes highlight research based on epidemiological analysis of a prospective cohort of LBLP 
patients consulting in primary care. 
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 Figure 2.2 Outline of chapters in this thesis  
   
The current chapter.  
The background context for the research in this thesis were discussed in 
Chapter One.  
1. Introduction 
2. Rationale, aims and objectives 
This chapter uses systematic review methods to collate and synthesise 
the previously published research describing the epidemiology of 
neuropathic pain in LBLP patients in settings that were primary care or 
in any setting that seemed to be the first point of contact for these 
patients 
3. Systematic review 
This chapter provides an outline of the design and methods used to 
answer the research aims in this thesis. The research in Chapters 5 to 9 
in this thesis are based on data collected from an prospective, 
observational, treatment cohort based in primary care and this chapter 
provides specific detail on the methods used across all four analysis 
chapters. 
4. Design and methods 
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This chapter describes the prevalence of LBLP patients with neuropathic 
pain and compares the characteristics of patients with and without 
neuropathic pain at baseline. Cases of neuropathic pain in this chapter 
were identified based on two approaches using three definitions. 
5. Prevalence and characteristics 
The research in this chapter compares the clinical course of LBLP patients 
with neuropathic pain at baseline in terms of pain intensity and leg and 
back-related disability over short, intermediate and long-term follow-up 
compared to those without. As with research in the previous chapter, the 
results in this chapter are reported for two approaches and three 
definitions of neuropathic pain.  
6. Clinical course 
This chapter describes the change in the presence of neuropathic pain over 
short, intermediate and long-term follow-up and identifies a sub-group of 
patients with persistent neuropathic pain. Patients with neuropathic pain and 
persistent neuropathic pain were identified based on one approach and 
definition.  
7. Change in the presence of neuropathic pain  
In this chapter, the characteristics and clinical course of patients with persistent 
neuropathic pain compared to those without are investigated. Potential 
prognostic factors are identified and the prognostic value of certain 
characteristics of LBLP patients with neuropathic pain that may be associated 
with the outcome of interest, persistent neuropathic pain are reported in what is 
exploratory prognostic factor research. 
8. Prognosis of patients with neuropathic pain 
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2.4 Summary  
This chapter has presented the rationale, aims and objectives underlying the research 
in this thesis, and an outline and a brief summary of subsequent chapters are 
provided. The following chapter will describe a systematic review of the prevalence, 
characteristics and prognosis of LBLP patients with and without neuropathic pain, 
designed to investigate the current gap in the knowledge base.  
 
In this chapter, a description of the pain medications prescribed in primary 
care to LBLP patients with neuropathic pain (based on two approaches and 
three definitions) is reported. The chapter then describes the proportion of 
LBLP patients with refractory neuropathic pain based on an understanding 
of the results reported in Chapters 6 (clinical course) and 7 (change in the 
presence of neuropathic pain).  
9. Prescribing patterns of pain medication 
This final chapter collates and critically re-examines the findings from each 
element of the analyses presented in this thesis. The implications for future 
research are discussed and suggestions of how this thesis can inform clinical 
practice are provided.  
10. Discussion and conclusions 
Shaded boxes highlight research based on epidemiological analysis of a prospective cohort of 
LBLP patients consulting in primary care. 
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Chapter Three. Neuropathic pain in low back-related leg pain: 
prevalence, characteristics and prognosis. A systematic review of 
the literature.  
3.1 Introduction 
Current pain research has predominantly been conducted in specialist pain centres 
based often in tertiary care. It is likely that populations drawn from these setting are 
systematically different to primary care patients which limits the generalisability of 
these findings to patients who consult in primary care. The prevalence of neuropathic 
pain in LBLP patients remains unclear, as does its clinical course and factors associated 
with its prognosis, especially in primary care. This chapter presents the rationale for, 
methods and findings of a systematic review of observational studies examining the 
prevalence, clinical course and prognostic indicators of neuropathic pain in LBLP 
patients consulting in settings identified as the first point of contact for this 
population, either in primary care or specialist clinics or services. 
3.2 Aims 
The primary aim of this systematic review was to synthesise currently available 
knowledge about the epidemiology of neuropathic pain in patients consulting with 
LBLP. The specific objectives of the review were to collate, critically appraise and 
synthesise the current published evidence on the prevalence, characteristics and 
prognosis of neuropathic pain in LBLP patients who consulted in settings that seemed 
to be the first point of contact for this population. 
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3.3 Methods 
3.3.1 Protocol registration 
A protocol of this systematic review was registered and can be accessed on the 
PROSPERO international prospective register of systematic reviews (through the web 
address http://www.crd.york.ac.uk/PROSPERO/ using the registration number 
CRD42015023388).  
3.3.2 Search strategy 
Electronic databases MEDLINE, EMBASE, CINAHL, AMED, Web of Science Core 
Collection and TRIP were searched from inception of each database to August 2015 
and the search was re-run in January 2018 to identify any new publications as detailed 
in Table 3.1. The search was not restricted to specific languages. The search strategy 
was developed in consultation with information specialists and used all key words and 
MeSH terms to explore the most important key areas: LBLP, neuropathic pain, and 
epidemiology. Appendix A1 presents the full search strategy for all six electronic 
databases. A supplementary search was carried out by bibliography screening and 
citation tracking of included articles (Hayden et al. 2009), relevant systematic reviews 
and original articles of case identification tools (Bennett 2001, Bouhassira et al. 2005, 
Freynhagen et al. 2006a). A search of the grey literature was carried out, seeking 
unpublished research in doctoral theses and from conference proceedings, via the 
internet search engines Google Scholar and OpenGrey.  
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Table 3.1 Details of electronic databases searched 
*All databases were searched in a range of dates, from inception to the date of search
 Initial search 2nd Search 
Database Interface Date of search Date ranges* Interface Date of search Date ranges 
Medline HDAS 28/07/2015 1964 to date of 
search 
OvidSP 02/01/2018 2015 to date of 
2nd search 
CINAHL HDAS 27/07/2015 1981 to date of 
search 
EBSCO 03/01/2018 July 2015 to date 
of 2nd search 
EMBASE OvidSP 03/08/2015 1974 to 2015 
week (30) 
OvidSP 03/01/2018 2015 to date of 
2nd search 
AMED OvidSP 03/08/2015 1985 to 2015 
month (8) 
EBSCO 03/01/2018 August 2015 to 
date of 2nd search 
Web of Science 
Core Collection 
Web of Science 05/08/2015 1970 to date of 
search 
Web of Science 02/01/2018 2015 to date of 
2nd search 
TRIP Tripdatabase.com 05/08/2015 n/a Tripdatabase.com 02/01/2018 n/a 
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3.3.2 Study selection 
Eligibility criteria to assist with study selection were developed for this review, an 
itemised description of the inclusion and exclusion criteria can be found in Table 3.2. 
The study design, participants (for example, the age of the participants), presence or 
absence of pain with neuropathic characteristics, clinical setting in which the study was 
carried out and the study outcomes were all considered for eligibility.  
Table 3.2 Eligibility criteria for study selection 
Published studies were included if they fulfilled any of the following criteria: 
 Cohort study, case control, cross-sectional study designs available as full text 
 Human participants, over 18 years 
 Clearly defined groups of patients with and without neuropathic pain (for 
example, through using neuropathic case ascertainment tools, clinical history 
and clinical examination) 
 Participants with low back-related leg pain 
 Primary care, or clinical settings identified as the first point of contact for 
patients with low back-related leg pain where assessment and treatment of 
the population could be applied in primary care. Including: 
o occupational settings 
o physiotherapy outpatients, general practice, osteopathic or 
chiropractic clinics 
o secondary care 
 Data reporting prevalence or incidence, clinical course of the condition, 
characteristics associated with prognosis of the condition (for example, 
severity of pain, duration of pain, back/leg pain disability) 
Published studies were excluded if they fulfilled any of the following criteria: 
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 Intervention studies (e.g. RCTs), case studies, small case series, systematic 
reviews, guidelines and medical reference 
 Animal subjects 
 Specific neuropathic pain conditions. Including: 
o diabetes, cancer, HIV, multiple sclerosis, Guillain Barre syndrome, 
spinal cord injuries 
 Low back pain patients where related leg pain is not clearly defined  
  Populations with specific back pain conditions. Including: 
o pregnant women, post-surgical patients, ankylosing spondylitis, 
rheumatoid arthritis, lumbar spinal stenosis, herniated discs, failed 
back surgery syndrome, osteoporosis, serious spinal pathology (cauda 
equina, malignancy, fractures, spinal infection) 
 Other settings. Including:  
o Settings where spinal surgery, spinal cord stimulation, caudal epidural 
or facet joint injections or spinal nerve root blocks were carried out 
Abbreviations: HIV, human immunodeficiency virus. RCT, randomised controlled trial. 
 
3.3.3 Data extraction  
All citations identified from the electronic databases were directly imported into an 
online reference management system (Endnote X7.4) and duplicates were removed. 
Eligible studies were selected on title first by one reviewer (SH) at which point citations 
clearly not relevant based on the eligibility criteria were removed. Where there was 
insufficient information in the title, the abstract was retrieved. Screening of titles with 
abstracts was completed by two independent reviewers (SH and SS). Full papers were 
retrieved and assessed if the abstract provided insufficient information. Disagreements 
were resolved by consensus. Two independent reviewers (SH and SS, KK or KD) 
extracted data from eligible papers using a bespoke data extraction form. Collected 
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information included: study name, authors and publication year; publication language; 
study design; study population; sampling methods; definition of LBLP, participant 
characteristics; definition of neuropathic pain; method of case ascertainment for 
neuropathic pain; description of prevalence; characteristics associated with 
neuropathic pain (including characteristics of pain, disability, psychological 
characteristics, quality of life scores, clinical examination and medication use); clinical 
course of condition and factors associated with prognosis. A full copy of the data 
extraction form can be found in Appendix A2. Authors were contacted for further data 
or clarification where required. 
3.3.4 Risk of bias (quality assessment) 
Two quality assessment tools were used in this review (Hoy et al. 2012b, Hayden et al. 
2013). One to appraise the evidence on prevalence (Hoy et al. 2012b) and one to 
appraise the evidence on characteristics and prognosis (Hayden et al. 2013). Hoy et al., 
(2012) developed a tool to assess risk of bias in prevalence studies. This tool includes 
ten specific items, four of which are related to external validity and six related to 
internal validity, with each item rated as being either at low or high risk of bias. In this 
review, in the case where there was insufficient information for a judgement to be 
made for a particular item, the item was assigned as high risk of bias. Each included 
study was then assigned an overall risk of study bias as ‘low’, ‘moderate’ or ‘high’. 
Studies with eight or more items scored as low risk were considered overall to be of 
‘low risk of bias’, those with six to seven items scored as low risk were considered 
overall to be of ‘moderate risk of bias’, and those with five or fewer items scored as 
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low risk were considered overall to be of ‘high risk of bias’. This way of scoring the 
overall risk of bias has been done before by previous systematic reviews (Aminde et al. 
2016, Gupta and Simpson 2015, Usenbo et al. 2015). 
The Quality in Prognosis Study (QUIPS) tool (Hayden et al. 2013) was used to appraise 
individual studies providing data on characteristics and prognosis. This tool 
investigates six domains where there is a risk of bias: study participation; study 
attrition; measurement of prognostic factors; measurement of outcomes; 
measurement of and controlling for confounding variables; statistical analysis and 
reporting. The different domains were assigned as having ‘low’, ‘moderate’, ‘high’ or 
that the reviewer was unsure of the risk of bias, or that the domain was not relevant. 
The study was then assigned as having ‘low’, ‘moderate’ or ‘high’ risk of bias. The 
reviewers were not blinded to authors, institutions, or journal of publication, this was 
applicable for both tools. Disagreements were resolved by discussion and consensus 
between the two reviewers. All studies, regardless of their quality were included for 
critical appraisal and synthesis. 
3.3.5 Data analysis  
For each of the studies identified, data on prevalence, characteristics and prognosis 
were extracted. It was anticipated that studies to be included in this review would 
have considerable variability in participants, in the approaches used to define 
neuropathic pain and in the study settings and that this would make it unlikely that the 
quantitative data from studies could be pooled together into single summary 
estimates. Therefore, a narrative synthesis was anticipated (and subsequently 
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conducted), with textual description of studies and tabulation of results (Deeks et al.). 
An exploration of robustness of the synthesis and an exploration of relationships 
between and within studies formed part of this narrative review.  
3.4 Results 
3.4.1 Studies identified 
The initial search (July/August 2015) of electronic databases yielded 24,948 articles 
(Figure 3.1 shows a flow chart adapted from the PRISMA flow chart (Moher et al. 
2009)). An additional three articles were identified through other sources; two titles 
were retrieved from citation tracking of relevant systematic reviews and of original 
articles of case identification tools, the third title was identified through citation 
tracking of included articles. 88 full text articles were assessed for eligibility, just under 
half (n=41) were excluded because data could not be extracted on LBLP patients or 
because the population were patients with LBLP conditions clearly requiring specialist 
care (for example; failed back surgery syndrome), two articles were excluded because 
the population described consulted in tertiary care centres and were not directly 
comparable to primary care samples (Figure 3.1 summarises all reasons for excluded 
studies). Twelve full text articles from the first search were included in the review, with 
a further three full text articles identified in the 2nd search (Appendix A3 shows a flow 
chart of the 2nd systematic search and study selection). All fifteen included articles 
underwent quality assessment and data extraction. 
  
51 
 
 
  
Figure 3.1. Flow chart of systematic search and study selection (adapted from the PRISMA 
flow chart) (Moher et al., 2009) 
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Titles screened after duplicates removed (n = 18,027) 
Titles and abstracts 
screened (n = 556) 
Records excluded  
(n = 17,471) 
Full-text articles excluded, with reasons (n=76): 
• Neuropathic pain not measured (n=4) 
• Neuropathic pain related to specific health 
condition (n=3) 
• Population not LBP (n=23), or LBLP (n=12), 
or were a specific LBLP population (for 
example, failed back surgery syndrome) 
(n=6) 
• Tertiary care settings (n=2) 
• Outcome not of interest to the study (n=5) 
• Study design not appropriate or not 
available (n=21) 
Full-texts included for 
qualitative synthesis  
(n = 12) 
Full-text articles assessed 
for eligibility (n= 88) 
Records excluded  
(n = 468) 
Records identified through initial database 
searching 
EMBASE 10,853 MEDLINE 6,250 , Web of 
science 5,123, CINAHL 1,449, Trip 984, AMED 
339 (n = 24,948) 
Additional records identified 
through other sources (n = 3) 
Full-texts included for 
qualitative synthesis after 
the 2nd search  
(n = 15) 
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3.4.1.1 Summary of included studies 
A summary of the included studies is presented in Table 3.3. None of the studies 
included in this systematic review directly aimed to estimate prevalence or describe 
the characteristics of LBLP patients with neuropathic pain. However, it was possible to 
extrapolate data to estimate prevalence of neuropathic pain in LBLP patients in ten of 
the studies (Attal et al. 2011, Ouédraogo et al. 2012, Schafer et al. 2011, Walsh et al. 
2012, Morsø et al. 2011, Uher and Bob 2013, Beith et al. 2011, Hüllemann et al. 2017, 
Orita et al. 2016, Gierthmühlen et al. 2017). Eleven studies reported on characteristics 
(Beith et al. 2011, Freynhagen et al. 2008, Morsø et al. 2011, Schafer et al. 2011, 
Tutoglu et al. 2015, Uher and Bob 2013, Walsh and Hall 2009, Smart et al. 2012a, 
Mahn et al. 2011, Defrin et al. 2014, Gierthmühlen et al. 2017), and from the three 
studies that provided longitudinal data, it was possible to derive information on 
prognosis from two studies (Morsø et al. 2011, Hüllemann et al. 2017). A total of 
50,769 patients were included in all 15 studies. The majority (9 out of 15) of samples 
had less than 100 patients, one study had a sample size of 45,457 (Hüllemann et al. 
2017). There was wide variability in the characteristics of the LBLP patient population 
in the included studies, with mixed pain severity and duration, and the classification of 
LBLP by some studies was closely associated with the definition of neuropathic pain. 
Two studies described characteristics of neuropathic pain in LBLP without a 
comparison group relevant to the study (Mahn et al. 2011, Smart et al. 2011), one 
study described characteristics of patients without neuropathic pain who may have 
included LBP patients without leg pain (Gierthmühlen et al. 2017). One study described 
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characteristics with an alternative comparison group (Defrin et al. 2014), neuropathic 
pain in LBLP patients with or without allodynia. These four studies were included in the 
review because of the relevance of the reported characteristics. There was some 
consistency in the age and the proportion of females to males across the studies 
(samples were predominantly female).  
3.4.1.2 Case definition of neuropathic pain 
Neuropathic pain was most commonly identified using case ascertainment tools, either 
in isolation (Beith et al. 2011, Tutoglu et al. 2015, Uher and Bob 2013, Morsø et al. 
2011, Ouédraogo et al. 2012, Hüllemann et al. 2017, Orita et al. 2016) or in addition to 
clinical history and examination (Attal et al. 2011, Schafer et al. 2011, Walsh and Hall 
2009, Gierthmühlen et al. 2017). Three studies (Freynhagen et al. 2008, Defrin et al. 
2014, Mahn et al. 2011) used their definition of LBLP to assume a neuropathic 
component, so all patients in these studies were considered to have neuropathic pain. 
All studies were published since the IASP redefinition and grading system for 
neuropathic pain (Treede et al. 2008) and this was cited by six out of the fifteen studies 
(Attal et al. 2011, Defrin et al. 2014, Freynhagen et al. 2008, Smart et al. 2012a, Schafer 
et al. 2011, Orita et al. 2016). With reference to the IASP grading system, the most 
common working hypothesis of neuropathic pain was ‘probable’ (Attal et al. 2011, 
Freynhagen et al. 2008, Schafer et al. 2011). Three studies defined neuropathic pain 
using a mechanisms based classification, without specific reference to the IASP 
definition (Walsh and Hall 2009, Uher and Bob 2013, Smart et al. 2012a).  One study 
defined neuropathic pain with reference to the original IASP definition of neuropathic 
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pain (‘pain initiated or caused by a primary lesion or dysfunction in the nervous 
system’) (Tutoglu et al. 2015).  
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Table 3.3 Summary of all fifteen studies included in the systematic review  
Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Attal et al. 
(2011b), France 
Cross-
sectional 
Mixed* LBLP > 3 
months 
symptom 
duration and VAS 
≥4/10 (QTSFD† 
groups 2 to 4) 
N = 92 
41% M 
Age: 54 (14) 
Yes DN4 QTSFD group 
4: Probable 
MDT pain clinics or 
rheumatology 
centres 
Beith et al. 
(2011), UK 
Cross-
sectional 
Mixed* LBLP N=227 
(NR)% M 
Age: NR 
Yes PainDETECT Possible Physiotherapy 
referrals in primary 
care and secondary 
care 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Defrin et al. 
(2014), Israel 
Case 
control 
Sciatica > 3 
months with 
radicular pain 
into the leg** 
N = 74 
47%  M 
Age: 66 (NR) 
No 
(neuropathic 
pain in LBLP 
with vs 
without 
allodynia) 
Clinical history 
including imaging 
and 
electrophysiology 
Probable Pain clinic 
Freynhagen et al. 
(2008), Germany 
Case 
control 
Sciatica (chronic 
unilateral leg 
pain) 
Radicular pain: 
N=15 
42% M 
Age: 54 (16) 
Yes Clinical history, 
examination and 
imaging/ 
electrophysiology 
where indicated 
Not defined Pain medicine, 
neurology and 
neurosurgery 
setting 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Pseudoradicular 
pain: N=12, 
44%M 
Age: 52 (16) 
Gierthmühlen et 
al. (2017), 
Germany 
Cross-
sectional 
LBLP > 3 months N=51 (51)%M, Age: 
61 (12) 
Yes Clinical history, 
examination, MRI 
imaging and 
separately 
PainDETECT 
Not defined Department of 
Neurology after 
consulting from 
local medical 
practices or in 
response to an 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
announcement in a 
local newspaper 
Hüllemann et al. 
(2017), 
Germany 
Cross-
sectional 
with 
follow-
up data 
Mixed* LBP, 
categorised into 
4 groups by pain 
location, 3 out of 
4 groups with 
LBLP‡ 
Group 2: N=30,000 
(NR)% M 
Age: 58 (15) 
Group 3: N=12,988 
(NR)% M 
Age: 54 (15) 
Group 2: N=2,469 
No PainDETECT Possible 862 primary care 
outpatient centres 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
(NR)% M 
Age: 54 (15) 
Mahn et al. 
(2011), 
Germany 
Cross-
sectional 
Sciatica ** N=2094 
42% M 
Age: 59 (14) 
No History, clinical 
assessment, leg 
pain worse than 
back pain 
Probable 450 outpatient 
centres (primary 
and secondary 
care) 
Morsø et al. 
(2011), Denmark 
Cross-
sectional 
with 
follow up 
data 
Mixed* LBLP > 3 
months and 
<12months 
N=145 
39% M 
Age: 50 (15) 
Yes PainDETECT Possible Outpatient spine 
centre in 
secondary care 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Orita et al. (2016) Cross-
sectional 
Mixed* LBP, 
categorised into 
by pain location 
Neuropathic: 
N = 737 
(47)%M 
Nociceptive: 
N = 1067 
(48)%M 
Yes Japanese 
neuropathic 
screening 
questionnaire 
Not defined 137 Medical 
institutions 
(orthopaedic 
hospitals, general 
hospitals and 
university 
hospitals) 
Ouédraogo et al. 
(2012), 
Burkina Faso 
Cross-
sectional 
Mixed* LBLP N = 66 
(NR)%M 
Age: NR 
Yes DN4 Not defined Rheumatology, 
neurology and 
neurosurgery 
clinics 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Schafer et al. 
(2011), Germany 
Cross-
section 
al follow 
up data 
Mixed* LBLP > 6  
weeks and NRS 
>3/10 § 
N = 74 
40% M 
Age: 48 (13) 
Yes LANSS and clinical 
assessment to 
determine neural 
related leg pain 
classification 
Not defined MDT pain clinics 
Smart et al. 
(2012a), 
UK & Ireland 
Cross-
sectional 
Mixed* LBP +/- 
leg pain|| 
 
N = 474 
44% M 
Age: 44 (NR) 
No Clinical indicators 
derived from a 
mechanisms based 
classification 
system 
Not defined 4 hospital sites: 
back pain clinics 
(assessments done 
by 
physiotherapists) 
  
62 
 
Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Tutoglu et al. 
(2015), 
Turkey 
Case 
control 
Sciatica (lumbar 
discopathy on 
neuroimaging) 
N=73 
40% M 
Age: for sciatica 
group with 
neuropathic pain: 
53 (10), 
For sciatica group 
without 
neuropathic pain: 
50 (7) 
Yes DN4 Not defined Physical medicine 
and rehabilitation 
outpatient clinic 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
Uher and Bob 
(2013), 
Czech Republic 
Cross-
sectional 
Sciatica (L4, L5 or 
S1 radicular 
syndrome & 
lumbar disc 
herniation or 
foraminal 
stenosis on 
neuroimaging) 
N=66 
42% M 
Age: 58 (NR) 
Yes PainDETECT (Czech 
version) 
Not defined Neurology 
inpatients 
Walsh and Hall 
(2009), 
Ireland 
Cross-
sectional 
Mixed* LBLP§ N=45 
49% M 
Age: 46 (11) 
Yes S-LANSS and clinical 
assessment to 
determine 
Not defined Back pain clinic 
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Study author, 
date and country 
Study 
design 
LBLP Population Population 
(Number in sample, 
proportion of male, 
mean age ((years) 
(standard 
deviation)) 
Comparator 
group: LBLP 
patients with 
vs without 
neuropathic 
pain 
Method of 
measuring 
neuropathic pain 
Grade of 
neuropathic 
pain (Treede 
et al. 2008) 
Setting 
neuropathic related 
leg pain 
Abbreviations: DN4, Doleur Neuropathique en 4. LANSS, Leeds Assessment of Neuropathic Symptoms and Signs. LBLP, low back-related leg pain.  NR, not reported. NRS, 
numerical rating scale. M, male. MDT, multi-disciplinary team. MRI, magnetic resonance imaging. L4, L5, S1, lumbar spinal nerve roots. QTSFD, Quebec task force 
classification of spinal disorder. S-LANSS, Self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs. VAS, visual analogue scale. 
* Mixed LBLP: heterogeneous samples of LBP (where leg pain is clearly defined) or LBLP that include both clinical diagnosis of sciatica and referred leg pain. 
† QTSFD, classified as group 2 to 4: Group 2, pain in the lumbar area with proximal radiation (i.e., to lower limb, but not beyond the knee). Group 3, pain in the lumbar area 
radiating below the knee and no neurological signs. Group 4, pain in the lumbar area radiating towards the foot in a dermatomal distribution, associated with sensory 
deficits or other neurological signs.  
‡ LBLP patients were classified into group 2 to 4. Group 2, pain in the lumbar area radiating to above knee. Group 3, pain in the lumbar region radiating to below knee (but 
not the foot). Group 4, pain in the lumbar region radiating to at least one foot. 
§ Diagnostically classified into one of four groups, neuropathic sensitisation, denervation, peripheral nerve sensitisation or musculoskeletal. 
‖ Diagnostically classified into one of three groups, peripheral neuropathic pain (PNP), central neuropathic pain and nociceptive pain. PNP was made up of 91% LBLP and 9% 
predominant low back pain; central neuropathic and nociceptive pain were predominantly low back pain (61% and 82% respectively). 
** In this study, radicular pain was considered synonymous to neuropathic pain. 
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3.4.2 Prevalence 
3.4.2.1 Quality assessment of prevalence studies 
All ten of the studies providing a prevalence estimate for of neuropathic pain in LBLP 
underwent quality assessment by two independent reviewers using a tool specific to 
risk of bias for prevalence studies (Hoy et al. 2012b). A third independent reviewer was 
necessary to determine the risk of bias of one domain in four of the studies where 
agreement could not be reached by the two reviewers. External validity in the included 
studies was at higher risk of bias (see Table 3.4 for a summary and Appendix A4 for the 
full results of the quality assessment process) for nine out of ten studies compared to 
the domains covering internal validity. Six out of the ten studies were deemed to be of 
moderate risk of bias (Attal et al. 2011, Orita et al. 2016, Ouédraogo et al. 2012, 
Schafer et al. 2011, Uher and Bob 2013, Walsh and Hall 2009), one study was at high 
risk of bias (Gierthmühlen et al. 2017). Further research is likely or very likely to have 
an important impact on the confidence in the prevalence estimate and may also 
change the estimate derived from each of these studies (Hoy et al. 2012b). Three of 
the studies (Beith et al. 2011, Morsø et al. 2011, Hüllemann et al. 2017) were 
considered to be of low risk of bias where further research is very unlikely to change 
the confidence in the reported estimate. 
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3.4.2.2 Prevalence estimates in included studies 
Prevalence estimates were derived from a total of 12,551 patients in the ten studies 
(Table 3.5 summarises the prevalence of neuropathic pain in the studies included in 
this review). None of the studies reported confidence intervals for the prevalence 
estimates and all but two studies (Hüllemann et al. 2017, Orita et al. 2016) utilised 
small samples, one of which was at low risk of bias (Hüllemann et al. 2017). Across the 
studies, the prevalence of neuropathic pain in LBLP varied from 5% to 80%. The 
prevalence of neuropathic pain in LBLP patients varied from 5% in patients with 
referred leg pain who were referred to a neurology department after consulting in a 
primary care setting, or who responded to an announcement in a local newspaper 
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Table 3.4. Summary of quality assessment (described as risk of bias) of 
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(Gierthmühlen et al. 2017), to 80% in a sample of patients with LBLP associated with 
neurological signs who were recruited from either pain clinics or rheumatology 
settings . The prevalence of neuropathic pain in LBLP patients estimated using 
PainDETECT to identify cases of “possible” neuropathic pain, in studies at low risk of 
bias (Hüllemann et al. 2017, Beith et al. 2011, Morsø et al. 2011) ranged from 19% to 
22%. In two studies using used samples that categorised patients in part or entirely 
based on location of pain in the leg (Attal et al. 2011, Hüllemann et al. 2017), 
neuropathic pain was less prevalent in patients with pain above the knee (15% to 20%) 
compared to those with pain below the knee (25% to 80%). The prevalence of 
neuropathic pain was higher in populations of LBLP with sciatica  (Uher and Bob 2013, 
Attal et al. 2011, Gierthmühlen et al. 2017) compared to mixed populations of LBLP 
(i.e., sciatica and referred pain) (for example, (Beith et al. 2011, Morsø et al. 2011, 
Hüllemann et al. 2017)). Not all patients with a clinical diagnosis of sciatica had 
“possible” neuropathic pain based on PainDETECT and a few (5%) diagnosed with 
referred leg pain had a neuropathic type of pain. PainDETECT  (Freynhagen et al. 
2006a) was the most commonly used tool to derive an estimate of prevalence 
(Gierthmühlen et al. 2017, Hüllemann et al. 2017, Morsø et al. 2011, Uher and Bob 
2013, Beith et al. 2011), estimates were no higher than 46% (for patients with chronic 
sciatica) (Uher and Bob 2013). Neuropathic pain in LBLP patients identified using the 
Japanese neuropathic screening questionnaire was highly prevalent (78%) (Orita et al. 
2016), similarly in four out of five patients with a clinical diagnosis of sciatica had 
neuropathic pain as identified using the DN4 (Attal et al. 2011).  
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Table 3.5 Studies showing prevalence of neuropathic pain in LBLP, grouped by method 
of defining neuropathic pain 
Study  Numerator  Denominator (N) Prevalence of 
neuropathic pain 
(%)* 
Clinical examination   
Gierthmühlen 
et al. (2017) 
Clinical diagnosis of 
sciatica and relevant 
findings on MRI 
LBLP (n=51) 37 
DN4    
Attal et al. 
(2011)  
DN4 ≥ 4 LBLP (n=92)  49 
 
QTSFD† group 2 (n=27) 15 
 
QTSFD† group 3 (n=38) 39 
 
QTSFD† group 4 (n=27) 80 
Ouédraogo et 
al. (2012) 
DN4 ≥ 4 LBLP (n=66) 61 
LANSS/ s-LANSS    
Schafer et al. 
(2011) 
  
LANSS ≥12 and clinical 
examination confirming 
neuropathic pain 
LBLP (n=74) 26 
Clinical examination 
confirming neuropathic 
pain but with LANSS <12 
LBLP (n=74) 47 
Walsh and Hall 
(2009)  
S-LANSS ≥12 and clinical 
examination confirming 
neuropathic pain 
LBLP (n=45) 33 
Clinical examination 
confirming neuropathic 
pain but with S-LANSS <12 
LBLP (n=45) 40 
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Study  Numerator  Denominator (N) Prevalence of 
neuropathic pain 
(%)* 
PainDETECT    
Gierthmühlen 
et al. (2017) 
“Possible” neuropathic 
pain component 
Clinical diagnosis of 
sciatica and relevant 
findings on MRI (n=19) 
31 
“Possible” neuropathic 
pain component 
Referred leg pain (n=42) 5 
Hüllemann et 
al. (2017) 
“Possible” neuropathic 
pain component 
LBLP (n=45,457) 22 
“Possible” neuropathic 
pain component 
Group 2, pain in the 
lumbar area radiating to 
above knee (n=30,000) 
20 
“Possible” neuropathic 
pain component 
Group 3, pain in the 
lumbar region radiating to 
below knee (but not the 
foot) (n=12,988) 
25 
“Possible” neuropathic 
pain component 
Group 4, pain in the 
lumbar region radiating to 
at least one foot (n=2,469) 
34 
Morsø et al. 
(2011) 
“Possible” neuropathic 
pain component 
LBLP (n=145) 19 
“Uncertain” neuropathic 
pain classification  
LBLP (n=145) 26 
Uher and Bob 
(2013)  
“Possible” neuropathic 
pain component 
Acute and sub-acute 
sciatica (n=40) 
43 
“Uncertain” neuropathic 
pain classification 
Acute and sub-acute 
sciatica (n=40) 
28 
“Possible” neuropathic 
pain component 
Chronic sciatica (n=26) 46 
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Study  Numerator  Denominator (N) Prevalence of 
neuropathic pain 
(%)* 
“Uncertain” neuropathic 
pain classification 
Chronic sciatica (n=26) 27 
Beith et al. 
(2011) 
 
“Possible” neuropathic 
pain component 
LBLP (n=227) 23 
“Uncertain” neuropathic 
pain classification 
LBLP (n=227) 27 
Japanese neuropathic screening questionnaire 
Orita et al. 
(2016) 
Highly likely, or likely to 
have a neuropathic pain 
component (score ≥4) 
LBLP (n=1804) 78 
Abbreviations: DN4, Doleur Neuropathique en 4 (Bouhassira et al. 2005). Japanese neuropathic 
screening questionnaire (Ogawa 2010). LANSS, Leeds Assessment of Neuropathic Symptoms and Signs 
(Bennett 2001). LBLP, Low back-related leg pain. PainDETECT (Freynhagen et al. 2006a). QTSFD, Quebec 
task force classification of spinal disorder. S-LANSS, Self-report version of the Leeds Assessment of 
Neuropathic Symptoms and Signs (Bennett et al., 2005). 
* The denominator is total number (N) of LBLP in the sample.  
† QTSFD, classified as group 2 to 4: Group 2, pain in the lumbar area with proximal radiation (i.e., to 
lower limb, but not beyond the knee). Group 3, pain in the lumbar area radiating below the knee and no 
neurological signs. Group 4, pain in the lumbar area radiating towards the foot in a dermatomal 
distribution, associated with sensory deficits or other neurological signs. 
 
3.4.3 Characteristics  
3.4.3.1 Quality assessment of studies describing characteristics and prognosis 
Twelve of the included studies underwent quality assessment using the QUIPs tool, by 
two independent reviewers. A third independent reviewer was necessary to determine 
the risk of bias of three domains in two of the studies where agreement could not be 
reached by the two reviewers. Table 3.6 summarises the risk of bias for each of the 
domains of the QUIPS tool (Hayden et al. 2013) (see Appendix A4 for the full results of 
the quality assessment process for studies reporting characteristics and prognosis). 
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Four of the included studies were considered by two independent reviewers to be of 
low risk of bias (Gierthmühlen et al. 2017, Mahn et al. 2011, Schafer et al. 2011, Walsh 
and Hall 2009) and eight studies were considered to be of moderate risk of bias (Beith 
et al. 2011, Defrin et al. 2014, Freynhagen et al. 2008, Hüllemann et al. 2017, Morsø et 
al. 2011, Smart et al. 2011, Tutoglu et al. 2015, Uher and Bob 2013).  
  
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Study participation
Study Attrition
Prognostic Factor
Outcome
Confounding factor
Analysis
Overall risk of bias
Table 3.6. Summary of quality assessment (described as risk of bias) of the eleven 
included studies used to describe characteristics and prognosis
High
Low
Moderate
Unsure or Not relevant
Risk of bias: 
% of included studies 
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3.4.3.2 Characteristics of neuropathic pain in included studies 
Eleven studies described characteristics of neuropathic pain in LBLP, of which eight 
studies compared LBLP patients with neuropathic pain to LBLP patients with non-
neuropathic pain (Beith et al. 2011, Freynhagen et al. 2008, Morsø et al. 2011, Smart et 
al. 2011, Tutoglu et al. 2015, Uher and Bob 2013, Schafer et al. 2011, Walsh and Hall 
2009) or LBP patients with or without leg pain (Gierthmühlen et al. 2017). The 
characteristics of neuropathic pain in LBLP are summarised in Table 3.7 and described 
in more detail in the following section, in terms of pain characteristics (for example 
pain location in the leg), clinical examination findings, LBLP-related disability, 
psychological characteristics, health related quality of life and medication use. 
3.4.3.2.1 Pain characteristics  
3.4.3.2.1.1 Pain intensity 
Six of the included studies described the association of pain intensity and neuropathic 
pain in LBLP (Freynhagen et al. 2008, Schafer et al. 2011, Smart et al. 2012a, Walsh and 
Hall 2009, Gierthmühlen et al. 2017). Visual analogue scales or numerical rating scales 
were used to determine pain intensity in all of the studies. Pain intensity was reported 
to be more severe in LBLP patients with neuropathic pain in all but two studies 
(Freynhagen et al. 2008, Walsh and Hall 2009). Only one study provided information 
on pain intensity in both the leg and the back (Morsø et al. 2011).  
3.4.3.2.1.2 Pain duration and pain location 
Four of the included studies reported on pain duration (Defrin et al. 2014, Schafer et 
al. 2011, Smart et al. 2012a, Gierthmühlen et al. 2017) and four reported on pain 
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location (Beith et al. 2011, Schafer et al. 2011, Smart et al. 2012a, Freynhagen et al. 
2008). Both duration and location will be described in turn below. Two studies 
reported pain duration in LBLP patients with neuropathic pain in comparison to those 
without (Gierthmühlen et al. 2017, Schafer et al. 2011), neither study reported any 
difference between the two groups. The majority of patients in each of the four studies 
reported pain duration for at least three months, and in many instances pain duration 
was over one-year, but it is not clear whether this is as a result of sampling methods or 
whether it is a feature of neuropathic pain. With respect to pain location, from the 
results of the four studies included in this review, it is likely that LBLP patients with 
neuropathic pain present with pain below the knee, but it is also likely that LBLP 
patients with non-neuropathic pain may also present with pain below the knee. 
Although the location of pain in the leg appears to be a sensitive indicator of 
neuropathic pain, it does not seem that pain below the knee is a specific indicator of 
neuropathic pain in LBLP patients.  
3.4.3.2.2 LBLP-related disability 
Four studies compared LBLP-related disability (Morsø et al. 2011, Schafer et al. 2011, 
Walsh and Hall 2009, Gierthmühlen et al. 2017) between patients with components of 
neuropathic pain and those without. Two of the studies (Schafer et al. 2011, Smart et 
al. 2011) used the LBP specific Roland-Morris Disability Questionnaire (RMDQ) (Roland 
and Morris 1983), one study (Walsh and Hall 2009) used the Oswestry Disability Index 
(ODI) (Fairbank et al. 1980) and one used the Hannover Functional Ability 
Questionnaire (FFbH-R) (Kohlmann and Raspe 1994). In all but one study 
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(Gierthmühlen et al. 2017), LBLP participants with neuropathic pain reported 
significantly higher levels of disability compared to participants with non-neuropathic 
pain. In one of the studies, the difference between groups was also clinically important 
difference (Morsø et al., 2011). In the study by Gierthmühlen et al. (2017) a similar 
proportion of patients with and without neuropathic pain had LBLP-related disability 
but this may be a function of the small sample size (n=51). 
3.4.3.2.3 Psychological variables 
3.4.3.2.3.1 Depression 
Seven studies reported on depression in neuropathic LBLP, using several different 
measurement tools. Four of the included studies used the depression subscale of the 
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith 1983) (Schafer et 
al. 2011, Smart et al. 2012a, Walsh and Hall 2009, Gierthmühlen et al. 2017), two 
studies used the Beck Depression Inventory (Beck 1970) (Tutoglu et al. 2015, Uher and 
Bob 2013), the remaining study (Mahn et al. 2011) used the Patient Health 
Questionnaire (Lowe et al. 2004). Moderate to severe depression was reported in 42% 
of LBLP patients with neuropathic pain (Mahn et al. 2011). Neuropathic LBLP was 
associated with more severe depression compared to non-neuropathic LBLP in studies 
where neuropathic pain was defined using a case ascertainment tool (Tutoglu et al. 
2015, Uher and Bob 2013). Whether LBLP patients with neuropathic pain had more 
severe depression was not conclusive across all studies, in three studies with low risk 
of bias, Walsh and Hall (2009), Schafer et al (2011) and Gierthmühlen et al (2017) 
reported no differences in depression severity in LBLP patients with and without 
neuropathic pain, all three studies defined neuropathic pain based on clinical 
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examination. Evidence on depression in patients with neuropathic pain compared to 
those without is inconsistent amongst the studies included in this systematic review. 
3.4.3.2.3.2 Anxiety 
Anxiety levels were reported by six of the included studies. HADS was used to record 
anxiety by four of the five included studies (Schafer et al. 2011, Smart et al. 2012a, 
Walsh and Hall 2009, Gierthmühlen et al. 2017), the Beck anxiety inventory (Beck et al. 
1988) was used by one study (Tutoglu et al. 2015) and the Zung self-rating anxiety 
scale (Zung 1971) was used by Uher et al., (2013). Three of the studies were of low risk 
of bias (Gierthmühlen et al. 2017, Schafer et al. 2011, Walsh and Hall 2009). Three of 
the studies reported more severe anxiety in LBLP patients with neuropathic pain 
compared to non-neuropathic pain (Schafer et al. 2011, Tutoglu et al. 2015, Uher and 
Bob 2013) and two studies found no difference in anxiety levels between LBLP with 
and without neuropathic pain (Walsh and Hall 2009, Gierthmühlen et al. 2017). 
Despite Schafer et al (2011) reporting that LBLP patients with neuropathic pain had 
more severe anxiety compared to patients without neuropathic pain, the clinical levels 
of anxiety in the whole cohort was low, and patients with neuropathic pain reported 
only mild levels of anxiety. Normal to mild levels of anxiety were also found in the 
cohorts reported by Walsh and Hall (2009) and Smart et al., (2011), in the study by 
Gierthmühlen et al (2017) a third of patients (4 out of 12) with neuropathic pain were 
considered to have possible anxiety. From studies with low risk of bias, there is 
inconsistent evidence that patients with neuropathic pain report higher levels of 
anxiety compared to those without and this in part, may be due to small samples.  
  
76 
 
3.4.3.2.3.3 Fear avoidance 
Fear avoidance measured using the Fear avoidance beliefs questionnaire (FABQ) 
(Waddell et al. 1993) was reported by two of the included studies (Schafer et al. 2011, 
Walsh and Hall 2009). Neither study reported any significant differences in the work 
subscale of the FABQ, but Walsh and Hall (2009) reported significant differences in the 
physical activity subscale between LBLP groups with and without neuropathic pain.  
3.4.3.2.3.4 Sense of coherence, suppression and alexithymia 
Sense of coherence (Antonovsky 1993), alexithymia (Parker et al. 2003) and 
suppression (Hasenbring et al. 1994) were psychological characteristics reported in 
addition to depression, anxiety and fear avoidance for LBLP patients with neuropathic 
pain, using validated scales. Morsø et al. (2011) reported that LBLP patients had 
significantly lower sense of coherence (a high sense of coherence assists a patient with 
coping) if they presented with underlying neuropathic pain compared to patients with 
non-neuropathic pain. The same study also reported those patients with LBLP and 
neuropathic pain are more likely to be depressed suppressors compared to those 
without neuropathic pain. Suppression is a cognitive coping strategy whereby the 
patient suppresses the perception of pain in order to continue with daily activities, but 
suppression itself leads to emotional distress. Alexithymia, which describes one’s 
trouble understanding and communicating how one feels, was associated with more 
severe symptoms in LBLP patients with neuropathic pain, compared to LBLP patients 
with both ambiguous pain and non-neuropathic pain (Uher and Bob 2013). Overall, it is 
difficult to make any clear conclusions whether these psychological characteristics are 
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features of neuropathic pain, or that they might be due to the differences in the 
samples used in the studies.  
3.4.3.2.4 Health related quality of life 
Four of the included studies reported on aspects of quality of life and general health, 
including sleep. Findings on health related quality of life and sleep will be described in 
turn below. The short form (SF-36) health survey (Ware 2000) and the shorter version 
(SF-12) health survey were used to report on quality of life by two studies (Tutoglu et 
al. 2015, Gierthmühlen et al. 2017). Morsø et al (2011) used a numerical rating scale 
(0-10) for participants to self-report general health. Two out of the three studies, both 
with moderate risk of bias, reported that general health in LBLP patients with 
neuropathic pain was worse than those with non-neuropathic pain (Morsø et al. 2011, 
Tutoglu et al. 2015). Two studies (Mahn et al. 2011, Gierthmühlen et al. 2017) reported 
on sleep using the Medical Outcome Study sleep scale (Hays et al. 2005). The study by 
Mahn et al (2011) reported that sleep was optimal in 37.1% of LBLP patients with 
neuropathic pain and patients with neuropathic pain commonly reported sleep 
disturbance and somnolence. It is not clear whether sleep is any more disturbed in 
LBLP with neuropathic pain compared to those patients without neuropathic pain. 
3.4.3.2.5 Neurological examination  
Two of the included studies (Freynhagen et al., 2008, Defrin et al., 2014) used 
quantitative sensory testing (QST) to determine the presence or absence of any 
sensory signs associated with neuropathic pain. One study reported the presence of 
sensory symptoms (burning pain, prickling pain, allodynia, numbness, pain attacks, 
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light pressure pain and spontaneous pain) derived from self- in patients defined as 
having neuropathic pain based on clinical examination report (Gierthmühlen et al. 
2017). Freynhagen et al., (2008) also reported the clinical characteristics of patients 
clinically diagnosed with either radicular (which they considered synonymous to 
neuropathic pain) or pseudoradicular pain.  
When using QST as an extension of normal neurological examination, LBLP patients 
clinically assessed to have non-neuropathic pain were as likely to have sensory changes 
as LBLP patients who were clinically assessed to have neuropathic pain (Freynhagen et 
al. 2008). Characteristics of neurological examination based on the study by 
Freynhagen et al. (2008) suggest that it is likely that more patients with neuropathic 
pain have sensory deficits and changes in straight leg raise, but that the presence of 
sensory symptoms may not be a specific indicator of neuropathic pain (Gierthmühlen 
et al. 2017, Freynhagen et al. 2008).  
The study by Defrin et al (2014), based on findings from QST, reported that the 
majority of LBLP patients with neuropathic pain were found to have allodynia on the 
symptomatic leg but the presence of allodynia did not significantly affect the intensity 
of self-reported leg pain (base on a numerical rating scale (NRS)). The findings of the 
study by Defrin et al., (2014) are without comparison to a non-neuropathic group but 
as with the findings by Freynhagen et al., (2008) they provide a description of findings 
from the clinical examination of LBLP patients with neuropathic pain.  
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3.4.3.2.6 Pain medications 
Three of the included studies reported on medication use of LBLP patients with 
neuropathic pain. Two out of three studies, both at moderate risk of bias, reported 
that patients with neuropathic pain more commonly used pain medications compared 
to those without (Morsø et al. 2011, Freynhagen et al. 2008) and there was some 
evidence that patients with neuropathic pain used stronger pain medications more 
often (Freynhagen et al. 2008). In one study at low risk of bias, there was no difference 
in the current pain medications used by patients with and without neuropathic pain 
(Gierthmühlen et al. 2017). There was inconsistent evidence of pain medication use by 
patients with neuropathic pain compared to those without and it is not clear from 
these studies whether medication use is a feature of neuropathic pain or as a result of 
the sampling methods used. 
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Table 3.7 Studies showing characteristics of neuropathic pain  
Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
Pain intensity (Freynhagen 
et al. 2008)  
 
NRS 0 to 10 (unspecified 
whether for back or leg) 
Mean 6.4 (SD 1.8) Mean 5.3 (SD 2.3) 0.19 
(Morsø et al. 
2011)  
 
NRS 0 to 10 leg pain 
 
Leg pain median 8.0, IQR 5.3 
to 8.0 
 
Leg pain median 4.0, IQR 1.0 
to 6.0 
0.012 
NRS 0 to 10 back pain Back pain median 7.0, IQR 
5.0 to 8.8 
Back pain median 6.0, IQR 
4.0 to 7.0 
0.000 
(Schafer et al. 
2011)  
 
NRS 0 to 10 (unspecified 
whether back or leg) 
Neuropathic sensitisation 
mean 5.8 (SD 1.7); 
peripheral nerve 
sensitisation mean 5.3 (SD 
Mean 4.6 (SD 1.4) 0.031 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
1.7); denervation mean 4.6 
(SD 1.5) 
(Tutoglu et al. 
2015)  
 
VAS 0 to 10 (unspecified 
whether back or leg) 
Mean 8.0 (SD 1.6) Mean 6.6 (SD 3.4)  0.033 
(Walsh and 
Hall 2009)  
 
VAS 0 to 10  (unspecified 
whether back or leg) 
Neuropathic sensitisation 
mean 6 (SD 3); peripheral 
nerve sensitisation mean 7 
(SD 2); denervation mean 6 
(SD 3)  
Mean 5 (SD 3) 0.23 
 
(Gierthmühlen 
et al. 2017) 
NRS 0 to 10 (unspecified 
whether for back or leg)  
 
Mean 5.6 (SD 1.5) Mean 4.0 (2.5) <0.05 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
Pain location (Beith et al. 
2011)  
% reporting pain below the 
knee 
79% of LBLP patients with 
possible neuropathic pain, 
74% of LBLP with uncertain 
pain 
57%  n/a 
(Freynhagen 
et al. 2008)   
 
% reporting pain in the leg Radiating pain below the 
knee: in S1 dermatomal 
distribution 25%, in L5 
dermatomal distribution 
50%, to L4 17%, to L4 & L5 
8% 
Radiating pain to the gluteal 
region or thigh (but not 
below knee) 100% 
n/a 
(Schafer et al. 
2011)  
 
% reporting pain below knee Neuropathic sensitisation 
80.0%, peripheral nerve 
sensitisation 88.9%, 
denervation 71.4% 
73.7% 0.71 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
(Smart et al. 
2012a)  
Predominant pain location Back 9%, back/thigh 19%, 
unilateral leg pain below 
knee 59%, back and 
unilateral leg pain below 
knee 11%, bilateral leg pain 
below knee 1% 
n/a n/a 
Pain duration (Defrin et al. 
2014) * 
Years With allodynia mean 5.7  (SD 
5.6) 
Without allodynia mean 2.7  
(SD 2.9) 
n/a n/a 
(Schafer et al. 
2011)  
 
Current episode (months)  Neuropathic sensitisation 
mean 7.0 (SD 18.4); 
peripheral nerve 
sensitisation mean 6.0 (SD 
Mean 10.6 (SD 12.2) 0.76 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
12.5); denervation mean 7.3 
(SD 11.3) 
(Smart et al. 
2012a)  
Current episode 0 to 12 weeks (34%), 4 to 12 
months (43%), 1 year and 
over (23%) 
n/a n/a 
(Gierthmühlen 
et al. 2017) 
 Unknown n=7 (13.7%) 
¼ to 1 year n=9 (17.5%) 
>1 to 2 years n=3 (5.9%) 
>5 to 10 years n=4 (21.1%) 
More than 10 years n=17 
(33.3%) 
Unknown n=0 (0%) 
¼ to 1 year n=7 (21.9%) 
>1 to 2 years n=2 (6.3%) 
>5 to 10 years n=7 (21.9%) 
More than 10 years n=14 
(43.8%) 
 
ns 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
LBLP-related disability (Morsø et al. 
2011)  
 
RMDQ (0 to 23 NRS) Median 18, IQR 14 to 20  Median 10, IQR 7 to 15 0.000 
(Schafer et al. 
2011)  
RMDQ (0 to 24 NRS) Neuropathic sensitisation 
mean 10.5 (SD 4.0); 
peripheral nerve 
sensitisation mean 5.3 (SD 
1.7); denervation mean 8.7 
(SD 4.5)  
Mean 6.5 (SD 3.3) 0.014 
(Gierthmühlen 
et al., 2017) 
FFbH-R Normal (80-100%): n=2 
(16.7%) 
Moderate (60-79%): n=6 
(50.0%) 
Normal (80-100%): n=11 
(35.5%) 
Moderate (60-79%): n=9 
(29.0%) 
ns 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
Relevant impairment (< 
60%): 4 (33.4%) 
Relevant impairment (< 
60%): 11 (35.5%) 
(Walsh and 
Hall 2009) 
ODI† 
 
Neuropathic sensitisation 
mean 37 (SD 5); peripheral 
nerve sensitisation mean 52 
(SD 17); denervation mean 
32 (SD 10) 
 
Mean 30 (SD 10) 0.001 
Psychological 
characteristics 
(depression) 
(Mahn et al. 
2011)* 
PH9 None (23%), mild (35%), 
moderate (37%), severe 
(5%). 
n/a n/a 
 
(Schafer et al. 
2011)  
HADS§  Neuropathic sensitisation 
mean 9.1 (SD 4.6); 
peripheral nerve 
sensitisation mean 4.9 (SD 
Mean 7.2 (SD 4.0) 0.37 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
2.5); denervation mean 5.6 
(SD 3.6) 
(Smart et al. 
2012a)  
HADS§  Mean 7.0 (SD 4.4) n/a n/a 
(Tutoglu et al. 
2015) 
BDI‡ Mean 20.9 (SD 12.4) Mean 5.9 (SD 5.4) <0.001 
(Uher and Bob 
2013)  
BDI-II‡ Neuropathic pain group 
mean 14.4 (SD 9.2); 
ambiguous pain mean 12.9 
(SD 7.6) 
Mean 9.3 (SD 5.0) <0.01 
(Walsh and 
Hall 2009)  
HADS§ Neuropathic sensitisation 
mean 7 (SD 4); peripheral 
nerve sensitisation mean 8 
Mean 5 (SD 3) 0.12 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
(SD 4); denervation mean 5 
(SD 3) 
(Gierthmühlen 
et al., 2017) 
HADS§ Mean 5.0 (SD 4.5) 
Score ≥ 8: n=2 (16.7%)  
Mean 6.3 (SD 4.0) 
Score ≥ 8: n=10 (33.3%) 
 
ns 
ns 
Psychological 
characteristics 
(anxiety) 
(Schafer et al. 
2011)  
HADS§ Neuropathic sensitisation 
mean 9.1 (SD 4.6); 
peripheral nerve 
sensitisation mean 4.9 (SD 
2.5); denervation mean 5.6 
(SD 3.6) 
Mean 7.2 (SD 4.0) 0.013 
 
(Smart et al. 
2012a)  
HADS§ Mean 7.5 (SD 4.4) n/a n/a 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
(Tutoglu et al. 
2015)  
BAI‡ Mean 10.2 (SD 10.8) Mean 3.1 (SD 3.7) <0.001 
(Uher and Bob 
2013)  
SAS|| Neuropathic pain  mean 
42.9 (SD 8.5); ambiguous 
pain mean 39.2 (SD 7.3) 
Mean 35.8 (SD 8.5) <0.01 
(Walsh and 
Hall 2009)  
HADS§ Neuropathic sensitisation 
mean 9 (SD 4); peripheral 
nerve sensitisation mean 10 
(4); denervation mean 7 (SD 
3) 
Mean 7 (SD 2) 0.14 
(Gierthmühlen 
et al., 2017) 
HADS§ Mean 5.7 (SD 4.9) 
Score ≥ 8: n=4 (33.3%)  
 
Mean 7.0 (SD 4.2) 
Score ≥ 8: n=15 (50.0%) 
ns 
ns 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
Psychological 
characteristics (fear 
avoidance) 
(Schafer et al. 
2011)  
FABQ** Neuropathic sensitisation 
mean 39.1 (SD 19.1); 
peripheral nerve 
sensitisation mean 36.4 (SD 
18.8); denervation mean 
34.3 (SD 19.0) 
Mean 29.8 (SD 21.2) 0.51 
 
(Walsh and 
Hall 2009)  
FABQ** - Physical activity Neuropathic sensitisation 
mean 16 (SD 3); peripheral 
nerve sensitisation mean 20 
(SD 4); denervation mean 12 
(SD 5) 
Mean 18 (SD 3) 0.001 
(Walsh and 
Hall 2009)  
FABQ** - Work Neuropathic sensitisation 
mean 22 (SD 11); peripheral 
nerve sensitisation mean 21 
 Mean 22 (SD 13) 0.99 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
(SD 11); denervation mean 
21 (SD 13) 
Health related quality 
of life 
(Morsø et al. 
2011)  
Self-rated general health (0-
10) 
Median 2, IQR 1 to 3 Median 3, IQR 2 to 4 0.001 
 
(Tutoglu et al. 
2015)  
 SF-36†† physical function  
(NRS 0 to 100) 
Mean 44.3 (SD 26.3)  Mean 77.7 (SD 24.7) <0.001 
   SF-36†† physical role Mean 31.9 (SD 40.8) Mean 56.8 (SD 43.2) <0.001 
  SF-36†† emotional role Mean 35.2 (SD 42.9) Mean 64.0 (SD 42.6) <0.001 
  SF-36†† social function Mean 36.7 (SD 42.9) Mean 53.7 (SD 18.1) <0.001 
  SF-36†† mental health Mean 47.2 (SD 13.5) Mean 55.1 (SD 11.6) <0.001 
  SF-36†† energy/vitality Mean 36.8 (SD 19.1) Mean 51.1 (SD 13.4) <0.001 
  SF-36†† pain Mean 37.3 (SD 18.9) Mean 55.0 (SD 22.8) <0.001 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
  SF-36†† general health Mean 36.1 (SD 13.3) Mean 40.8 (SD 10.9) <0.001 
(Gierthmühlen 
et al., 2017) 
State of health (NRS 0 to 
100) 
Mean 63.8 (SD 22.5) Mean 59.5 (SD 18.9)  ns 
  SF-12†† mental health Mean 53.3 (SD 11.5) Mean 45.9 (SD 12.4) ns 
 
 
SF-12†† physical health Mean 34.9 (SD 8.2) 
 
Mean 38.8 (SD 8.7) ns 
Health related quality 
of life (sleep) 
(Mahn et al. 
2011) *  
 
 MOS sleep scale 
†† 
Disturbance mean 45 (SD 
25), somnolence mean 40 
(SD 22), sleep adequacy 
mean 51 (SD 28). Optimal 
sleep 37% 
n/a n/a 
(Gierthmühlen 
et al., 2017) 
MOS sleep scale 
†† 
Disturbance mean 42.4 (SD 
20.6), somnolence mean 
43.1 (SD 20.5), sleep 
Disturbance mean 40.1 (SD 
21.8), somnolence mean 
41.5 (SD 21.9), sleep 
ns 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
adequacy mean 61.4 (SD 
22.5)  
adequacy mean 62.6 (SD 
22.5) 
Items from 
neurological 
examination 
(Freynhagen 
et al. 2008)  
 
Clinical examination  Positive neural tension tests 
(proportion of sample, 42%), 
positive straight leg raise 
(50%), reflex deficit (25%), 
sensory deficit (58%), motor 
deficit (25%) 
 
Positive straight leg raise 
(proportion of sample, 13%), 
sensory deficit (20%) 
n/a 
Pain descriptors (Mahn et al. 
2011) * 
Self-reported neuropathic 
characteristics 
Burning (25%), prickling 
(26%), allodynia (10%), 
attacks (32%), thermal 
induced pain (8%), 
numbness (16%), pressure 
induced pain (21%) 
n/a n/a 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
 (Gierthmühlen 
et al., 2017) 
Burning pain Back, n=7 (36.8%), leg, n=10 
(52.6%) 
n=3 (9.4%) <0.05 
 Prickling pain Back n=11 (57.9%), leg, n=15 
(78.9%) 
n=7 (21.9%)  <0.01 
 Self-reported allodynia  Back, n=7 (36.8%), leg, n=3 
(15.8%) 
n=2 (6.3%) <0.01 
 Self-reported numbness  Back, n=13 (68.4%), leg, 
n=13 (68.4%) 
n=3 (9.4%) <0.05 
 Pain attacks Back, n=10 (52.6%), leg, n=8 
(42.1%) 
n=17 (53.1%) ns 
 Light pressure pain Back, n=12 (63.2%), leg, n=8 
(31.6%) 
n=14 (43.8%) ns 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
 
 
Spontaneous pain Back, n=13 (68.4%), leg, 
n=11 (57.9%) 
n=9 (28.1%) <0.01 
Pain medication  (Gierthmühlen 
et al., 2017) 
Current pain medication  NSAID n=24 (47.1%) 
Weak opioids n=0 (0%) 
Antidepressants and/or 
anticonvulsants n=1 (2%) 
None n=15 (29.4%) 
NSAID n=17 (53.1%) 
Weak opioids n=0 (0%) 
Antidepressants and/or 
anticonvulsants n=1 (3.1%) 
None n=11 (34.4%) 
ns 
 (Freynhagen 
et al. 2008) 
Current pain medication NSAID or Cox-2 n=6 (50%) 
Weak or strong opioids n=10 
(83.3%) 
Antidepressants and/or 
anticonvulsants n=5 (41.7%) 
NSAID or Cox-2 n=8 (53.3%) 
Weak or strong Opioids n=2 
(13.3%) 
Antidepressants and/or 
anticonvulsants n=1 (6.7%) 
n/a 
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Characteristic 
associated with 
neuropathic pain 
Study Outcome measure used LBLP patients with 
neuropathic pain 
LBLP with non-neuropathic 
pain 
Reported 
P 
Skeletal muscle relaxant n=0 
(0%) 
None n=0 (0%) 
Skeletal muscle relaxant n=2 
(13.3%) 
None n=6 (40%) 
 (Morsø et al. 
2011) 
Taking pain medication  n=21 (75%) n=40 (52%) 0.025 
Abbreviations: BAI, Beck anxiety inventory. BDI, Beck depression inventory. BDI-II, Beck depression inventory (Czech version). Cox-2, Cox-2 inhibitor FABQ, Fear avoidance 
beliefs questionnaire. FFbH-R, Hannover Functional Ability Questionnaire. IQR, interquartile range. LBLP, low back-related leg pain. MOS, Medical outcome study.  n/a, not 
applicable. Ns, non-significant.  NRS, numerical rating scale. NSAID, non-steroidal anti-inflammatory drug. ODI, Oswestry Disability Index. PH9, patient health questionnaire. 
RMDQ, Roland Morris Disability Questionnaire. SAS, Zung self-rating anxiety scale (Czech version). SD, standard deviation. SF-36, the Short Form (36) Health Survey. TAS-20, 
Toronto alexithymia scale (Czech version) where alexithymia is defined as being functionally unaware of your emotions. VAS, visual analogue scale. 
* Characteristics derived from case control studies and the reported associations are for LBLP patients with neuropathic pain only. 
† ODI is a 10 item scale using a 0 to 5 Likert scale, and is reported as a %.  
‡ BAI, BDI and BDI-II consist of 21 items, using a 0 to 3 Likhert scale with a maximum possible score of 63.   
§ HADS consists of two (one for anxiety, one for depression) scales with 7 items, using 0 to 3 Likhert scale, with a maximum possible score of 21 on each scale.  
|| SAS consists of 20 items, using 1 to 4 Likhert scale, the score ranges from 20 to 80. 
** FABQ is comprised of a physical activity component (total score of 24, 4 items) and a work component (total score of 42, 7 items).  
†† Each item of SF-12, SF-36 and the MOS Sleep scale is scored on a 0 to 100 scale, higher scores indicate greater disability. 
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3.4.4 Prognosis 
Three studies reported longitudinal data (Morsø et al. 2011, Schafer et al. 2011, 
Hüllemann et al. 2017), one of which described overall prognosis (clinical course) 
(Morsø et al. 2011) and one described the change in the presence of neuropathic pain 
over time (Hüllemann et al. 2017). None of the three studies provided any evidence of 
prognostic factors of neuropathic pain in LBLP. Each of the studies are described in 
turn below.  
Schafer et al. (2011) reported on patient outcomes following treatment, patients were 
clinically assessed to have neuropathic LBLP, both with and without neuropathic 
characteristics (patients were classified into one of three neuropathic pain groups, 
neuropathic sensitisation, denervation, peripheral nerve sensitisation and one non-
neuropathic pain group, musculoskeletal). They reported that the greatest 
improvement in outcomes was in LBLP patients with peripheral nerve sensitisation, 
and the least improvement in LBLP patients with neuropathic sensitisation. A number 
of potential limitations were acknowledged by the authors (Schafer et al. 2011): short 
follow-up time (mean duration of treatment varied from 25 days to 33 days), lack of 
control group, and a large proportion of ineligible patients.  
Morsø et al. (2011) followed up LBLP patients at three and twelve months (outcomes 
were back and leg pain intensity, leg and back-related disability and self-reported 
general health) and showed that for both patient groups (with neuropathic and 
without neuropathic pain) most outcomes improved over time (see Table 3.8 for a 
summary of the study by Morsø et al. (2011)). At three and twelve months, LBLP 
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patients with neuropathic pain remained worse compared to those with non-
neuropathic pain in all outcomes except back pain intensity.  
Hüllemann et al. (2017) followed up LBLP patients with pain duration less than three 
months at baseline, who re-attended three to twelve months after their initial visit. 
Patients with pain duration at baseline greater than three months who re-attended on 
two occasions (three to twelve months and twelve to 24-months) after their initial visit 
were also followed up. In patients who re-attended and had complete observations at 
each time point, mean neuropathic pain (based on PainDETECT) was reported and did 
not change over time (see Table 3.9 for a summary of this study). The domains relating 
to confounding and attrition for the study by Hüllemann et al (2017) were assessed to 
be at high risk of bias (see Appendix A4) (the overall risk of bias was moderate) 
because very few patients were followed up and it is likely that patients who re-
attended were different to those who did not, further research is likely to change the 
estimate provided by this study.
  
99 
 
Table 3.8 Study by Morsø et al. (2011) showing overall prognosis* of neuropathic pain in low back-related leg pain (n=145) 
Outcome LBLP patients with neuropathic pain* 
 
LBLP patients with non-neuropathic pain* Difference in median values 
between patients with and 
without neuropathic pain§ 
Base
-line 
3 months 12 months Base-
line 
3 months 12 months Base-
line 
3 
months 
12 
months 
Med Med P Med P Med Med P Med P P P P 
Back pain intensity  
(NRS 0-10) 
7.0 5.2 0.011 4.3 0.001 6.0 4.0 0.002 4.8 0.003 0.012 0.054 0.214 
Leg pain intensity 
(NRS 0-10) 
8.0 6.0 0.007 4.0 0.002 4.0 2.3 0.023 1.7 0.032 >0.001 0.001 0.022 
LBLP-related 
disability  
(RMDQ 0-23) 
17.5 14.0 0.016 13.5 0.008 10.0 9.0 0.001 5.0 >0.001 >0.001 >0.001 0.009 
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Outcome LBLP patients with neuropathic pain* 
 
LBLP patients with non-neuropathic pain* Difference in median values 
between patients with and 
without neuropathic pain§ 
Base
-line 
3 months 12 months Base-
line 
3 months 12 months Base-
line 
3 
months 
12 
months 
Med Med P Med P Med Med P Med P P P P 
Self-reported 
general health† 
2.0 3.0 0.072 3.0 0.012 3.0 4.0 >0.001 4.0 0.004 0.001 0.010 0.033 
Abbreviations: Med, Median value, NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire. * using results obtained through personal communication 
with the author †PainDETECT was used to ascertain neuropathic pain status ‡ Self-reported general health was rated on a 7 point Likert scale where “unbearable” was 
scored as 0 and “excellent” as 7. § Differences in median values are shown as reported P value
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Table 3.9 Study by Hüllemann et al. (2017) showing change in the presence of neuropathic pain in low back-related leg pain  
 PainDETECT* scores at baseline  
Baseline Follow-up at  3 to 12 
months 
Follow-up at 12 to 24 
months 
n Mean (SD) Mean (SD) P Mean (SD) P 
Patients with pain duration < 3 months† 
Pain radiating to above knee (group 2) 86 11.3 (6.4) 11.1 (6.4) 0.85 - - 
Pain radiating to below knee (but not the foot) (group 3) 48 13.3 (6.7) 13.5 (6.7) 0.90 - - 
Pain radiating to at least one foot (group 4) 19 14.1 (7.8) 10.6 (7.8) 0.08 - - 
Patients with pain duration > 3 months‡ 
Pain radiating to above knee (group 2) 267 13.4 (6.7) 13.6 (6.8) 0.61 13.7 (6.3) 0.51 
Pain radiating to below knee (but not the foot) (group 3) 173 14.9 (6.2) 15.4 (6.3) 0.27 14.7 (6.6) 0.70 
Pain radiating to at least one foot (group 4) 51 15.0 (7.4) 16.0 (5.8) 0.20 14.8 (6.3) 0.79 
Abbreviations: n, count. SD, standard deviation of mean. * PainDETECT was used to ascertain neuropathic pain status, a score of ≤ 12 indicates a neuropathic component is 
likely, a score of 13 to 18 indicates a neuropathic component may be present and a score ≥ 19 indicates a neuropathic component is likely. †Patients with complete data for 
baseline and at the 1st follow-up were analysed. ‡Patients with pain who had complete data for baseline and 2 follow-up visits were analysed. 
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3.5 Discussion 
This is the first systematic review to look at the prevalence, characteristics and 
prognosis of neuropathic pain in LBLP. Heterogeneity of the included studies 
prevented meta-analysis, but comparisons between studies and settings were still 
possible in relation to study quality, strengths and weaknesses and study design. 
3.5.1 Prevalence 
In this systematic review, prevalence estimates were extrapolated from data from ten 
studies that were based in either primary care or in clinical settings that patients could 
feasibly have accessed directly as first contact care, and therefore the population 
samples were considered to be similar. Overall prevalence estimates reported in this 
systematic review varied widely (5% to 80%). There was some consistency for the 
prevalence of “possible” neuropathic LBLP, based on PainDETECT, which was reported 
between 19% and 22%. This is not the first review to report variation in prevalence 
estimates, variation is reported in reviews of neuropathic pain populations in the 
general population (irrespective of clinical condition) (van Hecke et al. 2014) and in 
populations seeking care for non-specific LBP (Hush and Marcuzzi 2012, Fishbain et al. 
2014). Variation in the reported neuropathic pain prevalence estimates in this 
systematic review is likely in part to be a function of the patient sample in each study, 
as the majority of included studies had small sample sizes and the uncertainty around 
the prevalence estimate from each study remains unknown as the studies did not 
report confidence intervals. Another reason for variation is likely to be due to the 
methods used by each study for defining neuropathic pain cases. 
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Variation in prevalence due to differences in the case ascertainment tools is 
reasonable to consider (van Hecke et al. 2014). In a study included in this review, 
Walsh and Hall (2009) reported prevalence of 33% (15 out of 45 patients) using s-
LANSS but in a different study using the same cohort (both studies were conducted at 
the same time), a prevalence of 42% (19 out of 45 patients) was reported when using 
the DN4. The later study by Walsh et al. (2012) demonstrates that case ascertainment 
tools may identify different patients due to subtle differences in the tools’ questions 
and the presence or absence of clinical examination tests within each tool 
(VanDenKerkhof et al. 2015). Identification of LBLP subgroups on the basis of the 
presence or absence of neuropathic characteristics is supported by previous research 
in patients with LBLP and other neuropathic pain conditions such as painful diabetic 
neuropathy and post-herpetic neuralgia (Baron et al. 2012). The results of this 
systematic review show that LBLP patients with sciatica show higher prevalence of 
neuropathic pain than those samples with mixed cases of sciatica and referred leg 
pain, but not all patients with sciatica have neuropathic pain, whereas some patients 
have referred leg pain which is neuropathic. These results support the argument for 
the presence of distinct subgroups of LBLP patients with neuropathic pain. It is 
important to determine whether those LBLP patients with neuropathic pain present 
with worse morbidity compared to those without. 
3.5.2 Characteristics and prognosis 
The included studies in this systematic review reported some consistent evidence for 
more severe pain intensity in LBLP patients with neuropathic pain. In part, this is 
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consistent with the literature on the wider group of patients with neuropathic LBP, 
(Freynhagen et al. 2006b, Kew et al. 2017) but it is not clear whether LBLP patients 
with neuropathic pain report more severe leg or back pain, or both. Eight of the 
studies included in this review, albeit at moderate risk of bias, found that LBLP patients 
with neuropathic pain reported more severe back and leg pain related disability, 
health related quality of life, pain intensity, depression and anxiety than those without 
neuropathic pain. The three remaining studies (Schafer et al. 2011, Walsh and Hall 
2009, Gierthmühlen et al. 2017), assessed to be of low risk of bias, reported fewer 
differences in pain duration, LBLP-related disability, depression, anxiety, and health 
related quality of life between patients with and without neuropathic pain. Unlike the 
other included studies, these three used clinical assessment to identify cases of 
neuropathic pain in LBLP patients. In clinical practice, especially in settings such as 
primary care, the use of case ascertainment tools is rare and neuropathic pain is more 
commonly defined using clinical history and examination. All three studies, had small 
samples and it may be argued they lacked the power to detect any differences in 
characteristics between groups. Gierthmühlen et al. (2017) used a comparator group 
that may have included LBP patients with or without leg pain, and as LBP patients 
without leg pain report less pain-related morbidity (Konstantinou et al. 2013), this may 
have inflated differences between subgroups. Comparison to a wider group of LBP by 
Gierthmühlen et al. (2017) adds confidence in the finding that LBLP patients with 
neuropathic pain based on clinical diagnosis present with fewer differences in LBP-
related morbidity compared to those cases defined by case ascertainment tools.  
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Individual components from history taking (pain location) and neurological clinical 
examination were reported in a number of studies included in this review. In five of 
the studies (Beith et al. 2011, Freynhagen et al. 2008, Smart et al. 2011, Schafer et al. 
2011, Gierthmühlen et al. 2017), pain below the knee was associated with neuropathic 
pain, but not all patients with neuropathic pain had below knee pain. This finding, that 
individual components of clinical history and examination (pain location, neurological 
findings) are not specific indicators of neuropathic pain, is supported by the wider 
literature on LBP patients with neuropathic pain. Freynhagen et al (2008) and 
Gierthmühlen et al (2017) reported that patients with non-neuropathic pain have 
sensory deficits and positive findings on neural tension tests. The finding that 
neurological signs and deficits might not be exclusive to patients with neuropathic pain 
is supported by who reported that patients with neuropathic characteristics were 
more typical of sciatica patients but neuropathic characteristics were not restricted to 
patients clinically diagnosed with sciatica. Conversely, a subgroup of patients with a 
clinical diagnosis of sciatica have no features of neuropathic pain (Mahn et al. 2011, 
Walsh and Hall 2009, Schafer et al. 2011), and patients with referred leg pain may have 
features of pain that is neuropathic. The underlying mechanism of LBLP is thought to 
be mixed, where neuropathic and nociceptive mechanisms coexist, but in some 
circumstances inflammatory mechanisms can produce similar characteristics to 
neuropathic mechanisms (for example, pain attacks and allodynia). The results of this 
review suggest that there may be subgroups of LBLP patients with or without 
neuropathic pain but it is not clear whether these subgroups differ in their future 
clinical outcomes or in their response to targeted treatments. 
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Two of the three identified studies with longitudinal data described prognosis in LBLP 
patients with neuropathic pain (Morsø et al. 2011, Hüllemann et al. 2017). Morsø et al 
(2011) found that both patients with and without neuropathic characteristics 
improved over time, but that LBLP patients with neuropathic characteristics improved 
to a lesser extent in terms of disability, pain and self-reported general health, 
compared to those without neuropathic pain. Hüllemann et al 2017 reported that the 
presence of neuropathic pain in LBLP did not change over time in patients who re-
attended a pain clinic although confidence in this result is low as it was likely that the 
patients who attended a follow-up appointment were different to those who did not. 
Morsø et al (2011) did not report whether LBLP may change from a neuropathic state 
to non-neuropathic and vice versa, and neither study investigated prognostic factors 
associated with recovery/non-recovery in terms of pain or disability, in LBLP patients 
with neuropathic pain.  
It is physiologically feasible that underlying nociceptive stimuli causing LBLP, for 
example degeneration of an intervertebral disc, over time may involve microscopic 
nerve fibres (Baron et al. 2016). This involvement may lead to secondary lesions of the 
nerve fibres and give rise to neuropathic signs and symptoms in patients who initially 
presented with nociceptive pain. Conversely, neuropathic pain is often assumed to 
persist but there is a lack of empirical evidence to fully understand whether patients 
who initially present with neuropathic pain continue to have signs and symptoms of 
neuropathic pain over time. Prognostic research offers the opportunity for clinicians 
and patients to understand what is likely to happen to pain and other symptoms, in 
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the future. The apparent absence of prognostic research in LBLP patients with 
neuropathic pain highlights a gap in the literature warranting future research. 
This systematic review shows low levels of agreement on the characteristics of LBLP 
with neuropathic pain derived from cross-sectional studies, and it highlights a gap in 
the evidence in the description of these patients in primary care. Cross-sectional 
studies can provide valid evidence of associations for stable characteristics, such as 
gender. In the context of this systematic review, depression and anxiety is, in some 
studies, associated with neuropathic pain in LBLP patients, but depression is also linked 
to the number of pain locations (Gerrits et al. 2014). It is not clear from this systematic 
review whether LBLP patients with neuropathic pain have higher levels of depression 
or anxiety or whether this is a spurious finding confounded by the number of pain 
locations. One of the key weaknesses of cross-sectional data is that they do not offer 
any temporal relationship and thus prognosis can only be derived from longitudinal 
research. Identifying subgroups of LBLP patients with or without neuropathic pain and 
investigating the prognosis of these patients is important in order to describe and 
understand the likelihood of different outcomes (Croft et al. 2015). 
3.5.3 Strengths and weaknesses 
This review used a comprehensive systematic approach that was applied throughout 
the study. An exhaustive search strategy was developed and six search engines 
searched, additional searches and citation tracking was also executed, however some 
supporting evidence may have been missed, for example, studies not published as full 
text or unpublished student studies. An important strength of this review is the use of 
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two quality assessment tools, one for prevalence studies and one for the studies on 
characteristics and prognosis of neuropathic pain in LBLP. 
3.5.4 Implications for research and clinical practice 
This systematic review highlights the need for high quality research to describe the 
epidemiology of neuropathic pain in LBLP patients in primary care. There is a clear gap 
in the evidence of both cross-sectional description of baseline characteristics as well as 
the prognosis of neuropathic pain in this patient population. It is important to 
determine whether the prognosis of these different groups of LBLP patients differ over 
time to inform both clinicians and LBLP patients.  
3.6 Conclusions 
A comprehensive search of the literature and systematic review was carried out on the 
epidemiology of neuropathic pain in LBLP in primary care, looking at specific objectives 
on prevalence, characteristics and prognosis. A number of studies were identified that 
described prevalence and characteristics, two studies described prognosis. Prevalence 
of neuropathic LBLP based on PainDETECT was estimated to be between 19 and 22%, 
otherwise there was a wide variation in prevalence estimates (5% to 80%). There was 
some evidence of higher levels of morbidity in LBLP patients with neuropathic pain 
compared to those without, and evidence that there may be subgroups of LBLP 
patients with and without neuropathic pain in both those clinically diagnosed with 
sciatica or referred leg pain. Limitations in the available literature have been identified 
and discussed, and applying the findings of this review to current clinical practice in 
primary care and in settings similar to primary care should be done with caution. 
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Future research investigating the prognosis of LBLP patients with and without 
neuropathic pain is likely to inform patients of likely course over time and will inform 
decision making in clinical practice. The subsequent chapter reports on the methods 
and study design used to investigate the epidemiology of neuropathic pain in this 
patient population.  
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Chapter Four. Study design and methods  
4.1 Introduction  
This Chapter outlines the design and methods used in research in the subsequent 
chapters (Chapters 5 to 9) of this thesis. All of the analyses in the research in this thesis 
are based on data from a prospective cohort, the Assessment and Treatment of Leg 
pain Associated with the Spine (ATLAS), led by researchers at Keele University in the 
UK. A detailed report is provided on the population of interest, LBLP patients 
consulting in primary care, including a report on the inclusion criteria of the study, the 
methods used for data collection and a description is provided on the clinical 
management of patients in the ATLAS study. The definitions of neuropathic pain and 
selected characteristics used in research in this thesis are given and are followed by a 
description of the study sample, a report on the response to follow-up and an account 
on how missing data is dealt within this thesis is provided.  
4.2 Data source 
ATLAS was a prospective, observational, multi-centred cohort of LBLP patients who 
consulted and were treated in primary care. The reader is referred to Konstantinou et 
al. (2012a) for the protocol of the ATLAS study, a brief summary of the study is 
provided below. 
4.3 Population of interest 
Patients aged 18 years and over who consulted with their general practitioner (GP) 
with LBLP, in practices in North Staffordshire and Stoke-on-Trent, were invited to take 
part in the ATLAS study. Patients were considered to have LBLP if they presented with 
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leg pain of any duration that spread from the back beyond the gluteal fold to 
anywhere in the leg. Pain was considered to include unpleasant sensations such as pins 
and needles or numbness. Patients were excluded from ATLAS if there was suspected 
serious spinal pathology, previous spinal surgery, pregnancy, they were receiving 
physiotherapy treatment (or osteopathy, chiropractic) or were under the care of a 
secondary care consultant for the same condition, and those with serious physical or 
mental co-morbidity that would prevent them attending the research clinic or undergo 
the study’s procedures, or inability to read and speak English.  
4.4 Recruitment procedure and data collection 
Participants were recruited to the ATLAS study between April 2011 and March 2013. 
Potentially eligible patients were identified at consultation with their GP by the use of 
Read codes (Hassey et al. 2001). Identified participants were sent information about 
the study and were invited to telephone the research centre to find out more about 
the study and to make an appointment at the ATLAS research clinic (a LBLP clinic set in 
the community). Appointments were offered within 10 working days of participants 
contacting the research centre; a participant information sheet and a study 
questionnaire were sent to the participant at this point. At the ATLAS research clinic, 
all patients were screened for potential eligibility by a study nurse and informed 
consent was gained if the patient wished to be included in the study. Consent to 
review patients’ medical records was also requested. Full eligibility was determined by 
a full clinical examination by one of the study’s physiotherapists. The recruitment 
procedures and flow of patients who were eligible and consented to join the ATLAS 
  
114 
 
study is summarised in Figure 4.1, for further details of the recruitment procedure the 
reader is directed to the study protocol (Konstantinou et al. 2012a).  
Data were collected at baseline at three follow-up points: four months, twelve months 
and three years. At the twelve month follow-up point patients were asked for consent 
to be contacted again at three years. At each follow-up point data were collected using 
postal self-complete questionnaires. Reminders were sent to non-responders at each 
point. Electronic prescribing and consulting records for consenting study participants 
were obtained as part of medical record information from the GP practices 
participating in the ATLAS study for the period of four months before the time of 
attending the first appointment at the ATLAS research clinic and three years after. All 
patients in the ATLAS study were invited for a magnetic resonance imaging (MRI) scan 
within 10 days of attending an assessment at the ATLAS research clinic, except in cases 
where the test was contraindicated or when an MRI scan was already available in the 
previous six-months for the same clinical presentation (further details on the reporting 
of MRI scans in ATLAS is provided in section 4.9.7 (page 132).  
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Figure 4.1 ATLAS study flow diagram (adapted from Konstantinou et al. (2015)) 
   
Four month follow-up (n=402)  
Missing follow-up (s-LANSS) (9%, 
n=26) 
Invitations sent (n=2087) 
Patient records imported (n=2087) 
Appointments made (n=1367) 
Appointments attended (n=1310)  
Eligible and consenting (n=614) 
In study n=609 (5 exclusions due to 
serious pathology on MRI) 
9% (n=55) did not undergo MRI 
Twelve month follow-up (n=451)  
Missing follow-up (s-LANSS) (23%, 
n=102) 
Permission given for further contact 
at three years (n= 301) 
Three year follow-up (n=293)  
Missing follow-up (s-LANSS) (9%, n=25) 
No appointment made (n=720), 
Invited patients did not contact 
research centre (n=641), clinic 
refusals (n=41), pre-clinic 
ineligibles (n=38) 
Patient medical records available to 
review (MRR) (n=574) 
 
Not consenting (n=2), unable to link 
MRR data to ATLAS (n=2), GP surgeries 
not participating (n=13), no data 
available (n=23) 
Not interested (n=356), not consenting 
(n=47), ineligible (n=293) 
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4.5 Clinical examination  
At the ATLAS research clinic, patients underwent a standardised clinical examination 
by an experienced musculoskeletal physiotherapist to determine full eligibility, 
diagnosis, and decide a treatment plan. All participants in the ATLAS study were 
classified as having sciatica or referred leg pain by clinical diagnosis at the time of the 
clinical examination. Diagnosis was based on the assessor’s clinical judgement.  In the 
context of the ATLAS study, the term sciatica is indicative of radicular pain with or 
without neurological deficits. All physiotherapists in the ATLAS study were given 
training in the study’s procedures. Criteria for clinical diagnosis of sciatica and referred 
leg pain were agreed following consensus from a Delphi study involving 
representatives from low back pain disciplines (Konstantinou et al. 2012b). Suggested 
differentiating signs and symptoms between sciatica and referred leg pain described in 
the training manual are summarised in Table 4.1 below. There was fair agreement 
between clinicians when making a diagnosis of sciatica or referred leg pain (Stynes et 
al. 2015). 
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Table 4.1 Differentiating signs and symptoms of sciatica and referred leg pain 
 
 
Sciatica Referred leg pain 
Pain descriptors Sharp-toothache like, 
cramping, tingling, burning 
Deep-dull ache 
Pain distribution Dermatomal distribution 
Leg often worse than back 
Pain often below the knee 
Non dermatomal distribution 
Not often below the knee 
Cough/ sneeze/ 
strain 
Often worse with coughing/ 
sneezing/ straining 
Not effected by coughing/ 
sneezing 
Neurodynamic 
testing 
Often positive 
neurodynamic tests (for 
example, straight leg raise) 
Normal neurodynamic tests 
Neurological testing Variable neurological 
findings 
Normal neurological findings 
 
4.6 Care pathways  
Clinical management of patients in the ATLAS study were agreed a priori and are 
documented in full in the ATLAS protocol ((Konstantinou et al. 2012a), a summary is 
provided below. Patients in the study received clinical management based on current 
best clinical evidence and guidelines within the capacity of local NHS facilities and 
resources. The treatment provided to patients was under the discretion of the treating 
physiotherapist in consultation with the patient. For those patients where 
physiotherapy management was indicated, up to six (on average) treatment sessions 
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(of 30 minutes) were delivered over a six to eight week period. If a patient’s symptoms 
worsened or failed to improve, pathways were in place so that appropriate referrals 
could be made to a specialist spinal services for further assessment and management 
including onward referral to spinal surgeons, pain specialists and rheumatologists. 
Section 4.9.9 provides a detailed report of how the care provided to patients in the 
ATLAS study was recorded in this thesis. 
4.7 Case definitions of neuropathic pain 
The research in this thesis presents results based on two different approaches using 
three definitions of neuropathic pain. For a report on the background to the 
approaches see Chapter 1, section 1.3.1 (page 10).  
4.7.1 Definition based on a case ascertainment tool 
To complete the epidemiological description of neuropathic pain in this patient 
population, the self-report version of Leeds Assessment of Neuropathic Symptoms and 
Signs (s-LANSS) (Bennett et al. 2005) was used. The maximum score for s-LANSS is 24, 
this research used a cut-value of 12 (found to be the optimum cut-value for classifying 
cases of neuropathic pain (Bennett et al. 2005)) to describe patients with “possible” 
neuropathic pain (Smith et al. 2012a, Bennett et al. 2005). Patients with s-LANSS score 
of less than 12 were described non-neuropathic pain. Study participants completed s-
LANSS as part of the baseline health survey questionnaire, four and twelve months 
after baseline and also three years after baseline.  
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4.7.2 Definition based on clinical diagnosis 
Cases of neuropathic pain were also determined by clinical diagnosis. This method of 
determining cases of neuropathic pain was adapted from the NeuPSIG classification 
system first described by Treede et al. (2008) and which was updated by Finnerup et 
al. (2016) (See Figure 1.2 (page 11) for a summary of the NeuPSIG classification). Cases 
of neuropathic pain that could have been described as “unlikely”, “possible” and 
“probable” were identified (see Table 4.2). It was not possible to determine “definite” 
neuropathic pain because areas of sensory abnormality specific to the painful area 
were not recorded in this research. 
Table 4.2 Neuropathic pain definitions based on clinical diagnosis 
Description Diagnostic certainty of 
neuropathic pain  
Clinical diagnosis of sciatica 
Evidence of possible or clear nerve root compression on 
MRI scan 
Probable 
Clinical diagnosis of sciatica 
Without evidence of possible or clear nerve root 
compression on MRI scan 
Possible 
Clinical diagnosis of referred leg pain Unlikely 
Abbreviation: MRI, magnetic resonance imaging 
 
4.8 Data management  
The research summarised in Chapters 5 to 9 of this thesis comprises secondary 
analyses of the ATLAS study data. The majority of data were collected, entered into a 
  
120 
 
database and cleaned prior to the analyses within this secondary research 
commencing. Some data had been recorded, either by clinical examination or self-
report, but had not been entered in the database for the primary analysis, these 
included information on pain medication use at baseline and pain pattern. Therefore, 
data on pain medication use and pain pattern were entered into a Microsoft Excel 
spreadsheet by the thesis researcher. Checks were completed (one in ten) throughout 
data entry and any errors or omissions were identified. Once data cleaning was 
completed, the researcher transferred the data into the statistical software, Stata (see 
section 4.12 (page 149) for a details on the statistical software used in this thesis).  
In preparation for analysis, the thesis researcher visually inspected all variables to 
determine the number of missing observations, to approximate the distribution and to 
identify observations that were erroneously coded. Where indicated variables were re-
coded in preparation for analysis. For descriptive analysis, some continuous variables 
(for example data on anxiety and depression using the Hospital Anxiety and 
Depression Scale (HADS) (see section 4.9.5 (page 128)) were categorised or 
dichotomised based on the optimal cut-off points for the respective tool. Where 
possible, this process was done in accordance with existing literature 
recommendations. The following section (4.9) provides the details of the selected 
variables.  
4.9 Selected characteristics 
The analyses in this thesis are based on understanding the association between 
neuropathic pain and a number of characteristics of interest that were identified from 
  
121 
 
the published literature and were available within the ATLAS dataset. This section gives 
a brief description of each of the characteristics obtained from the self-report 
questionnaires, clinical examination data, MRI and electronic medical records. 
4.9.1 Sociodemographic  
4.9.1.1 Age and sex 
The age (from date of birth) at time of completing the study baseline questionnaire 
and sex of each participant was obtained from self-report; age was reported as a 
continuous variable.  
4.9.1.2 Socio-economic status 
The current job title of each participant, or most recent among those not working, was 
obtained from the baseline questionnaire and was used as a proxy for socio-economic 
status (Office of National Statistics 2010). Socioeconomic status, as determined by job 
title, was collapsed into three main groups: managerial and professional occupations, 
intermediate occupations, routine and manual occupations. This three-class grouping 
is a recognised approach for the examination of social class (Rose and Pevalin 2003). 
Numbers for those who had never worked and the long-term unemployed, were also 
reported. 
4.9.1.3 Smoking status 
Participants were asked if they were a current smoker, the required response been 
either “yes” or “no”. If the participant answered “no”, they were then asked if they 
had ever smoked (the required response was “yes” or “no”). The responses to the two 
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questions were amalgamated and reported as one variable for smoking status 
describing participants who were current smokers, ex-smokers or who had never 
smoked.  
4.9.1.4 Body mass index  
Body mass index (BMI) was calculated as a continuous variable in kilograms per metre2 
(kg/m2).  
4.9.2 Health status 
Biologically plausible characteristics that may be associated with neuropathic pain 
were determined from self-report, these were general health and history of other 
health problems including diabetes, reports of fatigue and sleep difficulties.  
4.9.2.1 General health 
Patients were asked how they perceived their general health, taken from the Short 
Form 36 Health Survey, where self-reported general health is reported as either 
“excellent”, “very good”, “good”, “fair”, or “poor” (Ware 2000). General health was 
reported as four categories, “excellent or very good”, “good”, “fair”, or “poor”. 
4.9.2.2 Co-morbidities 
Co-morbidities were recorded from a list of five possible conditions (chest problems, 
heart problems, hypertension, diabetes, circulation in legs). Comorbidities were 
categorised as “no other health problems”, “one or other health problems”, or “two or 
more health problems”. Painful diabetic neuropathy is a neuropathic condition and the 
  
123 
 
proportion of patients who self-reported diabetes in the sample was presented 
separately.  
4.9.2.3 Fatigue and difficulties with sleep  
Fatigue and difficulties with sleep were taken from a question about the patient’s 
identity with their pain from an adapted version of the Illness Perceptions 
Questionnaire (IPQ-R) (Moss-Morris et al. 2002). Patients were presented with a 
statement, “tell us whether you have experienced either of these symptoms because 
of your back and/ or leg problem: 1) fatigue and 2) sleep difficulties” where the 
required response was either “yes” or “no”. 
4.9.3 Pain characteristics 
Pain intensity, duration, location, pain pattern (constant or intermittent pain) and the 
presence of widespread pain were self-reported and recorded for the purposes of this 
study. Information on pain characteristics (pain intensity, duration, widespread pain) 
were obtained from self-report questionnaires, additional information (pain location 
and pattern) was derived from the clinical examination. 
4.9.3.1 Pain intensity 
At baseline, back pain intensity was determined using a pain index by averaging three 
0 to 10 numerical rating scales for least, current and usual back pain over the previous 
two weeks (Dunn et al. 2010). This question was repeated for baseline leg pain 
intensity and was presented as a distinct characteristic to back pain intensity. At 
follow-up, to determine whether patients continued to have leg pain the following 
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question was presented to patients, “Has the pain from your back spread down your 
leg or legs in the last two weeks?” The required response was either “yes” or “no”. 
Those patients who responded “yes” (and were deemed to be having leg pain at 
follow-up) were then asked to rate their least, current and usual leg pain, as at 
baseline. At follow-up, leg pain intensity and separately, back pain intensity, were 
determined in the same way as at baseline by taking the mean of least, current and 
usual back pain over the previous two weeks. The highest pain intensity was 
determined to be the highest of either mean back pain intensity or mean leg pain 
intensity.  
4.9.3.2 Pain duration 
Information on back pain duration was derived from the question, “Have you had this 
current bout/episode of back pain for….” to which there were seven discrete response 
categories, “less than 2 weeks”, “2 to 6 weeks”, “6 to 12 weeks”, 3 to 6 months”, “7 to 
12 months” and “more than 12 months”. For this study, duration was categorised into 
three groups, less than six weeks, six to twelve weeks and greater than three months. 
The question was repeated for leg pain and presented distinct from back pain 
duration. The response to this question relies on accurate recall of pain duration and 
there is some evidence (Jordan et al. 2006) that self-reported duration of pain is a 
reasonable approach to take in epidemiological surveys.  
4.9.3.3 Widespread pain 
Widespread pain for this research was defined as pain present above and below the 
waist, in the right- and left-hand sides of the body and in the axial skeleton. This 
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satisfies the American College of Rheumatology 1990 criteria for fibromyalgia (Wolfe 
et al. 1990). Widespread pain was derived from a single question. Patients were asked, 
“In the past 4 weeks have you had pain that has lasted for one day or longer in any 
part of your body, other than your back or legs” and they were asked to indicate this 
by shading their painful area on a full body manikin (front and back views). The 
manikin was divided into 44 mutually exclusive areas, and these were recorded by 
using a standard transparent template marked with borders (Lewis et al. 2002). This 
method for detecting widespread pain has previously been used (McBeth et al. 2014) 
and has shown to be valid and reliable (Lacey et al. 2005).  
4.9.3.4 Pain location 
Three characteristics were recorded during clinical examination that described the 
location of pain including the part with worse pain: presence of pain below the knee, 
presence of pain in both legs and whether leg pain was worse than back pain. Patients 
were asked whether their pain extended below the knee, this was recorded by the 
physiotherapist on a full body chart and recorded as dichotomous answers, “yes” or 
“no” for both the right and left legs. For analysis, results for the presence of pain below 
the knee in one or both legs, were combined and reported as one variable. The body 
chart also described whether patients had pain in both legs, this was reported as 
dichotomous answers, “yes” or “no”. During the clinical assessment patients were 
asked whether the leg pain was worse than the back pain or not, leading to 
dichotomous answers and “yes” or “no” respectively.  
  
126 
 
4.9.3.5 Pain pattern 
Information on whether the pain pattern was constant or intermittent was derived 
from the clinical examination. Patients were asked whether their pain in the back, 
thigh or lower leg (depending on their presenting pain) was constant to which the 
physiotherapist circled (“yes”) where the pain was constant, if any. Similarly, patients 
were then asked if their pain was intermittent and it was recorded in the same way as 
for constant pain. The responses were categorised into “yes” or “no” for constant and 
intermittent symptoms and were reported as the proportion describing constant 
symptoms. 
4.9.3.6 Pain quality 
Whether or not patients reported burning pain quality was derived from the fifth 
individual item of s-LANSS. Patients were asked if “in the area where you have pain, 
does your skin feel hot like a burning pain?” The responses were categorised as “I 
don’t have burning pain (no)”, or “I get burning pain often (yes)”.   
4.9.4 Limitations in activities, participation and risk of persistent disability 
Three self-report measures were used to capture limitations in activities, participation 
and risk of persistent disability due to LBLP.  
4.9.4.1 LBLP-related disability 
LBLP-related disability was measured with the Roland Morris Disability Questionnaire 
(RMDQ) (Roland and Morris 1983) leg version (Patrick et al. 1995) which has 23 items 
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scored from 0 to 23 with higher scores indicating higher disability. RMDQ was reported 
as a continuous variable.  
4.9.4.2 Interference with work performance 
Information on work interference because of back or leg pain were derived from the 
baseline questionnaire using a 0 to 10 numerical rating scale. Patients were asked “on 
average, to what extent has your back or leg pain affected your performance at work 
since your back or leg pain started?” The patients rated their work performance where 
0 is “not at all” and 10 is “the pain is so bad that I am unable to do my job” (Kigozi et al. 
2014). Pain interference with work performance was only applicable to those currently 
working, it was reported on a continuous scale.  
4.9.4.3 Risk of persistent pain-related disability 
The Keele STarT Back screening tool (Hill et al. 2008) is a simple tool that helps 
clinicians identify modifiable risk factors (biomedical and psychological) for back pain-
related disability. The nine-item tool consists of eight statements that the patient can 
either “agree” or “disagree” with and one question (“overall, how bothersome has 
your back pain been in the last two weeks?) to which the patient can answer using a 
five-point categorical scale ranging from “not at all” to “extremely”. STarT Back is 
scored on a nine-item scale and stratifies patients as at low, medium or high risk of 
persistent disability because of LBP. Low, medium and high risk categories for STarT 
Back were reported in the investigations in this thesis. 
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4.9.5 Psychological characteristics and illness perceptions 
Four different self-report scales were used to report psychological variables and illness 
perceptions, these were Hospital Anxiety and Depression Scale (HADS) (Zigmond and 
Snaith 1983), two domains from IPQ-R (Moss-Morris et al. 2002) and Pain Self-Efficacy 
Questionnaire (PSEQ) (Nicholas 2007).  
4.9.5.1 Symptoms of anxiety and depression 
HADS consists of two scales (one for anxiety, one for depression) each with seven 
statements with a maximum possible score of 21 on each scale measuring the severity 
of anxiety and depression. Statements include, “I feel tense or wound up”, or 
“worrying thoughts go through my mind” to which the patient confirms or refutes on a 
four-point categorical scale (scored 0 to 3), “most of the time”, “a lot of the time”, 
“from time to time occasionally”, or “not at all”. Higher scores indicate higher levels of 
anxiety and depressive symptoms. HADS anxiety is categorised as normal (scores 0 to 
7), possible/mild cases (scores 8 to 10), probable/moderate cases (scores 11-15) and 
severe cases (scores > 16). For this study, scores for HADS moderate and severe cases 
were amalgamated and reported as one group as few patients in the study scored 
more than 16; the same categories were set for the depression scale. Symptoms of 
anxiety and depression using HADS were reported for descriptive purposes 
categorically and separately on a continuous scale. 
4.9.5.2 Illness perceptions 
The two domains from IPQ-R were personal control and timeline (acute to chronic). 
For both domains patients were presented with statements and five levels to which 
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they agree with a specific statement (“strongly agree”, “agree”, “neither agree or 
disagree”, “disagree” or “strongly disagree”). The statement related to personal 
control was, “There is a lot which I can do to control my back and / or leg symptoms” 
and timeline, “My back and, or leg problem will last for a long time”. Both domains 
were then categorised further into either “agree or strongly agree” versus “disagree or 
strongly disagree”.  
4.9.5.3 Pain self-efficacy 
Pain self-efficacy is a concept developed by Bandura (1977). Self-efficacy is the degree 
to which an individual believes they can successfully cope with difficult situations, in 
the context of this research, the degree to which a patient has confidence in carrying 
out normal activities and tasks of daily living despite having pain. This research used 
the pain self-efficacy questionnaire (PSEQ) to determine the confidence of an 
individual to perform a range of tasks and the confidence with more generalised 
constructs such as coping with pain. It consists of 10 statements (for example, “I can 
enjoy things, despite the pain” to which the individual answers on a 0 to 6 categorical 
scale, where 0 represents “not at all confident” and 6 represents “completely 
confident”. PSEQ is scored on a 0 to 60 scale, where higher scores reflect stronger self-
efficacy beliefs. It was retained as continuous scale for the purposes of this study.  
4.9.6 Neurological examination 
The neurological examination was carried out as part of the clinical examination as 
recommended in LBP guidelines (Chou et al. 2007) and specialist books (for example 
Examination of the Lumbar Region in Neuromusculoskeletal Examination and 
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Assessment (Mercer and Finucane 2011) (pages 329 to 330). This included the 
components described below. 
 4.9.6.1 Muscle strength 
Muscle strength was tested in relation to specific lower limb myotomes according to 
the 6-point grading scale for manual muscle testing that is widely described (for 
further details of how muscle testing was carried out see Principles of Manual Muscle 
Testing in Hislop and Montgomery (2002) (pages 1 to 8)) where:  
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
For this research, the grades 0 to 3 were amalgamated into one category and three 
categories were reported, “0 to 3/5”, “4/5” and “5/5”.  
4.9.6.2 Reflex change 
Any change in either knee or ankle reflexes were recorded and categorised into 
normal, slightly reduced, significantly reduced and absent. The categories for 
significantly reduced and absent reflexes were then amalgamated. 
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4.9.6.3 Sensory loss or gain 
4.9.6.3.1 Sensory loss 
Sensation to pin-prick (using semi-sharp, single use neurological examination pins 
called Neurotip) specific to dermatomes in the lower limb(s) were described as 
“normal”, “reduced pin-prick sensation”, “loss of pin-prick sensation” and “total 
anaesthesia”. Sensation to pin-prick is reported in Chapter 5 and presented as one of 
three categories, “normal”, “reduction of pin-prick sensation” or “loss of pin-prick 
sensation” where “loss of pin-prick sensation” and “total anaesthesia” were 
amalgamated into one category. In Chapters 7 to 9 the variable reporting sensation to 
pin-prick was amalgamated further and was presented as a binary variable, “normal” 
or “reduction or loss of pin-prick sensation”. 
4.9.6.3.2 Sensory gain 
Hyperalgesia is an increased pain response to painful stimuli and allodynia is pain 
response to normally non-painful stimuli, both considered to be gains of sensory 
function. The presence of allodynia was recorded in response to light touch with one 
finger and hyperalgesia was recorded when the reaction to pin-prick was extreme. The 
presence or absence of either hyperalgesia or allodynia were recorded and presented 
as one variable. 
4.9.6.4 Presence of pins and needles 
The presence of pins and needles was derived from the clinical examination and was 
recorded as either “yes” or “no” as reported by the patient. 
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4.9.6.5 Colour change 
Whether or not patients reported colour change in the painful area was derived from 
the second individual item of s-LANSS. Patients were asked if in the area of pain the 
skin changes colour (more mottled or more red) when the pain is particularly bad. The 
responses were categorised as “The pain does not affect the colour of my skin (no)”, or 
“I have noticed that the pain does make my skin look different (yes)”.   
4.9.6.6 Neural tension tests 
Neural tension tests examine the elongation of nerves in a limb (Elvey 1997). In this 
research three tests that are routinely used in clinical practice were used to detect the 
presence of neural tension. These tests were the straight leg raise, which is carried out 
by passively elevating the leg with the knee extended; the femoral stretch where the 
patient is in a prone position, knee passively flexed to the thigh and the examiner 
passively extends the hip to increase the stretch on the femoral nerve; and the slump 
test, where the patient sits head forward, leg outstretched and toes point upwards, 
the examiner gently eases the patient forward to increase the stretch on the sciatic 
nerve. Reproduction of the patient’s leg pain is considered positive (Butler 1991). Any 
positive neural tension test was considered to indicate the presence of neural tension 
(“yes” or “no”). 
4.9.7 Neuroimaging 
MRI is the best available diagnostic imaging modality for LBLP as it provides excellent 
resolution of spinal structures allowing for assessment of nerve root compression. 
Patients had an MRI scan, except in contra-indicated cases or when the patient did not 
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wish to have a scan. MRIs were scored by a single assessor, a Consultant 
Musculoskeletal Radiologist in the NHS Trust Hospital in Stoke-on-Trent. The assessor 
was blind to any clinical information relating to the patient’s symptoms other than the 
clinical presentation (low back and leg pain), the painful leg(s) were not disclosed. A 
summary report on the MRI scan was provided indicating the presence or absence of 
definite or possible nerve root compression by lumbar spinal level (lumbar levels L3/4, 
L4/5 and L5/S1) and by side (right and/or left). The reason(s) for the nerve root 
compression were also given (for example, bulge, protrusion, sequestration or stenotic 
features) as is normal practice in radiological reporting (Konstantinou et al. 2015). 
Evidence of clear or possible nerve root compression on MRI was amalgamated and 
reported as a binary variable (“yes” or “no”). 
4.9.7.1 Procedure for reporting MRI to patients 
When the MRI results were available, the physiotherapist discussed these with the 
patient. Interpretation of MRI results and language used to convey MRI results was 
included in the training the study physiotherapists received. Four of the study 
physiotherapists were also spinal extended scope practitioners and the ATLAS cohort 
was conducted under the auspices of the local Spinal Interface Service, with clinicians 
from this service contributing to MRI interpretation as needed, for both patients and 
GPs. As per normal clinical practice, GPs received a copy of the MRI report alongside 
the clinic letter when a patient completed their treatment and were discharged to the 
care of their GP.    
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4.9.8 Health care use 
Health care use in this thesis is reported based on data collected in two ways. Firstly, 
the number of physiotherapy treatment sessions that patients attended were 
recorded by the ATLAS study team, as were the number of referrals made by the 
study’s physiotherapists to specialist spinal services. These were amalgamated and 
recorded as one variable with three categories for “0 to 2 physiotherapy sessions”, “3 
or more physiotherapy sessions” and “onward referrals”.  It was not known what 
proportion of patients were either lost to follow-up during physiotherapy treatment or 
who were discharged following a complete course of treatment. Secondly, the number 
of consultations that patients made with their GP or with specialist nurse practitioners 
in primary care was determined from electronic medical records.  
4.9.8.1 Pain medications 
This thesis describes the pain medication use in LBLP patients with neuropathic pain 
with data collected in two ways. Firstly, research in Chapter 5 (prevalence and baseline 
characteristics) describes the pain medication use of LBLP patients with and without 
neuropathic pain derived from information recorded in the clinical assessment, and 
then Chapter 9 (prescribing patterns of pain medication) describes the patterns of pain 
medications prescribed to patients with neuropathic pain derived from primary care 
electronic prescribing and consulting records for patients in the Atlas study. Regarding 
pain medications reported in Chapter 5, the assessing physiotherapist recorded the 
patients self-reported drug history, both prescribed medication and those bought over 
the counter were recorded during the clinical consultation, only the name of the 
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medication was recorded. For patients who consented to having their electronic 
prescribing and consulting records reviewed (see Figure 4.1 (page 115) for a summary 
of those patients who consented to a review of medical and prescription records), the 
name, dosage and quantity prescribed to an individual patient was recorded.  
In both chapters, medication was categorised into a number of groups based on 
recommendations from existing literature (see Table 4.3 for details on how pain 
medication was categorised in this thesis). The first group of pain medications was the 
group recommended for first line treatment of neuropathic pain (Amitriptyline, 
Gabapentin, Pregabalin or Duloxetine) based on evidence from UK guidelines for non-
specialist settings (NICE CG173 2013). The second to fourth groups were classified 
according to equipotent medications based on a previously published categorisation 
system for pain medication in UK primary care (Bedson et al. 2013). The second group 
were basic analgesics, the third were opioids, and the fourth were non-steroidal anti-
inflammatory medications. Opioids were categorised further for research in Chapter 9 
by the strength of the opioids prescribed. These groups comprised weak to moderate 
strength opioids and strong to very strong opioids, made possible given their specific 
names, dosages and quantities were recorded. Nefopam is not an opioid (Kim et al., 
2014) but it is considered to be equipotent to opioids with moderate strength and was 
classified along with opioids of weak to moderate strength. The fifth group of 
medications was skeletal muscle relaxants based on evidence that these drugs are 
associated with a reduction in pain intensity in acute episodes of LBP with or without 
leg pain (Qaseem et al. 2017). Groups one to five were mutually exclusive of one 
  
136 
 
another. Tramadol is not considered a first line neuropathic pain medication but it is a 
recommended medication for patients with acute episodes of neuropathic pain (NICE 
CG173 2013). For this reason, for research in Chapter 9, Tramadol was categorised 
depending on dosage into either weak or moderate strength opioid (Group 3a) or 
strong to very strong opioid (Group 3b) and into a sixth group of pain medications, a 
broader group of neuropathic pain medications.  
 
Table 4.3 Categorisation of pain medications in this thesis 
Group Description Chapter 5 
Prevalence and 
characteristics  
Chapter 9 
Prescribing patterns of pain medications  
1 First-line 
neuropathic 
pain 
medication 
Amitriptyline 
Duloxetine  
Gabapentin 
Pregabalin 
Amitriptyline 
Duloxetine  
Gabapentin 
Pregabalin 
2 Basic 
analgesia 
Paracetamol 
Topical Ibuprofen  
Topical Diclofenac 
Paracetamol  
Ibuprofen (200mg-400mg)  
Topical Ibuprofen, Topical Diclofenac 
3 
 
Opioids Buprenorphine  
Co-codamol  
Co-dydramol  
Co-proxamol  
Codeine  
Dihydrocodeine  
Nefopam  
3a. Weak to 
moderate 
opioids (+/- 
combination 
with 
paracetamol)  
 
Buprenorphine 
(<10mcg/hour)  
Co-codamol  
Co-dydramol  
Co-proxamol 
Codeine (<15mg) 
Dihydrocodeine (<30mcg) 
Tramadol (<50mg)  
Nefopam* 
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Group Description Chapter 5 
Prevalence and 
characteristics  
Chapter 9 
Prescribing patterns of pain medications  
Morphine  
Tramadol  
Oxycodone 
3b. Strong to 
very strong 
opioids 
Buprenorphine 
(>10mcg/hour)  
Morphine  
Tramadol (≥50mg)  
Oxycodone  
Dihydrocodeine (≥30mg) 
Codeine (≥30mg) 
4 Non-
steroidal 
anti-
inflammatory 
medication 
Diclofenac  
Etoricoxib  
Ibuprofen  
Meloxicam  
Naproxen 
Diclofenac  
Etoricoxib  
Ibuprofen (>400mg)  
Meloxicam  
Naproxen 
5 Skeletal 
muscle 
relaxants 
Diazepam Diazepam 
6 Neuropathic 
pain 
medication  
 Tramadol 
Amitriptyline  
Duloxetine  
Gabapentin 
Pregabalin 
Abbreviations: mcg, microgram. mg, milligram 
* Nefopam acts through central mechanisms distinct to the action of opioids but is considered to be 
equipotent with opioids of moderate strength 
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4.10 Study sample  
4.10.1 Completion of baseline data and clinical examination 
In total, 2087 potentially eligible patients were identified at the time of a primary care 
consultation and were invited to the ATLAS study, of which, 641 did not contact the 
research centre to make an appointment. 1310 potentially eligible patients made and 
attended appointments (Figure 4.1, see p115). After attending the first appointment, 
the absence and/or recovery from leg pain was the most common reason for 
ineligibility (n=136 out of 293) following the baseline assessment in the ATLAS clinic. 
Please see Konstantinou et al. (2015) for further details of the flow through the study 
and detailed reasons for excluding potential patients before or following the baseline 
assessment.  
Those who were ineligible, or were not interested in participating in the study were 
more often male (63% vs 57%), slightly older (mean age 55 vs 50 years) and slightly 
more often from the least deprived area tertile (36% vs 31%) compared to those who 
did take part. These are common findings when comparisons have been made in 
previous literature (Konstantinou et al., 2015).  
A total of 609 LBLP patients who completed baseline assessment were eligible, 
provided consent and were included in the ATLAS study. At baseline, three patients did 
not complete all seven of the questions that make up s-LANSS; all 609 patients were 
assessed for a clinical diagnosis. Nine percent of patients (n=55) did not undergo MRI, 
most cited claustrophobia as the reason for declining an MRI, four had 
contraindications for the procedure (Konstantinou et al., 2015). Less than 5% of other 
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baseline characteristics were missing. At baseline, self-reported general health, belief 
that leg and/or back pain symptoms will last a long time and back pain duration all had 
less than 1% (n=4) missing observations. Up to 4% (n=26) of observations were missing 
for socio-economic status, risk of persistent disability because of back pain/leg pain 
(STarT Back), pain self-efficacy (PSEQ) and leg pain duration at baseline. All other 
baseline characteristics were complete. 
4.10.2 Response to follow-up  
Of the 609 patients who completed baseline questionnaires, 402 (66.0%) completed 
the questionnaire at four-months, 450 (73.9%) at twelve months and 293 (48.1%) at 
three-years. Of the 402 patients who were followed up at four-months, 26 (6%) 
patients did not complete or partially completed s-LANSS. There was incomplete s-
LANSS data at both twelve months (102 out of 450 cases, 23%) and at three-years (25 
out of 293, 9%). Patients who responded to follow-up at four-months were older (54 
years compared to 42 years), fewer scored 12 or greater on s-LANSS (45% compared to 
55%), slightly higher proportion had a clinical diagnosis of sciatica (77% compared to 
70%) and they had slightly lower LBLP-related disability (mean RMDQ 12.1 compared 
to 13.7) at baseline. This was consistent at both twelve-months and three-years. 
Patients who responded to follow-up questionnaires self-reported fewer co-
morbidities and were more likely to agree or strongly agree with the statement “what I 
can do determines whether back and/or leg pain gets better”, and less likely to believe 
that either their leg or back pain symptoms would last for a long time. See Table 4.4 for 
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a detailed description of the baseline characteristics of patients who either responded 
to the follow-up questionnaires or were lost to follow-up at each time point. 
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Table 4.4 Baseline characteristics of participants followed-up and lost to follow-up 
 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
Sociodemographic characteristics 
Female  246 (61.7) 136 (65.7) 294 (65.8) 88 (55.4) 183 (62.9) 199 (63.2) 
Age,  mean (SD) 54.2 (13.0) 42.3 (12.1) 52.9 (13.2) 42.5 (13.0) 54.2 (12.7) 46.4 (13.9) 
Socio-
economic 
status 
Higher 
managerial, 
administrative 
and professional 
occupations 
90 (23.2) 38 (18.8) 102 (23.7) 26 (16.4) 72 (25.7) 56 (18.1) 
Intermediate 
occupations 
103 (26.6) 54 (26.7) 110 (25.5) 47 (29.6) 70 (25.0) 87 (28.1) 
Routine and 
manual 
occupations 
182 (46.9) 100 (49.5) 204 (47.3) 78 (49.1) 133 (47.5) 149 (48.1) 
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 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
Never worked 
and long-term 
unemployed 
13 (3.4) 10 (5.0) 15 (3.5) 8 (5.0) 5 (1.8) 18 (5.8) 
Health status 
Co-
morbidities* 
No other health 
problems 
226 (56.6) 144 (69.6) 261 (58.4) 109 (68.6) 167 (57.4) 203 (64.4) 
One other 
health problem 
111 (27.8) 46 (22.2) 124 (27.7) 33 (20.8) 86 (29.6) 71 (22.5) 
Two or more 
other health 
problems 
62 (15.5) 17 (8.2) 62 (13.9) 124 (27.7) 38 (13.1) 41 (13.0) 
Self-reported 
general health  
Excellent/ very 
good 
101 (25.3) 44 (21.4) 112 (25.1) 33 (20.8) 74 (25.4) 71 (22.6) 
Good 111 (27.8) 60 (29.1) 122 (24.4) 49 (30.8) 74 (25.4) 97 (30.9) 
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 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
Fair 157 (39.4) 82 (39.8) 179 (40.1) 60 (37.7) 122 (41.9) 117 (37.3) 
Poor 30 (7.5) 20 (9.7) 33 (7.4) 17 (10.7) 21 (7.2) 29 (9.2) 
Pain characteristics 
Back pain intensity (0-10), mean 
(SD) 
5.2 (1.6) 5.6 (1.6) 5.2 (1.6)  5.7 (1.6) 5.1 (1.6)  5.4 (1.6) 
Leg pain intensity (0-10), mean 
(SD) 
5.2 (2.4) 5.3 (2.3) 5.2 (2.4) 5.4 (2.4) 5.1 (2.4) 5.3 (2.4) 
Duration of 
back pain 
symptoms in 
current 
episode  
Less than 6 
weeks 
148 (37.2) 69 (33.5) 168 (37.8) 49 (30.8) 113 (39.1) 104 (33.0) 
6 to 12 weeks 84 (21.1) 41 (19.9) 94 (21.1) 31 (19.5) 59 (20.4) 66 (21.0) 
> 3 months 166 (41.7) 96 (46.6) 183 (41.1) 79 (49.7) 117 (40.5) 145 (46.0) 
Duration of leg 
pain 
Less than 6 
weeks 
164 (42.8) 87 (44.2) 195 (45.5) 56 (37.1) 129 (45.9) 122 (40.8) 
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 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
symptoms in 
current 
episode 
6 to 12 weeks 81 (21.2) 38 (19.3) 85 (19.8) 34 (22.5) 52 (18.5) 67 (22.4) 
> 3 months 138 (36.0) 72 (36.6) 149 (34.7) 85 (19.8) 100 (35.6) 110 (36.8) 
Limitations in activities and risk of persistent disability 
RMDQ, mean 
(SD) 
 12.1 (5.7) 13.7 (5.6) 12.1 (5.7) 14.1 (5.5) 12.0 (5.7) 13.2 (5.7) 
Pain 
interference 
with work 
(0=10), mean 
(SD) † 
 5.5 (3.0) 6.5 (2.6) 5.6 (3.0) 6.4 (2.7) 5.4 (3.1) 6.2 (2.8) 
Risk of 
persistent 
Low risk 60 (15.4) 22 (11.0) 64 (14.9) 18 (11.5) 44 (15.8) 38 (12.4) 
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 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
disability 
(STarT Back) 
 Medium risk 188 (48.7) 686 (43.0) 211 (49.1) 63 (40.4) 142 (50.9) 132 (43.0) 
 High risk 138 (35.8) 92 (46.0) 155 (36.1) 75 (48.1) 93 (33.3) 137 (44.6) 
Psychological characteristics and illness perceptions 
HADS (0-21) 
(depression), 
mean (SD) 
 6.0 (3.9) 7.1 (4.2) 6.0 (3.9) 7.4 (4.2) 6.2 (3.9) 6.5 (4.1) 
HADS (0-21) 
(anxiety), 
mean (SD) 
 7.5 (4.1) 8.3 (4.2) 7.5 (4.1) 8.7 (4.1) 7.4 (4.1) 8.2 (4.1) 
PSEQ (0-60), 
mean (SD) ‡ 
 36.1 (14.7) 30.4 (13.5) 35.5 (14.2) 30.4 (14.7) 35.6 (14.7) 32.9 (14.3) 
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 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
IPQR- Illness 
perceptions 
Timeline 
“back/leg pain 
will last for a 
long time” 
(agree or 
strongly agree) 
209 (52.4) 135 (65.2) 239 (53.5) 105 (66.0) 145 (49.8) 199 (63.2) 
Personal control 
“what I can do 
determines 
whether 
back/leg pain 
gets better” 
(agree or  
strongly agree) 
156 (39.3) 66 (32.2) 179 (40.3) 43 (27.2) 127 (43.8) 95 (30.5) 
  
147 
 
 4 Months 12 Months 3 Years 
Key baseline characteristics Followed up 
(n=402; 66%)  
Lost to follow-
up (n=207; 
34%) 
Followed up 
(n=450; 74%) 
Lost to follow-
up (n=159; 
26%) 
Followed up 
(n=293; 48%) 
Lost to follow-
up (n=316; 
52%) 
Neuroimaging 
Clear or possible nerve root 
compression on MRI 
212 (57.9) 83 (45.6) 230 (56.1) 65 (47.1) 160 (59.5) 135 (48.4) 
Neuropathic pain definitions 
Clinical diagnosis of sciatica§  306 (76.7) 144 (69.6) 336 (75.2) 114 (71.7) 221 (76.0) 229 (72.7) 
s-LANSS ≥12§  180 (45.1) 113 (54.6) 209 (46.8) 84 (52.8) 135 (46.4) 158 (50.2) 
All figures are frequencies (percentages) unless stated otherwise as mean (SD), denominator varies for some characteristics due to missing data or not applicable case. 
Abbreviations: HADS, Hospital Anxiety and Depression scale. IPQ-R, Illness Perceptions Questionnaire-revised. PSEQ, Pain Self-efficacy Questionnaire. RMDQ, Roland Morris 
Disability Questionnaire leg version. SD, standard deviation. S-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and Signs neuropathic pain 
scale 
*Co-morbidities include self-reported chest problems, heart problems, raised blood pressure, diabetes, and circulation problems in the leg 
† Applicable to those currently in paid job 
‡ Higher scores on PSEQ reflect stronger self-efficacy beliefs 
§ Patients with a clinical diagnosis of sciatica and/or an s-LANSS score ≥12 are described as having “possible” neuropathic pain  
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4.11 Missing data 
Section 4.10.3 highlights some differences in baseline characteristics between patients 
who responded to questionnaires at follow-up compared to those who did not, these 
differences can lead to potential bias (von Elm et al. 2007, Sterne et al. 2009). Missing 
data can also lead to imprecision because of a loss of power (Horton and Kleinman 
2007). In this thesis methods used to deal with missingness were based on likelihood 
approaches (Chapter 6 and 8) and multiple imputation (MI) (Chapter 7, 8 and 9). MI is 
advocated (Vandenbroucke et al. 2014) for replacing the missing observations with 
plausible estimates creating a predefined number of imputed datasets. The following 
section (section 4.11.1) describes the assumptions of MI and the details of the 
imputation model. Sensitivity analyses were carried out comparing analyses using 
complete cases and those using imputed data, the results of each sensitivity analysis is 
summarised within each chapter where missing data could have caused some concern. 
4.11.1 Multiple imputation 
MI assumes that data are missing at random, that is missing values are related to other 
observed characteristics. Data from all 609 patients was used to impute missing values 
on the outcomes used in this thesis (these were neuropathic pain based on s-LANSS, 
pain intensity using the highest of three 0 to 10 NRS for leg and back pain intensity and 
LBLP-related disability using RMDQ) and baseline characteristics with missing data. 
Characteristics that were associated with missingness at each of the three follow-up 
points were included in the imputation model, as well as characteristics that were 
consistently associated with the three definitions of neuropathic pain at baseline and 
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all characteristics that were included in any multivariable models. Checks were made 
for collinearity between characteristics before entering them into the final imputation 
model. Multiple imputation by chained equations (MICE) (van Buuren and Oudshoorn 
2000) was used to generate the imputations. Imputation of continuous variables was 
based on predictive mean matching which combines standard linear regression with 
the nearest neighbour imputation approaches. Imputation of binary variables was 
based on logistic regression while that of ordinal variables was based on ordered 
logistic regression. Using MI, missing values are imputed M times based on a rule of 
thumb, where M is at least equal to the percentage of incomplete cases (White et al. 
2011).  In this research, a large proportion of the primary end-point which was 
neuropathic pain (defined using s-LANSS) was missing. At three-years, 341 
observations for s-LANSS were either completely or partially missing (56.0%) therefore 
60 imputed sets of data were created. The 60 multiply-imputed sets were combined to 
give a single mean estimate according to Rubin’s rules (Rubin 1987).  
4.12 Statistical software 
All statistical analyses in this thesis were performed using Stata version 14.0 (Stata 
Corporation, College Station, Texas, USA). The Stata command impute was used to 
generate the imputed datasets and the mi procedure was used to analyse the imputed 
datasets. All generated variables and analytic code were prepared and stored in Stata 
do-file format. This allows for replication and storage of data for future reference. 
Specific details of analysis are presented in the methods and results sections of 
Chapter 5 through to Chapter 9.  
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4.13 Summary 
The ATLAS study is a three year prospective observational cohort of LBLP patients who 
consulted with their GP in primary care. Investigations undertaken in Chapters 5 to 9 of 
this thesis were nested in this programme of work. This chapter outlined the ATLAS 
study design, methods, data collection procedures and methods used to account for 
missing data. The next chapter presents the first analysis investigating the prevalence 
and characteristics of this patient population with and without neuropathic pain.  
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Chapter Five. Prevalence and characteristics of neuropathic pain in 
primary care patients with low back-related leg pain 
5.1 Introduction 
Previous chapters of this thesis have highlighted gaps in the evidence from 
epidemiological research, including a description of the characteristics of patients with 
low back-related leg pain (LBLP) of neuropathic nature (see Chapter 3 for results of a 
systematic review of the literature). This chapter describes the prevalence of 
neuropathic pain in LBLP patients who consulted their GP in  practices participating in 
the ATLAS cohort study in North Staffordshire and Stoke-on-Trent, UK, and the 
characteristics of those with and without neuropathic pain. Comparisons are made 
between the results of this research and relevant literature, and the clinical 
implications of these findings are discussed.  
5.2 Aims and objectives  
5.2.1 Overall aim 
To provide point prevalence estimates and describe the characteristics of LBLP primary 
care patients with neuropathic pain. 
5.2.2 Objectives 
1. To provide estimates of the point prevalence of neuropathic pain in LBLP patients 
seeking treatment in primary care.  
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2. To describe the baseline characteristics of LBLP patients with neuropathic pain, 
defined by case ascertainment tools and clinical examination, compared to those 
without neuropathic pain.  
3. To examine the association between baseline characteristics of LBLP patients and 
neuropathic pain defined by case ascertainment tools and clinical examination. 
5.3 Methods 
A full description of the data source, population of interest, methods used to identify 
cases of neuropathic pain and a description of the selected variables have been 
described previously in this thesis (see Chapter 4, Study design and methods) and are 
summarised below in sections 5.3.1 to 5.3.3.  
5.3.1 Study design 
The research presented in this chapter is based on a cross-sectional, secondary 
analysis of baseline characteristics of patients in a prospective treatment cohort study 
of LBLP patients who consulted with their GP in primary care (ATLAS cohort). 
5.3.2 Neuropathic pain definitions 
Neuropathic pain cases were identified using two different approaches and three 
definitions (summarised in Figure 5.1), for a full description of each of the three 
definitions used see Chapter 4, section 4.7 (page 118).
 153 
 
Figure 5.1 Neuropathic pain definitions, grouped by certainty of definition  
 
 
 
 
 
 
5.3.3 Selected characteristics of interest 
The analyses in this chapter describe key characteristics of LBLP patients with and 
without neuropathic pain that were identified from the published literature and were 
available within the ATLAS dataset. The key characteristics used for research in this 
chapter are summarised in table 5.1.The reader is referred to Chapter 4 for a detailed 
report on each of the characteristics reported below. 
  
Possible neuropathic pain 
s-LANSS ≥ 12 
Probable neuropathic pain 
Clinical diagnosis of sciatica 
with possible or clear nerve 
root compression on 
neuroimaging 
Abbreviation: s-LANSS, self-report version of Leeds Assessment for Neurological Symptoms and 
Signs neuropathic pain scale.  
Clinical diagnosis of sciatica 
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Table 5.1 Summary of key characteristics used to describe patients with neuropathic 
pain medication in research in chapter five. 
Baseline characteristics Responses on categorical scale Continuous 
scale 
Sociodemographic characteristics  
Female sex Yes - 
Age  - Years 
Socio-economic status  Higher managerial, 
administrative and professional 
occupations 
- 
Intermediate occupations - 
Routine and manual occupations - 
Never worked and long-term 
unemployed 
- 
Smoking status Never - 
Ex-smoker - 
Current - 
BMI - Kg/m2 
Health status 
Co-morbidities* No other health problems - 
One other health problem - 
Two or more other health 
problems 
- 
Self-reported diabetes - 
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Self-reported general health  Excellent/ very good - 
Good - 
Fair - 
Poor - 
Fatigue  Yes - 
Sleep difficulties  Yes - 
Pain characteristics  
Back pain intensity  - 0-10 
Leg pain intensity  - 0-10 
Constant pain symptoms Yes - 
Pain described as burning pain  Yes  
Duration of back pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
Duration of leg pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
Widespread pain†  Yes - 
Leg pain worse than back pain Yes - 
Pain location Presence of pain below the knee - 
 Presence of pain in one leg - 
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Limitations in activities  
LBLP-related disability (RMDQ)  - 0-23 
Pain interference with work (0-10) ‡|   - 0-10 
Risk of persistent disability due to 
back pain (STarT Back)  
Low risk - 
Medium risk - 
High risk - 
Psychological characteristics and illness perceptions  
HADS (depression)  Normal (0 to 7) - 
Possible (mild) cases (8 to 10) - 
Probable (moderate/ severe 
cases (≥11) 
- 
HADS (anxiety)  Normal (0 to 7) - 
Possible (mild) cases (8 to 10) - 
Probable (moderate/ severe 
cases (≥11) 
- 
Pain self-efficacy (PSEQ)§ - 0-60 
Illness perceptions (IPQ-R), Timeline 
“back/leg pain will last for a long 
time” 
Agree or strongly agree - 
Illness perceptions (IPQ-R), Personal 
control “what I can do determines 
whether back/leg pain gets better” 
Agree or strongly agree - 
Neurological examination findings  
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Muscle strength||  5/5 - 
4/5 - 
0/5 or 1/5 or 2/5 or 3/5 - 
Presence of either reduced or 
absent lower limb reflex  
None - 
Slightly reduced - 
Significantly reduced or absent - 
Sensation to pin-prick in the leg(s) Normal - 
Reduction to pin-prick 
Loss to pin-prick 
Presence of allodynia or 
hyperalgesia in the leg(s) ** 
Yes - 
Neural tension test †† (any positive 
test) 
Yes - 
Presence of pins and needles Yes - 
Pain affects the colour of patients 
skin 
Yes  
Neuroimaging   
Clear or possible nerve root 
compression  
Yes - 
Pain medication ‡‡   
Number of pain medications  None - 
One - 
Two or more - 
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Type of pain medication (one or 
more) 
First-line neuropathic pain 
medication 
- 
Basic analgesics - 
Opioids - 
NSAID’s - 
Skeletal muscle relaxants - 
Abbreviations: BMI, body mass index. CI, confidence intervals. HADS, Hospital Anxiety and Depression 
scale. Kg/m2, kilograms per metre2. IPQ-R, Illness perceptions questionnaire-revised. NSAID, non-
steroidal anti-inflammatory drugs. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris 
Disability Questionnaire leg version.  
* Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes, and circulation problems in the leg. 
† Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
‡ Applicable to those currently in paid job. 
§ Higher scores on PSEQ reflect stronger self-efficacy beliefs 
|| Muscle strength was tested according to a 6-point grading scale where; 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
** Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes). 
†† Neural tension tests; straight leg raise, femoral stretch and slump test. 
‡‡ Pain medications include self-reported history of prescribed medications and those purchased over 
the counter  
 
5.4 Statistical analysis 
Point prevalence was estimated for the three definitions of neuropathic pain 
previously described (s-LANSS score of 12 or greater, clinical diagnosis of sciatica, and 
clinical diagnosis of sciatica with clear or possible evidence of nerve root compression 
on MRI). Descriptive statistics (mean and standard deviation (SD) for continuous 
variables and frequency and percentage for categorical variables) were used to 
describe characteristics of interest in those with neuropathic pain as defined by each 
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of the three definitions. Logistic regression was used to examine the association 
between neuropathic pain (based on the three definitions) and characteristics of 
interest. The analysis in this chapter is based on complete cases. 
5.5 Results  
In total, 609 patients with LBLP were eligible and consented to participate in the ATLAS 
study, all of these patients received a clinical diagnosis of sciatica or referred leg pain 
and 554 patients had an MRI. Three patients did not complete all seven items of the s-
LANSS.  
5.5.1 Prevalence of neuropathic pain  
Just under one quarter (23.0%, 127 out of 551) of LBLP patients were defined as having 
neuropathic pain using all three definitions. Nearly four in ten patients (38.3%, 232 out 
of 606) were defined as having neuropathic pain based on s-LANSS and clinical 
diagnosis of sciatica. One in ten (10.7%, 61 out of 606) LBLP patients were defined as 
having neuropathic pain based on s-LANSS but were not defined as having neuropathic 
pain by clinical diagnosis of sciatica either with or without evidence of nerve root 
compression. Table 5.2 presents the estimated prevalence of neuropathic pain in these 
patients. The distribution and overlap of LBLP patients with or without neuropathic 
pain based on the three definitions are then summarised in Figure 5.1. 
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Table 5.2 Prevalence of neuropathic pain in patients based on three definitions  
Definition of neuropathic pain  Estimated prevalence 
s-LANSS ≥ 12  293 out of 606, 48.4% 
Clinical diagnosis of sciatica 452 out of 609, 74.2% 
Clinical diagnosis of sciatica with clear or possible evidence 
of nerve root compression 
252 out of 554, 45.5% 
Abbreviation: s-LANSS, self-report version of Leeds Assessment of Neurological Symptoms and Signs 
neuropathic pain scale 
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Figure 5.1 Venn diagram depicting the overlap between patients with and without 
neuropathic pain at baseline based on three case definitions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers are percentages of the total in the study 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment 
of Neurological symptoms and signs 
*Evidence of clear or possible nerve root compression on MRI
Sciatica with MRI* 
Sciatica 
  
  
16 
s-LANSS ≥ 12 
Referred 
leg pain 23 
23 
15 
12 
11 
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5.5.2 Characteristics of patients with neuropathic pain defined by s-LANSS  
5.5.2.1 Sociodemographic characteristics  
Over two-thirds (68.3%) of LBLP patients with neuropathic pain were female, and the 
odds of presenting with neuropathic pain was 1.55 times higher for female patients 
(odds ratio (OR) 1.55, 95% confidence interval (CI) 1.10 to 2.16). Over half (50.4%) of 
patients with neuropathic pain were in routine and manual occupations with the odds 
of presenting with neuropathic pain increasing by 64% for patients in routine and 
manual occupations compared to those in higher managerial, administrative and 
professional occupations (OR 1.64, CI 1.07 to 2.50). Patients with neuropathic pain 
reported not being in paid work more often than those without (65.0% vs 56.4%) but 
when adjusted for socio-economic status there was no association between not having 
a paid job and neuropathic pain (OR 1.22, CI 0.87 to 1.73).  
5.5.2.2 Health status 
LBLP patients with neuropathic pain defined in this way most commonly reported fair 
general health (39.7%), one in ten (10.6%) patients reported poor general health, the 
remaining patients reported having excellent, very good or good general health. The 
odds of presenting with neuropathic pain increased in those patients who reported 
poor health, fair health and good health compared to those with excellent or very 
good health. A high proportion of patients with neuropathic pain reported fatigue 
(74.3%) and difficulties with sleep (88.4%) due to back and leg pain. The odds of 
presenting with neuropathic pain increased for patients reporting fatigue (OR 1.56, CI 
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1.10 to 2.23) and for patients reporting difficulty with sleep due to back or leg pain (OR 
1.68, CI 1.06 to 2.66). 
5.5.2.3 Pain characteristics 
The proportion of patients with widespread pain, pain in one leg and with leg pain 
worse than back pain, were similar between patients with and without neuropathic 
pain. Back pain and leg pain duration was also similar between the two groups. 
Mean (SD) back pain intensity was slightly higher among the patients with neuropathic 
pain (5.5 (1.6)) compared to those without (5.1 (1.6)). For patients with neuropathic 
pain mean (SD) leg pain intensity was 5.8 (2.3), with the odds of having neuropathic 
pain increasing by 20% (OR 1.20, CI 1.12 to 1.29) for every one unit increase in leg pain 
intensity. Over three-quarters (77.8%) of patients with neuropathic pain reported 
having pain below the knee. The odds of presenting with neuropathic pain was nearly 
twice that of patients without pain below the knee (OR 1.98, CI 1.38 to 2.87).  
5.5.2.4 Limitations in activities, participation and risk of persistent disabling pain 
Patients with neuropathic pain reported LBLP-related disability (RMDQ) mean (SD) 
score of 13.8 (5.6), for every one-unit increase in disability score, the odds of having 
neuropathic pain increased by 8% (OR 1.08, CI 1.05 to 1.11).  
5.5.2.5 Psychological and illness perception variables 
The odds of having neuropathic pain increased in those patients with moderate/severe 
depressive symptoms (OR 4.14, CI 2.53 to 6.78) and in those with mild symptoms (OR 
1.95, CI 1.29 to 2.96) compared to those without depressive symptoms. As regards 
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anxiety symptoms, the odds of having neuropathic pain increased in those patients 
with moderate/severe anxiety (OR 3.30, CI 2.22 to 4.87) compared to those without 
anxiety. There was a significant association between pain self-efficacy and neuropathic 
pain. LBLP patients with neuropathic pain reported mean (SD) pain self-efficacy score 
of 30.8 (14.6), for every one-unit reduction in pain self-efficacy, the odds of having 
neuropathic pain increased by 3% (OR 0.97, CI 0.97 to 0.98). 
5.5.2.6 Neurological examination findings 
Mild muscle weakness (4 out of 5 on a 0 to 5 grading scale) but not severe muscle 
weakness (0 to 3 on a 0 to 5 grading scale) was associated with neuropathic pain. 
Having significantly reduced or absent reflexes was associated with neuropathic pain, 
but slightly reduced reflexes was not. The odds of presenting with neuropathic pain 
was associated with either a reduction (OR 1.64, CI 1.16 to 2.33) or loss (OR 2.49, CI 
1.35 to 4.60) of pin-prick sensation in the leg(s), pins and needles in the leg(s) (OR 5.8, 
CI 4.08 to 8.23) and pain that affected the colour of the skin (OR 13.45, CI 5.70 to 
31.70).  
A small proportion of patients were found to have an increased pain response to either 
painful or non-painful stimuli on examination (58 out of 609, 9.5%) and the odds of 
presenting with neuropathic pain was 2.75 times higher for LBLP patients who 
reported this pain characteristic (CI 1.52 to 4.97). Four out of ten patients (256 out of 
609, 42%) self-reported having an increased pain response to either painful or non-
painful stimuli (determined from the third item of s-LANSS). Six out of ten (35 out of 
58, 60.3%) LBLP patients who self-reported increased pain response to either painful 
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or non-painful stimuli were found to have the same pain response on clinical 
examination, suggesting a moderate level of agreement between self-report and 
clinical examination findings.  
5.5.2.7 Neuroimaging 
The odds of presenting with neuropathic pain for patients with either clear or possible 
nerve root compression on MRI were no different compared to those without (OR 
0.93, CI 0.66 to 1.30).  
5.5.2.8 Pain medication  
Patients with neuropathic pain were as likely to report having purchased pain 
medication over the counter or having been prescribed basic analgesia, first line 
neuropathic pain medication, non-steroidal anti-inflammatory medication (for 
example diclofenac sodium or naproxen) and skeletal muscle relaxants (diazepam) for 
back and leg pain compared to those without. Patients using two or more analgesic 
medications were more likely to present with neuropathic pain compared to those 
patients who reported taking no medications (OR 1.83, CI 1.11 to 3.01).  
Patients using any opioid were more likely to present with neuropathic pain compared 
to those not taking any (OR 1.54, CI 1.11 to 2.12). Similar proportions of patients used 
Co-codamol (a weak to moderate strength opioid) with (34.5%, 101 out of 293) and 
without neuropathic pain (35.1%, 110 out of 313) but a higher proportion of patients 
with neuropathic pain used a strong or very strong opioid (one of Buprenorphine, 
Codeine, Co-dydramol, Nefopam, Dihydrocodeine, Tramadol, Morphine and/or 
Oxycodone) (23.9%, 70 out of 293) compared to those without (13.4%, 42 out of 313).  
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Table 5.3 Baseline characteristics of patients with neuropathic pain based on s-LANSS 
Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Sociodemographic characteristics    
Female (n=606) 200 (68.3) 182 (58.2) 1.55 (1.10, 2.16) 
Age, mean (SD) 
(n=606) 
 
49.8 (13.5) 50.4 (14.2) 1.00 (0.99, 1.01) 
Socio-economic 
status (n=590) 
Higher 
managerial, 
administrative 
and 
professional 
occupations 
49 (17.4) 79 (25.7) 1 
Intermediate 
occupations 
71 (25.2) 86 (27.9) 1.33 (0.83, 2.14) 
Routine and 
manual 
occupations 
142 (50.4) 140 (45.5) 1.64 (1.07, 2.5) 
Never worked 
and long-term 
unemployed 
20 (7.1) 3 (1.0) 10.75 (3.03, 
38.07) 
Never 99 (33.9) 127 (40.6) 1 
 167 
 
Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Smoking status 
(n=605) 
Ex-smoker 80 (27.4) 105 (33.6) 0.98 (0.66, 1.45) 
Current 113 (38.7) 81 (25.9) 1.79 (1.21, 2.64) 
BMI (kg/m2), 
mean (SD) 
(n=598) 
 
29.7 (6.1) 29.5 (5.6) 1.01 (0.98, 1.03) 
Health status     
Co-morbidities‡, 
(n=606) 
No other health 
problems 
180 (61.4) 190 (60.7) 1 
One other 
health problem 
74 (25.3) 75 (26.8) 0.89  (0.60, 1.31) 
Two or more 
other health 
problems 
39 (13.3) 31 (11.1) 1.13 (0.66, 1.91) 
Self-reported 
diabetes  
25 (8.5) 22 (7.0) 1.23 (0.68, 2.24) 
Self-reported 
general health 
(n=605) 
Excellent/ very 
good 
52 (17.8) 93 (29.7) 1 
Good 93 (31.9) 78 (24.9) 2.13 (1.35, 3.36) 
Fair 116 (39.7) 123 (39.3) 1.69 (1.10, 2.58) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Poor 31 (10.6) 19 (6.1) 2.92 (1.50, 5.67) 
Fatigue (n=593)  214 (74.3) 198 (64.9) 1.56 (1.10, 2.23) 
Sleep difficulties 
(n=601) 
 258 (88.4) 253 (81.9) 1.68 (1.06, 2.66) 
Pain 
characteristics 
    
Back pain 
intensity (0-10), 
mean (SD) 
(n=600) 
 5.5 (1.6) 5.1 (1.6) 1.15 (1.04, 1.27) 
Leg pain 
intensity (0-10) 
mean (SD), 
(n=578) 
 5.8 (2.3) 4.7 (2.4) 1.20 (1.12, 1.29) 
Constant pain 
symptoms 
(n=594) 
 221 (75.4) 177 (58.8) 2.15 (1.51, 3.06) 
Pain described 
as burning pain 
(n=606) 
 165 (56.3) 55 (17.6) 6.05 (4.18, 8.77) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Duration of back 
pain symptoms 
in current 
episode (n=604) 
< 6 weeks 98 (33.7) 119 (38.0) 1 
6 to 12 weeks 65 (22.3) 60 (19.2) 1.32 (0.87, 2.04) 
> 3 months 128 (44.0) 134 (42.8) 1.16 (0.81, 1.66) 
Duration of leg 
pain symptoms 
in current 
episode (n=580) 
< 6 weeks 110 (39.3) 141 (47.0) 1 
6 to 12 weeks 61 (21.8) 58 (19.3) 1.18 (0.75, 1.86) 
> 3 months 109 (38.9) 101 (33.7) 1.41 (0.96, 2.08) 
Widespread 
pain § (n=590) 
 124 (42.9) 125 (41.5) 1.05 (0.74, 1.47) 
Leg pain worse 
(n=604) 
 138 (47.4) 139 (44.4) 1.13 (0.82, 1.56) 
Pain location 
(n=606) 
Pain below the 
knee  
228 (77.8) 200 (63.9) 1.98 (1.38, 2.87) 
Pain in one leg 211 (72.0) 244 (78.0) 0.73 (0.50, 1.06) 
Limitations in activities, participation and risk of persistent disabling pain 
LBLP-related 
disability 
 13.8 (5.6) 11.5 (5.6) 1.08 (1.05, 1.11) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
(RMDQ, 0-23), 
mean (SD) 
(n=606) 
Pain 
interference 
with work (0-10) 
|| (n=360), mean 
(SD)  
 6.3 (3.0) 5.4 (3.0) 1.11 (1.03, 1.20) 
Risk of 
persistent 
disability due to 
back pain (STarT 
Back) (n=530) 
Low risk 29 (10.2) 53 (17.6) 1 
Medium risk 120 (42.3) 154 (51.0) 1.57 (0.92, 2.7) 
High risk 135 (47.5) 95 (31.5) 2.7 (1.56, 4.7) 
Psychological characteristics and illness perceptions 
Depression 
(HADS) (n=606) 
Normal (0 to 7) 155 (52.9) 235 (75.1) 1 
Possible (mild) 
cases (8 to 10) 
67 (22.9) 52 (16.6) 1.95 (1.29, 2.96) 
Probable 
(moderate/sev
ere) cases (≥11)  
71 (24.2) 26 (8.3) 4.14 (2.53, 6.78) 
Normal (0 to 7) 118 (40.6) 196 (62.6) 1 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Anxiety (HADS) 
(n=604) 
Possible (mild) 
cases (8 to 10) 
60 (20.6) 60 (19.2) 1.66 (1.08, 2.54) 
Probable 
(moderate/ 
severe) cases 
(≥11) 
113 (38.8) 57 (18.2) 3.30 (2.22, 4.87) 
Pain self-
efficacy (PSEQ, 
0-60)† (n=590), 
mean (SD) 
 30.8 (14.6) 37.4 (13.8) 0.97 (0.96, 0.98) 
Illness 
perceptions 
(IPQ-R)  
Timeline 
“back/leg pain 
will last for a 
long time” 
(agree or 
strongly agree) 
(n=602) 
175 (59.7) 169 (54.0) 1.26 (0.92, 1.74) 
Personal 
control “what I 
can do 
determines 
whether 
104 (35.9) 118 (37.8) 0.92 (0.66, 1.28) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
back/leg pain 
gets better” 
(agree or 
strongly agree) 
(n=606) 
Neurological examination findings 
Muscle 
weakness** 
(n=606) 
5/5 231 (78.8) 270 (86.3) 1 
4/5 56 (19.1) 36 (11.5) 1.81 (1.15, 2.86) 
0 to 3/5 6 (2.1) 7 (2.2) 1.00 (0.33, 3.02) 
Reflex change 
(n=606) 
None 222 (75.8) 265 (84.7) 1 
Slightly 
reduced 
19 (6.5) 11 (3.5) 2.06 (0.96, 4.43) 
Significantly 
reduced or 
absent 
52 (17.8) 37 (11.8) 1.68 (1.06, 2.65) 
Sensation to 
pin-prick in the 
leg(s) (n=606) 
Normal 150 (51.2) 204 (65.2) 1 
Reduction to 
pin-prick 
110 (37.5) 91 (29.1) 1.64 (1.16, 2.33) 
Loss to pin-
prick 
33 (11.3) 18 (5.8) 2.49 (1.35, 4.60) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Presence of 
allodynia or 
hyperalgesia in 
the leg(s)§§ 
(n=606) 
 40 (13.7) 17 (5.4) 2.75 (1.52, 4.97) 
Neural tension 
test‡‡ (any 
positive test, 
n=606) 
 168 (57.3) 165 (52.7) 1.21 (0.87, 1.66) 
Pins and 
needles in the 
leg(s) (n=606) 
 209 (71.3) 84 (28.7) 5.80 (4.08, 8.23) 
Pain affects the 
colour of 
patients skin 
(n=606) 
 61 (20.8) 6 (1.9) 13.45 (5.70, 
31.7) 
Neuroimaging     
Clear or possible 
nerve root 
compression 
(n=551) 
 142 (52.8) 154 (54.6) 0.93 (0.66, 1.30) 
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Characteristics* Neuropathic pain   
(s-LANSS  12) 
Unadjusted 
odds ratio 
(95% CI) 
Yes,  
n=293  
(48.4%) 
No,  
n=313 
(51.7%) 
Pain medications §§ (n=606)    
Number of pain 
medications 
None 34 (11.6) 49 (15.7) 1 
One 103 (35.2) 141 (45.1) 1.05 (0.63, 1.75) 
Two or more 156 (53.2) 123 (39.3) 1.83 (1.11, 3.01) 
Type of pain 
medication (one 
or more)  
First-line 
neuropathic 
pain 
medication  
35 (12.0) 32 (10.2) 1.19 (0.72, 1.98) 
Basic analgesics  147 (50.2) 142 (45.4) 1.21 (0.88, 1.67) 
Opioids 178 (60.8) 157 (50.2) 1.54 (1.11, 2.12) 
NSAID’s 49 (16.7) 46 (14.7) 0.17 (0.75, 1.81) 
Skeletal muscle 
relaxants  
8 (2.7) 5 (1.6) 1.73 (0.56, 5.35) 
Figures are frequencies (percentages) unless stated otherwise as mean (SD). 
Odds ratio (confidence intervals) underlined highlights characteristics associated with neuropathic pain.  
Abbreviations: BMI, body mass index. CI, confidence intervals. HADS, Hospital Anxiety and Depression 
scale. Kg/m2, kilograms per metre2. IPQ-R, Illness perceptions questionnaire-revised. NSAID, non-
steroidal anti-inflammatory drugs. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris 
Disability Questionnaire leg version.  SD, standard deviation. S-LANSS, self-report version of Leeds 
Assessment for Neurological Symptoms and Signs neuropathic pain scale. 
*Denominator varies for some characteristics due to missing data or not applicable case. 
† Higher scores on PSEQ reflect stronger self-efficacy beliefs 
‡ Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes, and circulation problems in the leg. 
§ Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
|| Applicable to those currently in paid job. 
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** Muscle strength was tested according to a 6-point grading scale where; 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
§§ Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-
painful stimuli (for example, brush strokes). 
‡‡ Neural tension tests; straight leg raise, femoral stretch and slump test. 
§§ Pain medications include self-reported history of prescribed medications and those purchased over 
the counter  
 
5.5.3 Characteristics of patients with neuropathic pain based on a clinical 
diagnosis of sciatica  
There were no significant differences in characteristics that described health status 
and pain medication use between patients with and without neuropathic pain. LBLP 
patients with neuropathic pain reported higher mean (SD) leg pain intensity compared 
to those without (5.6 (2.3) vs. 4.2 (2.2)).  For every one-unit increase in NRS score for 
leg pain intensity, the unadjusted odds of presenting with neuropathic pain increased 
by 32% (OR 1.32, CI 1.21 to 1.44). There was a significant association between 
neuropathic pain and pain self-efficacy. LBLP patients with a clinical diagnosis of 
neuropathic pain reported mean (SD) pain self-efficacy (PSEQ) 33.3 (14.7), for every 
one-unit reduction in PSEQ the odds of having neuropathic pain (sciatica) increased by 
2% (OR 0.98, CI 0.97 to 1.00). Characteristics describing pain location and 
characteristics of the neurological examination were strongly associated with 
neuropathic pain. LBLP patients with either clear or possible nerve root compression 
on MRI were over 3 times more likely to have neuropathic pain compared to those 
without (OR 3.23, CI 2.15 to 4.85).  
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Table 5.4 Baseline characteristics of patients with neuropathic pain defined by clinical 
diagnosis of sciatica 
Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Sociodemographic characteristics    
Female (n=609) 277 (61.3) 106 (67.52) 0.76 (0.52, 1.12) 
Age, mean (SD) 
(n=609) 
 
50.4 (14.0) 49.5 (13.7) 1.01 (0.99, 1.02) 
Socio-economic 
status (n=593) 
Higher 
managerial, 
administrative 
and professional 
occupations 
89 (20.3) 40 (25.8) 1 
Intermediate 
occupations 
120 (27.4) 38 (24.5) 1.42 (0.84, 2.39) 
Routine and 
manual 
occupations 
210 (48.0) 73 (47.1) 1.29 (0.82, 2.04) 
Never worked 
and long-term 
unemployed 
18 (4.3) 4 (2.6) 2.13 (1.68, 6.68) 
Smoking status 
(n=608) 
Never 169 (37.5) 58 (36.9) 1 
Ex-smoker 131 (29.1) 56 (35.7) 0.80 (0.52, 1.24) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Current 151 (33.5) 43 (27.4) 1.21 (0.77, 1.89) 
BMI (kg/m2), 
mean (SD) 
(n=601) 
  29.8 (6.0) 29.1 (5.6) 1.02 (0.99, 1.05) 
Health status     
Co-morbidities ‡, 
(n=608) 
No other health 
problems 
277 (61.3) 94 (59.9) 1 
One other 
health problem 
122 (27.0) 36 (22.9) 1.15 (0.74, 1.78) 
Two or more 
other health 
problems 
53 (11.7) 27 (17.2) 0.67 (0.40, 1.12) 
Self-reported 
diabetes  
37 (8.2) 11 (7.0) 1.18 (0.59, 2.38) 
Self-reported 
general health 
(n=608) 
Excellent/ very 
good 
111 (24.6) 35 (22.3) 1 
Good 124 (27.5) 48 (30.6) 0.81 (0.49, 1.35) 
Fair 177 (39.3) 63 (40.1) 0.89 (0.55, 1.43) 
Poor 39 (8.7) 11 (7.0) 1.12 (0.52, 2.41) 
Fatigue (n=593)  214 (74.3) 198 (64.9) 1.18 (0.79, 1.78) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Sleep difficulties 
(n=604) 
 385 (85.8) 129 (83.2) 0.82 (0.50, 1.36) 
Pain 
characteristics 
    
Back pain 
intensity (0-10), 
mean (SD) 
(n=603) 
 5.3 (1.6) 5.3 (1.6) 0.98 (0.87, 1.09) 
Leg pain intensity 
(0-10), mean (SD) 
(n=581) 
 5.6 (2.3) 4.2 (2.2) 1.32 (1.21, 1.44) 
Constant pain 
symptoms 
(n=597) 
 305 (68.7) 96 (62.8) 1.30 (0.89, 1.91) 
Pain described as 
burning pain 
(n=609) 
 166 (36.7) 55 (35.0) 1.08 (0.74. 1.57) 
Duration of back 
pain symptoms in 
current episode 
(n=607) 
< 6 weeks 174 (38.6) 44 (28.2) 1 
6 to 12 weeks 96 (21.3) 30 (19.2) 0.81 (0.48, 1.37) 
> 3 months 181 (40.1) 82 (52.6) 0.59 (0.37, 0.85) 
< 6 weeks 192 (44.2) 59 (39.6) 1 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Duration of leg 
pain symptoms in 
current episode 
(n=583) 
6 to 12 weeks 94 (21.7) 26 (17.5) 1.11 (0.66, 1.87) 
> 3 months 148 (34.1) 64 (43.0) 0.71 (0.47, 1.07) 
Widespread pain 
§ (n=592) 
 171 (38.8) 79 (52.3) 0.58 (0.40, 0.84) 
Leg pain worse 
(n=607) 
 251 (55.8) 28 (17.8) 5.81 (3.71, 9.10) 
Pain location 
(n=609) 
Pain below the 
knee  
375 (83.0) 55 (35.0) 9.03 (6.00, 
13.60) 
Pain in one leg 368 (81.4) 89 (56.7) 3.35 (2.26, 4.97) 
Limitations in activities, participation and risk of persistent disabling pain 
LBLP-related 
disability 
(RMDQ) (0-23), 
mean (SD) 
(n=609) 
 12.9 (5.7) 11.9 (5.7) 1.03 (0.997, 
1.06) 
Pain interference 
with work (0-10)  
||  (n=361), mean 
(SD)  
 6.0 (2.9) 5.4 (2.8) 1.08 (0.99, 1.17) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Risk of persistent 
disabling pain 
(STarT Back) 
(n=589) 
Low risk 53 (12.1) 29 (19.1) 1 
Medium risk 212 (48.5) 64 (42.1) 1.81 (1.06, 3.09) 
High risk 172 (39.4) 59 (38.8) 1.60 (0.93, 2.74) 
Psychological characteristics and illness perceptions 
Depression 
(HADS) (n=609) 
Normal (0 to 7) 295 (65.3) 97 (61.8) 1 
Possible (mild) 
cases (8 to 10) 
82 (18.1) 37 (23.6) 0.73 (0.46, 1.14) 
Probable 
(moderate/seve
re) cases (≥11) 
75 (16.6) 23 (14.7) 1.07 (0.64, 1.80) 
Anxiety (HADS) 
(n=607) 
Normal (0 to 7) 249 (55.2) 67 (43.0) 1 
Possible (mild) 
cases (8 to 10) 
86 (19.1) 34 (21.8) 0.68 (0.42, 1.10) 
Probable 
(moderate/ 
severe) cases 
(≥11) 
116 (25.7) 55 (35.3) 0.57 (0.37, 0.86) 
Pain self-efficacy 
(PSEQ, 0-60)† 
 33.3 (14.7) 36.6 (13.9) 0.98 (0.97, 
0.997) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
(n=593), mean 
(SD) 
Illness 
perceptions  
(IPQ-R)  
Timeline 
“back/leg pain 
will last for a 
long time” 
(agree or 
strongly agree) 
(n=605) 
249 (55.1) 96 (61.5) 0.78 (0.54, 1.13) 
Personal control 
“what I can do 
determines 
whether 
back/leg pain 
gets better” 
(agree or 
strongly agree) 
(n=609) 
162 (36.2) 62 (36.2) 0.87 (0.60, 1.27) 
Neurological examination findings 
Muscle weakness 
** (n=608) 
5/5 347 (76.8) 156 (100.0) 1 
4/5 92 (20.4) 0 (0.00) - 
0 to 3/5 13 (2.9) 0 (0.00) - 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Reflex change 
(n=609) 
None 341 (75.4) 149 (94.9) 1 
Slightly reduced 30 (6.6) 0 (0.00) - 
Significantly 
reduced or 
absent 
81 (17.9) 8 (5.1) 4.42 (2.09, 9.38) 
Sensation to pin-
prick in the leg(s) 
(n=609) 
Normal 226 (50.0) 130 (82.8) 1 
Reduction to 
pin-prick 
175 (38.7) 26 (16.6) 3.87 (2.43, 6.16) 
Loss to pin-prick 51 (11.3) 1 (0.64) 29.33 (4.01, 
214.78) 
Presence of 
allodynia or 
hyperalgesia in 
the leg(s)§§ 
(n=609) 
 47 (10.4) 11 (7.0) 1.54 (0.78, 3.05) 
Neural tension 
test‡‡ (any 
positive test, 
n=609)  
 324 (71.7) 11 (7.0) 33.60 (17.61, 
64.10) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
Pins and needles 
in the leg(s) 
(n=609) 
 256 (56.6) 49 (31.2)  2.88 (1.96, 4.23) 
Pain affects the 
colour of patients 
skin (n=609) 
 51 (11.3) 16 (10.3) 1.12 (0.62, 2.03) 
Neuroimaging     
Clear or possible 
nerve root 
compression 
(n=554) 
 252 (60.7) 45 (32.4) 3.23 (2.15, 4.85) 
Pain medication§§ (n=609)    
Number of pain 
medications   
None 61 (13.5) 23 (14.7) 1 
One 177 (39.2) 69 (44.0) 0.97 (0.56, 1.68) 
Two or more 214 (47.4) 65 (41.4) 1.24 (0.71, 2.16) 
Type of pain 
medication  
First-line 
neuropathic 
pain medication  
54 (12.0) 13 (8.3) 1.50 (0.80, 2.84) 
Basic analgesics  216 (47.8) 73 (46.5) 1.05 (0.73, 1.52) 
Opioids 260 (57.5) 77 (49.0) 1.42 (0.98, 2.03) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica) 
Unadjusted 
odds ratio 
(95% CI) 
Yes, n=452 
(74.2%) 
No, n=157 
(25.8%) 
NSAID’s 68 (15.0) 27 (17.2) 0.85 (0.52, 1.39) 
Skeletal muscle 
relaxants  
11 (2.4) 2 (1.5) 1.93 (0.42, 8.82) 
Figures are frequencies (percentages) unless stated otherwise as mean (SD) 
Odds ratio (confidence intervals) underlined highlights characteristics associated with neuropathic pain. 
Abbreviations: BMI, body mass index. CI, confidence intervals. HADS, Hospital Anxiety and Depression 
scale. Kg/m2, kilograms per metre2. IPQ-R, Illness perceptions questionnaire-revised. NSAID, non-
steroidal anti-inflammatory drugs. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris 
Disability Questionnaire leg version.  SD, standard deviation.  
*Denominator varies for some characteristics due to missing data or not applicable case. 
† Higher scores on PSEQ reflect stronger self-efficacy beliefs 
‡ Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes, and circulation problems in the leg. 
§ Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
|| Applicable to those currently in paid job. 
** Muscle strength was tested according to a 6-point grading scale where; 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
§§ Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes). 
‡‡ Neural tension tests; straight leg raise, femoral stretch and slump test. 
§§ Pain medications include self-reported history of prescribed medications and those purchased over 
the counter  
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5.5.4 Characteristics of patients with neuropathic pain based on a clinical 
diagnosis plus evidence of possible or clear nerve root compression on MRI 
The odds of having a clinical diagnosis of neuropathic pain (with evidence of nerve root 
compression) was 50% less for female patients (OR 0.50, CI 0.35 to 0.70). The mean 
age (SD) of patients with neuropathic pain was 51.9 (13.1) years and for every one-
year increase in age the odds of having neuropathic pain increased by 2% (OR 1.02, CI 
1.01 to 1.03).  
More severe leg pain intensity was associated with neuropathic pain, for every one-
unit increase in NRS score for leg pain intensity, the odds of having neuropathic pain 
(sciatica with nerve root compression) increased by 29% (OR 1.29, CI 1.19 to 1.40). 
Patients with neuropathic pain reported more severe LBLP-related disability (RMDQ) 
mean score (SD) of 13.3 (5.3), for every one-unit increase in the RMDQ score, the odds 
of having neuropathic pain increased by 4% (OR 1.04, CI 1.02 to 1.08). Patients with 
moderate/severe depressive symptoms were 1.80 times more likely to present with 
neuropathic pain compared to those without these symptoms (OR 1.80, CI 1.13 to 
2.87). LBLP patients with a clinical diagnosis of neuropathic pain with evidence of 
nerve root compression reported lower pain self-efficacy scores compared to those 
without (mean (SD) PSEQ 32.2 (14.6) vs. 36.6 (14.1)). Characteristics that described 
pain location and characteristics of the neurological examination were strongly 
associated with neuropathic pain.
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Table 5.5 Baseline characteristics of patients with neuropathic pain based on a clinical 
diagnosis of sciatica and evidence of nerve root compression on MRI 
Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Sociodemographic characteristics    
Female (n=554) 137 (54.4) 213 (70.5) 0.50 (0.35, 0.70) 
Age, mean (SD) 
(n=554) 
 
51.9 (13.1) 48.5 (14.2) 1.02 (1.01, 1.03) 
Socio-economic 
status (n=540) 
Higher 
managerial, 
administrative 
and 
professional 
occupations 
53 (21.7) 70 (23.7) 1 
Intermediate 
occupations 
65 (26.6) 81 (27.4) 1.06 (0.65, 1.72) 
Routine and 
manual 
occupations 
118 (48.4) 134 (45.3) 1.16 (0.75, 1.80) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Never worked 
and long-term 
unemployed 
8 (3.3) 11 (3.7) 0.96 (0.36, 2.56) 
Smoking status 
(n=553) 
Never 93 (36.9) 110 (36.5) 1 
Ex-smoker 76 (30.2) 93 (30.9) 0.97 (0.64, 1.46) 
Current 83 (32.9) 98 (32.6) 1.00 (0.67, 1.50) 
BMI (kg/m2),  
mean (SD) 
(n=549) 
 
29.8 (5.9) 29.1 (5.6) 1.02 (0.99, 1.05) 
Health status     
Co-morbidities‡, 
(n=554) 
No other health 
problems 
157 (62.3) 187 (61.9) 1 
One other 
health problem 
67 (26.6) 76 (25.2) 1.05  (0.71, 1.55) 
Two or more 
other health 
problems 
28 (11.1) 39 (12.9) 0.86 (0.50, 1.45) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Self-reported 
diabetes  
20 (7.9) 22 (7.3) 1.10 (0.58, 2.06) 
Self-reported 
general health 
(n=553) 
Excellent/ very 
good 
65 (25.9) 67 (22.0) 1 
Good 66 (26.3) 90 (29.8) 0.76 (0.47, 1.20) 
Fair 100 (39.8) 122 (40.4) 0.84 (0.55, 1.30) 
Poor 20 (8.0) 23 (7.6) 0.90 (0.45, 1.79) 
Fatigue (n=543)  171 (69.5) 209 (70.4) 1.04 (0.72, 1.51) 
Sleep difficulties 
(n=549) 
 211 (84.4) 253 (84.6) 1.02 (0.64, 1.62) 
Pain characteristics 
Back pain 
intensity (0-10), 
mean (SD) 
(n=543) 
 5.3 (1.7) 5.3 (1.6) 0.99 (0.89, 1.10) 
Leg pain 
intensity (0-10) 
 6.0 (2.3) 4.6 (2.3) 1.29 (1.19, 1.40) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
mean (SD), 
(n=542) 
Constant pain 
symptoms 
(n=542) 
 173 (70.0) 202 (68.5) 1.08 (0.75, 1.55) 
Pain described as 
burning pain 
(n=554) 
 87 (34.5) 112 (37.1) 0.89 (0.63, 1.27) 
Duration of back 
pain symptoms 
in current 
episode (n=552) 
Less than 6 
weeks 
97 (38.5) 97 (32.3) 1 
6 to 12 weeks 58 (23.0) 58 (19.3) 1.00 (0.63, 1.58) 
> 3 months 97 (38.5) 145 (48.3) 0.67 (0.46, 0.98) 
Duration of leg 
pain symptoms 
in current 
episode (n=530) 
Less than 6 
weeks 
106 (43.8) 121 (42.0) 1 
6 to 12 weeks 57 (23.6) 54 (18.8) 1.20 (0.76, 1.90) 
> 3 months 79 (32.6) 113 (39.2) 0.80 (0.54, 1.18) 
Widespread pain 
§ (n=540) 
 71 (28.6) 156 (53.4) 0.35 (0.24, 0.50) 
 190 
 
Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Leg pain worse 
(n=552) 
 166 (66.1) 88 (29.2) 4.73 (3.30, 6.77) 
Pain location 
(n=554) 
Pain below the 
knee  
216 (85.7) 178 (58.9) 4.18 (2.74, 6.37) 
Pain in one leg 210 (83.3) 205 (67.9) 2.37 (1.57, 3.56) 
Limitations in activities, participation and risk of persistent disabling pain 
LBLP-related 
disability 
(RMDQ, 0-23), 
mean (SD) 
(n=554) 
 13.3 (5.3) 11.9 (5.9) 1.04 (1.02, 1.08) 
Pain interference 
with work (0-10) 
|| (n=333), mean 
(SD)  
 6.3 (2.8) 5.5 (3.0) 1.10 (1.02, 1.19) 
Risk of persistent 
disability due to 
back pain (STarT 
back) (n=530) 
Low risk 27 (11.2) 48 (16.3) 1 
Medium risk 116 (48.1) 139 (47.1) 1.48 (0.87, 2.53) 
High risk 98 (40.7) 108 (36.6) 1.61 (0.94, 2.78) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Psychological characteristics and illness perceptions  
Depression 
(HADS) (n=554) 
Normal (0 to 7) 155 (61.5) 200 (66.2) 1 
Possible (mild) 
cases (8 to 10) 
44 (17.5) 64 (21.2) 0.89 (0.57, 1.37) 
Probable 
(moderate/seve
re) cases (≥11) 
53 (21.0) 38 (12.6) 1.80 (1.13, 2.87) 
Anxiety (HADS) 
(n=553) 
Normal (0 to 7) 137 (54.6) 149 (49.3) 1 
Possible (mild) 
cases (8 to 10) 
50 (19.9) 62 (20.5) 0.88 (0.57, 1.36) 
Probable 
(moderate/ 
severe) cases 
(≥11) 
64 (25.5) 91 (30.1) 0.76 (0.52, 1.14) 
Pain self-efficacy 
(PSEQ, 0-60)† 
(n=542), mean 
(SD) 
 32.2 (14.6) 36.1 (14.1) 0.98 (0.97, 0.99) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Illness 
perceptions  
(IPQ-R) 
Timeline 
“back/leg pain 
will last for a 
long time” 
(agree or 
strongly agree) 
(n=554) 
133 (52.8) 181 (59.9) 0.75 (0.53, 1.05) 
Personal control 
“what I can do 
determines 
whether 
back/leg pain 
gets better” 
(agree or 
strongly agree) 
(n=551) 
92 (36.8) 105 (34.9) 1.09 (0.77, 1.54) 
Neurological examination findings 
Muscle 
weakness ** 
(n=553) 
5/5 191 (75.8) 270 (89.7) 1 
4/5 50 (19.8)  31 (10.3) 2.28 (1.40, 3.70) 
0 to 3/5 11 (4.4) 0 (0.0) - 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Reflex change 
(n=554) 
None 169 (67.1) 281 (93.1) 1 
Slightly reduced 22 (8.7) 3 (1.0) 12.19 (3.60, 41.4) 
Significantly 
reduced or 
absent 
61 (24.2) 18 (6.0) 5.63 (3.22, 9.86) 
Sensation to pin-
prick in the leg(s) 
(n=554) 
Normal 125 (49.6) 199 (65.9) 1 
Reduction to 
pin-prick 
95 (37.7) 86 (28.5) 1.76 (1.22, 2.54) 
Loss to pin-prick 32 (12.7) 17 (5.6) 3.00 (1.60, 5.62) 
Presence of 
allodynia or 
hyperalgesia in 
the leg(s)§§ 
(n=554) 
 24 (9.5) 30 (9.9) 0.95 (0.54, 1.68) 
Neural tension 
test‡‡ (any 
positive test, 
n=554) 
 185 (73.4) 122 (40.4) 4.07 (2.84, 5.85) 
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Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Pins and needles 
in the leg(s) 
(n=554) 
 137 (54.4) 140 (46.4) 1.38 (0.99, 1.93) 
Pain affects the 
colour of 
patients skin 
(n=554) 
 28 (11.2) 28 (9.3) 1.22 (0.70, 2.12) 
Pain medication§§ (n=554)    
Number of pain 
medications   
None 32 (12.7) 37 (12.3) 1 
One 97 (38.5) 124 (41.1) 0.90 (0.53, 1.56) 
Two or more 123 (48.8) 141 (46.7) 1.01 (0.59, 1.72) 
Type of pain 
medication (one 
or more)  
First-line 
Neuropathic 
pain medication  
33 (13.1) 28 (9.3) 1.47 (0.86, 2.52) 
Basic analgesics  113 (44.8) 154 (51.0) 0.78 (0.56, 1.09) 
Opioids 151 (59.9) 165 (54.6) 1.24 (0.88, 1.74) 
NSAID’s 46 (18.3) 40 (13.3) 1.46 (0.92, 2.32) 
 195 
 
Characteristics* Neuropathic pain  
(Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression) 
Unadjusted odds 
ratio 
(95% CI) 
Yes,  
n=252 (45.5%) 
No,  
n=302 
(54.5%) 
Skeletal muscle 
relaxants  
8 (3.2) 5 (1.7) 1.95 (0.63, 6.03) 
Figures are frequencies (percentages) unless stated otherwise as mean (SD) 
Odds ratio (confidence intervals) underlined highlights characteristics associated with neuropathic pain.  
Abbreviations: BMI, body mass index. CI, confidence intervals. HADS, Hospital Anxiety and Depression 
scale. Kg/m2, kilograms per metre2. IPQ-R, Illness perceptions questionnaire-revised. NSAID, non-
steroidal anti-inflammatory drugs. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris 
Disability Questionnaire leg version.  SD, standard deviation.  
*Denominator varies for some characteristics due to missing data or not applicable case. 
† Higher scores on PSEQ reflect stronger self-efficacy beliefs 
‡ Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes, and circulation problems in the leg. 
§ Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
|| Applicable to those currently in paid job. 
** Muscle strength was tested according to a 6-point grading scale where;  
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
§§ Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes). 
‡‡ Neural tension tests; straight leg raise, femoral stretch and slump test. 
§§ Pain medications include self-reported history of prescribed medications and those purchased over 
the counter  
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5.5.5 Characteristics of patients with neuropathic pain across three definitions  
Figures 5.2 to 5.5 summarise the overlap and distribution of characteristics that are 
described in this research and are associated with neuropathic pain. Figure 5.4 
summarises the characteristics that were consistently similar or different in LBLP 
patients with neuropathic pain compared to those without, across all three definitions. 
Figure 5.5 summarises pain medication history reported by patients with and without 
neuropathic pain and includes a summary (Figure 5.5b) of the most common pain 
medication used, as reported by patients with neuropathic pain. 
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Figure 5.2 Characteristic associated with only one definition of neuropathic pain  
• Back pain duration > 3 months  
• Currently smoking 
• Difficulties with sleep and/or fatigue 
• More severe back pain intensity 
• Pain pattern (constant) 
• Pain quality (burning) 
• Mild symptoms of depression 
• Mild, moderate or severe symptoms of anxiety 
• Nerve root compression on MRI 
• The presence of an increased response to either 
non-painful or painful stimuli 
• Pain affecting the appearance of the skin 
• Older age 
• Male sex 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and signs 
*Evidence of clear or possible nerve root compression on MRI.  
Sciatica with MRI* 
s-LANSS ≥ 12 
Sciatica 
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Figure 5.3 Characteristic associated with two definitions of neuropathic pain  
• The pain characteristics, leg pain worse than 
back pain, pain in one leg, and the absence of 
widespread pain 
• The presence of severe myotomal weakness, 
neural tension, pins and needles and a slight 
reduction in reflexes 
• Socio-economic status, in particular patients 
who had never worked or were long-term 
unemployed 
Sciatica with MRI* 
s-LANSS ≥ 12 
Sciatica 
• More severe LBLP-related disability 
• High risk of pain related persistent disability 
• Moderate or severe symptoms of depression 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and signs 
*Evidence of clear or possible nerve root compression on MRI 
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Patients without neuropathic pain 
 Associated with neuropathic pain: 
• More severe leg pain intensity  
• Presence of pain below the knee  
• Weaker belief in which patient believes he/she can cope with 
normal activities despite being in pain (pain self-efficacy) 
• Reduction in sensation to pin-prick 
• The presence of mild muscle weakness (myotomal)  
• A significant reduction or absence in reflex 
Not associated with neuropathic pain:  
• BMI  
• The number of other self-reported health problems (co-
morbidities) 
• Self-reported history of diabetes 
• Duration of leg pain  
• Patient’s perception of their ability to influence and control their 
symptoms  
• Patient’s perception that their back and/or leg problem was 
going to last a long time 
Figure 5.4 Characteristics consistently associated with neuropathic pain across all three definitions and characteristics that were similar between 
patients with and without neuropathic pain 
Sciatica with MRI* 
s-LANSS ≥ 12 
Sciatica 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and signs 
*Evidence of clear or possible nerve root compression on MRI.  
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Not associated with neuropathic pain:  
 Associated with neuropathic pain (s-LANSS): 
Figure 5.5 Summary of pain medication use in patients with and without neuropathic pain  
• Self-reported use of two or more types of pain 
medication † 
• Self-reported use of opioid medication † 
Sciatica with MRI* 
s-LANSS ≥ 12 
Sciatica 
Patients without neuropathic pain 
• Self-reported use of one type of pain  medication † 
• Self-reported use of basic pain medication†  
• Self-reported use of first-line neuropathic 
medication  
• Self-reported use of non-steroidal anti-
inflammatory medication† 
• Self-reported use of skeletal muscle relaxants 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and signs 
*Evidence of clear or possible nerve root compression on MRI.  
†Pain medications that include prescribed medications and those purchased over the counter 
‡Percentages are given for one definition of neuropathic pain (s-LANSS ≥ 12) but were similar across all three definitions   
Amitriptyline 
Tramadol 
Ibuprofen† 
Paracetamol† 
Co-codamol† 
b. Pain medication type most commonly 
reported (percentage‡)  a. Association with neuropathic pain  
35% 
29% 
27% 
8% 
8% 
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5.6 Discussion  
The aims of this research were to provide point prevalence estimates and to describe 
the characteristics of LBLP primary care patients with neuropathic pain, using case 
ascertainment tools and clinical examination to define cases of possible and/or 
probable neuropathic pain. As there is no “gold standard” diagnostic test for 
neuropathic pain, cases were defined in three ways, i) using s-LANSS, ii) clinical 
diagnosis of sciatica and iii) clinical diagnosis of sciatica with evidence of nerve root 
compression on MRI, to allow comparisons to be made. In this section, the baseline 
results are discussed and compared to previous literature. The strengths and 
weaknesses of these analyses are then discussed before considering some of the 
implications of the results for future research and clinical practice.  
5.6.1 Prevalence  
This is the first research, to the author’s knowledge, that aimed to estimate the 
prevalence of neuropathic pain in LBLP patients consulting in primary care in the UK.  
The results of this research show there is considerable variation in the prevalence of 
neuropathic pain in this patient population depending on the definition used. The 
lower estimate was found in LBLP patients with probable neuropathic pain defined as 
having sciatica plus evidence of nerve root compression, the highest estimate was 
found in those patients with possible neuropathic pain defined as having a clinical 
diagnosis of sciatica (without taking into account MRI findings). Just under one quarter 
of patients were considered to have neuropathic pain consistently across all three 
definitions.  
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Similar to the prevalence estimates presented in this chapter, estimates derived from 
studies included in the systematic review in this thesis (the reader is referred to 
Chapter 3) varied considerably. In previous research using the s-LANSS to identify cases 
of neuropathic pain as in this research and in a similar patient population with LBLP, 
prevalence was estimated as 33% (based on research using 45 LBLP patients by Walsh 
and Hall (2009)) which is somewhat lower to the prevalence presented here (48%). 
Previous prevalence estimates of neuropathic pain based on clinical diagnosis of 
sciatica are barely more comparable. Based on one study of LBLP patients (n=51) with 
a clinical diagnosis of sciatica with evidence of nerve root compression based on MRI, 
prevalence was estimated to be 37% (Gierthmühlen et al. 2017). The variation in 
prevalence estimates derived from the current research and in comparison to those 
previously published highlights the complexity of defining neuropathic pain in this 
patient population. 
Nearly a quarter of patients defined as having neuropathic pain using the most 
stringent definition (clinical diagnosis and evidence of nerve root compression on 
imaging), did not have neuropathic pain as defined by s-LANSS. Conversely, a 
proportion (11%) of patients in the study clinically diagnosed with referred leg pain 
had neuropathic pain as defined by s-LANSS. Sciatica is assumed to be neuropathic in 
nature (Dworkin 2002) but the evidence from this study and from others (for example 
the study by Mahn et al. (2011)), lends support to the argument that the pain 
mechanism underlying cases of sciatica is not exclusively neuropathic, or perhaps in 
some cases, non-neuropathic at all. On the other hand, referred pain which is assumed 
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to be due to nociceptive pain mechanisms (Bogduk 2009), may present with signs and 
symptoms of neuropathic pain, as suggested by the evidence from this and other 
studies (Walsh and Hall 2009, Schafer et al. 2011, Gierthmühlen et al. 2017). These 
results support the argument for the presence of distinct sub-groups of neuropathic 
pain in this patient population. In order to understand the potential relevance of sub-
groups of LBLP patients with neuropathic pain it is important to understand the 
prognosis of this patient population. A starting point is to describe and understand the 
baseline characteristics of LBLP patients with neuropathic pain. The following section 
will discuss the baseline characteristics of LBLP patients with neuropathic pain in this 
research, and make comparisons with existing literature. 
5.6.2 Baseline characteristics 
5.6.2.1 Key findings 
In this research, there was consistent evidence across the three definitions of 
neuropathic pain that leg pain intensity is higher compared to those without, pain is 
more commonly below the knee, and that LBLP patients with neuropathic pain report 
similar levels of back pain intensity compared to those without. Patients consistently 
(across three definitions) presented with mild (myotomal) muscle weakness and a 
significant reduction or loss of reflex and there was some but less consistent evidence 
of a presence of pins and needles, an increased pain response and neural tension. 
These characteristics provide an emerging description of the profile of this patient 
population. There was some consistent evidence (across two definitions) that patients 
report higher levels of LBLP-related disability which is comparable to other studies of 
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similar patient populations (Morsø et al. 2011, Schafer et al. 2011, Walsh and Hall 
2009). 
The findings on pain intensity are comparable to those of Morsø et al. (2011), which 
used PainDETECT to define neuropathic pain in LBLP patients. Other studies reported 
inconsistent findings on this variable, which is most likely due to presenting a 
composite score for pain including both low back and leg pain (Freynhagen et al. 2008, 
Schafer et al. 2011, Tutoglu et al. 2015, Walsh and Hall 2009, Gierthmühlen et al. 
2017). That leg pain intensity is higher in this patient population may be important 
prognostic information as higher pain levels are associated with worse outcome in 
back pain patients in primary care (Dunn et al. 2011), and in patients with post-
herpetic neuralgia (a condition which is considered neuropathic in nature) (Boogaard 
et al. 2015).  
Similarly, the findings that LBLP patients with neuropathic pain consistently presented 
with pain below the knee is also comparable to the reports of several previous studies 
(Schafer et al. 2011, Smart et al. 2012a, Freynhagen et al. 2008, Beith et al. 2011). Pain 
below the knee was associated with neuropathic pain defined using PainDETECT (Beith 
et al. 2011) and as defined by clinical diagnosis (Schafer et al. 2011, Smart et al. 2012a, 
Freynhagen et al. 2008) in LBLP patients. In the current study, as in previously 
published literature, pain below the knee was common in patients with and without 
neuropathic pain, it is not clear whether having pain below the knee is a precise 
indicator of neuropathic pain. 
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5.6.2.2 Characteristics related to definition of neuropathic pain 
Neuropathic pain is typically characterised by signs and symptoms that can be 
classified as either positive or negative (see Figure 1.1 (page 4) for a more detailed 
description of signs and symptoms of neuropathic pain). Patients with neuropathic 
pain defined using s-LANSS had more positive than negative signs and symptoms of 
neuropathic pain whereas those patients with neuropathic pain based on a clinical 
diagnosis of sciatica predominantly had negative signs. This provides evidence that the 
profile of patients with neuropathic pain defined using s-LANSS is distinct from those 
defined using clinical examination. This is not the first research to suggest that signs 
and symptoms vary between individual patients with neuropathic pain with the same 
clinical condition (for example see Mahn et al. (2011) and Baron et al. (2012)), and it is 
likely that the signs and symptoms of neuropathic pain represent variation in the 
underlying pathophysiological mechanisms in patients’ presenting symptoms (Baron et 
al. 2017). 
In the current research, characteristics related to sociodemographic profile, health 
status, LBLP-related pain severity and disability, psychological and illness perception 
variables, and history of either prescribed or over-the-counter pain medication in 
patients with and without neuropathic pain, were described for all three case 
definitions. There is evidence from previous research (see the results of a Systematic 
review in this thesis, Chapter 3, Section 3.4.3.2.3 (page 74) Psychological 
characteristics) that patients with neuropathic pain based on clinical examination 
present with fewer differences in characteristics such as depression and anxiety (for 
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example see Gierthmühlen et al. (2017), Walsh and Hall (2009) compared to those 
with neuropathic pain based on case ascertainment tools (for example, see Tutoglu et 
al. (2015), Uher and Bob (2013)). It is reasonable to suggest that the presence of more 
positive signs of neuropathic pain may be more distressing than negative signs and 
may explain why patients with neuropathic pain based on s-LANSS present with worse 
LBLP-morbidity, but based on the study design used in the research in this chapter this 
is purely speculative. 
Previous research on neck and upper-limb pain patients with neuropathic pain based 
on clinical diagnosis, investigated similar characteristics in patients clinically diagnosed 
with neuropathic pain and reported that patients with “possible” and “probable” 
neuropathic pain were similar in terms of signs, symptoms, pain severity and pain 
medication use (Tampin et al. 2013). This is the first time to the author’s knowledge, 
that LBLP patients with “possible” and “probable” neuropathic pain based on clinical 
diagnosis have been compared. Imaging can be useful for identifying cases of serious 
pathology such as suspected cauda equina, suspected malignancy and following the 
traumatic onset of pain, and when invasive management options such as surgery are 
being considered. The argument raised by the findings of this research being that 
clinical diagnosis alone is sufficient for defining neuropathic pain, this is particularly the 
case for patients who consult in primary care where routine imaging is not 
recommended by clinical guidelines (NICE NG59 2016).  
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5.6.2.3 Psychological characteristics and pain duration  
The presence of neuropathic pain was consistently associated with lower pain self-
efficacy. Self-efficacy is a patient’s degree of confidence in their ability to perform 
normal activities and tasks (such as household chores and increasing activity levels) 
despite being in pain. The current study provides new evidence that LBLP patients with 
neuropathic pain irrespective of definition, report lower pain self-efficacy. This 
research is the first to report pain self-efficacy in this specific population of LBLP 
patients with neuropathic pain, previous studies also found that patients with chronic 
pain thought to be neuropathic in nature reported less confidence in coping with pain 
compared to those with non-neuropathic pain.  Previous research in LBP patients in 
primary care reported that pain self-efficacy was one of four psychological variables 
that was strongly related to worse back pain-related disability six months after 
consultation (Foster et al. 2010).  
In this research there was no association between duration of leg pain and 
neuropathic pain and this was consistent across the three definitions of neuropathic 
pain. Longer back pain duration (greater than three months) was associated with 
neuropathic pain, defined by sciatica clinical diagnosis, but not in the other two 
definition of neuropathic pain. From previous studies that reported pain duration, 
there was some evidence that LBLP patients with neuropathic pain report similar pain 
duration to those patients without (Schafer et al. 2011, Gierthmühlen et al. 2017). In 
LBP populations, the duration of symptoms at baseline has been reported to influence 
the course (Hestbaek et al. 2003) and it is considered an important prognostic 
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indicator for poor outcome (Dunn et al. 2010). Although it is often assumed that 
neuropathic pain persists over time, it is not clear from the results of the current study 
and others, whether primary care LBLP patients with neuropathic pain go on to have 
persistent symptoms. 
5.6.2.4 Pain medication use 
In this research, LBLP patients with neuropathic pain commonly reported having been 
prescribed or purchased over-the-counter pain medication. Patients with neuropathic 
pain (across the three definitions) were no more likely to self-report having been 
prescribed or having purchased pain medication at baseline compared to those 
without. Patients with neuropathic pain based on s-LANSS presented with higher back 
pain intensity, worse health status and psychological morbidity and this in part may 
contribute to the increased use or prescription of medications found in this study. Few 
patients in this research reported having used specific medication for neuropathic pain 
and LBLP patients with neuropathic pain used specific medication for first line 
treatment of neuropathic pain no more often compared to those without. These 
results are comparable to previous studies reporting medication use in chronic pain 
patients with neuropathic pain (Torrance et al. 2007). In previous research, increased 
use of pain medication has been reported in LBLP patients with neuropathic pain 
based on clinical diagnosis (Freynhagen et al. 2008) and on PainDETECT (Morsø et al. 
2011).  It is not possible, using a cross-sectional study design, to investigate whether 
patients using pain medication gained effective pain relief and this is addressed further 
 209 
 
using longitudinal data in Chapter 9, a detailed report of further limitations of this 
study design are provided in the section below. 
 5.6.3 Strengths and limitations 
Strengths of this research include the large number of patients and the wide variety of 
characteristics, allowing a very detailed description of LBLP patients with and without 
neuropathic pain, in terms of their sociodemographic, pain and disability related 
characteristics as well as their general health and psychological profile. Additionally, 
this is the first research to describe prevalence and characteristics of LBLP patients 
with neuropathic pain by s-LANSS and also according to the NeupSIG definitions, first 
published by Treede et al. (2008) and updated by Finnerup et al. (2016). This is a novel 
approach for this patient population and in the absence of a gold standard for 
neuropathic pain, it provides interesting and useful insights.  
Patients with neuropathic pain defined by a clinical diagnosis of sciatica and those with 
the more stringent neuropathic pain definition of sciatica and evidence of nerve root 
compression, shared large number of similarities in pain characteristics and findings of 
neurological examination. This is explained by the fact that these two definitions of 
neuropathic pain were defined in the same way (in terms of clinical assessment) other 
than the evidence of nerve root compression on MRI. Further to this, findings from 
neurological examination were found to be very strongly associated with neuropathic 
pain (defined as a clinical diagnosis of sciatica either with or without evidence of nerve 
root compression), the implication being a risk of bias. Incorporation bias can lead to 
an overestimation of the strength of an association between a characteristic and an 
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outcome, in this research neuropathic pain (Worster and Carpenter 2008). In this 
research, the comparison of patients with neuropathic pain defined in three ways, 
adds confidence about the characteristics of these patients, regardless of method of 
definition. Despite some evidence of incorporation bias in this research overall there is 
little impact on the main findings of the study. 
Possible errors arising from the classification of pain medications (called 
misclassification bias) is a further limitation of the study design. An example of 
potential misclassification in research in this chapter is the categorisation of Co-
codamol and Codeine. Co-codamol and Codeine in the current research were 
categorised as an opioid, however they are often purchased by patients over-the-
counter in weak doses and it may be more representative to classify them as basic 
analgesia or as weak opioids. Research in Chapter 9 of this thesis addresses these 
problems using data collected from the review of medical records.  
5.6.4 Implications for clinical practice and research 
Clinicians working in primary care are often interested in questions concerning the 
presentation of conditions. Whilst cross-sectional research does not imply causality or 
any indication of timeline, it is useful for providing a description of a condition, in this 
instance, neuropathic pain in patients with LBLP. This research has identified that in 
many cases in primary care, LBLP may have underlying mechanisms that are 
neuropathic and LBLP patients with neuropathic pain consistently report higher leg 
pain intensity, pain below the knee and worse pain self-efficacy compared to those 
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without. They may also present with neurological changes on clinical examination 
characteristic of sensory loss.  
This research reported large variation in prevalence estimates between definitions of 
neuropathic pain which highlights the complexity of identifying neuropathic pain in 
LBLP patients in the absence of a gold standard. Despite some consensus for the 
methods of defining neuropathic pain there is still considerable controversy (see Spahr 
et al. (2017) and Ochoa (2009) for examples) and there is an argument that the 
dichotomous nature of the classification system (patients either have pain that is 
nociceptive or neuropathic) is not appropriate for back pain patients (Kosek et al. 
2016). Where conditions are difficult to define, or diagnose, prognosis of the condition 
becomes more important. There is a need for high quality research on the prognosis of 
LBLP patients with neuropathic pain, both in terms of determining clinical course 
(overall prognosis) and prognostic factors that are linked to the persistence of 
neuropathic pain over time.  
LBLP patients with neuropathic pain based on PainDETECT have been reported to have 
higher mean pain intensity and higher mean pain-related disability over time 
compared to those patients without (Morsø et al. 2011). Analysis of longitudinal data 
in Chapter 6 will investigate the clinical course of LBLP patients with neuropathic pain 
at baseline based on the three definitions used in this chapter in terms of pain 
intensity and LBLP-related disability over time compared to those patients without. 
Characteristics including leg pain intensity, the presence of a reduction or loss to pin-
prick sensation that may be associated with neuropathic pain at baseline will be used 
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in research found in later chapters (Chapter 8) investigating prognostic factors of 
persistent neuropathic pain in this patient population. 
Finally, the current findings provide a snapshot of medication use in patients with and 
without neuropathic pain who had recently consulted their general practice. Research 
in Chapter 9 reports on a longitudinal analysis of electronic medical and prescribing 
records collected from GP surgeries of consenting patients in the ATLAS study which 
investigates the pain medications prescribed to patients with neuropathic pain at 
baseline.  
5.7 Conclusions 
In the research in this chapter, the prevalence and characteristics of LBLP patients with 
neuropathic pain were investigated. There was considerable variation in prevalence 
estimates between the three definitions of neuropathic pain (ranging from 46% to 
74%). Patients with neuropathic pain (irrespective of neuropathic pain definition) 
reported higher leg pain intensity, worse pain self-efficacy, more frequently had pain 
below the knee compared to those without. Patients across all three definitions 
presented with negative signs of neuropathic pain, those with neuropathic pain based 
on s-LANSS presented with more positive signs than negative signs suggesting the 
profile of neuropathic pain varies within LBLP patients. Patients defined as having 
neuropathic pain based on the stringent definition of sciatica with evidence of nerve 
root compression on MRI presented with a similar profile as patients defined as having 
sciatica irrespective of imaging findings, suggesting that imaging in primary care is no 
more useful than clinical examination alone in the identification of cases of 
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neuropathic pain. Research in Chapter 6 will investigate the clinical course of LBLP 
patients with neuropathic pain using the three definitions described in this research, 
this will contribute to a better understanding of each of the three neuropathic pain 
profiles identified in the current chapter.  
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Chapter Six. Clinical course of patients with and without 
neuropathic pain consulting in primary care with low back-related 
leg pain 
6.1 Introduction  
Previous chapters of this thesis have highlighted the gaps in the published evidence 
from epidemiological research about the prognosis and the clinical course of LBLP 
patients with or without neuropathic pain (see Chapter 3 for results of a systematic 
review of the literature). This chapter describes the clinical course of LBLP patients 
with and without neuropathic pain in terms of pain intensity and LBLP-related 
disability, over three years. Comparisons are made between the results of this 
research and relevant literature, and the clinical and research implications of these 
findings are discussed.  
6.2 Aims and objectives 
6.2.1 Overall aim 
To describe the clinical course of LBLP patients with neuropathic pain at baseline in 
terms of pain intensity and LBLP-related disability over short, intermediate and long 
term time points, and compare to those without. 
6.2.2 Objectives 
1. To provide a comparison of the clinical course of LBLP patients with and 
without neuropathic pain defined by case ascertainment tools and clinical 
examination in terms of pain intensity over a three year follow-up period. 
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2. To provide a comparison of the clinical course of LBLP patients with and 
without neuropathic pain defined by case ascertainment tools and clinical 
examination in terms of leg and back pain-related disability over a three year 
follow-up period. 
6.3 Methods 
Full details of the study design, data collection, methods used to identify cases of 
neuropathic pain have been described previously in this thesis (see Chapter 4, Study 
design and methods) and are summarised below in sections 6.3.1 to 6.3.3.  
6.3.1 Study design  
As in Chapter 5, the research presented in this chapter is based on secondary analysis 
of patients in the ATLAS cohort study. The reader is referred to Chapter 4, section 4.3 
(page 112), for a detailed report of the population of interest, inclusion and exclusion 
criteria in the ATLAS study. The research in this chapter uses ATLAS cohort study data 
from baseline and then three follow-up points: four months, twelve months and three 
years. 
6.3.2 Neuropathic pain definitions 
Neuropathic pain in this chapter was based on the three definitions previously 
described in the research in Chapter 5. Two of the definitions of neuropathic pain 
could be described as “possible” neuropathic pain (those based on s-LANSS and a 
clinical diagnosis of sciatica), the third definition could be described as having 
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“probable” neuropathic pain (based on a clinical definition of sciatica with evidence of 
nerve root compression on MRI).  
6.3.3 Measures of clinical course 
Pain intensity and leg and back-related disability at baseline, four-months, twelve-
months and three-years, were used to describe the clinical course of this patient 
population. Pain intensity was determined as the highest of mean leg pain intensity or 
mean back pain intensity in the previous two-weeks where leg pain was determined as 
the mean of three 0-10 NRS for current, usual and least leg pain over the previous two 
weeks and back pain as the mean of current, usual and least back pain over the 
previous two weeks. LBLP-related disability was measured using the RMDQ (Roland 
and Morris 1983) leg version (Patrick et al. 1995) which has 23 items scored from 0 to 
23 with higher scores indicating higher disability.  
6.4 Statistical analysis 
Linear mixed-effect models were used to estimate the unadjusted mean of pain 
intensity and disability at all follow-up time-points (four months, twelve months and 
three years) in order to describe the clinical course of patients. The models included a 
neuropathic pain indicator variable by time interaction to obtain the estimated means 
(and 95% CI), at each follow-up time-point. Margins plots were used to summarise the 
information on the clinical course graphically. CI were obtained to evaluate the 
uncertainty of estimates with respect to missing data (Ibrahim et al. 2012). Models 
were fitted separately for pain intensity and disability. Further models were fitted to 
describe the effects of baseline scores on clinical course (adjusted mean and (95% CI)) 
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by including the baseline pain intensity and separately baseline disability by time 
interaction in the model. This process was then repeated to investigate the clinical 
course of patients with and without neuropathic pain using the other definitions of 
neuropathic pain (based on a clinical diagnosis of sciatica with and without evidence of 
nerve root compression on imaging). 
6.5 Results 
6.5.1 Study population  
Physiotherapy treatment received by patients with and without neuropathic pain 
based on the three definitions of neuropathic pain was largely similar (Table 6.1 
summarises the treatment received by LBLP patients based on three definitions of 
neuropathic pain). The proportion of patients with neuropathic pain referred for 
further treatment or investigations ranged from 12.9% to 18.7% for three definitions 
of neuropathic pain. A higher proportion of patients with neuropathic pain based on a 
clinical diagnosis of sciatica with evidence of nerve root compression on MRI were 
referred for an epidural injection or for further investigation and management by 
spinal surgeons (14.3%, 36 out of 251) compared to those with neuropathic pain based 
on s-LANSS (7.5%, 22 out of 293) or sciatica without evidence of nerve root 
compression (8.0%, 36 out of 449).  Few patients without a diagnosis of sciatica were 
referred for an epidural injection or to spinal surgeons (n=4). See Chapter 4, section 
4.10 (page 138) for a report on the response to follow up and a description of baseline 
characteristics of patients who completed questionnaires at follow-up compared to 
those who did not.  
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Table 6.1 Treatment (care pathway) received by patients across three definitions of neuropathic pain  
Care pathway (n=606) 
Neuropathic pain definition 
s-LANSS  12 Clinical diagnosis of sciatica 
Clinical diagnosis of sciatica 
with clear or possible 
evidence of nerve root 
compression 
Yes, n=293 No, 
n=310 
Yes, n=449 No, 
n=157 
Yes, n=251 No, 
n=300 
Physiotherapy (0 to 2 sessions) 126 (43.0) 157 (50.7) 198 (44.1) 85 (54.1) 91 (36.3) 151 (50.3) 
Physiotherapy (3 or more sessions) 126 (43.0) 125 (40.3) 193 (43.0) 60 (38.2) 113 (45.0) 127 (42.3) 
Number of referrals for further treatment or 
investigation* 
41 (14.0) 28 (9.0) 58 (12.9) 12 (7.6) 47 (18.7) 22 (7.3) 
Referrals 
to/for 
Pain specialists (pain clinic) 14 (4.8) 7 (2.3) 16 (3.6) 6 (3.8) 6 (2.4) 15 (5.0) 
Epidural injections or to spinal surgeons 22 (7.5) 18 (5.8) 36 (8.0) 4 (2.6) 36 (14.3) 4 (1.3) 
Spinal pain service (ESP practitioners) 9 (3.1) 10 (3.2) 15 (3.3) 5 (3.2) 12 (4.8) 7 (2.3) 
Figures are frequencies (percentages)  
S-LANSS, self-report version of Leeds Assessment for Neurological Symptoms and Signs neuropathic pain scale. 
* Referrals were made for treatment (for example epidural injections, pain management) or for further investigation (including referrals to Extended Scope Physiotherapy 
(ESP) practitioners in a dedicated spinal pain service, spinal surgeons and pain specialists).
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6.5.2 Clinical course of pain intensity 
Pain intensity (the highest of either mean leg or mean back pain intensity) across all 
three definitions decreased over time and most of the change occurred between 
baseline and four-months (see Boxes 6.2 to 6.4 for a comparison of the pain intensity 
over three years in LBLP patients with neuropathic pain to those without). Mean 
(unadjusted) pain intensity of patients with neuropathic pain at baseline (across three 
definitions) ranged from 6.1 to 6.3, decreasing to between 3.8 and 4.3 at four-months. 
Improvement in pain intensity plateaued around four months and changed very little 
at three years for all three definitions (mean pain intensity of patients with 
neuropathic pain at three-years ranged from 3.3 to 3.9 for three definitions). When 
baseline pain intensity was adjusted for in all the three definitions, patients with 
neuropathic pain based on s-LANSS had significantly higher mean pain intensity at 
twelve months and three-years compared to those without, this difference was not 
consistent across the two other definitions. After adjusting for baseline scores, 
patients with neuropathic pain (based on a clinical diagnosis of sciatica) had lower 
mean pain intensity compared to those patients without; this was statistically 
significant at twelve months (p = 0.011) and at three years (p=0.01). Those patients 
with sciatica plus MRI evidence of nerve root compression had lower mean pain 
intensity at four months (p=0.004), twelve months (p<0.001) and at three years 
(p=0.007) compared to those without, after adjusting for baseline pain intensity.  
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Box 6.1 Three year clinical course (mean pain intensity*) of patients with and without 
neuropathic pain (based on s-LANSS) at baseline 
Unadjusted clinical course 
 
Clinical course adjusted for baseline pain score 
Follow-up point Neuropathic pain (s-LANSS  12) p 
Yes, n=293 (48.4%) No, n=313 (51.7%) 
Baseline 5.9 (5.7 to 6.1) 5.9 (5.7 to 6.1) - 
Four months 4.0 (3.8 to 4.3) 3.7 (3.4 to 4.0) 0.118 
Twelve months 4.3 (4.0 to 4.5) 3.1 (2.8 to 3.3) < 0.001 
Three years 3.7 (3.4 to 4.1) 3.1 (2.8 to 3.4) 0.02 
Abbreviations: NRS, numerical rating scale. s-LANSS, self-report version of the Leeds Assessment of 
Neuropathic Symptoms and Signs neuropathic pain scale. *Highest of leg or back pain intensity (mean of 3 
NRS, 0-10)). 95% confidence intervals are shown in parentheses 
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Box 6.2 Three year clinical course (mean pain intensity*) of patients with and without 
neuropathic pain (based on a clinical diagnosis of sciatica) at baseline 
Unadjusted clinical course 
 
Clinical course adjusted for baseline pain score 
Follow-up point Neuropathic pain (clinical diagnosis of sciatica) p 
Yes, n=452 (74.2%) No, n=157 (25.8%) 
Baseline 5.9 (5.7 to 6.1) 5.9 (5.7 to 6.1) - 
Four months 3.8 (3.6 to 4.0) 4.1 (3.7 to 4.5) 0.205 
Twelve months 3.5 (3.3 to 3.7) 4.1 (3.7 to 4.5) 0.011 
Three years 3.2 (3.0 to 3.5) 4.0 (3.5 to 4.4) 0.01 
Abbreviations: NRS, numerical rating scale.  
*Highest of leg or back pain intensity (mean of 3 NRS, 0-10)). 95% confidence intervals are shown in 
parentheses 
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 Box 6.3 Three year clinical course (mean pain intensity*) of patients with and without 
neuropathic pain (based on a clinical diagnosis of sciatica with evidence of nerve root 
compression) at baseline  
Unadjusted clinical course 
 
Clinical course adjusted for baseline pain score 
 Follow-up point Neuropathic pain (clinical diagnosis of sciatica 
with evidence of nerve root compression) 
p 
Yes, n=252 (45.5%) No, n=302 (54.5%) 
Baseline 5.9 (5.7 to 6.1) 5.9 (5.7 to 6.1) - 
Four months 3.6 (3.3 to 3.9) 4.3 (4.0 to 4.5) 0.004 
Twelve months 3.1 (2.8 to 3.4) 4.2 (3.9 to 4.4) <0.001 
Three years 3.0 (2.7 to 3.3) 3.7 (3.4 to 4.0) 0.007 
Abbreviations: NRS, numerical rating scale.  
*Highest of leg or back pain intensity (mean of 3 NRS, 0-10)). 95% confidence intervals are shown in 
parentheses 
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6.5.3 Clinical course of leg and back pain-related disability  
As with pain intensity, the course of LBLP patients with and without neuropathic pain, 
in terms of mean LBLP-related disability, improved over time for patients using all 
three definitions of neuropathic pain (see Boxes 6.4 to 6.6 for a comparison of LBLP-
related disability over three years in patients with neuropathic pain to those without) 
and most of the change occurred between baseline (mean unadjusted RMDQ scores 
ranged from 12.9 to 13.8 across the three definitions) and four months (mean 
unadjusted RMDQ scores ranged from 8.6 to 11.5). Compared to patients without 
neuropathic pain, when baseline RMDQ scores were adjusted, patients with 
neuropathic pain based on s-LANSS had higher RMDQ scores at four months (p=0.013), 
at twelve months (p<0.001) and at three years (p=0.016). This finding was specific to 
patients with neuropathic pain based on s-LANSS; patients with neuropathic pain as 
defined by clinical diagnosis of sciatica (with or without evidence of nerve root 
compression) did not have significantly different RMDQ scores compared to those 
without. Patients without neuropathic pain defined using s-LANSS had lower LBLP 
related disability at follow-up compared to those patients without neuropathic pain 
defined by clinical diagnosis of sciatica either with or without evidence of nerve root 
compression.   
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Box 6.4 Three year clinical course (leg and back pain-related disability*) of patients 
with and without neuropathic pain (based on s-LANSS) at baseline 
Unadjusted clinical course 
 
Clinical course adjusted for baseline RMDQ score 
 Follow-up point Neuropathic pain (s-LANSS  12) p 
Yes, n=293 (48.4%) No, n=313 (51.7%) 
Baseline 12.3 (11.8 to 12.8) 12.3 (11.8 to 12.8) - 
Four months 9.0 (8.3 to 9.6) 7.7 (7.1 to 8.3) 0.013 
Twelve months 9.2 (8.6 to 9.8) 6.7 (6.1 to 7.3) <0.001 
Three years 6.7 (6.0 to 7.4) 5.3 (4.7 to 6.0) 0.016 
Abbreviations: NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire leg 
version. s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs 
neuropathic pain scale. *LBLP-related disability measured using RMDQ adapted for leg pain. 95% 
confidence intervals are shown in parentheses 
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Box 6.5 Three year clinical course (leg and back pain-related disability*) of patients 
with and without neuropathic pain (clinical diagnosis of sciatica) at baseline 
Unadjusted clinical course 
 
Clinical course adjusted for baseline RMDQ score 
Follow-up point Neuropathic pain (clinical diagnosis of sciatica) p 
Yes, n=452 (74.2%) No, n=157 (25.8%) 
Baseline 12.3 (11.8 to 12.8) 12.3 (11.8 to 12.8) - 
Four months 8.2 (7.7 to 8.7) 8.5 (7.6 to 9.4) 0.706 
Twelve months 7.9 (7.4 to 8.3) 7.9 (7.1 to 8.8) 0.911 
Three years 5.8 (5.2 to 6.3) 6.7 (5.7 to 7.7) 0.149 
Abbreviations: NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire (RMDQ) leg 
version. 
* LBLP-related disability measured using RMDQ adapted for leg pain. 95% confidence intervals are 
shown in parentheses 
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Box 6.6 Three year clinical course (leg and back pain-related disability*) of patients with 
and without neuropathic pain (clinical diagnosis of sciatica with evidence of nerve root 
compression) at baseline 
Unadjusted clinical course 
 
Clinical course adjusted for baseline RMDQ score 
 Follow-up point Neuropathic pain (clinical diagnosis of sciatica 
with evidence of nerve root compression) 
p 
Yes, n=252 (45.5%) No, n=302 (54.5%) 
Baseline 12.2 (11.7 to 12.8) 12.2 (11.7 to 12.8) - 
Four months 8.1 (7.4 to 8.7) 8.4 (7.7 to 9.0) 0.554 
Twelve months 7.3 (6.6 to 7.9) 8.3 (7.7 to 8.9)  0.047 
Three years 5.4 (4.6 to 6.1) 6.2 (5.5 to 7.0) 0.15 
Abbreviations: NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire (RMDQ) leg 
version. 
 * LBLP-related disability  measured using RMDQ adapted for leg pain. 95% confidence intervals are shown 
in parentheses 
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6.6 Discussion   
The research in this chapter investigates for the first time, the clinical course of LBLP 
patients consulting in primary care with and without neuropathic pain according to 
three definitions of neuropathic pain over short, intermediate and long-term follow-
up. The clinical course of patients with and without neuropathic pain at baseline in 
terms of pain intensity and LBLP-related disability, showed some consistent similarities 
irrespective of the definitions used. Most improvement in both pain and disability 
occurred shortly after consultation in primary care, between baseline and four-
months, followed by a plateau through to three years follow-up.  
This pattern of improvement was expected as the clinical course of LBP patients has 
been shown to have a rapid pattern of improvement within the first three to four 
months, followed by further but smaller improvements, up to twelve months (Artus et 
al. 2014). The finding that the clinical course is worse in patients with neuropathic pain 
based on s-LANSS compares with previous research on the clinical course (over 12 
months) of LBLP patients using PainDETECT to define neuropathic pain (Morsø et al. 
2011). The course of patients with neuropathic pain based on clinical diagnosis of 
sciatica (with or without nerve root compression) was more favourable than that of 
patients with neuropathic pain based on s-LANSS. This supports the argument that the 
course of sciatica seems to be favourable in most cases (Vroomen et al. 2000) and 
suggests that the course of LBLP patients with neuropathic pain being worse than for 
those without, is dependent on the definition of neuropathic pain.  
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One of the assumptions underpinning the research in this thesis, and is Supported by 
anecdotal and some empirical evidence is that the clinical course of patients with 
neuropathic pain is worse compared to those without. This would suggest that in the 
group of patients with “probable” neuropathic pain (those patients with a clinical 
diagnosis of sciatica with evidence of nerve root compression) the clinical course 
would be worse compared to those with “possible” neuropathic pain (those more 
broadly defined as a clinical diagnosis of sciatica without evidence of nerve root 
compression), but as reported above, this was not found. One potential reason for the 
course of this group of patients is that they may have received more targeted care, 
particularly by the twelve month follow-up; the majority of patients who were referred 
for an epidural injection or for further assessment and management by spinal 
surgeons, had a diagnosis of sciatica with evidence of nerve root compression on MRI. 
The suggestion being that variation in treatment received by study participants may 
have contributed to some imprecision in estimates in terms of pain intensity and LBLP-
related disability; this being particularly so for patients with a clinical diagnosis of 
sciatica with or without evidence of nerve root compression. The absolute number of 
patients in this cohort who were referred for further treatment was low (between 
approximately one in five and one in eight depending on neuropathic pain definition). 
The differences in pain and disability between patients with and without neuropathic 
pain (with or without evidence of nerve root compression) were often small with no 
obvious clinical relevance. This adds some confidence that that the course of patients 
with sciatica (either with or without evidence of nerve root compression) was similar 
to those without. 
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This research provides evidence that challenges the perception that the clinical course 
of patients with neuropathic pain is worse compared to those without with the 
exception of those patients with neuropathic pain based on s-LANSS. It is clear from 
existing literature that the clinical course does not represent the course of individual 
LBP patients (Kongsted et al. 2016) but the average prognosis for a heterogeneous 
population, and there is growing epidemiological evidence from cohorts of LBP 
patients that distinct sub-groups of patients have different courses or trajectories (for 
example, Dunn et al. (2006)). This is also relevant to patients with neuropathic pain as 
it is thought that the underlying pathophysiological mechanisms are not homogenous 
across either LBP or LBLP (Baron et al. 2016). Research in future chapters will 
investigate the presence and clinical course of distinct sub-groups of patients with 
neuropathic pain. 
6.6.1 Strengths and limitations 
A strength of this study was the use of a large prospective cohort of patients to 
investigate the clinical course of patients with and without neuropathic pain based on 
more than one definition of neuropathic pain which allows for direct comparisons 
between definitions. A further strength is the use of mixed-effects models for repeated 
measures which take into account fixed effects (presence or absence of neuropathic 
pain at baseline), random effects (individual patients) and interaction between time 
and the outcome (pain intensity or LBLP-related disability) during model development.  
Missing data was the main limitation of the research in this chapter. Fewer patients 
with neuropathic pain based on s-LANSS at baseline responded to follow-up, a slightly 
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higher proportion of patients had a diagnosis of sciatica and those who were followed 
up had lower RMDQ scores at baseline (see Chapter 4, section 4.10.2 (page 140) for a 
full report on response to follow-up). The implication of this being a risk of selection 
bias. Selection bias in cohort studies often relates to when there are differences in 
patients who are lost to follow-up compared to those who respond. In this research, 
missing data was accounted for by the use of mixed-effects models using likelihood-
based approaches. Accounting for missing data in this way and separately adjusting for 
baseline pain intensity and disability provides some confidence in the key finding that 
the course of neuropathic pain rapidly improves and varies depending on definition.  
6.6.2 Implications for clinical practice and research 
This research contributes to an increased understanding of the nature of neuropathic 
pain which is important information for LBLP patients, clinicians and researchers. The 
key findings that: clinical course of neuropathic pain varies depending on the definition 
of neuropathic pain used, and the clinical course of patients with neuropathic pain is 
not always worse compared to those without, have implications for both clinical 
practice and future research. The information is important to researchers as there is 
ongoing debate about the best definition to use for neuropathic pain in both 
epidemiological and basic science research. Future research in this thesis will identify 
sub-groups of patients with neuropathic pain based on the change in presence of 
neuropathic pain over time. 
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6.7 Conclusions 
In this chapter, the clinical course of LBLP patients with and without neuropathic pain, 
over a three year time period was investigated. LBLP patients with and without 
neuropathic pain at baseline improve in terms of pain intensity and LBLP-related 
disability, with the most improvement occurring between baseline and four months. 
The extent of the improvement in patients with neuropathic pain depended on the 
definition of neuropathic pain, only the clinical course of LBLP patients with 
neuropathic pain defined using s-LANSS seems to be worse compared to those 
without. Future chapters in this thesis will describe change in the presence of 
neuropathic pain over time and will describe the clinical course and prognostic factors 
of patients with persistent neuropathic pain.  
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Chapter Seven. Change in the presence of neuropathic pain in 
patients consulting in primary care with low back-related leg pain 
7.1 Introduction  
The previous chapter of this thesis highlighted that the clinical course of patients with 
neuropathic pain improves rapidly by short term follow up. This chapter describes LBLP 
patients with or without neuropathic pain at baseline in terms of the change in the 
presence or absence of neuropathic pain at baseline, short term, intermediate and 
long-term follow-up. The chapter first describes the frequency of neuropathic pain in 
LBLP patients at baseline and the three other time points. The chapter then identifies 
sub-groups of LBLP patients with or without neuropathic pain at baseline in terms of 
the change in the presence or absence of neuropathic pain over time before describing 
the baseline characteristics of these sub-groups. As in previous chapters, comparisons 
between the results of the research in this chapter and relevant literature are made 
and the clinical and research implications of these findings are then discussed.  
7.2 Aims and objectives 
7.2.1 Overall aim 
To describe the change in the presence of neuropathic pain in LBLP patients with and 
without neuropathic pain at baseline over short, intermediate and long term time 
points. 
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7.2.2 Objectives 
3. To describe the frequency of neuropathic pain over short, intermediate and 
long-term time points in LBLP patients who consult in primary care. 
4. To identify distinct sub-groups of LBLP patients by the change in the presence 
of neuropathic pain over time.  
5. To describe the baseline characteristics of sub-groups of LBLP patients 
identified by change in the presence of neuropathic pain. 
7.3 Methods 
Full details of the study design, data collection, methods used to identify cases of 
neuropathic pain, baseline characteristics and methods for handling missing data have 
been described previously in this thesis (see Chapter 4, Study design and methods) and 
are summarised below in sections 7.3.1 to 7.3.3. 
7.3.1 Study design  
As in previous chapters, the research presented in this chapter is based on secondary 
analysis of patients in the ATLAS cohort study. The reader is referred to Chapter 4, 
section 4.3 (page 112) for a detailed report of the inclusion and exclusion criteria in the 
ATLAS study. The research in this chapter uses ATLAS cohort study data from baseline 
and then three follow-up points, four months, twelve months and three years.  
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7.3.2 Neuropathic pain definitions 
In the ATLAS dataset repeated measures of neuropathic pain were collected for one 
definition (based on s-LANSS) which could be described as “possible” neuropathic, this 
definition was used for the purpose of the research in chapter. S-LANSS data were 
collected at baseline and at all three follow-up time-points.  
7.3.3 Baseline characteristics 
The analyses in this chapter describe key baseline characteristics of LBLP patients that 
were selected based on the following: those characteristics that may be important to 
the prognosis of neuropathic pain in this patient population (consistent findings across 
at least two definitions of neuropathic pain presented in Chapter 5 (Prevalence and 
characteristics of neuropathic pain in primary care patients with LBLP)), those 
characteristics considered important to the prognosis of LBLP patients, alternative 
definitions of neuropathic pain and items from neurological examination. The baseline 
characteristics used in this chapter are briefly summarised below. 
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Table 7.1 Summary of key characteristics used to describe patients in research in 
Chapter seven 
Baseline characteristics Categorical scale Continuous 
scale 
Sociodemographic characteristics  
Female sex Yes - 
Age  - Years 
Socio-economic status  Higher managerial, 
administrative and professional 
occupations 
- 
Intermediate occupations - 
Routine and manual 
occupations, never worked and 
long-term unemployed 
- 
Pain characteristics  
Leg pain intensity  - 0-10 
Back pain intensity  - 0-10 
Pain below the knee  Yes - 
Leg pain worse than back pain Yes - 
Presence of pain in one leg Yes - 
Duration of back pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
< 6 weeks - 
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Baseline characteristics Categorical scale Continuous 
scale 
Duration of leg pain symptoms in 
current episode 
6 to 12 weeks - 
> 3 months - 
Widespread pain* Yes - 
Limitations in activities   
RMDQ  - 0-23 
Risk of persistent disabling pain 
(STarT Back)  
Low risk - 
Medium risk - 
High risk  
Psychological variables  - 
HADS (depression)  - 0-21 
PSEQ† - 0-60 
Neurological examination findings   
Muscle strength† (Oxford scale 0-4) 5/5 - 
4/5  
0/5 or 1/5 or 2/5 or 3/5  
Presence of either reduced or absent 
lower limb reflex  
None - 
Slightly reduced - 
Significantly reduced or absent - 
Reduction or loss of sensation to pin-
prick 
Yes - 
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Baseline characteristics Categorical scale Continuous 
scale 
Presence of pins and needles Yes  
Presence of allodynia or hyperalgesia 
in the leg(s) § 
Yes - 
Neural tension test|| (any positive 
test) 
Yes - 
Other definitions of neuropathic 
pain  
  
Clinical diagnosis of sciatica** Yes - 
Neuroimaging   
Evidence of nerve root compression 
on MRI 
Yes  
Abbreviations: HADS, Hospital Anxiety and Depression scale. MRI, magnetic resonance imaging. PSEQ, 
pain self-efficacy questionnaire. RMDQ, Roland Morris Disability Questionnaire (RMDQ) leg version. 
*Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
††Higher scores on PSEQ reflect stronger self-efficacy beliefs 
‡Muscle strength was tested according to a 6-point grading scale where;  
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance  
§ Hyperalgesia is and increased pain response to painful stimuli. Allodynia is pain response to non-
painful stimuli (for example, brush strokes). 
|| Neural tension tests; straight leg raise, femoral stretch and slump test. 
**Patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain. 
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7.4 Statistical analysis 
7.4.1 Frequency of neuropathic pain in LBLP patients over baseline, short, 
intermediate and long-term time points 
The frequency (percentage) of neuropathic pain (based on s-LANSS definition) at each 
follow-up point over the three year time period along with 95% CI to describe the 
uncertainty around each point estimate, was estimated for LBLP patients at baseline 
and for those patients who responded to each subsequent follow-up point and had 
complete questionnaires for s-LANSS.  
7.4.2 Change in the presence of neuropathic pain in LBLP patients 
The different patterns of presenting with and without neuropathic pain per individual 
patient were tracked and the percentages of patients scoring 12 or greater or less than 
12 were recorded at baseline and each time-point over three years. Sub-groups of 
patients were defined empirically a posteriori based on the change in the presence or 
absence of neuropathic pain over time. The proportion of patients in these sub-groups 
were reported with 95% CI. Descriptive statistics were used to report the 
characteristics of patients in each sub-group. This analysis was based on patients who 
completed the baseline assessment and who responded to questionnaires at follow-up 
(see Chapter 4 section 4.10.2 (page 139) for full details of differences between patients 
who did and did not respond to follow-up). 
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 7.4.3 Missing data 
The analyses presented in this chapter uses data from patients who completed 
questionnaires at baseline and at each follow-up point. To take into account the 
uncertainty due to missing data, analyses were also carried out combining the results 
from 60 multiply-imputed datasets (the reader is referred to Chapter 4, section 4.11 
(page 148) for full details of the development of the imputation model and the 
assumptions made), a comparison of the two analyses was carried out which is 
summarised in section 7.5.4 and the results of these analyses are presented in the 
Appendix B.) 
7.5 Results 
7.5.1 Study population  
Of the 609 patients in the ATLAS study, 402 (66.0%) completed the study questionnaire 
at four-months, 450 (73.9%) at twelve months, and 316 (51.9%) at three-years. See 
Chapter 6, section 6.5.1 (page 217) for a full report on the treatments (care pathway) 
received.   
7.5.2 Frequency of neuropathic pain at baseline, short, intermediate and long 
term time points 
At baseline, nearly half of all LBLP patients had an s-LANSS score of 12 or greater. At 
four-months, a quarter of patients had a score of 12 or greater and this proportion 
remained similar at twelve-months and three-years. Figure 7.1 shows a summary of 
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the proportion of patients with neuropathic pain (based on s-LANSS) at baseline and at 
each of the three follow-up time-points. 
Figure 7.1 Proportion of patients with neuropathic pain at baseline and at three 
subsequent follow-up time-points  
 
7.5.3 Change in the presence of neuropathic pain in LBLP patients 
Four sub-groups were identified by the change in the presence of neuropathic pain 
based on s-LANSS over a three-year follow-up period: those with non-neuropathic 
pain, those who demonstrated developing neuropathic pain, those with non-persistent 
Abbreviation: LBLP, low back-related leg pain. s-LANSS, self-report version of the Leeds 
Assessment of Neuropathic Symptoms and signs neuropathic pain scale.  
Bars indicate 95% confidence intervals for certainty around the point estimate 
*Shown as patients who responded to follow-up  
48.4
25.0 22.6 21.6
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
%
 L
B
LP
 p
a
ti
e
n
ts
 w
it
h
 s
-L
A
N
S
S
 ≥
1
2
*
Baseline 4-months 12-months 3-years
 241 
 
neuropathic pain, and those with long-standing persistent neuropathic pain. Patients 
with an s-LANSS score of less than 12 at baseline and each follow-up point thereafter 
and were included in the sub-group of non-neuropathic pain. Those with an s-LANSS 
score of less than 12 at baseline and 12 or greater at one or more follow-up points 
were included in the sub-group of developing neuropathic pain. Patients with an s-
LANSS score of 12 or greater at baseline and at one (at most) of the three follow-up 
points were included in the sub-group of patients with non-persistent neuropathic 
pain. Patients with an s-LANSS score of 12 or greater at baseline and at two or more of 
the three follow-up points were described as having long-standing persistent 
neuropathic pain. 
During the three-year study period, over four out of ten patients were described as 
having non-neuropathic pain, this was the largest sub-group of patients. The second 
largest (56 out of 199, 28.1%) was the sub-group described as having non-persistent 
neuropathic pain, the majority of change in the presence of neuropathic pain occurred 
by four months (33 out of 199, 16.6%). A small minority (12 out of 199, 6.0%) of 
patients had an s-LANSS score of 12 or greater at baseline and at all of the three 
follow-up points, these patients were included in the sub-group of patients with long-
standing persistent neuropathic pain.  A very small proportion of patients (3 out of 
199, 1.5%) had an s-LANSS score of less than 12 at baseline and subsequently scored 
12 or greater at all of the three follow-up points, this sub-group of patients were 
included in the sub-group of patients with developing neuropathic pain. Tables 7.2 and 
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7.3 summarise the change in the presence of neuropathic pain over time including the 
identification of sub-groups of patients with and without neuropathic pain. 
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 Table 7.2 Change in the presence of neuropathic pain in patients over a three-year follow-up period. 
Presence or absence of neuropathic pain over 3-years (s-LANSS)* 
N 
(n=199) 
Proportion 
(%) 
95% 
Confidence 
Interval† 
Sub-group 
Baseline 4 months 12 months 3 years 
0 0 0 0 87 43.7 36.9 to 50.7 Non-neuropathic 
0 0 0 1 6 3.0 1.4 to 6.6 Developing 
0 0 1 0 7 3.5 1.7 to 7.2 Developing 
0 0 1 1 1 0.5 0.0 to 3.5 Developing 
0 1 0 0 3 1.5 0.0 to 4.8 Developing 
0 1 0 1 2 1.0 0.0 to 4.0 Developing 
0 1 1 0 2 1.0 0.0 to 4.0 Developing 
0 1 1 1 3 1.5 0.0 to 4.8 Developing 
1 0 0 0 33 16.6 12.0 to 22.5 Non-persistent 
1 0 0 1 7 3.5 1.7 to 7.2 Non-persistent 
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Presence or absence of neuropathic pain over 3-years (s-LANSS)* 
N 
(n=199) 
Proportion 
(%) 
95% 
Confidence 
Interval† 
Sub-group 
Baseline 4 months 12 months 3 years 
1 0 1 0 6 3.0 1.4 to 6.6 Non-persistent 
1 0 1 1 5 2.5 0.1 to 5.9 
Long-standing 
persistent 
1 1 0 0 10 5.0 2.7 to 9.1 Non-persistent 
1 1 0 1 5 2.5 0.1 to 5.9 
Long-standing 
persistent 
1 1 1 0 10 5.0 2.7 to 9.1 
Long-standing 
persistent 
1 1 1 1 12 6.0 3.4 to 10.4 
Long-standing 
persistent 
Abbreviation: s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and signs neuropathic pain scale 
*0 indicates s-LANSS score < 12 (non-neuropathic pain), 1 indicates s-LANSS score ≥ 12 (possible neuropathic pain) 
†Confidence intervals are for certainty around a point estimate. 
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Table 7.3 Proportion of patients by neuropathic pain sub-group (n=199) 
Sub-group* N Proportion 
(%) 
95% Confidence 
Interval† 
Non-neuropathic pain 87 43.7 36.9 to 50.7 
Non-persistent neuropathic pain 56 28.1 22.3 to 34.8 
Long-standing persistent neuropathic pain 32 16.1 11.6 to 21.9 
Developing neuropathic pain 24 12.1 8.2 to 17.4 
*Sub-groups: Non-neuropathic pain, s-LANSS < 12 at baseline and each follow-up point thereafter. 
Developing neuropathic pain, s-LANSS < 12 at baseline and ≥ 12 at one or more follow-up points. Non-
persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up 
points. Longstanding persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of 
the three follow-up points.  
†Confidence intervals are for certainty around a point estimate.  
 
7.5.3.1 Baseline characteristics of patients by neuropathic pain sub-groups 
Table 7.4 provides a summary of the baseline characteristics of patients by 
neuropathic pain sub-group. The subgroup with long-standing persistent neuropathic 
pain defined over the three year follow-up, reported the highest mean LBLP-related 
disability (13.6), this sub-group had the largest proportion of patients who were at high 
risk (STarT Back Tool score) of developing pain related persistent disability (50.0%), the 
lowest score for mean pain self-efficacy (31.4) and highest mean score for depression 
(7.5) (HADS). Patients in the sub-group of long-standing persistent neuropathic pain 
had the largest proportion of patients with allodynia and/or hyperalgesia (5 out of 32, 
15.6%) and over nine out of ten (93.8%) patients had a clinical diagnosis of sciatica at 
baseline.  
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Patients with an s-LANSS score consistently less than 12 at baseline and all three 
follow-up points (the sub-group of non-neuropathic pain), reported the least severe 
LBLP-related morbidity. Patients in this sub-group had the lowest mean leg pain 
intensity (4.2), lowest mean LBLP-related disability (10.5), and highest mean pain self-
efficacy (39.9). This sub-group also had the smallest proportion of patients with leg 
pain duration greater than three months (25.0%) and the smallest proportion of 
patients who were at high risk of pain-related persistent disability (20.0%). A 
substantial proportion of patients with non-neuropathic pain, according to s-LANSS, 
had a clinical diagnosis of sciatica (70.1%) with six out of ten patients (64.3%) having 
evidence of nerve root compression on imaging.  
The sub-group with non-persistent neuropathic pain included the highest proportion 
of patients with muscle weakness (26.8%) at baseline, and more patients in this sub-
group reported pain below the knee (82.1%). Patients in this sub-group reported high 
mean leg pain intensity (5.5), only the sub-group of patients with persistent 
neuropathic pain had higher scores for each of these characteristics. Patients in the 
sub-group of developing neuropathic pain, which was the smallest of the four sub-
groups, reported the highest mean back pain intensity (5.6), the second highest mean 
score for HADS for depression (6.3), had the lowest proportion of patients with a 
clinical diagnosis of sciatica (66.7%) but the highest proportion with evidence of nerve 
root compression on MRI (81.0%).
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Table 7.4 Baseline characteristics of patients by neuropathic pain sub-group over three-years (n=199) 
Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
Sociodemographic characteristics     
Female 49 (56.3) 38 (67.9) 19 (59.4) 15 (62.5) 
Age, mean (SD) 54.3 (13.0) 54.4 (11.5) 55.1 (9.1) 57.3 (10.6) 
Socio-economic 
status (n=194) 
Higher managerial, 
administrative and 
professional 
occupations 
23 (26.7) 14 (25.5) 5 (17.2) 12 (50.0) 
Intermediate 
occupations 
26 (30.2) 14 (25.5) 5 (17.2) 6 (25.0) 
Routine and manual 
occupations, never 
37 (43.0) 29 (52.7) 19 (65.5) 6 (25.0) 
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Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
worked and long-
term unemployed 
Pain characteristics     
Leg pain intensity (0-10), mean (SD) 
(n=192) 
4.2 (2.1) 5.5 (2.3) 5.7 (2.4) 5.4 (2.9) 
Back pain intensity (0-10), mean (SD) 
(n=198) 
4.7 (1.5) 5.0 (1.5) 5.2 (1.8) 5.6 (1.6) 
Leg pain worse (n=198) 45 (51.7) 28 (50.9) 19 (59.4) 10 (41.7) 
Pain location Pain below the 
knee 
58 (66.7) 46 (82.1) 27 (84.4) 16 (66.7) 
 Pain in one leg 67 (77.0) 46 (82.1) 22 (68.8) 19 (79.2) 
Less than 6 weeks 33 (37.9) 21 (38.2) 12 (37.5) 12 (50.0) 
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Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
Duration of back 
pain symptoms in 
current episode 
(n=198) 
6 to 12 weeks 21 (24.1) 13 (23.6) 9 (28.1) 3 (12.5) 
> 3 months 33 (37.9) 21 (38.2) 11 (34.4) 9 (37.5) 
Duration of leg pain 
symptoms in 
current episode 
greater > 3 months 
(n=193) 
Less than 6 weeks 45 (52.9) 20 (37.0) 11 (36.7) 11 (45.8) 
6 to 12 weeks 18 (21.2) 16 (29.6) 5 (16.7) 3 (12.5) 
> 3 months 22 (25.9) 18 (33.3) 14 (46.7) 10 (41.7) 
Widespread pain†  41 (48.2) 19 (34.6) 18 (56.3) 11 (45.8) 
Limitations in activities and risk of persistent disabling pain 
LBLP-related disability (RMDQ, 0-23), 
mean (SD) 
10.5 (5.5) 11.4 (5.2) 13.6 (5.7) 12.8 (5.4) 
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Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
Risk of 
persistent 
disability due 
to back pain 
(STarT Back) 
(n=194) 
Low risk 18 (21.2) 11 (20.4) 4 (12.5) 1 (4.4) 
Medium risk 50 (58.8) 25 (46.3) 12 (37.5) 14 (60.9) 
High risk 17 (20.0) 18 (33.3) 16 (50.0) 8 (34.8) 
Psychological characteristics 
HADS (depression) (0-21), mean 5.2 (3.6) 5.1 (3.2) 7.5 (4.6) 6.3 (3.2) 
PSEQ (0-60), mean (SD) ‡ 39.9 (12.9) 37.2 (14.4) 31.4 (14.5) 36.6 (14.0) 
Neurological examination findings     
Muscle strength§  5/5 70 (80.5) 41 (73.2) 28 (87.5) 21 (87.5) 
4/5 15 (17.2) 15 (26.8) 4 (12.5) 1 (4.2) 
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Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
0 to 3/5 2 (2.3) 0 (0.0) 0 (0.0) 2 (8.3) 
Reflex change None 75 (86.2) 45 (80.4) 21 (65.6) 21 (87.5) 
 Slightly reduced 3 (3.5) 2 (3.6) 3 (9.4) 2 (8.3) 
 Significantly 
reduced or absent 
9 (10.3) 9 (16.1) 8 (25.0) 1 (4.2) 
Reduction or loss of sensation to pin-prick  28 (32.2) 22 (39.3) 18 (56.3) 10 (41.7) 
Presence of allodynia or hyperalgesia ||   2 (2.3) 5 (8.9) 5 (15.6) 2 (8.3) 
Neural tension test (any positive test) ** 41 (47.1) 32 (57.1) 21 (65.6) 13 (54.2) 
Pins and needles  28 (32.2) 41 (73.2) 24 (75.0) 7 (29.2) 
Other definitions of neuropathic pain      
Clinical diagnosis of sciatica†† 61 (70.1) 47 (83.9) 30 (93.8) 16 (66.7) 
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Baseline characteristic  
(All figures are frequencies (percentages) 
unless stated otherwise as mean (SD))  
Neuropathic pain sub-group* over 3-years 
Non-neuropathic 
pain  
Non-persistent 
neuropathic pain  
Long-standing 
persistent 
neuropathic pain  
Developing 
neuropathic pain  
(n=87, 43.7%) (n=56, 28.1%) (n=32, 16.1%) (n=24, 12.1%) 
Neuroimaging     
Evidence of nerve root compression on 
MRI (n=186) 
54 (64.3) 27 (50.0) 18 (66.7) 17 (81.0) 
Abbreviations: HADS, Hospital Anxiety and Depression scale. MRI, magnetic resonance imaging. PSEQ, Pain Self-Efficacy Questionnaire. RMDQ, Roland Morris Disability 
Questionnaire leg version. s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs neuropathic pain scale 
*Sub-groups: Non-neuropathic pain, s-LANSS < 12 at baseline and each follow-up point thereafter. Developing neuropathic pain, s-LANSS < 12 at baseline and ≥ 12 at one or 
more follow-up points. Non-persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up points. Longstanding persistent 
neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of the three follow-up points. 
†Widespread pain was defined as pain present above and below the waist, in the right- and left-hand sides of the body and in the axial skeleton.  
‡Higher scores on PSEQ reflect stronger self-efficacy belief  
§ Muscle strength was tested according to a 6-point grading scale where; 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance  
|| Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful stimuli (for example, strokes) 
** Neural tension tests; straight leg raise, crossover straight leg raise, femoral stretch and slump test 
†† Patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain   
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7.5.4 Comparison of complete case analysis versus imputed data 
Estimates derived from complete case analysis and those based on imputed data were 
similar (the reader is referred to the Appendix B for the analysis in this chapter 
repeated using multiply imputes data). One exception where there were differences 
between estimates from complete case analysis and imputation was for evidence of 
nerve root compression, see Table 7.5 for a comparison between the two types of 
data. 
 Table 7.5 Evidence of nerve root compression across neuropathic pain sub-groups 
comparing imputed data and data using complete cases  
Sub-group* 
Estimates derived from 
complete case analysis 
Estimates derived from 
multiple imputation 
N Proportion 
(%) 
Proportion 
(%) 
95% 
Confidence 
Interval† 
Non-neuropathic pain 54 64.3 52.4  45.3 to 59.4 
Non-persistent neuropathic pain 27 50.0 50.3  42.4 to 58.1 
Longstanding persistent 
neuropathic pain 
18 66.7 57.7  46.1 to 69.2 
Developing neuropathic pain 17 81.0 60.3  47.4 to 73.3 
*Sub-groups: Non-neuropathic pain, s-LANSS < 12 at baseline and each follow-up point thereafter. 
Developing neuropathic pain, s-LANSS < 12 at baseline and ≥ 12 at one or more follow-up points. Non-
persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up 
points. Longstanding persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of 
the three follow-up points. 
† Confidence intervals are for certainty around a point estimate for imputed data. 
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7.6 Discussion   
The research in this chapter described the clinical course of LBLP patients by the 
change in the presence of neuropathic pain over time. This is the first research to the 
author’s knowledge to investigate the change in the presence of neuropathic pain over 
time in this patient population using a prospective study design. In this cohort of LBLP 
patients consulting in primary care, the presence of neuropathic pain changes over 
time, resolving for most patients who have neuropathic pain at initial consultation and 
only remaining persistent in a few. A large proportion of patients had non-neuropathic 
pain over the short-term, intermediate and long-term follow up, and very few patients 
with non-neuropathic pain at baseline developed neuropathic pain at follow-up. Four 
sub-groups were identified based on the change in the presence of neuropathic pain 
over three years, those with non-neuropathic pain, developing neuropathic pain, non-
persistent and longstanding persistent neuropathic pain. There were distinct 
differences in the patients’ profiles of these four sub-groups and in particular the sub-
group of patients with longstanding persistent neuropathic pain which was 
consistently found to have the most severe LBLP-related morbidity. This research 
challenges the common belief that neuropathic is persistent and is generally defined as 
a condition resulting from permanent nerve damage which is assumed to be 
irreversible (Merskey and Bogduk 1994). 
Patients with non-neuropathic pain at each time-point, had the least pain intensity, 
least LBLP-related disability and least psychological symptoms at baseline, whereas 
patients with persistent neuropathic pain reported the most severe LBLP-related 
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morbidity. This was not unexpected and is consistent with the findings of research in 
Chapters 5 (Prevalence and characteristics of LBLP patients) and 6 (Clinical course of 
LBLP patients) that patients with non-neuropathic pain present with less severe pain-
related morbidity and a more favourable course compared to those with neuropathic 
pain (based on s-LANSS). 
In this research, sensory loss and central sensitisation were thought to be the 
underlying pain mechanisms associated with persistent and non-persistent 
neuropathic LBLP at baseline (see Chapter 5 for a full report of the profile of patients 
with neuropathic pain based on s-LANSS). From the findings from neurological 
examination there is evidence of sensory loss, which may be due to axonal damage in 
patients with and without persistent neuropathic pain, with sensory loss found in a 
higher proportion of those with non-persistent neuropathic pain. This may suggest the 
presence of mechanisms that resolve quickly in and around the nerve root in patients 
with non-persistent neuropathic pain. In contrast, patients in the sub-group with long-
standing persistent neuropathic pain present at baseline with high levels of LBLP-
related morbidity which may be explained in large part by central rather than 
peripheral pain mechanisms (Nijs et al. 2015, Smart et al. 2012b). 
This research also identified a sub-group of patients with persistent neuropathic pain 
at four months, this sub-group was distinct in terms of presence of neuropathic pain 
because most of the change in the presence of neuropathic pain occurred by four 
months. This sub-group is interesting because the majority of improvement occurred 
between baseline and four months followed by a plateau thereafter which is 
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comparable to the time whereby the majority of tissue healing happens. This pattern 
of change between baseline and four months is similar to the pattern of rapid 
improvement in pain intensity and LBLP-related disability in patients with and without 
neuropathic pain reported in Chapter 6. It is likely that the course of patients with 
persistent neuropathic pain at four months is worse than those without, but this is not 
known. Identifying which patients will have persistent neuropathic at four months is 
important prognostic information for clinicians in primary care and may lead to better 
delivery of targeted treatments, such as neuropathic pain medication.  
The proportion of patients in the sub-group of developing neuropathic pain who did 
not seem to have neuropathic pain at baseline but were characterised by the presence 
of neuropathic pain at a later point, has not previously been estimated. Previous 
research of primary care consulters reported the mean neuropathic pain score (using 
PainDETECT) increased over time in some patients with back pain alone (Hüllemann et 
al. 2017). The patient sub-group of developing neuropathic pain in this research had 
longer leg and back pain duration at baseline suggesting the underlying mechanisms 
may in part be time dependent. An example would be degenerative intervertebral 
discs which may initially give rise to nociceptive stimuli causing LBLP and over time 
involve microscopic nerve fibres giving rise to neuro-inflammation (Cohen and Mao 
2014). In part, the underlying pain mechanisms in the sub-group of patients with 
developing neuropathic pain may well be explained by central sensitisation especially 
with the evidence that this sub-group present with highest back pain intensity and 
higher levels of depressive symptoms than patients in the non-neuropathic and non-
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persistent neuropathic pain sub-groups. Previous research in patients with persistent 
post-surgical pain (which is thought to be a neuropathic pain condition) showed that 
patients with initial high pain intensity more often reported neuropathic signs and 
symptoms at follow-up (Phillips et al. 2014, Lavand'homme et al. 2014). The sub-group 
of patients with developing neuropathic pain was the smallest in the current research 
(n=24 or 12%), in 16 patients the presence of neuropathic pain was recorded at just 
one of the three follow-up points and it is not clear whether this represents real 
change in the presence of neuropathic pain, especially as it is known that case 
ascertainment tools such as s-LANSS may over-identify or may fail to identify some 
patients with neuropathic pain.  For sub-groups to be clinically useful they should be 
stable over time (Kongsted et al. 2016) and this cannot be fully understood from this 
research, in part because of the small numbers. It would be of interest but out of the 
scope of this thesis, to investigate the epidemiology of patients with non-neuropathic 
pain who go on to develop neuropathic pain at a later point in time.  
7.6.1 Strengths and limitations  
The analyses in this research were based on a large prospective cohort of patients with 
long term follow-up, it is novel in its aims to investigate the change in presence of 
neuropathic pain over time in this patient population. A strength of this study was the 
use of techniques such as multiple imputation to account for missing data, 
observations derived from complete case analysis were similar to those based on 
imputed data. The exception being the observation that 81% patients in the sub-group 
of developing neuropathic pain were found to have evidence of nerve root 
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compression on MRI based on complete case analysis compared to 60% based on 
imputed data. The use of imputed data increased the confidence in interpreting the 
findings of this research. 
A posteriori identification of sub-groups ensured that each sub-group was clinically 
meaningful and in the absence of any previous research this was a strength of this 
study. A limitation of this research is the use of one definition of neuropathic pain (s-
LANSS) over time. It is possible that there may be important differences in the change 
in presence of neuropathic pain based on clinical examination over time compared to 
that based on s-LANSS. Similarly, the analysis in this research used data recorded at 
baseline and three follow-up time-points, this may contribute to uncertainty about the 
results for small sub-groups of patients with or without neuropathic pain, for example 
those with developing neuropathic pain. Data collection is a recognised challenge in 
epidemiology, particularly so in epidemiological research of neuropathic pain which is 
defined by many signs and symptoms collected by self-report and clinical examination.  
 7.6.2 Implications for clinical practice and research 
Identification of the change of neuropathic pain over time improves the understanding 
of the prognosis of this condition in LBLP patients who consult in primary care. This 
research is important because it informs clinicians and, in turn, patients that 
neuropathic pain (based on s-LANSS) does change over time and it is not always 
persistent by nature. Some of the findings of this research should be interpreted in 
clinical practice with caution, in particular those describing the smallest sub-group of 
developing neuropathic pain.  
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Future research in this thesis will investigate the clinical course of patients with 
persistent neuropathic pain and will investigate whether potential prognostic factors 
collected from self-report and clinical examination can predict which patients will have 
persistent neuropathic pain at four months follow-up. Future research outside the 
scope of this thesis could usefully investigate whether there are any characteristics of 
patients without neuropathic pain at baseline that can successfully predict the 
presence of neuropathic pain at a later point in time. 
7.7 Conclusions 
In this chapter, change in the presence of neuropathic pain over a three year time 
period was investigated. Neuropathic pain is not always persistent by nature, but it 
does remains persistent in a few patients over three years (16%) and these patients 
have the most severe LBLP-related disability. Change in presence of neuropathic pain 
in LBLP patients with neuropathic pain (based on s-LANSS) at baseline most commonly 
occurs by four months. Future chapters will investigate whether the clinical course of 
this sub-group of patients with persistent neuropathic pain at four months is worse 
compared to those without and will identify prognostic factors that are associated with 
persistent neuropathic pain at four months. 
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Chapter Eight. Prognosis of LBLP patients with neuropathic pain: 
Characteristics, clinical course and prognostic factors  
8.1 Introduction 
The systematic review in Chapter 3 highlighted a paucity of prognosis research and an 
absence of prognostic factor research in this patient population with neuropathic pain. 
Prognostic factors are characteristics of persons with a condition that are associated 
with a subsequent health outcome, in the context of this research characteristics of 
LBLP patients with neuropathic pain associated with persistent neuropathic pain. In 
this thesis, potential prognostic factors in LBLP patients with neuropathic pain were 
identified in part during cross-sectional analysis of data from LBLP patients with and 
without neuropathic pain, based on three definitions of neuropathic pain at baseline 
(see Chapter 5). In patients with neuropathic pain at baseline, most of the change in 
the presence of neuropathic pain occurred by four months which corresponds to the 
time that normal tissue healing takes place (Chapter 7).  LBLP patients with persistent 
neuropathic pain were identified in the previous chapter and are of interest because 
this sub-group of patients were characterised as having worse pain intensity and 
disability at baseline compared to those in the non-neuropathic pain sub-group and 
those with non-persistent neuropathic pain. This chapter reports on the 
characteristics, clinical course and prognostic factors of LBLP patients with neuropathic 
pain that may be associated with the outcome of persistent neuropathic pain. The 
results of this research are reported and comparisons made to relevant literature, 
before a discussion of the clinical and research implications of these results. 
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8.2 Aims and objectives 
8.2.1 Overall aim 
To investigate the overall prognosis of LBLP patients with neuropathic pain, in terms of 
clinical course and exploratory prognostic factor research.  
8.2.2 Objectives 
1. To describe the baseline characteristics of patients with and without persistent 
neuropathic pain at four months. 
2. To compare the clinical course in terms of pain intensity, leg and back pain-related 
disability over a three year follow-up period of patients with and without persistent 
neuropathic pain at four months. 
3. To identify potential prognostic factors associated with the outcome of persistent 
neuropathic pain in patients with neuropathic pain at baseline. 
4. To investigate the prognostic value of potential prognostic factors of LBLP patients 
with neuropathic pain that may be associated with persistent neuropathic pain. 
8.3 Methods 
Full details of the study design, data collection, methods used to identify cases of 
neuropathic pain and methods for handling missing data have been described in 
previous chapters (Chapter 4). Sections 8.3.1 to 8.3.4 summarise the details which are 
relevant to the research in this chapter.  
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8.3.1 Study design 
The research in this chapter is based on secondary analysis of the ATLAS study cohort 
using those LBLP patients with neuropathic pain at baseline. 
8.3.2 Data collection 
Data were collected at baseline and then the follow-up points at four months, twelve 
months and three years.  
8.3.3 Neuropathic pain definitions 
The analyses reported in this chapter were based on two definitions describing 
persistent neuropathic pain: (i) an s-LANSS score of 12 or above at baseline and at four 
months (Chapter 7 provided details of how the sub-group of patients with persistent 
neuropathic pain based on s-LANSS were identified); and (ii) a clinical diagnosis of 
sciatica at baseline and the presence of pain below the knee at four months, where 
pain below the knee was used as a proxy for sciatica (Dionne et al. 2008). In the 
absence of clinical examination, there is some evidence that the presence of pain 
below the knee can be a useful proxy indicator for a diagnosis of sciatica (Konstantinou 
et al. 2012c). The reader is referred to Chapter 4, section 4.5 (page 116) for details of 
how patients in this research were diagnosed with sciatica.  
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8.3.4 Measures 
8.3.4.1 Baseline characteristics 
Key baseline characteristics of LBLP patients with persistent neuropathic pain 
compared to those without are described. The method of data collection for key 
characteristics is briefly summarised below in Table 8.1. The reader is referred to 
Chapter 4, section 4.9 (page 120) for a full description of the method of data collection 
for each characteristic.  
Table 8.1 Summary of key characteristics used to describe patients with persistent 
neuropathic pain in research in Chapter eight 
Baseline characteristics Categorical scale Continuous 
scale 
Sociodemographic characteristics  
Female sex Yes/no - 
Age  - Years 
Socio-economic status  Higher managerial, 
administrative and 
professional occupations 
- 
Intermediate occupations - 
Routine, manual occupations, 
never worked and long-term 
unemployed 
- 
Pain characteristics  
Leg pain intensity  - 0-10 
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Baseline characteristics Categorical scale Continuous 
scale 
Back pain intensity  - 0-10 
Pain below the knee  Yes/no - 
Leg pain worse than back pain Yes/no - 
Duration of back pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
Duration of leg pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
Limitations in activities  
LBLP-related disability (RMDQ) - 0-23 
Psychological variables  
HADS (depression)  - 0-21 
Pain self-efficacy (PSEQ)* - 0-60 
Neurological examination findings  
Presence of muscle weakness†  5/5 - 
4/5 - 
0 to 3/5 - 
Presence of either reduced or absent 
lower limb reflex  
None - 
Slightly reduced - 
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Baseline characteristics Categorical scale Continuous 
scale 
Significantly reduced or 
absent 
- 
Reduction or loss of sensation to pin-
prick 
Yes/no - 
Presence of pins and needles Yes/no - 
Presence of allodynia or hyperalgesia in 
the leg(s) ‡ 
Yes/no - 
Neural tension test§ (any positive test) Yes/no - 
Neuroimaging   
Evidence of nerve root compression on 
MRI 
Yes/no - 
Abbreviations: HADS, Hospital Anxiety and Depression scale. MRI, magnetic resonance imaging. PSEQ, 
pain self-efficacy questionnaire. RMDQ, Roland Morris Disability Questionnaire leg version. 
* Higher scores on PSEQ reflect stronger self-efficacy beliefs 
† Muscle strength was tested according to a 6-point grading scale where;  
6. No visible flicker of movement or contraction 
7. Flicker of movement 
8. Full active movement with gravity counterbalanced 
9. Full active movement against gravity but not applied resistance 
10. Full active movement against gravity and some applied resistance 
11. Full active movement against gravity and strong resistance  
‡ Hyperalgesia is and increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes). 
 § Neural tension tests; straight leg raise, femoral stretch and slump test. 
 
8.3.4.2 Clinical course 
As in chapter 6, the analyses in this chapter compare the clinical course of patients in 
terms of pain intensity and leg and back-pain related disability at four, twelve months 
and three years. Pain intensity was determined as the highest mean of three 0 to 10 
NRSs for current, usual and least leg or back pain intensity in the previous two weeks. 
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LBLP-related disability was measured using the leg version of RMDQ (0 to 23) with 
higher scores indicating more severe disability. 
8.4 Statistical analysis 
8.4.1 Baseline characteristics  
Descriptive analysis (mean and SD for continuous variables and frequency and 
percentage for categorical variables) was used to report the characteristics of the LBLP 
patients with and without persistent neuropathic pain. This analysis was based on 
patients who completed both the baseline and the follow-up questionnaires at four 
months. 
8.4.2 Clinical course 
The clinical course of patients with and without persistent neuropathic pain was 
examined over the three year study period using repeated-measure linear mixed-
effect models to compare the unadjusted means of pain intensity and separately LBLP-
related disability at baseline and all three follow-up points. The reader is referred back 
to Chapter 6, Section 6.4.3 Statistical analysis for a detailed report on how models 
were developed. Further models were developed adjusted for baseline pain intensity 
and then disability. 
8.4.3 Exploratory prognostic factor research 
8.4.3.1 Start and end points 
To identify prognostic factors in LBLP with neuropathic pain, two different start and 
end points were identified depending on the definition of persistent neuropathic pain. 
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Firstly, for the definition of persistent neuropathic pain based on s-LANSS, the start 
point was s-LANSS score of 12 or greater at baseline and the end-point was persistent 
neuropathic pain based on s-LANSS at four months. Patients with s-LANSS score of 12 
or above at baseline and score less than 12 at four months were defined as having 
non-persistent neuropathic pain. Secondly, for the definition of persistent neuropathic 
pain based on a clinical diagnosis of sciatica the start point was clinical diagnosis of 
sciatica at baseline and the end point was the presence of pain below the knee at four 
months. Patients with a clinical diagnosis of sciatica at baseline and pain below the 
knee at four months were defined as having persistent neuropathic pain, and those 
with a clinical diagnosis of sciatica at baseline with an absence of pain below the knee 
at four months were defined as having non-persistent neuropathic pain. 
8.4.3.2 Identification of potential prognostic factors 
The decision to include certain characteristics as potential prognostic factors was made 
on the condition of each characteristic fulfilling one or more of five criteria. Box 8.1 
provides details of each of these five items.  
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Box 8.1 Criteria for investigating prognostic factors 
Factors were chosen on the condition of: 
A. Consistent associations with neuropathic pain across three definitions in LBLP 
patients*, or 
B. Known to be associated with poor outcomes in broader LBP populations, or 
C. Known to be important to underlying pathophysiological mechanisms of 
neuropathic pain, or  
D. Considered to be definitions of neuropathic pain, and  
E. Availability in the dataset 
*(see Chapter 5, Section 5.5.5 (page 196) for a summary of the consistent findings across three 
definitions of neuropathic pain) 
 
In addition to these five criteria, consideration was given to whether potential 
prognostic factors were closely related. Where prognostic factors were thought to be 
closely related, correlation coefficients were estimated and if correlation was present 
(r> 0.7) one of the two potential prognostic factors was dropped to limit the effects of 
collinearity. Priority was given to the prognostic factor with more consistent 
associations with neuropathic pain across three definitions. Characteristics were 
selected as potential prognostic factors, Table 8.2 lists these and summarises the 
criteria under which they were chosen. In preparation for analysis, selected prognostic 
factors that were continuous in the dataset were retained as continuous variables, all 
other factors were categorical and dummy variables were created for prognostic 
factors with more than two categories. The reader is referred back to Chapter 4 
(section 4.8 (page 119) and section 4.9 (page 120)) for details of how each of the 
factors were categorised.  
Table 8.2 Selected potential prognostic factors  
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Prognostic factor Criteria* Type of variable 
Age B Continuous 
Female sex B Binary 
Socioeconomic status B, E Categorical 
Leg pain duration in the current episode B, E Categorical 
Leg pain intensity A, B, E Continuous 
Pain self-efficacy A, E Continuous 
Clinical diagnosis of sciatica† D, E Binary 
s-LANSS score of 12 or greater† D, E Binary 
Clear or possible nerve root compression on 
MRI 
C, E Binary 
Reduction or loss in sensation to pin-prick A, C, E Binary 
Presence of pins and needles C, E Binary 
Pain below the knee A, C, E Binary 
*Factors were chosen on the condition of: 
Criteria 
A. Consistent associations with neuropathic pain across three definitions in LBLP patients  
B. Known to be associated with poor outcomes in broader LBP populations 
C. Known to be important to underlying pathophysiological mechanisms of neuropathic pain 
D. Considered to be definitions of neuropathic pain 
E. Availability in the dataset 
† Either/ or potential factor was used depending on start and end-point 
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8.4.3.3 Identification and prognostic value of factors associated with persistent 
neuropathic pain 
Binary logistic regression was used to examine the associations between any potential 
prognostic factor and the end-point, persistent neuropathic pain (based on two 
definitions). Factors were considered for multivariable logistic regression based on the 
strength of association with either definition of persistent neuropathic pain (p<0.25). 
Other factors considered for the multivariable model were those with greater clinical 
relevance (age, female sex, leg pain intensity and leg pain duration). It has been 
suggested that the number of events of the outcome per potential prognostic factor 
should not be less than one factor per ten events (Peduzzi et al. 1996). Given the size 
of the smallest sample in the analyses was 164 with 44% (n=72) having persistent 
neuropathic pain, a multivariable model had sufficient power to assess seven 
prognostic factors. Age, female sex, leg pain intensity and leg pain duration accounted 
for five factors giving sufficient power to investigate the prognostic value for a 
maximum of two further potential prognostic factors. Odds ratios with 95% confidence 
intervals and p values were reported to determine the strength of association of the 
chosen prognostic factors. This analysis combines results from 60 multiply-imputed 
datasets to take into account the uncertainty due to missing data. Please refer to 
Chapter 4, section 4.11.1 (page 148) for full details of the development of the 
imputation model and the assumptions made.  
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8.5 Results 
8.5.1 Baseline characteristics 
8.5.1.1 Persistent neuropathic pain based on s-LANSS 
In total, 44% (72 out of 164) of patients with neuropathic pain (based on s-LANSS) had 
persistent neuropathic pain at four months. Table 8.3 summarises the baseline 
characteristics of LBLP patients with persistent neuropathic pain compared to those 
with non-persistent neuropathic pain. They had similar mean back pain intensity, but 
higher leg pain intensity (6.2 (2.3) vs 5.6 (2.2)), higher mean LBLP-related disability 
scores (using RMDQ 0 to 23, (14.9 (5.1) vs 12.4 (5.4)) and higher depressive symptoms 
(using HADS 0 to 21, 7.9 (4.3) vs 5.9 (3.5), where scores 7 or below are indicative of 
non-clinical levels of symptoms). Higher proportions of patients with persistent 
neuropathic pain had evidence of nerve root compression on MRI (60.9%, 39 out of 64) 
compared to those without (50.6% (43 out of 85).   
Table 8.3 Baseline characteristics of patients with and without persistent neuropathic 
pain (based on s-LANSS) 
Baseline characteristics (n=164)* 
 
†Persistent neuropathic pain  
(s-LANSS ≥12 at baseline and at four 
months) 
Yes 
(n=72, 44%) 
No  
(n=92, 56%) 
Sociodemographic characteristics   
Female 45 (62.5) 62 (67.4) 
Age, mean (SD)  53.7 (13.0) 53.3 (12.3) 
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Baseline characteristics (n=164)* 
 
†Persistent neuropathic pain  
(s-LANSS ≥12 at baseline and at four 
months) 
Yes 
(n=72, 44%) 
No  
(n=92, 56%) 
Socio-economic 
status (n=157) 
Higher managerial, 
administrative and 
professional 
occupations 
15 (16.7) 9 (13.4) 
Intermediate 
occupations 
24 (26.7) 17 (25.4) 
Routine and manual 
occupations, never 
worked and long-term 
unemployed 
51 (56.7) 41 (61.2) 
Pain characteristics   
Leg pain intensity (0-10), mean (SD) (n=157) 6.2 (2.3) 5.6 (2.2) 
Back pain intensity (0-10), mean (SD) (n=162) 5.6 (1.7) 5.2 (5.6) 
Pain below the knee  60 (83.3) 72 (78.3) 
Leg pain worse than back pain (n=163) 37 (51.4) 50 (55.0) 
Duration of back 
pain symptoms in 
current episode 
(n=163) 
< 6 weeks 35 (38.5) 24 (33.3) 
6 to 12 weeks 22 (24.2) 13 (18.1) 
> 3 months 34 (37.4) 35 (48.6) 
< 6 weeks 35 (39.3) 23 (33.8) 
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Baseline characteristics (n=164)* 
 
†Persistent neuropathic pain  
(s-LANSS ≥12 at baseline and at four 
months) 
Yes 
(n=72, 44%) 
No  
(n=92, 56%) 
Duration of leg pain 
symptoms in 
current episode 
(n=157) 
6 to 12 weeks 23 (25.8) 12 (17.7) 
> 3 months 31 (34.8) 33 (48.5) 
Limitations in activities   
RMDQ (0-23), mean (SD)  14.9 (5.1) 12.4 (5.4) 
Psychological variables   
HADS (depression) (0-21), mean (SD)  7.9 (4.3) 5.9 (3.5) 
PSEQ‡ (0-60), mean (SD) (n=160) 29.4 (15.0) 34.3 (14.2) 
Neurological examination findings   
Presence of muscle 
weakness§  
5/5 68 (73.9) 59 (81.9) 
4/5 22 (23.9) 12 (16.7) 
0 to 3/5 2 (2.2) 1 (1.4) 
Presence of either 
reduced or absent 
lower limb reflex  
None 70 (76.1) 50 (69.4) 
Slightly reduced 4 (4.4) 9 (12.5) 
Significantly reduced 18 (19.6) 13 (18.1) 
Reduction or loss of sensation to pin-prick 34 (47.2) 39 (42.4) 
Presence of pins and needles 55 (76.4) 67 (72.8) 
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Baseline characteristics (n=164)* 
 
†Persistent neuropathic pain  
(s-LANSS ≥12 at baseline and at four 
months) 
Yes 
(n=72, 44%) 
No  
(n=92, 56%) 
Presence of allodynia or hyperalgesia in the 
leg(s)||  
9 (9.8) 10 (14.0) 
Neural tension test** (any positive test) 51 (55.4) 41 (56.9) 
Other Neuropathic pain definitions   
Clinical diagnosis of sciatica††  59 (81.9) 79 (85.9) 
Neuroimaging   
Evidence of nerve root compression on MRI 
(n=149) 
39 (60.9) 43 (50.6) 
Abbreviations: CI, confidence intervals. HADS, Hospital Anxiety and Depression scale. MRI, magnetic 
resonance imaging. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris Disability 
Questionnaire leg version. SD, standard deviation. 
*Based on data completed by patients who responded to questionnaires at baseline and four months. 
All figures are for frequency (percentage) unless stated as mean (SD) and the denominator varies for 
some characteristics varies due to missing or not-applicable cases in which case the denominator is 
reported in parentheses 
† LBLP patients with persistent neuropathic pain: s-LANSS ≥ 12 at baseline and ≥ 12 at four months. Non-
persistent neuropathic pain: s-LANSS ≥ 12 at baseline and < 12 at four months. 
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs 
 § Muscle strength was tested according to a 6-point grading scale where; 
No visible flicker of movement or contraction 
Flicker of movement 
Full active movement with gravity counterbalanced 
Full active movement against gravity but not applied resistance 
Full active movement against gravity and some applied resistance 
Full active movement against gravity and strong resistance  
|| Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes) 
** Neural tension tests; straight leg raise, femoral stretch and slump test. 
† † LBLP patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain 
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8.5.1.2 Persistent neuropathic pain based on a clinical diagnosis of sciatica 
In total, 41% (125 out of 301) of patients with neuropathic pain (based on a clinical 
diagnosis of sciatica) had persistent neuropathic pain at four months. Table 8.4 
summarises the baseline characteristics of LBLP patients with and without persistent 
neuropathic pain defined in this way. Patients with persistent neuropathic pain had 
higher mean back pain intensity (using NRS 0 to 10, 5.6 (1.5)) compared to those with 
non-persistent neuropathic pain (4.9 (1.6)), higher mean leg pain intensity (using NRS 0 
to 10, 6.3 (2.2) vs 5.2 (2.3)) and higher mean leg, LBLP-related disability scores (using 
RMDQ 0 to 23, 13.5 (5.4) vs 11.7 (5.8)), a higher proportion of patients with leg pain 
duration in the current episode of longer than three months (51 (42.2%) vs 50 (28.6%)) 
and lower mean pain self-efficacy (using PSEQ 0 to 60, 32.2 (14.9) vs 36.7 (14.4)). 
Table 8.4 Baseline characteristics of patients with and without persistent neuropathic 
pain (based on a clinical diagnosis of sciatica) 
Baseline characteristics (n=307)* 
 
†Persistent neuropathic pain 
(Clinical diagnosis of sciatica and 
pain below the knee at four 
months) 
Yes  
(n=125, 41%) 
No 
 (n=182, 59%) 
Sociodemographic characteristics   
Female  88 (70.4) 100 (55.0) 
Age, mean (SD)  55.7 (13.6) 53.8 (12.5) 
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Baseline characteristics (n=307)* 
 
†Persistent neuropathic pain 
(Clinical diagnosis of sciatica and 
pain below the knee at four 
months) 
Yes  
(n=125, 41%) 
No 
 (n=182, 59%) 
Socio-economic 
status (n=297) 
Higher managerial, 
administrative and 
professional occupations 
26 (21.9) 39 (21.9) 
Intermediate 
occupations 
31 (26.1) 49 (27.5) 
Routine and manual 
occupations, never 
worked and long-term 
unemployed 
62 (52.1) 90 (50.6) 
Pain characteristics   
Leg pain intensity (0-10), mean (SD) (n=294) 6.3 (2.2) 5.2 (2.3) 
Back pain intensity (0-10), mean (SD) (n=304) 5.6 (1.5) 4.9 (1.6) 
Pain below the knee 120 (96.0) 143 (78.6) 
Leg pain worse than back pain (n=306) 50 (40.0) 76 (42.0) 
Duration of back 
pain symptoms in 
current episode 
(n=306) 
< 6 weeks 44 (35.5) 77 (42.3) 
6 to 12 weeks 26 (21.0) 40 (22.0) 
> 3 months 54 (43.6) 65 (35.7) 
< 6 weeks 41 (33.9) 84 (48.0) 
6 to 12 weeks 29 (24.0) 41 (23.4) 
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Baseline characteristics (n=307)* 
 
†Persistent neuropathic pain 
(Clinical diagnosis of sciatica and 
pain below the knee at four 
months) 
Yes  
(n=125, 41%) 
No 
 (n=182, 59%) 
Duration of leg pain 
symptoms in current 
episode (n=296) 
> 3 months 51 (42.2) 50 (28.6) 
Limitations in activities   
RMDQ (0-23), mean (SD)  13.5 (5.4) 11.7 (5.8) 
Psychological variables   
HADS (depression) (0-21), mean (SD)  6.3 (4.0) 5.9 (3.9) 
PSEQ‡ (0-60), mean (SD) (n=300) 32.2 (14.9) 36.7 (14.4) 
Neurological examination findings   
Presence of muscle 
weakness§  
5/5 90 (72.0) 143 (78.6) 
4/5 27 (21.6) 36 (19.8) 
0 to 3/5 8 (6.4) 3 (1.7) 
Presence of either 
reduced or absent 
lower limb reflex  
None 100 (80.0) 134 (73.6) 
Slightly reduced 11 (8.8) 9 (5.0) 
Significantly reduced 14 (12.2) 39 (21.4) 
Reduction or loss of sensation to pin-prick 64 (51.2) 82 (45.1) 
Presence of pins and needles 77 (61.6) 99 (54.4) 
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Baseline characteristics (n=307)* 
 
†Persistent neuropathic pain 
(Clinical diagnosis of sciatica and 
pain below the knee at four 
months) 
Yes  
(n=125, 41%) 
No 
 (n=182, 59%) 
Presence of allodynia or hyperalgesia in the 
leg(s)||  
11 (8.8) 14 (7.7) 
Neural tension test** (any positive test) 79 (63.2) 128 (70.3) 
Other Neuropathic pain definitions   
s-LANSS ≥ 12 †† (n=305) 66 (53.7) 83 (45.6) 
Neuroimaging   
Evidence of nerve root compression on MRI 
(n=286) 
77 (67.0) 104 (60.8) 
Abbreviations: CI, confidence intervals. HADS, Hospital Anxiety and Depression scale. MRI, magnetic 
resonance imaging. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris Disability 
Questionnaire (RMDQ) leg version. SD, standard deviation. 
* Based on data completed by patients who responded to questionnaires at baseline and four months. 
All figures are for frequency (percentage) unless stated as mean (SD) and the denominator varies for 
some characteristics varies due to missing or not-applicable cases in which case the denominator is 
reported in parentheses. 
† LBLP patients with persistent neuropathic pain based on sciatica: clinical diagnosis of sciatica at 
baseline and pain below the knee at four months. Non-persistent neuropathic pain: clinical diagnosis of 
sciatica at baseline with no pain below the knee at four months. 
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs 
 § Muscle strength was tested according to a 6-point grading scale where;  
No visible flicker of movement or contraction 
Flicker of movement 
Full active movement with gravity counterbalanced 
Full active movement against gravity but not applied resistance 
Full active movement against gravity and some applied resistance 
Full active movement against gravity and strong resistance  
|| Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes). 
** Neural tension tests; straight leg raise, femoral stretch and slump test. 
† † LBLP patients with an s-LANSS score of 12 or greater are described as having “possible” neuropathic 
pain    
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8.5.1.3 Comparison of baseline characteristics across two definitions of persistent 
neuropathic pain 
Leg pain intensity and LBLP-related disability were consistently worse for patients with 
persistent neuropathic pain compared to those without across the two definitions. Of 
the six items from the neurological examination, all were similar for patients with 
persistent neuropathic pain compared to those with non-persistent neuropathic pain 
across both definitions of persistent neuropathic pain. Figure 8.1 summarises the 
characteristics that were similar for patients with and without persistent neuropathic 
pain consistently across two definitions.  
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• Socio-economic status, in particular patients who 
had never worked or were long-term unemployed 
• Age 
• Back pain duration in the current episode 
• Leg pain worse than back pain  
• Presence of pain below the knee 
• The presence of mild muscle weakness 
(myotomal) 
• A reduction or absence in reflex 
• Reduction or loss in sensation to pin-prick 
• The presence of pins and needles 
• The presence of a positive neural tension test 
• The presence of an increased response to either 
non-painful or painful stimuli (allodynia or 
hyperalgesia) 
Figure 8.1 Summary of baseline characteristics for LBLP patients with and without persistent neuropathic pain across two definitions.  
• More severe leg pain intensity in the previous two 
weeks 
• More severe LBLP-related disability 
Abbreviations: MRI, magnetic resonance imaging. s-LANSS, self-report version of the Leeds Assessment of Neurological symptoms and signs 
LBLP patients with persistent neuropathic pain based on:  1) s-LANSS, s-LANSS ≥ 12 at baseline and ≥ 12 at four months. Non-persistent neuropathic pain: s-LANSS ≥ 12 at baseline and < 12 at 
four months, 2) sciatica, clinical diagnosis of sciatica at baseline and pain below the knee at four months. Non-persistent neuropathic pain: clinical diagnosis of sciatica at baseline with no pain 
below the knee at four months. 
S-LANSS ≥ 12 Sciatica 
Characteristics similar across two definitions of neuropathic 
pain:  
Patients without non-persistent neuropathic pain 
• Symptoms of depression 
• Nerve root compression on 
MRI 
Characteristics different across two definitions of 
neuropathic pain:  
• More severe back pain 
intensity in the previous two 
weeks 
• Beliefs of pain self-efficacy 
• Female sex 
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8.5.2 Clinical course  
8.5.2.1 Persistent neuropathic pain based on s-LANSS 
Mean (unadjusted) pain intensity of patients with persistent neuropathic pain was 
higher at baseline, four months (6.4 v 3.2), twelve months (5.0 v 3.0) and at three 
years (4.8 v 2.9), compared to those with non-persistent neuropathic pain. When 
baseline pain intensity scores were adjusted to account for variability of scores, 
patients with persistent neuropathic pain had significantly higher scores at each of the 
three follow-up points, compared to those without. Mean (unadjusted) disability 
scores of patients with persistent neuropathic pain was higher at baseline, four 
months (12.7 v 6.7), twelve months (13.0 v 7.5) and at three years (8.8 v 5.8). When 
baseline disability scores were adjusted patients with persistent neuropathic pain had 
significantly higher scores at four months, but not twelve months or three years. See 
Box 8.2 and Box 8.3 for a summary of the clinical course of patients with and without 
persistent neuropathic pain based on s-LANSS. 
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Box 8.2 Three year clinical course (pain intensity*) of patients with and without persistent 
neuropathic pain (based on s-LANSS) at four months 
Unadjusted clinical course 
 
Clinical course adjusted for baseline pain score 
 Follow-up point Persistent neuropathic pain at four months‡ p 
Yes No 
Baseline 6.17 (5.8 to 6.6) 6.17 (5.8 to 6.6) - 
4 months 5.2 (4.7 to 5.6) 3.2 (2.8 to 3.6) 0.02 
12 months 5.1 (4.6 to 5.5) 3.5 (3.0 to 3.9) 0.002 
3 years 4.7 (4.2 to 5.3) 2.9 (2.4 to 3.6) 0.002 
Abbreviations: NRS, numerical rating scale. s-LANSS, self-report version of the Leeds Assessment of 
Neuropathic Symptoms and Signs neuropathic pain scale. *Highest of leg or back pain intensity (mean of 3 
NRS, 0-10)). ‡ Based on analysis of LBLP patients with neuropathic pain (s-LANSS ≥ 12) at baseline. Persistent 
neuropathic pain: s-LANSS ≥ 12 at four months. Non-persistent pain: s-LANSS < 12 at four months 
95% confidence intervals are shown in parentheses 
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 Box 8.3 Three year clinical course (leg and back-related disability*) of patients with and 
without persistent neuropathic pain (based on s-LANSS) at four months 
Unadjusted clinical course 
 
Clinical course adjusted for baseline RMDQ score 
 Follow-up point Persistent neuropathic pain at four months‡ p 
Yes No 
Baseline 13.3 (12.4 to 14.2) 13.3 (12.4 to 14.2) - 
4 months 11.8 (10.7 to 12.8) 7.2 (6.3 to 8.2) 0.02 
12 months 11.9 (10.8 to 13.0) 8.2 (7.2 to 9.1) 0.07 
3 years 7.9 (6.7 to 9.2) 5.9 (4.8 to 7.1) 0.13 
Abbreviations: NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire leg version. s-
LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs neuropathic pain 
scale.‡ Based on analysis of LBLP patients with neuropathic pain (s-LANSS ≥ 12) at baseline. Persistent 
neuropathic pain: s-LANSS ≥ 12 at four months. Non-persistent pain: s-LANSS < 12 at four months 
95% confidence intervals are shown in parentheses 
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8.5.2.2 Persistent neuropathic pain based on a clinical diagnosis of sciatica 
Mean (unadjusted) pain intensity of patients with persistent neuropathic pain was 
higher at baseline, four months (5.4 v 2.8), twelve months (4.2 v 2.9) and at three 
years (4.2 v 2.8), compared to those with non-persistent neuropathic pain. When 
baseline pain intensity scores were adjusted to account for variability of scores at 
baseline, patients with persistent neuropathic pain had significantly higher scores at all 
three time points. Mean (unadjusted) disability scores of patients with persistent 
neuropathic pain were higher at baseline, four months (11.8 v 6.0), twelve months 
(10.2 v 6.4) and at three years (7.8 v 5.0), compared to those with non-persistent 
neuropathic pain; this was also the case for mean adjusted disability scores at all three 
follow-up points. See Box 8.4 and Box 8.5 for a summary of the clinical course of 
patients with and without persistent neuropathic pain based on sciatica. 
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 Box 8.4 Three year clinical course (pain intensity*) of patients with and without persistent 
neuropathic pain (based on a clinical diagnosis of sciatica) at four months 
Unadjusted clinical course 
 
Clinical course adjusted for baseline pain score 
 Follow-up point Persistent neuropathic pain at four months‡ p 
Yes No 
Baseline 6.1 (5.8, 6.4) 6.1 (5.8, 6.4) - 
4 months 5.1 (4.8, 5.5) 3.0 (2.7, 3.3) <0.001 
12 months 3.9 (3.5, 4.3) 3.1 (2.8, 3.4) 0.006 
3 years 3.9 (3.4) 2.9 (2.6, 3.3) 0.002 
Abbreviations: NRS, numerical rating scale.*Highest of leg or back pain intensity (mean of 3 NRS, 0-10)). 
‡ Based on analysis of LBLP patients with neuropathic pain (clinical diagnosis of sciatica) at baseline. Persistent 
neuropathic pain: presence of pain below the knee at four months. Non-persistent pain: absence of pain 
below the knee at four months. 95% confidence intervals are shown in parentheses 
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Box 8.5 Three year clinical course (leg and back-related disability*) of patients with and 
without persistent neuropathic pain (based on a clinical diagnosis of sciatica) at four 
months 
Unadjusted clinical course 
 
Clinical course adjusted for baseline RMDQ score 
 Follow-up point Persistent neuropathic pain at four months‡ p 
Yes No 
Baseline 12.3 (11.6, 13.0) 12.3 (11.6, 13.0) - 
4 months 11.1 (10.2, 11.9) 6.4 (5.7, 7.1) <0.001 
12 months 9.5 (8.6, 10.3) 6.8 (6.1, 7.5) 0.007 
3 years 7.1 (6.2, 8.1) 5.1 (4.3, 5.9) 0.001 
Abbreviations: NRS, numerical rating scale. RMDQ, Roland Morris Disability Questionnaire leg version. 
‡ Based on analysis of LBLP patients with neuropathic pain (clinical diagnosis of sciatica) at baseline. 
Persistent neuropathic pain: presence of pain below the knee at four months. Non-persistent pain: absence 
of pain below the knee at four months. 95% confidence intervals are shown in parentheses. 
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8.5.2.3 Comparison of clinical course across two definitions of persistent neuropathic 
pain 
Using both definitions of persistent neuropathic pain, the clinical course of patients 
was consistently worse in terms of pain intensity compared to those with non-
persistent neuropathic pain at four months, twelve months and three years, using 
scores adjusted for baseline variability. The clinical course of patients with persistent 
neuropathic pain, adjusted for baseline variability in individual LBLP-related disability 
(using RMDQ) scores was worse at twelve months and three years compared to those 
without for one definition of persistent neuropathic pain, and at four months for both 
definitions of neuropathic pain. Mean adjusted and unadjusted pain intensity were 
higher for patients with persistent neuropathic pain based on s-LANSS at each of the 
three follow-up points compared to those with persistent neuropathic pain based on 
sciatica, this was also the case for disability scores.  
8.5.3 Identification of potential prognostic factors  
8.5.3.1 Persistent neuropathic pain based on s-LANSS 
Table 8.5 reports OR (and 95% CI) for univariable associations between each of the 
factors identified as having potential prognostic value in persistent neuropathic pain. 
Only pain self-efficacy was statistically significantly associated with persistent 
neuropathic pain, for every one unit reduction in pain self-efficacy score (using PSEQ), 
the odds of having persistent neuropathic pain increased by 2% (OR 0.98, CI 0.96 to 
0.998). Evidence of nerve root compression on MRI was not statistically associated 
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with persistent neuropathic pain (p=0.24) but was carried forward to the multivariable 
model. 
Table 8.5 Univariable associations between potential prognostic factors and persistent 
neuropathic pain at four months (based on s-LANSS) 
Prognostic factor *Persistent neuropathic pain 
(s-LANSS ≥12 at baseline and at 
four months), OR (95% CI) 
Age  1.01 (0.99, 1.03) 
Female sex  0.85 (0.47, 1.52) 
Socio-economic status Higher managerial, 
administrative and 
professional occupations 
1 
Intermediate 
occupations 
0.99 (0.39, 2.49) 
Routine and manual 
occupations,  never 
worked and long-term 
unemployed 
1.12 (0.48, 2.60) 
Leg pain intensity (0-10) 1.10 (0.97, 1.25) 
Pain below the knee  1.22 (0.60, 2.50) 
Duration of leg pain 
symptoms in current 
episode  
< 6 weeks 1 
6 to 12 weeks 0.82 (0.39, 1.74) 
> 3 months 1.21 (0.65, 2.28)  
Pain self-efficacy using PSEQ‡ (0-60) 0.98 (0.96, 0.998) 
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Abbreviations: CI, confidence intervals. MRI, magnetic resonance imaging. PSEQ, pain self-efficacy 
questionnaire.  
Results underlined highlight significance level p<0.05 
 Based on analysis of LBLP patients with neuropathic pain (s-LANSS ≥ 12) at baseline. Persistent 
neuropathic pain: s-LANSS ≥ 12 at four months. Non-persistent pain: s-LANSS < 12 at four months 
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs 
† † LBLP patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain    
 
8.5.3.2 Persistent neuropathic pain based on a clinical diagnosis of sciatica 
The univariable associations between each of the factors identified as having potential 
prognostic value in persistent neuropathic pain is summarised in Table 8.6. Four 
potential factors were significantly associated with persistent neuropathic pain; female 
sex (OR 1.95, CI 1.20 to 3.16); leg pain duration greater than three months (OR 1.91, CI 
1.12 to 3.26); leg pain intensity, for every one unit increase in leg pain intensity score, 
the odds of having persistent neuropathic pain increased by 21% (OR 1.21, CI 1.09 to 
1.35); pain self-efficacy, for every one unit reduction in PSEQ score, the odds of having 
persistent neuropathic pain increased by 2% (OR 0.98, CI 0.96 to 0.99). 
  
Reduction or loss of sensation to pin-prick 1.06 (0.61, 1.83) 
Presence of pins and needles 1.26 (0.68, 2.33) 
Clinical diagnosis of sciatica††  0.75 (0.38, 1.49) 
Evidence of nerve root compression on MRI  1.40 (0.80, 2.45) 
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Table 8.6. Univariable associations between potential prognostic factors and persistent 
neuropathic pain at four months (based on a clinical diagnosis of sciatica)  
Prognostic factor *Persistent neuropathic pain  
(Clinical diagnosis of sciatica 
and pain below the knee at four 
months)  OR (95% CI) 
Age  1.01 (0.99, 1.03) 
Female sex  1.95 (1.20, 3.16) 
Socio-economic 
status 
Higher managerial, 
administrative and professional 
occupations 
1 
Intermediate occupations 0.96 (0.49, 1.87) 
Routine and manual 
occupations,  never worked and 
long-term unemployed 
1.05 (0.58, 1.89) 
Leg pain intensity (0-10) 1.21 (1.09, 1.35) 
Duration of leg pain 
symptoms in current 
episode  
< 6 weeks 1 
6 to 12 weeks 1.38 (0.76, 2.52) 
> 3 months 1.91 (1.12, 3.26) 
PSEQ† (0-60) 0.98 (0.96, 0.99) 
Reduction or loss of sensation to pin-prick 1.28 (0.81, 2.02) 
Presence of pins and needles 1.34 (0.85, 2.13) 
s-LANSS ≥ 12 ‡ 1.45 (0.92, 2.30) 
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Abbreviations: CI, confidence intervals. OR, odds ratio. PSEQ, pain self-efficacy questionnaire.  
Results underlined highlight significance level p<0.05 
* Showing results for 60 multiply-imputed datasets, based on analysis of LBLP patients with neuropathic 
pain (clinical diagnosis of sciatica) at baseline. Persistent neuropathic pain: presence of pain below the 
knee at 4 months. Non-persistent pain: absence of pain below the knee at 4 months.  
†Higher scores on PSEQ reflect stronger self-efficacy beliefs 
‡ LBLP patients with s-LANSS ≥ 12 are described as having “possible” neuropathic 
 
The following section reports on the prognostic value of pain self-efficacy and evidence 
of nerve root compression on MRI. 
8.5.4 Prognostic value of selected factors 
8.5.4.1 Prediction of persistent neuropathic pain based on s-LANSS 
Neither evidence of nerve root compression on MRI nor pain self-efficacy were 
significantly associated with persistent neuropathic pain when included in the model 
with age, sex, leg pain intensity, duration of current leg pain. Results are presented in 
Table 8.7. 
  
Evidence of nerve root compression on MRI  1.27 (0.78, 2.08) 
 292 
  
Table 8.7 Multivariable associations between potential prognostic factors and 
persistent neuropathic pain (based on s-LANSS) at four months  
Abbreviations: CI, confidence intervals. PSEQ, pain self-efficacy questionnaire.  
* Showing results for 60 multiply-imputed datasets, based on analysis of LBLP patients with neuropathic 
pain (s-LANSS ≥ 12) at baseline. Persistent neuropathic pain: s-LANSS ≥ 12 at four months. Non-
persistent pain: s-LANSS < 12 at four months 
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs 
 
8.5.4.2 Prediction of persistent neuropathic pain based on a clinical diagnosis of sciatica 
When entered into a multivariable regression model, neither evidence of nerve root 
compression on MRI nor pain self-efficacy were significantly associated with persistent 
neuropathic pain. Leg pain intensity and female sex were associated with persistent 
neuropathic pain, summarised in Table 8.8. The odds of having persistent neuropathic 
pain was twice as high (OR 2.09, CI 1.24 to 3.53) for female patients compared to male 
Prognostic factor *Persistent neuropathic pain (s-
LANSS ≥12 at baseline and at four 
months),  OR (95% CI) 
Age 1.01 (0.98, 1.03) 
Female sex 0.94 (0.50, 1.76) 
Leg pain intensity (0-10) 1.02 (0.88, 1.19) 
Duration of leg pain 
symptoms in current 
episode  
< 6 weeks 1 
6 to 12 weeks 0.82 (0.37, 1.78) 
> 3 months 1.12 (0.58, 2.18) 
Pain self-efficacy using PSEQ‡ (0-60) 0.98 (0.96, 1.00) 
Evidence of nerve root compression on MRI 0.80 (0.15, 4.35) 
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patients. For every one unit increase in leg pain intensity, the odds of having persistent 
neuropathic pain increased by 13% (OR 1.13, CI 1.01 to 1.28).  
Table 8.8 Multivariable associations between potential prognostic factors and 
persistent neuropathic pain (based on a clinical diagnosis of sciatica) at four months  
Abbreviations: CI, confidence intervals. OR, odds ratio. PSEQ, pain self-efficacy questionnaire.  
Results underlined highlight significance level p<0.05 
* Showing results for 60 multiply-imputed datasets, based on analysis of LBLP patients with neuropathic 
pain (clinical diagnosis of sciatica) at baseline. Persistent neuropathic pain: presence of pain below the 
knee at 4 months. Non-persistent pain: absence of pain below the knee at 4 months.  
†Higher scores on PSEQ reflect stronger self-efficacy beliefs 
 
8.5.3.3 Prognostic value of factors across two definitions of persistent neuropathic pain 
In multivariable analysis of potential factors, neither evidence of nerve root 
compression on MRI nor pain self-efficacy was associated with persistent neuropathic 
pain. Female sex and leg pain intensity were associated with persistent neuropathic 
pain based on one definition (clinical diagnosis of sciatica). 
Prognostic factor * Persistent neuropathic pain 
(Clinical diagnosis of sciatica and 
pain below the knee at four 
months), OR (95% CI) 
Age 1.01 (0.99, 1.03) 
Female sex 2.09 (1.24, 3.53) 
Leg pain intensity (0-10) 1.13 (1.01, 1.28) 
Duration of leg pain 
symptoms in current episode  
< 6 weeks 1 
6 to 12 weeks 1.47 (0.77, 2.78) 
> 3 months 1.59 (0.91, 2.79) 
PSEQ† (0-60) 0.98 (0.97, 1.00) 
Evidence of nerve root compression on MRI 1.26 (0.74, 2.15) 
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8.6 Discussion 
The research in this chapter reports on the characteristics and prognosis of patients 
with persistent neuropathic pain and highlights exploratory prognostic factor research 
for two definitions of neuropathic pain. This section summarises the key findings, 
makes comparisons with existing literature, and following a section on the strengths 
and limitations of the research, considers the implications for clinical practice and 
research before drawing key conclusions.  
8.6.1 Baseline characteristics and clinical course 
Approximately four out of ten patients with neuropathic pain at baseline had 
persistent neuropathic pain at four months, irrespective of definition. Across both 
definitions, patients with persistent neuropathic pain presented with more severe leg 
pain intensity and leg and back pain-related disability at baseline. It was surprising that 
all of the six items from the neurological examination were similar for patients with 
and without persistent neuropathic pain across both definitions. This suggests that 
items from the neurological examination may be indicative of mechanisms underlying 
neuropathic pain when patients present at baseline but the same mechanisms may not 
explain persistent neuropathic pain. 
The clinical course in patients with persistent neuropathic pain was characterised by a 
gradual improvement of pain over short term (four months), intermediate (twelve 
months) and long-term (three years) follow up which is distinct to the broader group 
of patients either with or without neuropathic pain whose course rapidly improved by 
four months (the reader is referred to Chapter 6 for a detailed report on the clinical 
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course of patients with and without neuropathic pain). However the clinical course of 
LBLP patients with persistent neuropathic pain in terms of pain intensity seemed 
worse at each of the three follow-up points compared to those with non-persistent 
neuropathic pain, consistently for both definitions of persistent neuropathic pain, but 
less consistently in terms of LBLP-related disability. In part this may be due to small 
numbers in the group of patients with persistent neuropathic pain based on s-LANSS. 
Understanding the factors that predict which patients with neuropathic pain are likely 
to have persistent neuropathic pain is important since their likely future course will be 
worse than those patients who do not have persistent neuropathic pain. The following 
section discusses the findings from the exploratory prognostic factor analyses.  
8.6.2 Exploratory prognostic factor research 
The findings from the exploratory prognostic factor research in LBLP patients with 
neuropathic pain at baseline highlights the prognostic value of a small number of 
characteristics in this patient group. This type of research exploring the potential 
prognostic value of factors is important to inform further research that may develop 
and validate prognostic models that help identify those patients with neuropathic pain 
who are likely to have a poor outcome (Riley et al. 2013). In the current analyses only 
one factor, pain self-efficacy, was significantly associated with persistent neuropathic 
pain in univariable regression models, but lost significance when entered into a 
multivariable model with other potential factors considered to be clinically important 
in this patient population.  This finding was consistent across both definitions of 
persistent neuropathic pain. In the multivariable model, female sex and higher leg pain 
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intensity remained significantly associated with persistent neuropathic pain. However, 
this finding was observed using one (sciatica), not both, definitions of persistent 
neuropathic pain.  
The finding that higher leg pain intensity was associated with one definition of 
persistent neuropathic pain is perhaps not surprising since in a systematic review of 
patients with neuropathic pain (Boogaard et al. 2015) higher pain intensity predicted 
poor outcomes across several neuropathic pain conditions. In non-surgically treated 
sciatica patients (Verwoerd et al. 2013), higher leg pain intensity predicted poor 
outcomes, and in broader LBP populations in primary care pain severity was found to 
be associated with poorer outcomes (Dunn et al. 2011). Female sex in this research 
was associated with persistent neuropathic pain (sciatica) which is also comparable to 
previous research (Peul et al. 2008) in patients with sciatica plus evidence of nerve 
root compression. Sex hormones probably have an effect on the underlying 
mechanisms of pain and may contribute, in part, to sex differences seen in this 
research (Picavet 2010). However, it was unexpected that none of the potential 
prognostic factors selected were significantly associated with persistent neuropathic 
pain based on s-LANSS, this highlights the challenge in predicting which patients with 
neuropathic pain will have persistent neuropathic pain. A discussion follows on the 
complexities of prognostic research in patients with neuropathic pain, including 
consideration of the selection of potential prognostic factors and the definitions of 
persistent neuropathic pain in this research. 
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8.6.2.1 Potential prognostic factors 
In this research, the presence of pins and needles in the painful leg (a positive 
neuropathic sign) and the reduction or loss of sensation in the painful leg (a negative 
neuropathic sign) were identified as potential prognostic factors and there is some 
consensus amongst experts that these factors may predict poor outcomes in patients 
with neuropathic pain (Boogaard et al. 2011). However, in this research neither the 
presence of pins and needles in the painful leg nor the reduction or loss of sensation in 
the painful leg were associated with persistent neuropathic pain. The presence of pins 
and needles may be a sign of underlying pathophysiology such as demyelination and is 
thought to be an important positive sign of neuropathic pain, it is biologically plausible 
but there is an absence of evidence in the literature that the presence of pins and 
needles could be a potential prognostic factor of persistent neuropathic pain 
(Boogaard et al. 2015).  
A reduction or loss of sensation was not associated with persistent neuropathic pain in 
this research, a finding that is consistent with previous prognosis research (Martinez et 
al. 2012) investigating patients with persistent neuropathic pain (based on the DN4) 
three months after surgery (in which post-surgical pain is assumed to be a neuropathic 
pain condition). The results of the current research suggest that although negative 
signs characterise neuropathic pain conditions, a reduction or loss of sensation may 
not predict persistent neuropathic pain.  
The presence of an increased pain response is a positive sign of neuropathic pain and 
may predict persistent neuropathic pain (based on DN4) (Martinez et al. 2012). The 
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reason not to consider an increased pain response as a potential prognostic factor in 
the current analyses was methodological. Firstly, it was thought important to select 
strong prognostic factors for this research, where the strength of a factor is a function 
of the association between factor and outcome and secondly, on how common the 
factor occurs in a population (Steyerberg 2009). In this research with LBLP patients, 
there was some evidence that an increased pain response was associated with 
neuropathic pain (based on one definition) but it was not a common finding in this 
patient population (see Chapter 5 for a detailed report of the baseline characteristics 
of LBLP patients with and without neuropathic pain). Secondly, a limited number of 
factors could be selected due to the small numbers and priority was given to stronger 
predictors. Section 8.6.3 highlights the small sample size as a limitation of this 
research. An increased pain response is characteristic of neuropathic pain but it is not 
exclusive to neuropathic pain conditions and is likely to be a sign of central 
sensitisation. Previous chapters highlighted evidence that suggests the underlying pain 
mechanisms of neuropathic pain based on s-LANSS may in part be due to central 
sensitisation and there is considerable interest in the role of an increased pain 
response. Future empirical prognostic research with this patient population that 
investigates whether an increased pain response is associated with persistent 
neuropathic pain would be of value, but the challenge is the very low prevalence of 
this clinical sign in this population. It is likely that evidence of nerve root compression 
on MRI in part explains peripheral mechanisms of neuropathic pain in this patient 
population whilst other mechanisms may contribute to ongoing persistence. Other 
mechanisms and in particular inflammatory mechanisms may be particularly important 
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(Hung et al. 2017, Schmid et al. 2013) in persistent neuropathic pain (the reader is 
referred to Chapter 1, section 1.14 for a report on pain arising from inflammation). 
Inflammation may occur systemically because of chronic disease, obesity, medication 
use, smoking and heavy alcohol consumption (Hung et al. 2017) but in LBLP patients 
inflammation may also be dependent on symptom severity (Wang et al. 2016). In the 
future, understanding the role of inflammatory mechanisms underlying LBLP patients 
with and without neuropathic pain may provide greater explanation of the 
mechanisms underlying LBLP and provide a therapeutic target in this patient 
population (Hung et al. 2017).  
Over recent decades there has been increasing use of QST to understand the 
somatosensory function in patients with neuropathic pain. There is a paucity of 
evidence to help researchers or clinicians understand whether responses to QST in 
LBLP populations have prognostic value (Marcuzzi et al. 2016). In this research, 
prognostic factors selected from a large number of self-reported variables and routine 
clinical examination items has not resulted in clear identification of factors significantly 
associated with persistent neuropathic pain in patients initially presenting with 
neuropathic pain. It is possible that additional assessment of the prognostic value of 
QST variables in this patient population might be helpful. Overall, the results of the 
current research highlight that items from routine neurological examination, including 
MRI, deemed important for defining cases of neuropathic pain at baseline did not 
explain the presence of persistent neuropathic pain at four months.  
 300 
  
8.6.2.2 Definitions of persistent neuropathic pain 
In the current research, two definitions of persistent neuropathic pain based on either 
s-LANSS or clinical diagnosis of sciatica were used. In the absence of clinical 
examination data at four months the presence of pain below the knee was used as a 
proxy for sciatica at four months. This research is the first to explore prognostic factors 
using a prospective cohort of patients, the use of two definitions of persistent 
neuropathic pain allowed for comparisons to be made and conclusions to be drawn. 
The presence of pain below the knee is an acceptable proxy for sciatica but may over-
identify cases (Konstantinou et al. 2012c) and may have led to an over estimation of 
persistent neuropathic pain at four months. It is likely the sciatica prevalence in this 
patient group would have been lower than 41%, if based on clinical examination. 
Previous chapters have highlighted similarities but also distinct differences in baseline 
characteristics and clinical course in patients with neuropathic pain across the two 
approaches. It is plausible that prognostic factors thought to predict persistent 
neuropathic pain based on s-LANSS may not explain cases of persistent neuropathic 
pain based on sciatica. Further exploratory prognostic research may investigate 
whether there are factors common and/or unique to distinct definitions of persistent 
neuropathic pain in this patient population. 
A discussion follows on the strengths and limitations of this research, followed by 
consideration of the implications for future prognostic factor research in this patient 
population. 
 301 
  
8.6.3 Strengths and limitations 
The main strength of this research is the prospective cohort design, use of multiple 
imputation to account for missing data and use of more than one definition of 
persistent neuropathic pain. A further strength of this analysis is the approach to 
selecting potential prognostic factors from the available dataset, chosen as they were 
thought to be clinically potential important factors for poor prognosis in neuropathic 
pain conditions and separately in LBP populations. This approach of factor selection 
was chosen over variable selection based on univariable statistical significance, and it 
is thought to reduce potential bias and over-optimism of potential prognostic effects 
(Sun et al. 1996).  
The main limitation is the small number of both the outcome, persistent neuropathic 
pain (n=72) and a relatively small sample size (n=164) for patients with persistent 
neuropathic pain based on s-LANSS. This was an important consideration when 
interpreting differences and similarities in baseline characteristics, resulted in large 
confidence intervals around point estimates of pain intensity and LBLP-related 
disability when comparing clinical course and in few prognostic factors being able to be 
selected for the exploratory prognostic factor research. The number of factors selected 
for the multivariable model was thought to be conservative (a maximum of seven 
factors) but this may not have been conservative enough (van Smeden et al. 2016). 
This research was based on secondary analysis of a prospective cohort and future 
studies of prognostic factors in this patient population would need larger sample sizes 
than those in this study to provide more robust evidence about prognostic factors.  
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A second limitation may have been the method of selecting potential prognostic 
factors for this research. In part, potential factors were selected on the finding of 
consistent associations with neuropathic pain across three definitions in LBLP patients, 
hence a few prognostic factors were identified. Further and larger scale prognostic 
factor research is required to address these limitations. A third limitation is the use of a 
proxy for sciatica case definition at follow-up.  
8.6.4 Implications for clinical practice and research 
The current research highlights that the clinical course of a sub-group of LBLP patients 
with persistent neuropathic pain is not favourable at short term, intermediate and 
long-term follow up compared to those without. This prognostic information is 
important for clinicians and to patients who continue to consult with neuropathic pain 
in primary care. Leg pain intensity and female sex may predict those who will have 
persistent neuropathic pain but this should be interpreted in clinical practice with 
caution given the exploratory nature of this prognostic factor research.  
In terms of implications for research, this sub-group of patients is important because 
they were identified based on an unfavourable clinical course but this research 
highlights difficulty not only in predicting which patients have persistent neuropathic 
pain but also difficulty in defining persistent neuropathic pain. Replication of the 
analysis completed in this research in a larger sample of patients may shed more light 
particularly on the factors that predict persistent neuropathic pain, and allow for an 
investigation of a greater number of potential prognostic factors. Data collected from 
clinical examination and MRI at baseline and at a subsequent time point would allow 
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for further investigation of the usefulness of the definition of persistent neuropathic 
pain in this patient population. Finally, further research exploring the prognostic value 
of responses to QST or biomarkers of inflammatory mechanisms in this patient 
population, may add to the understanding of the factors that are associated with 
persistent neuropathic pain.    
8.7 Conclusions 
Persistent neuropathic pain affected approximately four out of ten LBLP patients with 
neuropathic pain who consult in primary care. Baseline leg pain intensity and LBLP-
related disability in patients with persistent neuropathic pain were worse compared to 
those without. Otherwise patients with persistent neuropathic pain were broadly 
similar and were difficult to distinguish from patients with non-persistent neuropathic 
pain based on patient profile at baseline. However, patients with persistent 
neuropathic pain, in terms of pain intensity, were consistently worse off up to three 
years follow-up compared to those without. Pain self-efficacy was not an independent 
factor associated with outcome in either of the two definitions of persistent 
neuropathic pain, neither was evidence of nerve root compression on MRI. There was 
some evidence that leg pain intensity and female sex were associated with persistent 
neuropathic pain based on a clinical diagnosis of sciatica and pain below the knee at 
four months but otherwise it was difficult to predict patients with persistent 
neuropathic pain four months after their consultation in primary care. The current 
prognostic research was based on small numbers of patients with persistent 
neuropathic pain so the findings should be interpreted with caution. Future larger 
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studies might contribute further to a better understanding of this important patient 
sub-group with persistent neuropathic pain.  
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Chapter Nine. Prescribing patterns of pain medications in LBLP 
patients with neuropathic pain 
9.1 Introduction  
The research in this chapter describes the patterns of prescribed pain medications, 
including specific neuropathic pain medication, in LBLP patients with neuropathic pain 
who consult in primary care. Previous chapters in this thesis highlighted that the 
clinical course of patients with neuropathic pain at baseline improves rapidly for most 
by short term (four months) follow up (Chapter 6), but the clinical course of patients in 
the persistent neuropathic pain sub-group was worse at long term (three years) follow 
up compared to those without persistent neuropathic pain (Chapter 8). The research in 
this chapter describes the prescribing patterns of pain medications in this patient 
population by short term, intermediate and longer term follow-up. It describes the 
change in pain intensity or LBLP-related disability in those patients who are prescribed 
neuropathic pain medication compared to those who are not. Finally, the research in 
this chapter identifies and describes those LBLP patients with refractory neuropathic 
pain. These patients experience significant, long-term signs and symptoms of 
neuropathic pain and do not respond to standard treatment such as neuropathic pain 
medication. The findings are compared to existing literature before considering their 
clinical and research implications.  
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9.2 Aims and objectives 
9.2.1 Overall aim 
To provide estimates and describe prescribing patterns for pain medications in LBLP 
patients with neuropathic pain who consult in primary care and to estimate the 
proportion of LBLP patients with refractory neuropathic pain.   
9.2.2 Objectives 
1. Provide estimates and describe prescribing patterns for pain medications, including 
specific neuropathic pain medication in LBLP patients with neuropathic pain.  
2. Describe the baseline characteristics of LBLP patients with neuropathic pain, and 
the number of primary care consultations for patients who were prescribed 
neuropathic pain medication compared to those who were not. 
3. Describe the proportion of LBLP patients with neuropathic pain who improve in 
terms of pain intensity or leg and back pain-related disability. 
4. Provide estimates of refractory neuropathic pain in LBLP patients with neuropathic 
pain consulting in primary care. 
9.3 Methods 
9.3.1 Study design 
The research presented in this chapter is based on secondary analysis of a prospective 
observational cohort of primary care LBLP patients who consulted with their general 
practitioner (see Chapter 4 Study design and Methods for a detailed report on the 
ATLAS study).  
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9.3.2 Data collection 
Data regarding prescribed pain medication were obtained from electronic prescribing 
and consulting records for consenting patients in the ATLAS study at participating 
general practices. Prescribing data were obtained for the four month (122 days) period 
before the date of first attendance at the ATLAS research clinic, and up to the 
subsequent three years (1464 days). This timescale ensured inclusion of prescribing 
data for the current episode of back and leg pain (62% to 67% of patients with 
neuropathic pain (depending on definition) reported the duration of their current 
episode of leg pain to be less than three months). The analyses in this chapter is based 
on complete cases.  
9.3.2.1 Pain medications 
The number of pain medications prescribed to an individual patient during the study 
period was considered for use in this analysis. Pain medications were then categorised 
into seven groups based on recommendations from existing literature (Bedson et al. 
2013, NICE CG173 2013, Qaseem et al. 2017). See Chapter 4, section 4.9.8.1 (page 134) 
for a detailed report on the categorisation of pain medication in the research in this 
chapter, a summary of this is given below in Table 9.1.   
Table 9.1 Summary of groups of pain medication in research in Chapter nine 
Pain medication group Example  
First-line neuropathic pain 
medication* 
Amitriptyline, Duloxetine,  Gabapentin or 
Pregabalin 
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Pain medication group Example  
Basic analgesia Paracetamol  
Weak to moderate opioids  
 
Co-codamol, Co-dydramol and weak 
dosages of Codeine or Dihydrocodeine 
Strong to very strong opioids Tramadol ≥50mg, Morphine or Oxycodone 
Non-steroidal anti-inflammatory 
medication 
Naproxen or Ibuprofen >400mg 
Skeletal muscle relaxants Diazepam 
Abbreviations: mg, milligram 
*Tramadol was also categorised into a seventh group of broader neuropathic pain medications 
(Tramadol, Amitriptyline, Duloxetine, Gabapentin, and Pregabalin) 
 
9.3.3 Definitions of neuropathic pain, refractory neuropathic pain and 
improvement 
As in previous chapters, the research in this chapter defines cases according to three 
definitions of neuropathic pain and one definition of persistent neuropathic pain (see 
Chapter 4, section 4.7 (page 118) for a full report on case definitions of neuropathic 
pain used in this thesis). Two definitions describe “possible” neuropathic pain, based 
on s-LANSS, and on clinical diagnosis of sciatica; one definition describes “probable” 
neuropathic pain based on a definition of clinical diagnosis of sciatica with evidence of 
nerve root compression on MRI. Persistent neuropathic pain was based on s-LANSS at 
baseline and at four months and describes a sub-group of patients with “possible” 
persistent neuropathic pain.  
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Refractory neuropathic pain in this research was based on the definition described by 
Smith et al. (2012a). LBLP patients with persistent neuropathic pain (s-LANSS score of 
12 or greater at baseline and at four months) who continue to experience leg pain 
intensity levels of 5 or more (from the mean of three 0-10 NRSs) or less than 30% 
reduction in leg and back pain-related disability (using RMDQ 0-23) at four months 
compared to baseline, and who were prescribed two or more neuropathic pain 
medications, were considered to have refractory neuropathic pain. Patients with leg 
pain intensity levels less than 5 at four months or at least 30% reduction in leg and 
back pain-related disability were considered to have improved. 
9.3.4 Baseline characteristics and consultations in primary care 
This section provides a summary of the characteristics of patients used in the analyses 
in this chapter (see Table 9.2). The reader is referred to Chapter 4, section 4.9 (page 
120) for a full description of the method of data collection for each characteristic. 
Table 9.2 Summary of key characteristics used to describe patients with neuropathic 
pain medication in research in Chapter nine 
Baseline characteristics Categorical scale Continuous 
scale 
Sociodemographic characteristics  
Female sex Yes/no - 
Age  - Years 
Socio-economic status  Higher managerial, 
administrative and 
professional occupations 
- 
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Baseline characteristics Categorical scale Continuous 
scale 
Intermediate occupations - 
Routine and manual 
occupations, never worked 
and long-term unemployed 
- 
Health Status   
Co-morbidities* No other health problems - 
One other health problem - 
Two or more other health 
problems 
- 
Self-reported diabetes - 
Self-reported general health Excellent/ very good - 
Good - 
Fair - 
Poor - 
Pain characteristics  
Leg pain intensity  - 0-10 
Back pain intensity  - 0-10 
Pain below the knee  Yes/no - 
Leg pain worse than back pain Yes/no - 
Duration of back pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
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Baseline characteristics Categorical scale Continuous 
scale 
> 3 months - 
Duration of leg pain symptoms in 
current episode 
< 6 weeks - 
6 to 12 weeks - 
> 3 months - 
Widespread pain†  Yes/no - 
Limitations in activities  
RMDQ  - 0-23 
Psychological variables  
HADS (depression)  - 0-21 
HADS (anxiety)  - 0-21 
PSEQ‡  - 0-60 
Neurological examination findings  
Presence of muscle weakness§  5/5 - 
4/5 - 
0 to 3/5 - 
Presence of either reduced or absent 
lower limb reflex  
None - 
Slightly reduced - 
Significantly reduced or absent - 
Reduction or loss of sensation to pin-
prick 
Yes/no - 
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Baseline characteristics Categorical scale Continuous 
scale 
Presence of pins and needles Yes/no - 
Presence of allodynia or hyperalgesia in 
the leg(s) || 
Yes/no - 
Neural tension test** (any positive test) Yes/no - 
Other Neuropathic pain definitions  
Clinical diagnosis of sciatica††  Yes/no - 
Persistent neuropathic pain at four 
months 
Yes/no - 
Neuroimaging   
Evidence of nerve root compression on 
MRI 
Yes/no - 
Primary care consultations   
Consultations with a GP or specialist 
nurse practitioner‡‡ 
1 to 3 visits - 
4 to 6 visits - 
More than 7 - 
Abbreviations: HADS, Hospital Anxiety and Depression scale. GP, general practitioner, MRI, magnetic 
resonance imaging. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris Disability 
Questionnaire (RMDQ) leg version 
* Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes and circulation problems in the leg 
† Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton 
‡ Higher scores on PSEQ reflect stronger self-efficacy beliefs 
§ Muscle strength was tested according to a 6-point grading scale where; 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance  
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|| Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful 
stimuli (for example, brush strokes) 
** Neural tension tests; straight leg raise, femoral stretch and slump test 
† † LBLP patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain 
((Treede et al. 2008, Finnerup et al. 2016) 
 ‡‡Number of consultations for the four month period before the date of index consultation at the ATLAS 
research clinic, and for the four month period thereafter. Data for consultations was derived from 
electronic medical records. 
 
9.4 Statistical analysis 
9.4.1 Patterns of pain medication prescriptions 
The frequency (percentage) of pain medication prescriptions within the electronic 
records of individual patients was summarised for LBLP patients with neuropathic pain 
(based on three definitions of neuropathic pain) four months before and after index 
consultation at the ATLAS research clinic. The frequency of one or more of the six 
categories of medications (first line neuropathic pain medication, basic pain 
medication, weak or moderate opioids, strong or very strong opioids, non-steroidal 
anti-inflammatory medication and skeletal muscle relaxants) and individual 
medications within these categories that were prescribed up to four months after 
index consultation at the ATLAS research clinic were summarised for patients with 
neuropathic pain. Next, the number of pain medication prescriptions for patients up to 
twelve months and then up to three years after index consultation at the ATLAS 
research clinic were estimated.  
9.4.2 Baseline characteristics and consultations in primary care 
Descriptive statistics (mean and SD for continuous variables and frequency and 
percentage for categorical variables) were used to describe characteristics of LBLP 
patients with neuropathic pain and the number of primary care consultations for those 
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patients prescribed neuropathic pain medication up to four months after index 
consultation at the ATLAS research clinic and to compare these patients with those not 
prescribed such medications. 
9.4.3 Estimates of LBLP patients with refractory neuropathic pain 
The proportion of LBLP patients with neuropathic pain (based on three definitions of 
neuropathic pain and one definition of persistent neuropathic pain) with a clinically 
important difference in terms of leg pain intensity or leg and back pain-related 
disability was estimated and then described for those patients who were prescribed 
one or more neuropathic pain medications up to four months after index consultation 
at the ATLAS research clinic compared to those who are not. The proportion of LBLP 
patients with refractory neuropathic pain was reported.  
The analyses presented in this chapter uses data from patients who completed 
questionnaires at baseline and at four months. As documented in previous chapters 
there was some uncertainty due to missing data at follow-up. Sensitivity analyses were 
carried out comparing analyses using complete cases and those using imputed data 
(the reader is referred to Chapter 4, section 11; Study design and methods, for full 
details of the development of the imputation model and the assumptions made), a 
comparison of the two analyses was carried out which is summarised in section 9.5.3 
and the results of these analyses are presented in the Appendix C. 
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9.5 Results 
The pain medications prescribed to patients with neuropathic pain are summarised in 
section 9.5.1 (Tables 9.3 and 9.4). A description of the baseline characteristics and the 
number of primary care consultations for those patients who were prescribed 
neuropathic pain medications by four months compared to those who were not is 
given in section 9.5.2 and in Table 9.5. The penultimate section (section 9.5.3) 
summarises the change in pain intensity or LBLP-related disability in those patients 
who were prescribed neuropathic pain medications compared to those who were not, 
this is also depicted in Figure 9.1. Finally, section 9.5.4 highlights an estimated 
proportion of patients with refractory neuropathic pain in this patient population.  
9.5.1 Patterns of pain medication prescriptions  
9.5.1.1 Comparing patients with neuropathic pain across three definitions 
Over eight out of ten (81.7%) of patients with neuropathic pain based on s-LANSS were 
prescribed at least one pain medication up to four months before and after index 
consultation at the ATLAS research clinic, the majority (164 out of 273, 60.1%) of 
patients were prescribed two or more pain medications. The proportion of patients 
prescribed pain medications was similar across all three definitions of neuropathic 
pain, this was consistent across all six groups of pain medications and similar for all 
individual medications within each category. Table 9.3 summarises the number of 
individual pain medications that were prescribed for LBLP patients based on three 
definitions of neuropathic pain four months before and after index consultation at the 
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ATLAS research clinic and is followed by a detailed report of the pain medications 
prescribed to patients with neuropathic pain based on one definition (s-LANSS). 
The category of medications most commonly prescribed were weak or moderate 
strength opioids, nearly six out of ten patients with neuropathic pain (n=159, 58.2%) 
received a prescription for these types of drugs. Approximately a third of patients were 
prescribed basic analgesics (n=95, 34.8%) and similarly a third of patients were 
prescribed non-steroidal anti-inflammatories (n=91, 33.3%). Just under three out of 
ten patients (n=80, 29.3%) were prescribed one or more first line neuropathic pain 
medications and over a quarter (n=71, 26.0%) were prescribed either strong or very 
strong opioids. Skeletal muscle relaxants (Diazepam) was the least common category 
of medication to be prescribed, for approximately one in ten patients (n=31, 11.4%).  
Co-codamol was the most commonly prescribed individual medication to these 
patients, over half (of those with neuropathic pain based on s-LANSS n=144, 52.8%) 
were prescribed Co-codamol up to four months before and after index consultation at 
the ATLAS research clinic, Naproxen was prescribed for over a quarter of patients 
(n=70, 25.6%), followed by Amitriptyline (n=66, 24.2%) and Tramadol to one in five 
patients (n=56, 20.5%). Over a quarter of patients were prescribed one neuropathic 
pain medication (including Tramadol) (n=72, 26.4%) and one in ten patients were 
prescribed two or more (n=33, 11.3%). Amitriptyline was the most frequent first line 
neuropathic pain medication prescribed, followed by Gabapentin (n=17, 6.2%). 
Pregabalin was prescribed for very few patients (n=7, 2.6%) and Duloxetine was rarely 
prescribed (n=1 0.4%). A small proportion of patients (n=24, 8.8%) were prescribed 
 317 
  
Amitriptyline and Tramadol four months before or after an index consultation in 
primary care. 
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Table 9.3 Pain medication prescribed in primary care for patients with neuropathic pain 
up to four months before and after index consultation* 
Number of pain medications 
prescribed for individual 
patients  
Neuropathic pain definition 
s-LANSS≥ 12 
(n=273) 
Clinical 
diagnosis of 
sciatica (n=423) 
Clinical 
diagnosis of 
sciatica with 
clear or possible 
nerve root 
compression on 
MRI (n=232) 
Total pain medications     
None 50 (18.3) 83 (19.6) 44 (19.0) 
One 59 (21.6) 105 (24.8) 47 (20.3) 
Two or more 164 (60.1) 235 (55.6) 141 (60.8) 
Basic pain medications (one or 
more) 
95 (34.8) 125 (29.6) 72 (31.0) 
Paracetamol 51 (18.7) 70 (16.6) 37 (16.0) 
Ibuprofen (200mg-400mg) 42 (45.4) 51 (12.1) 30 (12.9) 
Topical NSAIDs  21 (7.7) 28 (6.6) 18 (3.5) 
First line neuropathic pain 
medication (one or more) 
80 (29.3) 117 (27.7) 75 (32.3) 
Amitriptyline 66 (24.2) 101 (23.9) 62 (26.7) 
Gabapentin 17 (6.2) 24 (5.7) 18 (7.8) 
Duloxetine 1 (0.4) 1 (0.2) 1 (0.4) 
Pregabalin 7 (2.6) 7 (1.7) 5 (2.2) 
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Number of pain medications 
prescribed for individual 
patients  
Neuropathic pain definition 
s-LANSS≥ 12 
(n=273) 
Clinical 
diagnosis of 
sciatica (n=423) 
Clinical 
diagnosis of 
sciatica with 
clear or possible 
nerve root 
compression on 
MRI (n=232) 
Weak to moderate opioids (+/- 
combination with paracetamol) 
(one or more) 
159 (58.2) 252 (59.6) 144 (62.1) 
Co-codamol  144 (52.8) 223 (52.7) 130 (56.0) 
Codeine (≤15mg)  7 (2.6) 13 (3.1) 6 (2.6) 
Nefopam† 10 (3.7) 16 (3.8) 7 (3.0) 
Co-dydramol  9 (3.3) 14 (3.3) 11 (4.7) 
Others  2 (0.7) 2 (0.5) 2 (0.9) 
Strong to very strong opioids 
(one or more) 
71 (26.0) 104 (24.6) 64 (27.6) 
Tramadol (≥50mg) 56 (20.5) 90 (21.3) 56 (24.1) 
Dihydrocodeine (≥30mg) 21 (7.7) 27 (6.4) 13 (5.6) 
Codeine (≥30mg) 15 (5.5) 14 (3.3) 8 (3.5) 
Others 8 (2.9) 10 (2.4) 9 (3.9) 
NSAIDS (one or more) 91 (33.3) 136 (32.2) 87 (37.5) 
Naproxen 70 (25.6) 114 (27.0) 71 (30.6) 
Others 28 (10.3) 37 (8.8) 29 (12.6) 
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Number of pain medications 
prescribed for individual 
patients  
Neuropathic pain definition 
s-LANSS≥ 12 
(n=273) 
Clinical 
diagnosis of 
sciatica (n=423) 
Clinical 
diagnosis of 
sciatica with 
clear or possible 
nerve root 
compression on 
MRI (n=232) 
Skeletal muscle relaxants 
(Diazepam) 
31 (11.4) 49 (11.6) 37 (16.0) 
All figures are frequencies (percentage) of prescriptions to an individual  
* Prescribing data was obtained for the four month period before the date of first attendance at the 
ATLAS study research clinic and four month thereafter 
†Nefopam acts through central mechanisms distinct to the action of opioids but is considered to be 
equipotent with opioids of moderate strength 
 
The following section (9.5.1.2) reports the pain medications prescribed to LBLP 
patients with neuropathic pain up to three years after index consultation at the ATLAS 
research clinic. Section 9.5.2 then describes the baseline characteristics of patients 
with neuropathic pain based on one definition of neuropathic pain (s-LANSS) who were 
prescribed one or more neuropathic pain medications compared to those who were 
not. 
9.5.1.2 Comparing prescribing patterns of pain medication across three different time 
points 
The majority of prescriptions for pain medication were issued at or before the first four 
months following index consultation at the ATLAS research clinic. By three-years, 
three-quarters of patients (n=207, 75.8%) had been prescribed two or more pain 
medications, few patients (n=34, 12.5%) were not prescribed any pain medication, this 
is summarised in Table 9.4.  
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Table 9.4 Pain medication prescribed in primary care for patients with neuropathic pain 
(based on s-LANSS) up to four months before and three years after index consultation 
Number of pain medications 
prescribed for individual patients 
Follow-up (n=273) * 
Four months 
Twelve 
months 
Three years 
None 50 (18.3) 43 (15.8) 34 (12.5) 
One 59 (21.6) 45 (16.5) 32 (11.7) 
Two or more 164 (60.1) 185 (67.8) 207 (75.8) 
All figures are frequencies (percentages) and figures at twelve months and three years are cumulative 
* Prescribing data were obtained for the four month period before the date of index consultation at the 
ATLAS research clinic and four, twelve months and three years thereafter.  
 
9.5.2 Baseline characteristics of patients with neuropathic pain prescribed 
neuropathic pain medication  
Nearly four out of ten (n=105, 38.5%) LBLP patients with neuropathic pain based on s-
LANSS were prescribed one or more of the five pain medications recommended for 
treatment of neuropathic pain (Amitriptyline, Duloxetine, Gabapentin, Pregablin or 
Tramadol) up to four months before and after an index consultation the ATLAS 
research clinic.  The baseline characteristics of patients who were issued with at least 
one of the neuropathic pain medications (including Tramadol) compared to those who 
were not are summarised in Table 9.5. The mean age of these patients was older (52.2 
(SD 13.3) years) compared to those who were not prescribed these medications (48.6 
(13.4) years). A higher proportion of patients were in routine or manual occupations, 
had never previously worked or were unemployed were prescribed one or more 
neuropathic pain medications (67 out of 105, 69.1%) compared those who were not 
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(86 out of 168, 51.5%). Mean leg pain intensity (using NRS 0 to 10) reported by 
patients prescribed these medications was higher (6.6 (2.2)) compared to those who 
were not (5.3 (2.2)). They also more frequently reported leg pain that was worse than 
back pain (59 out of 105, 56.2%, vs 71 out of 166, 42.8%) and the presence of pins and 
needles (82 out of 105, 78.1% vs 112 out of 168, 66.7%). Mean LBLP-related disability 
(using RMDQ 0 to 23) was higher at baseline in patients prescribed neuropathic pain 
medication (15.5 (5.2)) compared to those who were not (12.8 (5.6)). They also had 
higher mean scores for depression symptoms (using HADS 0 to 21, 8.6 (4.1) vs 6.5 
(4.2)) and lower mean pain self-efficacy (using PSEQ 0 to 60, 26.4 (15.3) vs (33.4 (13.8)) 
than those patients who were not prescribed these medications. More patients 
prescribed medications recommended for neuropathic pain had evidence of nerve 
root compression on MRI (58 out of 93, 62.4%) compared to those without such 
prescriptions (73 out of 156, 46.8%). Patients who consulted with GP on more than  
seven occasions four months before and after an index consultation at the ATLAS 
research clinic were more frequently prescribed neuropathic pain medication (67 out 
of 105, 63.8% compared to 60 out of 168, 35.7%).   
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Table 9.5 Baseline characteristics of LBLP patients with neuropathic pain (based on s-
LANSS) by neuropathic pain medication prescribed four months before and after index 
consultation* 
Baseline characteristics (n=273) 
Neuropathic pain medication 
prescription† 
None  
N=168 (61.5%) 
One or more 
N=105 (38.5%) 
Sociodemographic characteristics   
Female  111 (66.1) 72 (68.6) 
Age (years), mean (SD)  48.6 (13.4) 52.2 (13.3) 
Socio-economic status 
(n=264) 
Higher managerial, 
administrative and 
professional occupations 
38 (22.8) 8 (8.3) 
Intermediate 
occupations 
43 (25.8) 22 (22.7) 
Routine and manual 
occupations, never 
worked and long-term 
unemployed 
86 (51.5) 67 (69.1) 
Health Status    
Co-morbidities‡ No other health 
problems 
108 (64.3) 60 (57.1) 
One other health 
problem 
35 (20.8) 33 (31.4) 
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Baseline characteristics (n=273) 
Neuropathic pain medication 
prescription† 
None  
N=168 (61.5%) 
One or more 
N=105 (38.5%) 
Two or more other 
health problems 
25 (14.9) 12 (11.4) 
Self-reported diabetes  14 (8.3) 11 (10.5) 
Self-reported general 
health (n=272) 
Excellent/ very good 35 (20.8) 13 (12.5) 
Good 54 (32.1) 37 (35.6) 
Fair 71 (42.3) 35 (33.7) 
Poor 8 (4.8) 19 (18.3) 
Pain characteristics   
Leg pain intensity (0-10), mean (SD) (n=261) 5.3 (2.2) 6.6 (2.2) 
Back pain intensity (0-10), mean (SD) (n=271) 5.2 (1.7) 5.9 (1.3) 
Pain below the knee  129 (76.8) 81 (77.1) 
Leg pain worse than back pain (n=271) 71 (42.8) 59 (56.2) 
Duration of back pain 
symptoms in current 
episode (n=277) 
< 6 weeks 64 (38.3) 28 (26.9) 
6 to 12 weeks 34 (20.4) 25 (24.0) 
> 3 months 69 (41.3) 51 (49.0) 
Duration of leg pain 
symptoms in current 
episode (n=263) 
< 6 weeks 71 (44.1) 35 (35.0) 
6 to 12 weeks 33 (20.5) 20 (20.0) 
> 3 months 57 (35.4) 45 (45.0) 
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Baseline characteristics (n=273) 
Neuropathic pain medication 
prescription† 
None  
N=168 (61.5%) 
One or more 
N=105 (38.5%) 
Widespread pain § 
(n=269) 
 76 (45.5) 38 (37.3) 
Limitations in activities   
RMDQ (0-23), mean (SD)  12.8 (5.6) 15.5 (5.2) 
Psychological variables   
HADS (depression) (0-21), mean (SD)  6.5 (4.2) 8.6 (4.1) 
HADS (anxiety) (0-21), mean (SD) (n=271) 8.4 (4.4) 9.6 (4.3) 
PSEQ|| (0-60), mean (SD) (n=266) 33.4 (13.8) 26.4 (15.3) 
Neurological examination findings   
Presence of muscle 
weakness**  
5/5 137 (81.6) 78 (74.3) 
4/5 29 (17.3) 24 (22.9) 
0 to 3/5 2 (1.2) 3 (2.9) 
Presence of either 
reduced or absent lower 
limb reflex  
None 139 (82.7) 68 (64.8) 
Slightly reduced 6 (3.6) 13 (12.4) 
Significantly reduced or 
absent 
23 (13.7) 24 (22.9) 
Reduction or loss of sensation to pin-prick 78 (46.4) 55 (52.4) 
Presence of pins and needles 112 (66.7) 82 (78.1) 
Presence of allodynia or hyperalgesia in the leg(s) †† 24 (14.3) 16 (15.2) 
 326 
  
Baseline characteristics (n=273) 
Neuropathic pain medication 
prescription† 
None  
N=168 (61.5%) 
One or more 
N=105 (38.5%) 
Neural tension test‡‡ (any positive test) 98 (58.3) 60 (57.1) 
Other Neuropathic pain definitions   
Clinical diagnosis of sciatica§§  129 (76.8) 86 (81.9) 
Persistent neuropathic pain at four months (n=156) 37 (39.0) 32 (52.5) 
Neuroimaging   
Evidence of nerve root compression on MRI (n=249) 73 (46.8) 58 (62.4) 
Primary care consultations   
Consultations with a GP 
or specialist nurse 
practitioner 
1 to 3 visits 58 (34.5) 18 (17.1) 
4 to 6 visits 50 (29.8) 20 (19.1) 
More than 7 60 (35.7) 67 (63.8) 
Figures are frequencies (percentages) unless stated otherwise as mean (SD) and the denominator varies 
for some participants due to missing data or not applicable case. 
Abbreviations: HADS, Hospital Anxiety and Depression scale. IPQ-R, Illness perceptions questionnaire-
revised. PSEQ, pain self-efficacy questionnaire. RMDQ, Roland Morris Disability Questionnaire leg 
version.  SD, standard deviation. S-LANSS, self-report version of Leeds Assessment for Neurological 
Symptoms and Signs neuropathic pain scale. 
* Prescribing data were obtained for the four month period before the date of index consultation at the 
ATLAS research clinic and four, twelve months and three years thereafter.  
† Neuropathic pain medications: Amitriptyline, Duloxetine, Gabapentin, Pregabalin and Tramadol 
‡ Co-morbidities include self-reported history of chest problems, heart problems, raised blood pressure, 
diabetes, and circulation problems in the leg. 
§ Widespread pain was defined as pain present above and below the waist, in the right- and left-hand 
sides of the body and in the axial skeleton.  
|| Higher scores on PSEQ reflect stronger self-efficacy beliefs 
** Muscle strength was tested according to a 6-point grading scale where;  
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance.  
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†† Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-
painful stimuli (for example, brush strokes). 
‡‡ Neural tension tests; straight leg raise, femoral stretch and slump test. 
§§ LBLP patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain  
 
9.5.3 Prescribed medications and proportion of patients with neuropathic pain 
with improvement four months after index consultation at ATLAS research clinic 
Across the three definitions of neuropathic pain, the proportion of patients who 
improved in terms of leg pain intensity or LBLP-related disability by four months was 
highest in patients with a clinical diagnosis of sciatica (214 out of 287, 74.6%). This was 
similar for patients with a clinical diagnosis of sciatica with evidence of nerve root 
compression (121 out of 166, 72.9%) and slightly lower for patients with neuropathic 
pain based on s-LANSS at baseline (117 out of 169, 69.2%). Just over half (36 out of 69, 
52.2%) of those with persistent neuropathic pain improved in terms of leg pain 
intensity and leg or back pain-related disability. Figure 9.1 summarises the proportion 
of patients who improved four months after an index consultation at the ATLAS 
research clinic, based on three definitions of neuropathic pain including those with 
persistent neuropathic pain (s-LANSS at four months). The findings are reported in 
three categories summarising the neuropathic pain medication prescribed to patients 
up to four months before and after an index consultation at the clinic. Three-quarters 
(76 out of 102, 74.5%) of patients with neuropathic pain based on s-LANSS not 
prescribed any neuropathic pain medication improved, compared to 68% (32 out of 
47) of those who were prescribed one of this group of medication and 45% (9 out of 
20) who were prescribed two medications in this group. The proportion of patients 
with neuropathic pain based on a clinical diagnosis of sciatica (either with or without 
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evidence of nerve root compression on MRI) who improved was slightly higher for all 
three categories reporting on prescriptions for neuropathic pain medications (see 
Figure 9.1). Just over a half (20 out of 37, 54.1%) of patients with persistent 
neuropathic pain not prescribed any neuropathic pain medication improved, 
compared to 57.1% (12 out of 21) of those who were prescribed one of this group of 
medication and a third (4 out of 11, 36.4%) who were prescribed two medications in 
this group. 
Figure 9.1 Bar chart showing proportion of patients with a clinically important 
difference in leg pain intensity and/or leg and back pain-related disability by four 
months 
 
* Proportion (n) of patients with improvement by neuropathic pain definition in those who were 
prescribed one or more neuropathic pain medications compared to those who were not.  
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9.5.3.1 Comparison of complete case analysis versus imputed data 
A sensitivity analysis was carried out using estimates from the combined results of 60 
multiply-imputed datasets. The proportion of patients who improved based on 
complete case analysis was higher compared to those estimates based on imputed 
data for those patients prescribed either none, or one neuropathic pain medication 
(for all three definitions of neuropathic pain and those with persistent neuropathic 
pain based on s-LANSS). For the category of patients prescribed two or more 
neuropathic pain medications, estimates derived from complete case analysis and 
those based on imputed data were similar. See Table 9.6 for a comparison between 
the two types of data for one definition of neuropathic pain (s-LANSS). The reader is 
referred to the Appendix C for the analysis in this chapter repeated using multiply 
imputes data. 
Table 9.6 Proportion of patients with neuropathic pain (based on s-LANSS) who 
improved by the number of neuropathic pain medications prescribed, comparing 
imputed data and data using complete cases  
Number of neuropathic pain 
medications* 
Estimates derived from 
complete case analysis 
Estimates derived from 
multiple imputation 
N Proportion 
(%) 
Proportion 
(%) 
95% 
Confidence 
Interval† 
None 76 74.5 68.3 60.5 to 76.0 
One 32 68.1 60.6 47.6 to 73.7 
Two or more 9 45.0 50.8 31.0 to 70.6 
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* Neuropathic pain medications: Amitriptyline, Duloxetine, Gabapentin, Pregabalin and Tramadol 
† Confidence intervals are for certainty around a point estimate for imputed data 
 
9.5.5 Estimates of LBLP patients with refractory neuropathic pain 
Seven patients with neuropathic pain at baseline and at four months (those defined as 
having persistent neuropathic pain) reported leg pain intensity greater than 5 or less 
than 30% reduction in leg and back pain-related disability despite having been 
prescribed two or more different neuropathic pain medications. These patients were 
considered to have refractory neuropathic pain. A sensitivity analysis was completed 
using a second definition of persistent neuropathic pain, based on a clinical diagnosis 
of sciatica at baseline and the presence of pain below the knee at four months. Results 
showed that the number of patients with refractory neuropathic pain was two (out of 
111).  
The following section discusses the prescribing patterns of pain medications in LBLP 
patients with neuropathic pain and the challenges of estimating the scale of the 
problem of refractory neuropathic pain in this patient population. 
9.6 Discussion  
The aims of research within this chapter were to estimate and describe prescribing 
patterns of pain medications in LBLP patients with neuropathic pain who consult in 
primary care and to provide estimates of LBLP patients with refractory neuropathic 
pain. In this section the results are discussed and compared to previous literature. As 
in previous chapters, the strengths and weaknesses of these analyses are discussed 
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before considering the implications of the results for clinical practice and future 
research.  
9.6.1 Prescribing patterns of pain medications in LBLP patients with neuropathic 
pain 
This research described the pain medication prescribed for patients with neuropathic 
pain four months before and after an index consultation in the ATLAS research clinic, 
this is believed to be novel research in this group of patients with LBLP. The results 
showed that in the defined time period over 80% of LBLP patients with neuropathic 
pain were prescribed at least one pain medication in primary care. This was consistent 
using two definitions of “possible” neuropathic pain and one of “probable” 
neuropathic pain. This is comparable to previous research reporting a similar 
proportion (83%) of patients with neuropathic pain who were prescribed pain 
medication in primary care (Berger et al. 2012). Describing the current prescription 
practice of pain medication in this patient population is important, as both patients 
and clinicians rely on pain medication for adequate management and relief of 
neuropathic pain symptoms (Smith et al. 2012b, Closs et al. 2007), and such 
prescription data can lead to an improved understanding of the prescribing practice in 
primary care for LBLP patients with neuropathic pain. 
Up to one third of patients with neuropathic pain were prescribed one or more first 
line neuropathic pain medications (Amitriptyline, Gabapentin, Pregablin and 
Duloxetine), which is a similar proportion and is comparable to previous studies 
investigating neuropathic pain medication use in neuropathic LBP and neck pain 
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conditions (Gore et al. 2007). In this research, Amitriptyline was the most frequently 
prescribed first line neuropathic pain medication, prescribed to approximately one 
quarter of patients (24% of patients with neuropathic pain based on s-LANSS) in the 
period before and after an initial consultation in primary care. Amitriptyline is 
recommended as the first choice neuropathic pain medication in primary care for 
patients with neuropathic pain conditions (Smith et al. 2012b) and previous research 
based in UK primary care settings report a similar proportion of patients with 
neuropathic LBP prescribed Amitriptyline (22%) (Hall et al. 2013). The majority of 
patients are not treated with neuropathic pain medication and previous cross-
sectional research (Gore et al. 2007, Torrance et al. 2013) has suggested that this 
points towards sub-optimal prescribing of medication for neuropathic pain. A 
discussion follows in section 9.6.3 (page 337) highlights whether the findings of this 
research suggest more patients in this population should be prescribed neuropathic 
pain medications. 
In this research weak to moderate strength opioids were the most commonly 
prescribed group of medications, approximately 60% of patients were prescribed 
medication of this type during the study period (four months up to and after the 
research clinic visit). Nearly as many as seven out of ten patients (69%) with 
neuropathic pain were issued a prescription for an opioid of any strength in the same 
study period. By comparison, this estimate appears to be over twice as high as 
previous estimates, for example the UK study by Ashworth et al. (2013) reported 33% 
of LBP patients with and without leg pain were prescribed opioids within a period of 14 
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days before and 28 days after consultation for LBP without or without leg pain, in 
primary care. When the sampling period in the current research was adjusted to be the 
same as in the study by Ashworth et al. (2013), 47% of patients had evidence in their 
record of a prescription for an opioid drug. It seems that more patients in the ATLAS 
cohort were prescribed opioid pain medication than the broader group of patients 
with LBP consulting in primary care. Higher prescribing may be appropriate given that 
LBLP patients with or without neuropathic pain consult in primary care with worse pain 
and back-pain related outcomes compared to those with LBP alone (Hill et al. 2011a, 
Konstantinou and Dunn 2008). There is limited evidence for the effectiveness of 
opioids in LBP pain conditions with or without neuropathic pain (Dowell et al. 2016) 
and opioids are now the most commonly prescribed type of medication in the United 
States (US) (Ivanova et al. 2011) which is currently thought of as an epidemic 
associated with at worst, dependency and death due to overdose (McCarthy 2012). It 
was beyond the scope of the research in this thesis to investigate whether LBLP 
patients with neuropathic pain responded to opioid medication, but may be the focus 
of future research given the high proportion of prescriptions to patients with 
neuropathic pain.  
Tramadol in this research is defined as a specific neuropathic pain medication (NICE 
CG173 2013) and can be considered in addition to other medications for patients with 
neuropathic pain (Smith et al. 2012b). Tramadol acts as both an opioid and a serotonin 
reuptake inhibitor (examples of other serotonin reuptake inhibitors are Citalopram and 
Sertraline which are used as anti-depressants) and a norepinephrine reuptake 
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inhibitor, it is suggested to be an effective type of pain medication for nociceptive pain 
and may be effective for neuropathic pain conditions (Duehmke et al. 2017). The 
proportion of patients prescribed Tramadol was lower in this research (21%) of LBLP 
patients than in previous research (Hall et al. 2013) of patients with neuropathic LBP 
(34%). LBP and LBLP are mixed pain conditions but LBLP is more often neuropathic 
than LBP (the reader is referred to Chapter 1 (section 1.5) for details of the distinction 
between LBP and LBLP in terms of pain mechanisms). It is likely that the sample of 
patients in the study by (Hall et al. 2013), unlike the current study, was not exclusively 
a cohort of LBLP patients and perhaps were prescribed Tramadol for nociceptive pain. 
The following section (9.6.2) discusses some of the key characteristics of patients who 
were prescribed neuropathic pain medication (including Tramadol) in the current study 
compared to those who were not. 
9.6.2 Characteristics of patients prescribed neuropathic pain medication 
It is apparent that patients prescribed at least one neuropathic pain medication 
(including Tramadol) had more severe leg pain intensity, higher LBLP-related disability 
and lower pain self-efficacy than those patients not prescribed such medication. This 
seems appropriate and in line with guidelines as pain severity and its impact on 
lifestyle including daily activities are key indications for treating patients with 
neuropathic pain with specific pain medication (NICE CG173 2013). Over two thirds 
(64%) of patients with neuropathic pain prescribed a neuropathic pain medication 
consulted with their GP on at least seven occasions four months preceding the index 
consultation at the research study clinic and up to four months after. This estimate 
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was higher than expected, as the crude annual consultation rate for persons attending 
primary care in the UK is 5 per person-year (Hobbs et al. 2016) but it is not clear 
whether patients consulted a lot before they were prescribed the medication, or 
whether they consulted more as a consequence of having a prescription for 
medication, for example for clinical reviews, or whether they consulted more despite 
having a prescription for neuropathic pain medication. In the ATLAS cohort, there was 
no evidence to suggest that patients who were issued with neuropathic pain 
medication reported more co-morbidities, poorer self-reported general health or more 
widespread pain at baseline compared to those who were not prescribed these 
medications. This suggests that patients who were prescribed neuropathic pain 
medications consulted predominantly for pain-related reasons such as clinical reviews 
to assess treatment effectiveness (NICE CG173 2013) or that these patients were not 
receiving adequate pain relief and re-consulted to seek further treatment. 
Patients who were prescribed one or more neuropathic pain medications more often 
reported leg pain worse than back pain, and pins and needles in the painful leg. During 
brief consultations in primary care, it is plausible that non-specialist clinicians such as 
GPs, identify patients with neuropathic pain by signs and symptoms such as leg pain 
worse than back pain and, or presence of pins and needles. This is not an unreasonable 
approach as the presence of pins and needles has been identified as a potential 
indicator of neuropathic pain (Smith et al. 2012a) and leg pain is more likely to be 
neuropathic than back pain alone. However, in the research reported in this thesis, 
neither of these characteristics were consistently associated with neuropathic pain 
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across all the three definitions of neuropathic pain in LBLP patients at baseline (see 
Chapter 5, Table 5.5 for a summary of characteristics that were consistent across three 
definitions of neuropathic pain) nor was there any evidence that any of these 
characteristics were associated with persistent neuropathic pain at four months 
follow-up (see Chapter 8, section 8.5.3 Exploratory prognostic factor research, for a 
detailed report of potential prognostic factors associated with persistent neuropathic 
pain at four months).  
In this study, most patients had an MRI for research purposes, but this does not reflect 
normal clinical practice in primary care and patients with neuropathic pain (based on s-
LANSS) who were prescribed neuropathic pain medication more often were found to 
have evidence of nerve root compression on MRI compared to those without. Whilst 
the MRI results were not available at the patients’ initial assessment in the ATLAS 
clinic, eventually the results were communicated back to the patient’s GP at some 
point during the patient’s treatment or, at the point of discharge from physiotherapy 
treatment in the ATLAS study. Whilst it appears that patients with evidence of nerve 
root compression on MRI were more likely to be prescribed pain medications, those 
patients with a clinical diagnosis of sciatica and evidence of nerve root compression on 
MRI were issued with a similar proportion of pain medications compared to the other 
neuropathic pain definitions.  
Patients prescribed specific neuropathic pain medication tended to be older and in 
routine, manual occupations, had never worked or were unemployed compared to 
those who were not. There is some evidence from the published literature that 
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primary care clinicians prescribe medications in general more often to older than 
younger patients (Macfarlane et al. 2012). Pain severity and the extent that pain 
interferes with daily life can increase with advancing age (Thomas et al. 2004) and 
older patients may be more willing to try neuropathic pain medication and may be less 
willing to try other approaches such as exercise (Macfarlane et al. 2012).  
Much of the evidence on how pain medication is prescribed in musculoskeletal pain 
focusses on opioid prescribing (for example qualitative research by Hutchinson et al. 
(2007) and Seamark et al. (2013)) as opioid use is associated with serious risks 
including overdose and death (Dart et al. 2015, Dowell et al. 2016). However, the 
prescription rates of neuropathic pain medications such as Pregabalin and Gabapentin 
have increased over recent years (Wettermark et al. 2014) and there are some 
concerns that such medications are associated with misuse including suicide (Schifano 
2014). Despite guidelines advocating the use of neuropathic pain medications in 
patients with neuropathic pain irrespective of clinical condition (NICE CG173 2013) and 
more specifically in patients with sciatica (NICE NG59 2016), little is known about what 
factors influence clinicians to prescribe these medications to LBLP patients. Future 
research may help to understand characteristics that predict which LBLP patients 
benefit from neuropathic pain medication. 
9.6.3 Refractory neuropathic pain  
The majority (approximately seven out of ten) of LBLP patients with neuropathic pain 
irrespective of neuropathic pain definition, improved in terms of a clinically important 
difference in leg pain intensity or LBLP related disability by four months follow-up and 
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therefore did not have refractory neuropathic pain. Whilst the design of this research 
does not permit robust comparison of treatment effectiveness of these medications, 
the findings suggest patients with neuropathic pain improve without specific 
neuropathic medications and that patients who are prescribed these drugs do not 
appear, on average, to have better clinical outcomes than those who are not. This 
research questions the call by some authors of previous research (Gore et al. 2007, 
Torrance et al. 2013) for greater prescribing of these medications for patients with 
neuropathic pain. This research also supports the notion that the majority of this 
patient population in primary care utilise few health care resources whilst a few utilise 
the most (Dunn et al. 2006, Stewart et al. 2015). A much smaller proportion of patients 
who were prescribed more than one neuropathic pain medication improved in terms 
of leg pain intensity or LBLP-related disability. It is likely that high levels of leg pain 
intensity or disability may have been the reasons for prescribing two or more 
neuropathic pain medications and suggests the presence of unmeasured confounding, 
the consequence being imprecision in estimates. In epidemiology this type of 
confounding is known as confounding by indication which is common when 
observational data using prescribing records (for example see Gross et al. (2009)) are 
examined to compare patients treated with different therapies (for example none vs 
one or more pain medications) (Vandenbroucke et al. 2014). Methods such as the 
propensity score (Haukoos and Lewis 2015) based on multivariable sample sizes are 
used to reduce the likelihood of confounding in observational data and require larger 
sample sizes than in this research. In this research the influence of potential 
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confounders cannot be ruled out, however there is also ongoing uncertainty regarding 
the effectiveness of individual neuropathic pain medications (Mathieson et al. 2017).  
The current research estimates that of the LBLP patients with neuropathic pain (a total 
of 169 patients) only seven (4%) had refractory neuropathic pain at four months based 
on a definition of refractory pain. When an alternative definition for persistent 
neuropathic pain was used the estimated proportion of refractory neuropathic pain 
remained very low (2 out of 111 or 2%). This is the first research to estimate the scale 
of the problem of refractory neuropathic pain in LBLP patients who consult in primary 
care using a definition of refractory neuropathic pain for which there is some 
consensus (Smith et al. 2012a). A previous survey of the UK general population 
identified 10 individuals with chronic pain which was neuropathic and refractory in 
nature out of 2,202 individuals with chronic pain, or 0.5% (Torrance et al. 2013). The 
estimate in this research is slightly higher which is not surprising since it is based on 
patients consulting in primary care rather than individuals sampled from the general 
population who are living with, but not necessarily consulting with, chronic pain. It is 
important to understand the extent to which patients with neuropathic pain who 
consult in primary care are affected by refractory pain as these patients are likely to be 
the most frequent users of health care services and the most likely to be referred to 
specialist pain services for further intensive and more expensive treatments.  
It has been estimated that over half of patients will not respond to an individual 
neuropathic pain medication (Moore et al. 2013).  The decision in the research to 
define refractory pain as the use of two neuropathic pain medications rather than 
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three or even four medications was made on the evidence that this patient population 
rapidly improve in terms of pain intensity and leg and back pain-related disability 
within the first four months after consulting with LBLP (see Chapter 6, section 6.5.3 
(page 223)). There is some agreement that patients with pain that is refractory use 
three or four neuropathic medications (Smith et al. 2012a) and this may have led to 
some classification of patients whose pain was not refractory but who may have 
benefited from a trial of a third medication. The absolute impact of this is likely to be 
very low as the number of patients with refractory neuropathic pain based on the use 
of two neuropathic medications was so small in this study. This is the first validation of 
the definition of refractory neuropathic pain proposed by Smith et al. (2012a) in this 
LBLP patient population in primary care which is important as LBLP patients with 
neuropathic pain are among the most common presentations of neuropathic pain in 
primary care. Comparisons of the scale of the problem of refractory neuropathic pain 
between primary care settings and specialist pain centres may be useful information 
for clinicians and pain researchers. 
9.6.4 Strengths and limitations 
The main strength of this research is the prospective study design using electronic 
prescribing and consulting records linked to patients in the ATLAS study, this allowed 
for a detailed description of medication use and improvement in symptoms over time 
and allowed for an estimation of the proportion of patients with refractory 
neuropathic pain. Other strengths include the large sample size and completeness of 
the general practice medical records (more than 94% of prescription data could be 
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accessed for this research). General practice medical records have accurate, complete 
and valid data for 99% of prescriptions and 98% of consultations (Hassey et al. 2001). 
A number of limitations have been identified that may have an impact on the 
interpretation of the findings of the analyses in this chapter. Firstly, the categorisation 
of pain medications did not account for medications that were used together which is 
common clinical practice (Bennett 2015) or sequentially. Understanding whether 
medications were prescribed sequentially or in combination would give a better 
understanding of the prescribing patterns of clinicians in primary care but was beyond 
the scope of this research. Secondly, it was not possible to determine whether patients 
were prescribed an adequate trial of a particular medication (Smith et al. 2012a) as 
this was secondary analysis of existing data and this information was not recorded in 
the dataset. The likely effect of accounting for an adequate trial of medication would 
be to make the definition of refractory neuropathic pain more stringent, thus reducing 
the number of patients with refractory pain further. Thirdly, the duration of pain 
medication use prior to study participation was unknown, in part this was accounted 
for by collecting data on prescriptions for the four months before the index 
consultation in the research clinic. The implication of not knowing the duration of pain 
medication use is that such prescriptions may have been made for other pain 
conditions, with the likely effect being an over-estimation of the reported findings. 
Fourthly, the analysis in this chapter included Nefopam as an equipotent pain 
medication to opioids of weak to moderate strength, this may have led to over-
estimation of the proportion of patients prescribed opioid medications. However, the 
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absolute number of patients who were prescribed Nefopam was small (4% (n=10) of 
patients with neuropathic pain based on s-LANSS) and the interpretation of the results 
remains the same with or without those prescribed Nefopam.  
Although the information on pain medication prescription was of high quality and 
complete for 94% of participants, there was considerable loss to follow-up from the 
self-report data collection (questionnaires) at four months. The analyses in the 
research reported in this chapter were based on complete cases which can lead to 
erroneous findings, especially in categories with smaller numbers, for example the 
number of patients who responded to follow-up at four months and were prescribed 
two or more neuropathic pain medications was low (n=20, based on s-LANSS). 
Estimates derived from combining the results of multiply-imputed datasets were more 
conservative than those derived using complete case analysis for patients who were 
prescribed at least one neuropathic pain medication and similar for those prescribed 
two or more of this type of medication. This suggests that the estimate of refractory 
pain using complete case analysis is justified in this research.  
9.6.5 Implications for clinical practice and research 
Perceptions by clinicians that neuropathic pain in this patient population is in large 
part refractory is not borne out in this research. The implication being that patients 
with and without neuropathic pain medication improve over time. However, pain 
medication including opioid medication is commonly prescribed despite strong 
evidence of benefit from previous research, this evidence may inform policies and 
guidelines on appropriate prescribing in this patient population.  
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The findings from this research cannot confirm or refute whether the prescription of 
neuropathic pain medication reduces suffering in this patient population. However, the 
findings appear to question the effectiveness of these medications. Future research is 
needed to determine the effectiveness of neuropathic pain medications, and indeed 
other treatments, for this patient population. Research that seeks to better 
understand the prescribing patterns in primary care for this patient population both in 
terms of qualitative and/or observational research with clinicians and patients would 
also be useful. Further validation of the definition of refractory neuropathic pain used 
in the analyses in this chapter is also recommended, in primary care settings and also 
in specialist pain centres.  
9.7 Conclusions 
In this chapter, the pain medications prescribed for LBLP patients with neuropathic 
pain, and in particular specific neuropathic pain medications, were investigated and an 
estimate of the proportion of patients with refractory neuropathic pain was reported. 
It appears that the recommendations within current national guidelines for prescribing 
neuropathic pain medications are generally adhered to. The majority (over 80%) of 
patients were prescribed some pain medication up to four months before and after 
attending the ATLAS research clinic, a third were prescribed specific neuropathic pain 
medications. Those patients who were prescribed one or more neuropathic pain 
medications had more severe leg pain intensity and higher LBLP-related disability. 
Seven patients or 4% (out of 169) were identified as having refractory neuropathic pain 
suggesting that few patients with persistent neuropathic pain also have refractory pain 
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in primary care. Further research could usefully contribute to a better understanding 
of the effectiveness of neuropathic pain medications in this patient population.  
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Chapter Ten. Discussions and conclusions 
The aim of this thesis was to investigate the epidemiology of neuropathic pain in LBLP 
patients who consult in primary care based on cases identified by clinical examination 
and through the use of a validated, self-completed case ascertainment tool. Figure 
10.1 highlights the key findings of this thesis. Some of these findings were novel and 
challenge commonly held assumptions in the clinical and research field of neuropathic 
pain whilst some findings add further evidence to existing research in the field. This 
chapter provides a synthesis of the key findings in this thesis and critically evaluates 
the strengths and limitations of the research. The implications of this work for clinical 
practice are then discussed before reflecting on how the findings can inform future 
research. 
 Figure 10.1 Key findings of the thesis 
Systematic review 
A synthesis of published literature highlighted the gap of epidemiological research in this 
patient population, in particular there was a paucity of evidence from prognostic research. 
• Prevalence estimates varied widely (from 5% to 80%) depending on the definition of 
neuropathic pain. 
• There was some evidence of: i) higher levels of LBLP-related morbidity in patients with 
neuropathic pain compared to those without, ii) more frequent reporting of LBLP-
related morbidity in patients with neuropathic pain based on clinical examination 
compared to those with neuropathic pain based on a case ascertainment tool. 
• Evidence (from one analysis) suggested that the clinical course of patients with 
neuropathic pain was worse compared to those without, there was a paucity of 
evidence on prognosis and no evidence of prognostic factors in this patient population. 
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Change in the presence of neuropathic pain (based on s-LANSS) 
The presence of neuropathic pain changed over time, it resolved in most patients, but 
remained persistent in a few. 
• By four months 25% of patients in the study had neuropathic pain. 
• A minority of patients (16%) had persistent neuropathic pain over three years. These 
patients presented with worse LBLP-related disability and higher leg pain intensity at 
baseline. 
Clinical course 
The clinical course of patients with neuropathic pain improved rapidly up to four months after 
baseline consultation and showed very little improvement thereafter. The extent of the 
improvement depended on the definition used. 
• The clinical course of patients with neuropathic pain based on s-LANSS was worse than 
those without, this was not the case for the two other definitions of neuropathic pain. 
Prevalence and characteristics  
Neuropathic pain was common. The characteristics of patients with neuropathic pain varied 
depending on the method used to define cases. 
• Prevalence of neuropathic pain varied from 48% to 74% depending on definition, many 
patients clinically diagnosed with sciatica did not have neuropathic pain based on the 
case ascertainment tool, s-LANSS.  
• Patients with neuropathic pain reported higher leg pain intensity, worse pain self-
efficacy, a higher proportion had pain below the knee and sensory loss based on 
findings from routine neurological examination compared to those without, across 
three definitions of neuropathic pain. 
• Patients with neuropathic pain based on s-LANSS presented with a distinct profile 
compared to those with a diagnosis of sciatica. LBLP-related morbidities such as 
depression, anxiety and worse general health were more common in patients with 
neuropathic pain based on s-LANSS. 
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Shaded boxes highlight research based on epidemiological analysis of a prospective cohort of LBLP 
patients consulting in primary care. 
 
10.1 Key findings 
In the research in this thesis, neuropathic LBLP in patients was common and varied 
from 48% to 74% according to the definition of neuropathic pain used (Chapter 5). 
There was evidence that many (68%) patients with neuropathic pain defined by a 
Prognosis of LBLP patients with neuropathic pain at baseline and four months 
The clinical course of patients with persistent neuropathic pain was worse compared to those 
with non-persistent neuropathic pain, but it was difficult to identify at baseline which 
patients would have persistent neuropathic pain four months later.  
• The clinical course of patients with persistent neuropathic pain, in terms of pain 
intensity, was worse up to three years after baseline compared to those without. 
• There was some evidence that leg pain intensity may be associated with persistent 
neuropathic pain but this was only found using one definition of neuropathic pain. 
• There was no evidence that prognostic factors from neurological examination 
(presence of pins and needles in the leg(s), a reduction or loss of pin-prick sensation in 
the painful leg and evidence of nerve root compression on MRI) were associated with 
persistent neuropathic pain at four months. 
Prescribing patterns of pain medications 
Pain medications were commonly prescribed to patients with neuropathic pain, with 
approximately three out of ten patients prescribed neuropathic pain medications. However, 
patients with neuropathic pain improved with or without specific neuropathic pain 
medication. 
• Very few patients (n=7, 4%) were identified as having refractory neuropathic pain; 
findings support the conclusion that the scale of the problem of refractory neuropathic 
pain in this patient population is not substantial. 
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diagnosis of sciatica were not identified as having neuropathic pain based on s-LANSS. 
Similarly, in the research reported in Chapter 3 (Systematic review) there was evidence 
that many patients with neuropathic pain based on sciatica were not identified as 
having neuropathic pain based on alternative neuropathic pain case ascertainment 
tools such as PainDETECT and DN4. The results of this thesis challenges the 
traditionally held belief that sciatica is a neuropathic pain condition (for example NICE 
NG59 2016). 
In the research in Chapter 5, there were characteristics common to patients with 
neuropathic pain across all three definitions of neuropathic pain; patients with 
neuropathic pain consistently reported higher leg pain intensity, lower pain self-
efficacy, a higher proportion reported pain below the knee and sensory deficits based 
on findings from routine neurological examination (Chapter 5). Similar to the findings 
of prevalence, the characteristics of patients with neuropathic pain varied depending 
on the method used to define cases. Patients with neuropathic pain based on s-LANSS 
were found to have a greater number of differences in LBLP-related morbidities 
compared to those with neuropathic pain based on a clinical diagnosis of sciatica with 
or without MRI evidence of nerve root compression. These findings were supported by 
the findings of previous studies highlighted in the systematic review in this thesis 
(Chapter 3). None of the previous studies aimed to describe the characteristics of LBLP 
patients with or without neuropathic pain and in part were limited by either small 
sample sizes or poorly defined comparator groups. Whilst the findings of previous 
studies are in the same direction as the findings of this research, it is this research that 
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provides the highest quality evidence to date on the characteristics of this patient 
population. 
Clinical course in terms of pain intensity and LBLP-related disability was worse for 
patients with neuropathic pain based on s-LANSS compared to those without, but the 
course of patients with neuropathic pain with a clinical diagnosis of sciatica (with or 
without evidence of nerve root compression on MRI) was no worse compared to those 
without (Chapter 6). Approximately 70% of patients with neuropathic pain at baseline, 
irrespective of definition, reported a clinically meaningful improvement in either pain 
intensity or disability four months after consulting in primary care, with little 
improvement thereafter. This research shows that it is not the presence of 
neuropathic pain per se that is associated with poor prognosis, but specifically the 
presence of neuropathic pain defined using the s-LANSS.  
The presence of neuropathic pain (based on s-LANSS) at baseline changed in the 
majority of patients over three years (Chapter 7). This challenges the belief that 
neuropathic pain, once present, is always persistent. The majority of the change in the 
presence of neuropathic pain had occurred by four months follow-up, when 25% of 
patients had neuropathic pain compared to 48% at baseline. Similarly, the most rapid 
improvement in the clinical course in terms of pain intensity and LBLP-related disability 
in patients with neuropathic pain, occurred by four months after baseline 
measurement. The course in terms of pain intensity of patients with persistent 
neuropathic pain at four months (presence of neuropathic pain at baseline and four 
months based on two definitions, sciatica and s-LANSS) was not characterised by a 
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rapid improvement in pain intensity and was worse up to three years after baseline 
compared with those with non-persistent neuropathic pain (Chapter 8). This suggests 
that neuropathic pain is not always persistent and the presence of neuropathic pain 
may change as the severity of a LBLP episode abates.  
Identifying the factors which predict cases of persistent neuropathic pain could inform 
future research to identify which patients with neuropathic pain at baseline will have 
persistent neuropathic pain at four months. In the research in this thesis, there was no 
evidence that potential prognostic factors from the neurological examination (such as 
presence of pins and needles in the leg(s), reduction or loss of pin-prick sensation in 
the painful leg), or evidence of nerve root compression on MRI, were associated with 
persistent neuropathic pain at four months (Chapter 8). Items from the neurological 
examination deemed important for defining cases of neuropathic pain at baseline did 
not explain the presence of persistent neuropathic pain at four months. Factors 
considered clinically important for LBLP patients with or without neuropathic pain 
(pain duration, pain self-efficacy and pain intensity) were statistically associated with 
persistent neuropathic pain at four months. In a multivariable model higher leg pain 
intensity predicted cases of persistent neuropathic pain (based on one definition). 
Evidence from this thesis supports an argument that persistent neuropathic pain in 
LBLP patients may be explained more by prognostic factors common to the broader 
group of LBP and LBLP patients with and without neuropathic pain than those factors 
thought to be signs and symptoms of underlying pathophysiological neuropathic pain 
mechanisms. It follows then that it is likely that persistent neuropathic pain in this 
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patient population also responds to treatments recommended for the broader LBP and 
LBLP patient populations irrespective of neuropathic status. 
The majority of patients (approximately 80%) with neuropathic pain (across the three 
definitions) were prescribed at least one pain medication in four months before and 
after an index consultation in primary care (Chapter 9). Patients with neuropathic pain 
(across three definitions) were no more likely to self-report having been prescribed or 
having purchased pain medication over-the-counter at baseline compared to those 
without (Chapter 5). A third of patients with neuropathic pain were prescribed 
medication recommended for first line treatment of neuropathic pain and there was 
evidence to suggest that patients improved with or without a prescription for this 
specific type of pain medication. This appears to be in line with recent evidence from a 
high quality randomised controlled trial (Mathieson et al. 2017) casting doubt about 
the effectiveness of neuropathic pain medications for this patient population. Current 
guidelines in the United States recommend non-pharmacological first-line treatment 
(Qaseem et al. 2017) rather than pharmacological care for LBP patients including LBLP 
patients with neuropathic pain. The research in this thesis suggests that LBLP patients 
with neuropathic pain based on a diagnosis of sciatica and in the absence of 
progressive or severe motor weakness may respond similarly to treatments to those 
without neuropathic pain. This challenges the current UK clinical guideline 
recommendations for low back pain and sciatica that advocate neuropathic pain 
medication for patients with sciatica (NICE NG59 2016) and recommend them as first-
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line treatment for patients with neuropathic pain irrespective of condition (NICE 
CG173 2013). 
Neuropathic pain is considered to be one of the most challenging pain syndromes to 
manage but this belief is not supported by the research in this thesis. Very few patients 
(4% based on s-LANSS) were identified as having refractory neuropathic pain, which is 
characterised by severe pain that does not respond to neuropathic pain medication 
(Chapter 9). This is a surprisingly low proportion of patients given the assumption that 
neuropathic pain is challenging to treat, patients with LBLP present with higher pain 
intensity, higher LBLP-related disability, and have poorer outcomes compared to 
patients with back pain alone. One consideration is that a proportion of LBLP patients 
without neuropathic pain and LBP patients with back pain alone either with or without 
neuropathic pain, also have severe pain that does not seem to respond to treatment. 
Future research may estimate the scale of refractory pain in a broader LBP population.  
An issue raised by research in this thesis is whether neuropathic LBLP pain based on s-
LANSS may be more indicative of the severity of symptoms of pain and related 
disability rather than a neuropathic phenotype. Signs and symptoms of neuropathic 
pain such as tingling, stabbing and electric shock-like pain are particularly distressing to 
patients (Ong et al. 2011) and the symptoms themselves can be difficult for patients to 
express (Yeung et al. 2017) and may be expressed in terms of pain severity 
(Gierthmühlen et al. 2017). Many of the findings in this research suggest that patients 
with neuropathic pain and persistent neuropathic pain based on s-LANSS (Chapters 5, 
7 and 8) presented with higher symptoms of anxiety and depression and lower pain 
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self-efficacy. Patients in the sub-group of persistent neuropathic pain based on s-
LANSS continued to report more severe symptoms of anxiety and depression (mean 
HADS score) beyond baseline compared to patients in other sub-groups (see Table 
10.1). The suggestion from these findings is that patients with neuropathic pain based 
on s-LANSS, and in particular those with persistent neuropathic pain, did worse over 
time because symptoms were primarily maintained by central rather than peripheral 
pain mechanisms. Centrally maintained mechanisms can be implicated in both 
neuropathic and nociceptive pain states, and there is considerable overlap between 
them (Cohen and Mao 2014). Whilst it is not clear from this research whether the 
presence of neuropathic pain may simply indicate severe LBLP, there is an argument 
that patients with neuropathic pain based on s-LANSS may reflect pain mechanisms 
shared with neuropathic pain, rather than actual nerve pathology (McWilliams and 
Walsh 2017).   
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Table 10.1 Symptoms of anxiety and depression (mean HADS) for neuropathic pain sub-
groups over three years 
 
Neuropathic pain sub-group† over three years  
Non-
neuropathic 
pain 
Non-
persistent 
neuropathic 
pain 
Longstanding 
Persistent 
neuropathic 
pain 
Developing 
neuropathic 
pain 
 (n=87, 
43.7%) 
(n=56, 
28.1%) 
(n=32, 
16.1%) 
(n=24, 
12.1%) 
HADS (depression) (0-21), mean (SD) 
Baseline* 5.2 (3.6) 5.1 (3.2) 7.5 (4.6) 6.3 (3.2) 
12-months 3.1 (3.1) 3.4 (3.5) 7.1 (4.3) 4.7 (3.1) 
3-years 3.1 (2.9) 3.2 (3.2) 6.5 (4.5) 5.4 (3.6) 
HADS (anxiety) (0-21), mean (SD)    
Baseline* 6.3 (3.3) 7.0 (4.6) 9.1 (5.0) 7.0 (3.5) 
12-months 4.5 (3.7) 4.9 (4.9) 8.6 (4.3) 5.4 (3.7) 
3-years 4.4 (3.7) 4.4 (4.3) 7.9 (4.3) 6.2 (3.8) 
Abbreviations: HADS, Hospital Anxiety and Depression scale. s-LANSS, self-report version of the Leeds 
Assessment of Neuropathic Symptoms and Signs neuropathic pain scale 
*HADS was not available within ATLAS dataset at 4-months. 
†Sub-groups: Non-neuropathic, s-LANSS < 12 at baseline and each follow-up point thereafter. 
Developing, s-LANSS < 12 at baseline and ≥ 12 at one or more follow-up points. Non-persistent, s-LANSS 
≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up points. Persistent, s-LANSS ≥ 12 at 
baseline and ≥ 12 at two or more of the three follow-up points.  
 
Patients with a clinical diagnosis of sciatica in this research met the criteria described 
in the hierarchical approach (Treede et al. (2008), updated by Finnerup et al. (2016)) as 
having either “possible” or “probable” neuropathic pain. There is some consensus for 
using s-LANSS (Smith et al. 2012a) for defining neuropathic pain cases. Patients with s-
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LANSS score ≥ 12 are at best described as having “possible” neuropathic pain without 
having to meet criteria reported by either Treede et al. (2008) or Finnerup et al. 
(2016). In the absence of a gold standard definition of neuropathic pain, debate is on-
going about the current hierarchical approach to defining neuropathic pain (Spahr et 
al. 2017, Kosek et al. 2016, Lynch et al. 2011). The usefulness of the hierarchical 
approach could be judged on whether the prognosis of cases with “probable” 
neuropathic pain is distinct from those with “possible” neuropathic pain. In the context 
of the findings of this research, there was no evidence to suggest that patients with 
“probable” neuropathic pain were worse at baseline or over time compared to those 
with “possible” neuropathic pain based on clinical examination. Patients with 
“possible” neuropathic pain based on s-LANSS were found to have poorer prognosis 
compared to those without. The clinical value of s-LANSS in this patient population 
may depend on whether the effects of treatment in patients with neuropathic pain 
based on s-LANSS (pharmacological or non-pharmacological) is superior to those 
identified as having neuropathic pain based on clinical examination. 
There have been suggestions in the previous literature that s-LANSS is less able to 
differentiate between LBLP patients with and without neuropathic pain in comparison 
to other neuropathic pain case ascertainment tools, for example DN4 (Gudala et al. 
2017). Case ascertainment tools, for example PainDETECT, LANSS, DN4 and s-LANSS 
described in Chapter 1 (section 1.3.1.2, (page 12)) that are commonly used in 
epidemiological pain research were developed using a reference standard based on 
clinical examination, often including patients with sciatica. There is an argument that 
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each tool either fails to identify patients with neuropathic pain and/or incorrectly 
identifies a proportion of patients without neuropathic pain in comparison to 
neuropathic pain based on clinical examination (Mathieson et al. 2015). Each of the 
tools share similar characteristics. Positive signs of neuropathic pain such as “prickling 
or tingling, pins and needles”, pain described as having an “electric shock or shooting” 
quality and “burning” are included in each tool but changes in appearance of the skin 
are only included in LANSS and s-LANSS. Based on the subtle differences of each tool, 
unique pain profiles are identified. In the absence of a gold standard for defining 
neuropathic pain cases this is a challenge for research and is not unique to s-LANSS. 
The implication of using different tools to identify cases of neuropathic pain is 
inevitably variation in prevalence estimates, characteristics, clinical course and 
prognostic factors between definitions; it is not clear what the implication is in terms 
of variation in response to treatment.  
10.3 Strengths and limitations of the thesis 
Specific strengths and limitations related to each objective in this thesis have been 
discussed within the preceding chapters. This section reflects more broadly on the 
strengths and limitations of this thesis as a whole.  
The majority of patients with neuropathic pain are assessed and managed in primary 
care. A key strength of this research is the use of patient data from a primary care 
setting and is likely to be representative of other first point of healthcare contact 
settings.  Consecutive patients consulting with LBLP with symptoms of any duration 
and pain severity were included in the current research making the results 
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generalisable to a broad spectrum of patients and not only to those with the worst 
symptoms. Studies often restrict eligibility of patients by pain severity or pain duration 
(see Attal et al. (2011) and Schafer et al. (2011) for examples) and results can only then 
be applied to patients with the most severe symptoms. Including consecutive patients 
also reduces the risk of selection bias at the point of recruitment when there are 
systematic differences in patients recruited compared to those who were not.  
This is the first prospective cohort of LBLP patients with neuropathic pain consulting in 
primary care, the cohort design allowed for investigation of the temporal relationship 
between neuropathic pain at baseline and outcomes in terms of pain intensity, LBLP-
related disability and the persistence of neuropathic pain. This is an important strength 
of this thesis and addresses the limitations of previous research of this patient 
population (for example, Hüllemann et al. 2017). A broad range of self-reported data 
and findings were collected from standardised clinical examination including those 
from MRI scans, this is an advantage of the prospective cohort study design. The 
majority of self-reported data was collected from validated scales in this population, 
for example the leg version of the RMDQ (Roland and Morris 1983, Patrick et al. 1995) 
to assess LBLP-related disability and the HADS (Zigmond and Snaith 1983) to assess 
symptoms of anxiety and depression. Using standardised approaches to define cases of 
neuropathic pain, characteristics and prognostic factors enabled comparisons between 
the results of the research in this thesis to previously published studies.  
In the future, further data collection at follow-up from the clinical examination and 
MRI scan would address a limitation of this study (which had these times of data 
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collection only at baseline), albeit with extra cost and potentially greater loss to follow-
up. The decision to use three definitions of neuropathic pain was driven by the 
absence of a perfect reference standard of neuropathic pain and allows for 
comprehensive prognostic research in this patient population. 
A potential limitation is the loss to follow up, which is a type of selection bias. 
However, missing data were accounted for and results from the sensitivity analyses 
using imputed data were comparable to those using complete cases. A further 
limitation that is a disadvantage of prospective treatment cohort studies of patients 
and applies to the longitudinal analysis in Chapters 6 to 9 is confounding due to 
treatment. Patients in this cohort were managed clinically based on current best 
clinical evidence. Patients mainly received a course of physiotherapy care, and a small 
number of patients (n=70) were referred for other treatments (for example epidural 
injections or pain management) or for further assessment (including referrals to 
Extended Scope Physiotherapy practitioners in a dedicated back pain service, spinal 
surgeons and pain specialists). All patients received care from their GPs, and this could 
include prescriptions of pain medication. Physiotherapy treatment was similar across 
the groups according to all three definitions of neuropathic pain used in this thesis (see 
Chapter 6, section 6.5.1 (page 217) for a report of treatment received by patients). 
There is a possibility that a positive response to treatment, for example to epidural 
injections in patients with sciatica with evidence of nerve root compression on MRI, 
may have influenced the clinical course of these patients reported in this thesis. 
Chapter 9, section 9.6.3 (page 337) provides an account of potential risk of 
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confounding by indication whereby patients with more severe LBLP-related morbidity 
were prescribed neuropathic pain medication more frequently which is a limitation of 
observational study designs, the implication of this is discussed in more detail in the 
section 10.5 (Implications for future research).  
Finally, a limitation that is worth consideration is whether the MRI findings or MRI 
reporting could have influenced treatment decisions in ATLAS. Firstly, the finding of 
possible or clear nerve root compression based on MRI was not associated with 
neuropathic LBLP based on s-LANSS (see Chapter 5, section 5.5.2.7 (page 165)) and this 
suggested the influence of MRI results on patient outcomes would have been similar 
for patients with and without neuropathic pain defined in this manner. Secondly, 
patients with neuropathic pain based on a clinical diagnosis of sciatica compared to 
those without (see Chapter 5, section 5.5.3 (page 175)) were over 3 times more likely 
to have either clear or possible nerve root compression on MRI however, only a small 
proportion of patients received interventions such as spinal injection or surgery 
because they reported worsening symptom severity which was clinically thought to be 
caused by the nerve root compression. Given the differences in pain and LBLP-related 
disability between patients with and without neuropathic pain (with or without 
evidence of nerve root compression) were often small with no obvious clinical 
relevance, the influence of MRI on treatment decisions, on patient outcomes and 
ultimately on the key findings of this thesis seems small. 
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10.4 Implications for clinical practice 
The research in this thesis informs clinicians of the likely prognosis of LBLP patients 
with neuropathic pain consulting in primary care, which is important given that the 
provision of prognostic information can help patients better understand and self-
manage their condition (Foster et al. 2018). The implications of research in this thesis 
have been discussed in preceding chapters, this section highlights the key information 
to be disseminated to clinicians treating this patient population in primary care. 
Clinicians should be aware that neuropathic pain is common in LBLP but the 
prevalence and clinical characteristics are likely to vary depending on the methods 
used to define neuropathic pain in clinical practice. Clinicians should also be aware that 
sciatica is not always a neuropathic condition. Evidence of nerve root compression 
from MRI increases the certainty of neuropathic pain but does not change the 
prognosis of patients with sciatica and as recommended by clinical guidelines (NICE 
NG59 2016) patients should only be referred for imaging when serious pathology is 
suspected (for example cauda equina or malignancy) and when interventions such as 
surgery are being considered.  
Approximately 70% of patients with neuropathic pain at baseline, report a clinically 
meaningful improvement in either pain intensity or LBLP-related disability four months 
after consulting in primary care. This suggests the majority of patients with 
neuropathic pain who consult in primary care will have a good outcome despite the 
beliefs that neuropathic pain is persistent and difficult to treat. It is commonly 
perceived that neuropathic pain has a tendency to be persistent, but over 50% of 
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patients with neuropathic pain (based on s-LANSS) at baseline did not have persistent 
neuropathic pain by four months. Clinicians could use these data to reassure patients 
of the expected course of their condition over the next four months.  
The clinical course of LBLP patients with neuropathic pain and the potential prognostic 
factors associated with future outcomes were similar to the broader group of LBP 
patients and indeed to the even broader group of patients with other MSK conditions 
(Green et al. 2018). The implication is that LBLP patients with neuropathic pain in 
primary care, in the absence of widespread or progressive neurological deficit should 
be treated, at least initially in the same way as LBP patients with no known cause.  
Patients should continue to be examined and given a diagnosis of sciatica when 
indicated and imaging should be reserved for those patients for whom the result is 
likely to change clinical management. Patients with neuropathic pain based on s-LANSS 
in this research were characterised as a more severe phenotype compared to those 
with neuropathic pain based on clinical diagnosis but there is insufficient evidence to 
suggest that routine use of s-LANSS in clinical practice would benefit patients. Despite 
clinical guidelines recommending neuropathic pain medication for patients considered 
to have neuropathic pain (based on sciatica) (NICE NG59 2016) evidence from this 
research suggests that these patients could be managed initially with non-
pharmacological care with or without pain medication (in a similar way to the broader 
population of patients with LBP) before specific neuropathic pain medication is 
recommended. 
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10.5 Implications for future research 
The research in Chapter 8 identified a sub-group of patients as having persistent 
neuropathic pain, half of these patients reported a clinically meaningful improvement 
in either pain intensity or LBLP-related disability at four months. The implication is that 
patients in this sub-group could benefit from earlier, more active treatment, however 
it was difficult to predict cases of persistent neuropathic pain using potential 
prognostic factors selected from clinical examination or self-report, limited in part 
because a larger sample size was needed for this type of analysis. The findings will 
inform the development of future cohort studies of neuropathic pain in this patient 
population in terms of: 1) sample size calculations since greater sample sizes may 
provide more robust estimates, 2) selection of potential prognostic factors, perhaps 
broadening these to include those that are considered biomarkers of inflammatory 
pain mechanisms or responses from QST (see Chapter 8, section 8.6.2.1 (page 297) for 
a discussion of potential prognostic factors of patients with persistent neuropathic 
pain. A further limitation of the research in this thesis was the use of a proxy (presence 
of pain below the knee at four months) to describe patients with persistent 
neuropathic pain based on a diagnosis of sciatica. Future prospective cohorts with this 
patient population with data collected from clinical examination including MRI at more 
than one time point would allow for further investigation of the change in presence of 
neuropathic pain over time and a more robust investigation of the usefulness of 
persistent neuropathic pain as a sub-group of patients with poor prognosis. In the 
future, the clinical value of identifying patients with persistent neuropathic pain may 
be evaluated by investigating whether more targeted treatment changes the long-term 
 363 
  
clinical course of this sub-group of patients, but the first challenge is predicting cases 
of persistent neuropathic pain based on baseline characteristics that can be routinely 
collected in primary care.  
This research challenges the current definitions used to identify patients with 
neuropathic pain. Sciatica is often thought to be neuropathic but in this research there 
were few differences between patients with sciatica with or without evidence of nerve 
root compression on MRI both at baseline and in terms of clinical course. S-LANSS 
identified a group of patients with severe pain but there was no evidence to suggest 
that underlying neuropathic pathophysiological mechanisms explained persistent 
neuropathic pain defined in this way. The focus of future neuropathic pain research 
should be to identify those patients who need more active treatment to help manage 
pain and symptoms of neuropathic pain whilst not over-treating those likely to 
improve. Stratified primary care for LBP patients with and without leg pain that 
matches treatment to the risk of LBP-related disability (Hill et al. 2011b, Foster et al. 
2014) has been incorporated into UK clinical guidelines for LBP and sciatica (NICE NG59 
2016). Stratified care for patients with sciatica may also be beneficial and is currently 
being investigated in a randomised trial (Foster et al. 2017). Evidence in this thesis 
suggests that stratified care for LBLP patients with neuropathic pain based on s-LANSS 
may be worth exploring further; this would involve agreeing matched treatments and 
comparing a model of stratified care versus usual care in a future clinical trial. 
The research in Chapter 9 identified that approximately 30% of patients with 
neuropathic pain were prescribed neuropathic pain medication, four months before or 
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after consulting in primary care. However, patients with neuropathic pain improved 
with and without such medication but there was evidence of confounding by 
indication, statistical methods to account for unmeasured confounding (for example 
propensity scores) are indicated in future observational cohort designs with larger 
sample sizes. Future research investigating the prescribing patterns of specific 
neuropathic pain medications in primary care, the characteristics that predict which 
LBLP patients benefit from neuropathic pain medications, and qualitative research 
investigating the factors that influence prescribing practice of clinicians in primary care 
is indicated and may lead to future studies that test interventions that are either based 
on, or incorporate the use of, neuropathic pain medications.   
10.6 Conclusions 
Neuropathic LBLP in primary care is common, estimates of point prevalence varied 
from 48% to 74% depending on the method used to define neuropathic pain. Many 
patients diagnosed with sciatica did not have neuropathic pain defined using s-LANSS. 
At baseline, LBLP-related morbidities such as depression, anxiety and worse general 
health were more common in patients with neuropathic pain based on s-LANSS 
compared to those with neuropathic pain based on sciatica. The clinical course of 
patients showed rapid improvements up to four months after baseline consultation 
across all three definitions of neuropathic pain with minimal improvement thereafter; 
the extent of improvement depended on the approach used to define cases. The 
presence of neuropathic pain was not always associated with poor prognosis. The 
presence of neuropathic pain (based on s-LANSS) changed over time, most commonly 
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by four months follow-up. The clinical course over three years of patients with 
persistent neuropathic pain at four months, based on two definitions, s-LANSS and 
clinical diagnosis of sciatica, was worse compared to those with non-persistent 
neuropathic pain. There was no evidence that factors from neurological examination 
were associated with persistent neuropathic pain at four months, there was more, 
although limited evidence that prognostic factors known to be important in the 
broader group of LBP patients were associated with persistent neuropathic pain. 
Patients with neuropathic pain were commonly prescribed pain medication, 
approximately 30% of patients with neuropathic pain (across all three definitions) were 
prescribed neuropathic pain medication, similar proportions improved without such 
medication. The research carried out informs clinical practice of the nature of 
neuropathic pain. It challenges the current perceptions that: sciatica is always a 
neuropathic pain condition, patients with neuropathic pain do worse over time 
compared with those without, and neuropathic pain is always persistent. The 
challenge in predicting cases of persistent neuropathic pain is highlighted with findings 
able to inform future research that attempts to better understand this. 
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Appendix A Supplementary data for Chapter Three 
Appendix A1 Full systematic search strategy 
Full details of search strategy used in Medline using the interface HDAS (number of 
results for each search term are denoted at the end of each line) 
 Search term  
LBLP 1. Medline; Exp BACK PAIN/; 30077 results.  
2. Medline; (Backache OR "back ache").ti,ab; 2163 results.  
3. Medline; lumbago.ti,ab; 1177 results.  
4. Medline; ((spine OR spinal) adj3 pain).ti,ab; 6171 results.  
5. Medline; ((spine OR spinal) adj3 disorder*).ti,ab; 2970 results.  
6. Medline; exp INTERVERTEBRAL DISC DEGENERATION/ OR exp 
INTERVERTEBRAL DISC DISPLACEMENT/ OR exp SPINAL 
STENOSIS/ OR exp SPONDYLITIS/ OR exp SPONDYLOSIS/; 51862 
results.  
7. Medline; (spondylitis OR spondylo*).ti,ab; 25254 results.  
8. Medline; ((slip* OR prolapse* OR herniat* OR intervertebral 
OR bulg* OR sequestration) adj3 (disc OR disk)).ti,ab; 15539 
results.  
9. Medline; ((((spine OR spinal OR foramin* OR central OR canal) 
adj3 (stenosis OR stenotic)))).ti,ab; 5943 results.  
10. Medline; ((back adj3 pain)).ti,ab; 34366 results.  
11. Medline; (leg adj3 pain).ti,ab; 4465 results.  
12. Medline; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 
OR 11; 115228 results.  
Neuropathic 
pain  
13. Medline; Exp PERIPHERAL NERVOUS SYSTEM DISEASES/; 
145789 results.  
14. Medline; "painDETECT".ti,ab; 77 results.  
15. Medline; "Douleur Neuropathique en 4 question*".ti,ab; 12 
results.  
16. Medline; LANSS.ti,ab; 91 results.  
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17. Medline; S-LANSS.ti,ab; 28 results.  
18. Medline; ((((neur* OR nerv*) adj6 (compress* OR damag* 
OR injur* OR symptom*)))).ti,ab; 137013 results.  
19. Medline; (((((neur* OR nerv*) adj3 (pain* OR discomfort* OR 
system*))))).ti,ab; 273367 results.  
20. Medline; 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19; 498012 
results.  
 
Radicular pain or  
sciatica 
21. Medline; ((radiculopath* OR radiculitis OR (radicular adj3 
syndr*))).ti,ab; 5510 results.  
22. Medline; RADICULOPATHY/ OR SCIATICA/; 7889 results.  
23. Medline; sciatica.ti,ab; 3525 results.  
24. Medline; 21 OR 22 OR 23; 12760 results.  
 
(LBLP) and 
(neuropathic 
pain), or 
(radicular pain or 
sciatica) 
25. Medline; (12 AND 20) OR 24; 22454 results 
Epidemiology 1 26. Medline; exp INCIDENCE/; 185434 results.  
27. Medline; inciden*.ti,ab; 631470 results.  
28. Medline; exp PREVALENCE/; 203571 results.  
29. Medline; prevalen*.ti,ab; 495302 results.  
30. Medline; exp EPIDEMIOLOGY/; 36504 results.  
31. Medline; epidemiol*.ti,ab; 277423 results.  
32. Medline; exp PROGNOSIS/; 1169144 results.  
33. Medline; exp DISEASE PROGRESSION/; 127594 results.  
34. Medline; prognos*.ti,ab; 399860 results.  
35. Medline; determinant*.ti,ab; 173284 results.  
36. Medline; characteristic*.ti,ab; 950207 results.  
37. Medline; factor*.ti,ab; 2359489 results.  
 395 
  
38. Medline; prevalen*.ti,ab; 495302 results.  
39. Medline; course.ti,ab; 438089 results.  
40. Medline; indicator*.ti,ab; 189297 results.  
41. Medline; subgroup* OR sub-group*.ti,ab; 152928 results.  
42. Medline; long-term.ti,ab; 560737 results.  
43. Medline; rate*.ti,ab; 2022693 results.  
44. Medline; occurrence*.ti,ab; 262047 results.  
45. Medline; progress*.ti,ab; 774215 results.  
46. Medline; predict*.ti,ab; 1020175 results.  
47. Medline; mediat*.ti,ab; 993432 results.  
48. Medline; model*.ti,ab; 1869597 results.  
49. Medline; risk.ti,ab; 1343317 results.  
 
Epidemiology 2 50. Medline; exp CROSS-SECTIONAL STUDIES/; 193842 results.  
51. Medline; "cross section*".ti,ab; 220058 results.  
52. Medline; exp COHORT STUDIES/; 1434244 results.  
53. Medline; cohort.ti,ab; 282637 results.  
54. Medline; follow-up.ti,ab; 659459 results.  
55. Medline; exp CASE-CONTROL STUDIES/; 718545 results.  
56. Medline; retrospective.ti,ab; 309410 results.  
57. Medline; ("case control" OR "case controlled").ti,ab; 86481 
results.  
58. Medline; prospective.ti,ab; 383341 results.  
59. Medline; (study OR studies).ti,ab; 6680769 results.  
60. Medline; ((patient* OR medical) adj3 (record* OR review* 
OR history*)).ti,ab; 293578 results.  
61. Medline; longitudinal.ti,ab; 153418 results.  
62. Medline; observation*.ti,ab; 640284 results.  
63. Medline; "time series".ti,ab; 17523 results.  
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64. Medline; inception.ti,ab; 9119 results.  
65. Medline; 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 
OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64; 8033978 results.  
Epidemiology 1 66. Medline; 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 
OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 
43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 29; 9255561 results.  
 
Epidemiology 1 
and 2 
67. Medline; 65 AND 66; 4875935 results 
Epidemiology of 
neuropathic pain 
in LBLP, sciatica 
and radicular 
pain.  
68. Medline; 25 AND 67; 7479 results.  
 
Limited to 
humans only.  
69. Medline; 68 [Limit to: Humans]; 6250 results.  
 
 
Full details of search strategy used in CINAHL using the interface HDAS 
 Search term  
LBLP 1. CINAHL; exp BACK PAIN/; 16150 results.  
2. CINAHL; ((Backache OR "back ache")).ti,ab; 166 results.  
3. CINAHL; lumbago.ti,ab.; 34 results.  
4. CINAHL; (((spine OR spinal) adj3 pain)).ti,ab; 1603 results.  
5. CINAHL; (((spine OR spinal) adj3 disorder*)).ti,ab; 652 results.  
6. CINAHL; exp INTERVERTEBRAL DISK DISPLACEMENT/; 1847 
results.  
7. CINAHL; exp SPONDYLOSIS/; 842 results.  
8. CINAHL; ((spondylitis OR spondylo*)).ti,ab; 2716 results.  
9. CINAHL; (((slip* OR prolapse* OR herniat* OR intervertebral 
OR bulg* OR sequestration) adj3 (disc OR disk))).ti,ab; 1761 
results.  
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10. CINAHL; (((spine OR spinal OR foramin* OR central OR canal) 
adj3 (stenosis OR stenotic))).ti,ab; 988 results.  
11. CINAHL; ((back adj3 pain)).ti,ab; 12896 results.  
12. CINAHL; ((leg adj3 pain)).ti,ab; 1062 results.  
13. CINAHL; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 
OR 11 OR 12; 25526 results. 
Neuropathic 
pain  
14. CINAHL; exp PERIPHERAL NERVOUS SYSTEM DISEASES/; 
19728 results.  
15. CINAHL; "painDETECT" OR "Douleur Neuropathique en 4 
question*" OR "S-LANSS" OR "LANSS".ti,ab; 85 results.  
16. CINAHL; (((neur* OR nerv*) adj6 (compress* OR damag* OR 
injur* OR symptom))).ti,ab; 9740 results.  
17. CINAHL; (((neur* OR nerv*) adj3 (pain* OR discomfort* OR 
system*))).ti,ab; 14443 results.  
18. CINAHL; 14 OR 15 OR 16 OR 17; 39144 results. 
Radicular pain or  
sciatica 
19. CINAHL; ((radiculopath* OR radiculitis OR (radicular adj3 
syndr*))).ti,ab; 963 results.  
20. CINAHL; exp RADICULOPATHY/; 938 results.  
21. CINAHL; exp SCIATICA/; 670 results.  
22. CINAHL; sciatica.ti,ab.; 525 results.  
23. CINAHL; 19 OR 20 OR 21 OR 22; 2187 results.  
 
(LBLP) and 
(neuropathic 
pain), or 
(radicular pain or 
sciatica) 
24. CINAHL; (13 AND 19) OR 23; 3584 results. 
Epidemiology 1 25. CINAHL; exp INCIDENCE/; 24827 results.  
26. CINAHL; inciden*.ti,ab.; 65811 results.  
27. CINAHL; exp PREVALENCE/; 31602 results.  
28. CINAHL; exp EPIDEMIOLOGY/; 303541 results.  
29. CINAHL; prevalen*.ti,ab.; 67951 results.  
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30. CINAHL; epidemiol*.ti,ab.; 28925 results.  
31. CINAHL; exp PROGNOSIS/; 159718 results.  
32. CINAHL; exp DISEASE PROGRESSION/; 17336 results.  
33. CINAHL; prognos*.ti,ab.; 27178 results.  
34. CINAHL; determinant*.ti,ab.; 15748 results.  
35. CINAHL; characteristic*.ti,ab.; 81818 results.  
36. CINAHL; factor*.ti,ab.; 214771 results.  
37. CINAHL; course.ti,ab.; 38784 results.  
38. CINAHL; indicator*.ti,ab.; 22523 results.  
39. CINAHL; ((subgroup* OR sub-group*)).ti,ab; 17372 results.  
40. CINAHL; long-term.ti,ab.; 65064 results.  
41. CINAHL; rate*.ti,ab.; 179131 results.  
42. CINAHL; occurrence*.ti,ab.; 17366 results.  
43. CINAHL; progress*.ti,ab.; 59097 results.  
44. CINAHL; predict*.ti,ab.; 113883 results.  
45. CINAHL; mediat*.ti,ab; 29586 results.  
46. CINAHL; model*.ti,ab.; 156915 results.  
47. CINAHL; risk.ti,ab; 229499 results.  
48. CINAHL; 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 
33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 
OR 43 OR 44 OR 45 OR 46 OR 47; 1038657 results. 
Epidemiology 2  49. CINAHL; exp CROSS SECTIONAL STUDIES/; 70011 results.  
50. CINAHL; "cross section*".ti,ab; 41389 results.  
51. CINAHL; exp PROSPECTIVE STUDIES/; 175309 results.  
52. CINAHL; exp RETROSPECTIVE DESIGN/; 82281 results.  
53. CINAHL; cohort.ti,ab; 52533 results.  
54. CINAHL; follow-up.ti,ab; 75826 results.  
55. CINAHL; retrospective.ti,ab.; 39964 results.  
56. CINAHL; prospective.ti,ab.; 57697 results.  
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57. CINAHL; exp CASE CONTROL STUDIES/; 33440 results.  
58. CINAHL; ("case control" OR "case controlled").ti,ab; 10422 
results.  
59. CINAHL; (study OR studies).ti,ab; 658359 results.  
60. CINAHL; longitudinal.ti,ab; 26986 results.  
61. CINAHL; (((patient* OR medical) adj3 (record* OR review* 
OR history*))).ti,ab; 40575 results.  
62. CINAHL; exp OBSERVATIONAL METHODS/; 14793 results.  
63. CINAHL; observation.ti,ab; 16920 results.  
64. CINAHL; inception.ti,ab; 2249 results.  
65. CINAHL; "time series".ti,ab; 1888 results.  
66. CINAHL; 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 
57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64 OR 65; 844747 
results. 
Epidemiology of 
neuropathic pain 
in LBLP, sciatica 
and radicular 
pain.  
67. CINAHL; 48 AND 66; 574315 results.  
68. CINAHL; 24 AND 67; 1449 results. 
 
B1.3 Full details of search strategy used in AMED using the interface OVID  
 Search term  
LBLP  1. exp backache/ 
2. (Backache or "back ache").ti,ab. 
3. lumbago.ti,ab. 
4. ((spine or spinal) adj3 pain).ti,ab. 
5. ((spine or spinal) adj3 disorder*).ti,ab. 
6. exp intervertebral disk degeneration/ or exp intervertebral 
disk hernia/ or exp vertebral canal stenosis/ or exp spondylitis/ 
or exp spondylosis/ 
7. (spondylitis or spondylo*).ti,ab. 
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8. ((slip* or prolapse* or herniat* or intervertebral or bulg* or 
sequestration) adj3 (disc or disk)).ti,ab. 
9. ((spine or spinal or foramin* or central or canal) adj3 (stenosis 
or stenotic)).ti,ab. 
10. (back adj3 pain).ti,ab. 
11. (leg adj3 pain).ti,ab. 
12. or/1-11 
Neuropathic 
pain  
13. exp peripheral neuropathy/ 
14. "painDETECT".ti,ab. 
15. "Douleur Neuropathique en 4 question*".ti,ab. 
16. "S-LANSS".ti,ab. 
17. "LANSS".ti,ab. 
18. ((neur* or nerv*) adj6 (compress* or damag* or injur* or 
symptom*)).ti,ab. 
19. ((neur* or nerv*) adj3 (pain* or discomfort* or 
system*)).ti,ab. 
20. or/13-19 
Radicular pain or  
sciatica 
 21. (radiculopath* or radiculitis or (radicular adj3 syndr*)).ti,ab. 
22. exp radiculopathy/ or exp sciatica/ 
23. sciatica.ti,ab. 
24. or/21-23 
(LBLP) and 
(neuropathic 
pain), or 
(radicular pain or 
sciatica) 
25. (12 and 20) or 24 
Epidemiology 1 26. exp incidence/ 
27. inciden*.ti,ab. 
28. exp prevalence/ 
29. prevalen*.ti,ab. 
30. exp epidemiology/ 
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31. epidemiol*.ti,ab. 
32. exp prognosis/ 
33. exp disease course/ 
34. prognos*.ti,ab. 
35. determinant*.ti,ab. 
36. characteristic*.ti,ab. 
37. factor*.ti,ab. 
38. course.ti,ab. 
39. indicator*.ti,ab. 
40. (subgroup* or sub-group*).ti,ab. 
41. long-term.ti,ab. 
42. rate*.ti,ab. 
43. occurrence*.ti,ab. 
44. progress*.ti,ab. 
45. predict*.ti,ab. 
46. mediat*.ti,ab. 
47. model*.ti,ab. 
48. risk.ti,ab. 
49. or/26-48 
Epidemiology 2 50. exp Epidemiologic methods/ 
51. exp cross-sectional study/ 
52. cohort.ti,ab. 
53. follow-up.ti,ab. 
54. retrospective.ti,ab. 
55. ("case control" or "case controlled").ti,ab. 
56. prospective.ti,ab. 
57. (study or studies).ti,ab. 
58. ((patient* or medical) adj3 (record* or review* or 
history*)).ti,ab. 
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59. longitudinal.ti,ab. 
60. observation*.ti,ab. 
61. "time series".ti,ab. 
62. inception.ti,ab. 
63. or 50-62 
Epidemiology 1 
and 2 
64. 49 and 63 
  
Epidemiology of 
neuropathic pain 
in LBLP, sciatica 
and radicular 
pain.  
65. 25 and 64 
 
Limited to 
humans only.  
66. limit 65 to human 
 
Full details of search strategy used in EMBASE using the interface OVID  
 Search term  
LBLP  1. exp backache/ 
2. (Backache or "back ache").ti,ab. 
3. lumbago.ti,ab. 
4. ((spine or spinal) adj3 pain).ti,ab. 
5. ((spine or spinal) adj3 disorder*).ti,ab. 
6. exp intervertebral disk degeneration/ or exp intervertebral 
disk hernia/ or exp vertebral canal stenosis/ or exp spondylitis/ 
or exp spondylosis/ 
7. (spondylitis or spondylo*).ti,ab. 
8. ((slip* or prolapse* or herniat* or intervertebral or bulg* or 
sequestration) adj3 (disc or disk)).ti,ab. 
9. ((spine or spinal or foramin* or central or canal) adj3 (stenosis 
or stenotic)).ti,ab. 
10. (back adj3 pain).ti,ab. 
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11. (leg adj3 pain).ti,ab. 
12. or/1-11 
Neuropathic 
pain  
13. exp peripheral neuropathy/ 
14. "painDETECT".ti,ab. 
15. "Douleur Neuropathique en 4 question*".ti,ab. 
16. "S-LANSS".ti,ab. 
17. "LANSS".ti,ab. 
18. ((neur* or nerv*) adj6 (compress* or damag* or injur* or 
symptom*)).ti,ab. 
19. ((neur* or nerv*) adj3 (pain* or discomfort* or 
system*)).ti,ab. 
20. or/13-19 
Radicular pain or  
sciatica 
21. (radiculopath* or radiculitis or (radicular adj3 syndr*)).ti,ab. 
22. exp radiculopathy/ or exp sciatica/ 
23. sciatica.ti,ab. 
24. or/21-23 
(LBLP) and 
(neuropathic 
pain), or 
(radicular pain or 
sciatica) 
25. (12 and 20) or 24 
Epidemiology 1 26. exp incidence/ 
27. inciden*.ti,ab. 
28. exp prevalence/ 
29. prevalen*.ti,ab. 
30. exp epidemiology/ 
31. epidemiol*.ti,ab. 
32. exp prognosis/ 
33. exp disease course/ 
34. prognos*.ti,ab. 
35. determinant*.ti,ab. 
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36. characteristic*.ti,ab. 
37. factor*.ti,ab. 
38. course.ti,ab. 
39. indicator*.ti,ab. 
40. (subgroup* or sub-group*).ti,ab. 
41. long-term.ti,ab. 
42. rate*.ti,ab. 
43. occurrence*.ti,ab. 
44. progress*.ti,ab. 
45. predict*.ti,ab. 
46. mediat*.ti,ab. 
47. model*.ti,ab. 
48. risk.ti,ab. 
49. or/26-48 
Epidemiology 2  50. exp cross-sectional study/ 
51. "cross section*".ti,ab. 
52. exp cohort analysis/ 
53. cohort.ti,ab. 
54. follow-up.ti,ab. 
55. exp case control study/ 
56. retrospective.ti,ab. 
57. ("case control" or "case controlled").ti,ab. 
58. prospective.ti,ab. 
59. (study or studies).ti,ab. 
60. ((patient* or medical) adj3 (record* or review* or 
history*)).ti,ab. 
61. longitudinal.ti,ab. 
62. observation*.ti,ab. 
63. "time series".ti,ab. 
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64. inception.ti,ab. 
Epidemiology 1 
and 2 
65. or/50-64 
66. 49 and 65 
Epidemiology of 
neuropathic pain 
in LBLP, sciatica 
and radicular 
pain.  
67. 25 and 66 
Limited to 
humans only.  
68. limit 67 to human 
 
 
Full details of search strategy used in Web of Science using the interface OVID  
 Search term  
LBLP  #1 TOPIC: ((Backache or "back ache")) 
#2 TS= lumbago 
#3 TS=((spine or spinal) NEAR/3 pain) 
#4 TS=((spine or spinal) NEAR/3 disorder*) 
#5 TS= (spondylitis or spondylo*) 
#6 TS=((slip* or prolapse* or herniat* or intervertebral or 
bulg* or sequestration) NEAR/3 (disc or disk)) 
#7 TS= ((spine or spinal or foramin* or central or canal) 
NEAR/3 (stenosis or stenotic)). 
#8 TS= (back NEAR/3 pain). 
#9 TS= (leg NEAR/3 pain) 
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 
Neuropathic 
pain  
#11 TS="painDETECT" 
#12 TS="Douleur Neuropathique en 4 question*". 
#13 TS="S-LANSS" 
#14 TS="LANSS" 
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#15 TS=((neur* or nerv*) NEAR/6 (compress* or damag* or 
injur* or symptom*)) 
#16 TS=((neur* or nerv*) NEAR/3 (pain* or discomfort* or 
system*)) 
#17 #16 OR #15 OR #14 OR #13 OR #12 OR #11 
Radicular pain or  
sciatica 
#18 TS=(radiculopath* or radiculitis or (radicular NEAR/3 
syndr*)). 
#19 TS=sciatica 
(LBLP) and 
(neuropathic 
pain), or 
(radicular pain or 
sciatica) 
#20 #19 OR #18 
Epidemiology 1 #21 TS=(inciden* OR prevalen* OR epidemiol* OR prognos* 
OR determinant* OR characteristic* OR factor* OR course OR 
(subgroup* or sub-group*) OR (long-term) OR rate* OR 
occurrence* OR progress* OR predict* OR mediat* OR model* 
OR risk*) 
Epidemiology 2  #22 TS=((cross-section* OR "cross section") OR cohort OR 
follow-up OR retrospective OR ("case control" or "case 
controlled") OR prospective OR (study or studies) OR ((patient* 
or medical) NEAR/3 (record* or review* or history*)) OR 
longitudinal OR observation* OR "time series" OR inception) 
Epidemiology of 
neuropathic pain 
in LBLP, sciatica 
and radicular 
pain.  
#23 #17 AND #10 
#24 #23 OR #20 
#25 #22 AND #21 
#26 #25 AND #24 
 
Full details of search strategy used in TRIP database  
 Search term  
LBLP sciatica or back pain or leg pain 
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Neuropathic pain  neuropathic pain 
Epidemiology  prevalence or characteristics or prognosis or epidemiology 
  
 408 
  
Appendix A2 Data extraction tool 
Reviewer  (please circle) SS/KD/KK 
Author 
and year  
 
Title   
 
Where domains are not reported please report as N/A. 
Study description 
Study design  
(longitudinal or cross sectional, or 
includes data of both types.)  
 
Study population 
Country of origin 
 
 
Setting  
(physiotherapy outpatients, 
general practice, osteopathic or 
chiropractic clinics, 
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neurology/neurosurgery, 
orthopaedics, pain clinic)  
Definition of low back pain, with 
or without leg pain defined for 
population in study. 
 
Inclusion criteria 
 
 
 
 
 
Exclusion criteria  
 
 
 
 
  
 
Methods and sampling  
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Methods of recruiting sample (eg 
phone, mail, consecutive clinic 
patients)  
 
Is sample size large enough to 
estimate prevalence with 
adequate precision? (eg, was a 
sample size calculation reported?) 
 
Number of invited participants in 
study sample.  
 
Number of participants in final 
sample size. 
 
Response rate (eg % returned 
questionnaires, complete data 
sets). 
 
How was neuropathic pain 
diagnosed or defined? 
Give details: by history taking, 
clinical examination, 
pharmalogical diagnostic 
approach or using questionnaire 
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tool (LANSS, S-LANSS, DN4, Pain 
Detect or other) 
If more than one method used 
specify each method.  
Was neuropathic pain AND other 
measurements carried out in a 
valid and reliable manner? (eg 
were measurements blind?). 
 
3.1 Complete for longitudinal data 
Primary time points at which 
measurements taken (record in 
months, years). 
 
Attrition (% drop outs) 
 
 
Characteristics of the population.  
(i.e. independent variables that may be investigated for prognostic value) 
Age (mean +/- range)  
Sex ratio of participants (%M)  
Episode duration of LBP/ leg pain. 
Consider, current episode for LBP/ 
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leg pain and time since ‘pain free 
month’ if reported.  
Pain intensity. Consider, current, 
average and ‘least’ pain for both 
back and leg pain. VAS or NRS.  
 
Other baseline characteristics of 
interest. Eg, proportion of the 
population who have had surgery.  
 
Results 
5.1 Complete for longitudinal data 
Longitudinal data: Evidence of 
incidence and associated 
prognostic factors between 
neuropathic pain and low back 
pain with or without leg pain.  
(Crude estimates of RR and 
multivariate model if available). 
 
5.2 Complete for cross sectional data 
Evidence of prevalence of 
neuropathic pain in study 
population. (Include 95% 
confidence intervals if available).  
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• Absolute numbers 
• Point prevalence 
• Period prevalence 
• Lifetime prevalence 
Cross-
sectional 
data:  
Associations 
between 
outcomes of 
interest 
between 
neuropathic 
pain and low 
back pain 
with or 
without leg 
pain.  
(0R and 
multivariate 
Pain 
(eg VAS/NRS/ 
current, average 
or least) 
 
 
 
 
 
 
 
 
Disability 
(eg RMDQ or 
ODI) 
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model if 
available, 
otherwise 
report as %, 
with p value). 
  
 
 
 
General health 
(eg EQ5D, SF36) 
Psychological 
function  
(eg HADS) 
Others (eg PSEQ) 
 
 
 
 
 
 
 
 
Other outcomes 
of interest:  
(eg % of pts with 
clinical 
characteristics 
common to 
neuropathic pain, 
eg allodynia, 
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burning pain as 
estimated for 
LANNS/ DN4 etc). 
Quantitative 
sensory testing 
(QST) profiles are 
not relevant to 
the study.  
Conclusions and limitations of study’s methods/ results 
Authors conclusion/s 
 
 
 
 
Conflict of interest/ funding   
Reviewers comments 
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Appendix A3 Flow chart of the 2nd systematic search and study selection 
The initial search was updated in January 2018 (adapted from the PRISMA flow chart 
(Moher et al., 2009))
Sc
re
e
n
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Titles screened after duplicates removed (n = 4,974) 
Titles and abstracts 
screened (n = 123) 
Records excluded  
(n = 4,851) 
Full-text articles excluded, with reasons (n=35): 
• Neuropathic pain not measured (n=2) 
• Population not LBP (n=7), or LBLP (n=3) 
• Tertiary care settings (n=10) 
• Study design not appropriate or not 
available (n=3), or full-text not available 
(n=6) 
• Full text identified in initial search (n=3) 
• Study uses same cohort of LBLP patients 
used for the analysis in this thesis (n=1) 
Full-text articles 
assessed for eligibility 
(n= 38) 
Records excluded  
(n = 85) 
Records identified through 2nd database search 
EMBASE 4,614, MEDLINE 1,396 , Web of science 
1,947, CINAHL 734, Trip 270, AMED 13 (n = 8,974) 
Additional full-texts 
included for qualitative 
synthesis after 2nd search  
(n = 3) 
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Appendix A4 Results of quality appraisal  
Results of quality assessment (described as risk of bias) of the ten included studies used to derive prevalence 
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2
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W
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2
0
0
9
 
Ex
te
rn
al
 v
al
id
it
y 
Target population High High High Low High High High High High High 
Sampling frame Low Low  High Low Low  High High Low  High Low  
Random selection Low  Low  High Low Low  Low  Low  Low  Low  Low  
Non-response bias  High Low High Low Low High  High  High  High  High  
In
te
rn
al
 v
al
id
it
y 
Case definition  
(LBLP and neuropathic pain) 
Low  Low  Low Low Low Low Low Low Low Low 
Validity and reliability of neuropathic pain  Low Low Low Low Low Low Low Low Low Low 
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Mode of data collection  Low Low Low Low Low Low Low Low Low Low 
Appropriate prevalence period reported Low Low Low Low Low Low Low Low Low Low 
A
n
al
ys
is
 Were the numerator(s) and denominator(s) 
for the parameter of interest appropriate? 
Low Low High Low Low Low Low Low Low Low 
 Overall risk of bias Mod Low High Low Low Mod Mod Mod Mod Mod 
 
 419 
  
Results of quality assessment (described as risk of bias) of the twelve included studies used to describe characteristics and prognosis 
 
Study 
participation 
Study 
Attrition 
Prognostic 
Factor 
Outcome Confounding 
factor 
Analysis Overall risk of 
bias 
Beith et al 2011 Moderate Not relevant Low Low Moderate Low Moderate 
Defrin et al 2014 Moderate Not relevant Moderate Not relevant Unsure Unsure Moderate 
Freynhagen et al 2008 Moderate Not relevant Low Moderate Not relevant Low Moderate 
Gierthmühlen et al 
2017 
Moderate Not relevant Low Low Not relevant Low Low 
Hüllemann et al 2016 Low High Not relevant Low High Unsure Moderate 
Mahn et al 2011 Low Not relevant Not relevant Not relevant Not relevant Low Low 
Morsø et al 2011 Moderate Low Low Low Moderate  Low Moderate 
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Study 
participation 
Study 
Attrition 
Prognostic 
Factor 
Outcome Confounding 
factor 
Analysis Overall risk of 
bias 
Schafer et al 2011 Low Low Moderate Low Low  Low Low 
Smart et al 2012 Low Not relevant Moderate Moderate Not relevant Low Moderate 
Tutoglu et al 2014 Unsure Not relevant Low Moderate Not relevant Moderate Moderate 
Uher and Bob 2013 High Not relevant Low Low Not relevant Low Moderate 
Walsh et al 2009 Low Not relevant Low Low Not relevant Low Low 
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Appendix B Supplementary data for Chapter Seven: analysis based 
on imputed data 
Proportion of patients with neuropathic pain (s-LANSS) at baseline and at three 
subsequent follow-up time-points  
Time Proportion (%) Confidence Interval (95%) 
* 
Baseline 48.4 44.4 to 52.4 
Four months 26.2 22.0 to 30.4 
Twelve months 24.8 20.5 to 29.1 
Three years 22.7 17.3 to 26.1 
*Confidence intervals are for certainty around a point estimate for imputed data.
  422 
Change in the presence of neuropathic pain in patients over a three year follow-up 
period 
Presence or absence of neuropathic 
pain over three years* 
Proportion 
(%) 
Confidence 
Interval (95%) 
† 
Sub-group 
Base-
line 
4 
months 
12 
months 
3 
years 
0 0 0 0 38.2 33.8 to 42.6 Non-neuropathic 
0 0 0 1 3.6 1.5 to 5.7 Developing 
0 0 1 0 3.3 1.5 to 5.5 Developing 
0 0 1 1 1.0 0.0 to 2.1 Developing 
0 1 0 0 2.4 0.1 to 3.9 Developing 
0 1 0 1 0.7 0.6 to 1.6 Developing 
0 1 1 0 1.3 0.2 to 2.5 Developing 
0 1 1 1 1.1 0.0 to 2.0 Developing 
1 0 0 0 18.3 14.7 to 22.0 Non-persistent 
1 0 0 1 3.7 1.7 to 5.7 Non-persistent 
1 0 1 0 3.7 1.6 to 5.7 Non-persistent 
1 0 1 1 2.1 0.6 to 3.6 Longstanding 
persistent 
1 1 0 0 5.6 3.3 to 8.0 Non-persistent 
1 1 0 1 2.6 0.8 to 4.4 Longstanding 
persistent 
1 1 1 0 5.5 3.3 to 7.8 Longstanding 
persistent 
1 1 1 1 6.8 4.3 to 9.4 Longstanding 
persistent 
Abbreviation: s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and signs 
neuropathic pain scale 
*0 indicates s-LANSS score < 12 (non-neuropathic pain), 1 indicates s-LANSS score ≥ 12 (possible 
neuropathic pain) 
†Confidence intervals are for certainty around a point estimate for imputed data. 
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Proportion of patients by neuropathic pain sub-group  
Sub-group* 
Proportion 
(%) 
Confidence 
Interval (95%) † 
Non-neuropathic pain 38.2 33.8 to 42.6 
Non-persistent neuropathic pain 31.3 27.1 to 35.5 
Longstanding persistent neuropathic pain 17.1 13.5 to 20.7 
Developing neuropathic pain 13.4 10.0 to 20.7 
Abbreviation: s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and signs 
neuropathic pain scale 
*Sub-groups: Non-neuropathic pain, s-LANSS < 12 at baseline and each follow-up point thereafter. 
Developing neuropathic pain, s-LANSS < 12 at baseline and ≥ 12 at one or more follow-up points. Non-
persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up 
points. Longstanding persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of 
the three follow-up points. 
†Confidence intervals are for certainty around a point estimate for imputed data. 
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Baseline characteristics of patients by neuropathic pain sub-group over three-years  
Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Sociodemographic characteristics     
Female 57.0 (50.4 to 63.6) 69.1 (61.8 to 76.4) 67.3 (56.6 to 78.0) 61.7 (49.7 to 73.8) 
Age, mean 50.5 (48.6 to 52.4) 49.9 (47.7 to 52.0) 49.7 (46.7 to 52.8) 50.4 (46.8 to 54.0) 
Socio-economic status: Routine and 
manual occupations, never worked and 
long-term unemployed 
48.0 (41.2 to 54.8) 55.3 (47.5 to 63.1) 59.4 (47.8 to 71.1) 46.4 (33.6 to 59.2) 
Pain characteristics     
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Leg pain intensity (0-10), mean 4.5 (4.2 to 4.8) 5.7 (5.3 to 6.0) 5.8 (5.3 to 6.4) 5.4 (4.8 to 6.0) 
Leg pain worse 46.2 (39.5 to 52.9) 49.8 (42.0 to 57.6) 45.7 (34.4 to 56.9) 37.8 (34.4 to 56.9) 
Pain location Pain below the 
knee 
64.1 (57.7 to 70.5) 75.9 (69.1 to 82.7) 80.7 (71.1 to 90.3) 67.1 (55.3 to 78.9) 
 Pain in one leg 77.1 (71.5 to 82.7) 74.8 (67.9 to 81.7) 66.6 (55.9 to 77.4) 79.0 (69.0 to 89.0) 
Duration of back 
pain symptoms in 
current episode  
Less than 6 
weeks 
38.7 (32.1 to 45.3) 32.8 (25.8 to 39.8) 35.3 (25.3 to 45.2) 35.5 (23.7 to 47.4) 
6 to 12 weeks 21.3 (15.7 to 26.9) 24.9 (18.4 to 31.4) 17.4 (9.3 to 25.6) 13.9 (4.9 to 22.9) 
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
> 3 months 40.0 (33.4 to 46.6) 41.2 (33.4 to 48.9) 45.5 (34.1 to 56.9) 55.1 (42.9 to 67.4) 
Duration of leg pain 
symptoms in 
current episode  
Less than 6 
weeks 
49.8 (43.0 to 56.6) 39.4 (32.0 to 46.7) 38.3 (28.2 to 48.4) 39.4 (27.6 to51.3) 
6 to 12 weeks 20.5 (14.9 to 26.0) 25.1 (18.5 to 31.7) 15.0 (6.8 to 23.2) 16.7 (7.4 to 26.0) 
> 3 months 29.3 (22.8 to 35.8) 35.3 (27.7 to 43.0) 45.3 (33.6 to 56.9) 48.2 (35.1 to 61.3) 
Widespread pain 40.5 (33.6 to 47.3) 35.8 (28.4 to 43.2) 55.4 (44.3 to 66.4) 43.3 (30.9 to 55.8) 
Limitations in activities and risk of persistent disabling pain 
RMDQ (0-23), mean 11.0 (10.2 to 11.7) 13.5 (12.7 to 14.4) 15.0 (13.8 to 16.2) 12.8 (11.5 to 14.2) 
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Risk of 
persistent 
disabling pain 
(STarT Back) 
Low risk 20.0 (14.7 to 25.4) 12.2 (7.3 to 17.2) 6.3 (0.8 to 11.8) 84.5 (0.8 to 16.1) 
Medium risk 50.6 (43.8 to 57.3) 44.4 (36.6 to 52.2) 37.7 (26.2 to 49.1) 51.8 (39.2 to 64.3) 
High risk 29.4 (23.1 to 35.7) 43.4 (35.5 to 51.3) 56.0 (44.5 to 67.6) 39.8 (27.5 to 52.0) 
Psychological characteristics 
HADS (depression) (0-21), mean 5.2 (4.7 to 5.6) 6.8 (6.2 to 7.5) 8.7 (7.7 to 9.7) 6.1 (5.3 to 7.0) 
PSEQ (0-60), mean‡ 38.2 (36.4 to 40.0) 32.2 (29.9 to 34.4) 27.6 (24.4 to 30.9) 34.3 (30.9 to 37.7) 
Neurological examination findings     
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Presence of muscle 
weakness§ 
5/5 14.3 (10.1 to 19.3) 23.8 (17.1 to 30.6) 16.0 (5.9 to 24.2) 12.1 (4.3 to 20.0) 
0 to 4/5 85.7 (81.1 to 90.4) 76.2 (69.7 to 82.7) 84.0 (78.6 to 92.1) 87.9 (80.1 to 95.7) 
Reflex change None 85.6 (80.9 to 90.3) 78.3 (72.0 to 84.5) 71.6 (61.9 to 81.2) 82.1 (72.9 to 91.4) 
Slightly reduced 3.3 (0.9 to 5.8) 5.2 (1.9 to 8.6) 8.7 (2.9 to 14.4) 4.0 (-0.8 to 8.9) 
Significantly 
reduced or 
absent 
11.1 (6.8 to 15.3) 16.5 (10.8 to 22.1) 19.8 (11.3 to 28.2) 13.8 (5.4 to22.1) 
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Reduction or loss of sensation to pin-
prick  
33.8 (27.4 to 40.2) 46.9 (38.9 to 54.9) 51.4 (39.3 to 63.5) 41.5 (29.0 to 54.0) 
Presence of allodynia or hyperalgesia||  4.7 (1.8 to 7.7) 12.2 (7.0 to 17.5) 15.9 (7.4 to 24.4) 10.4 (3.0 to 17.7) 
Neural tension test (any positive test) **  51.9 (45.4 to 58.4) 55.9 (48.3 to 63.5) 57.6 (46.7 to 68.6) 59.1 (47.6 to 70.6) 
Pins and needles  30.6 (24.6 to 30.6) 70.8 (63.5 to 78.2) 77.4 (67.3 to 87.5) 32.1 (21.2 to 78.2) 
Other definitions of neuropathic pain      
Clinical diagnosis of sciatica†† 69.8 (63.7 to 76.0) 78.2 (71.7 to 84.7) 80.5 (71.2 to 89.8) 71.5 (60.2 to 82.8) 
Neuroimaging     
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Baseline characteristic  
(shown as %, (95% confidence 
intervals*) unless stated as mean) 
Neuropathic pain sub-group† over three years 
Unchanged non-
neuropathic pain 
(40.4%) 
Neuropathic pain 
(non-persistent) 
(29.7%) 
Longstanding 
persistent neuropathic 
pain (15.6%) 
Developing 
neuropathic pain 
(14.3%) 
Evidence of nerve root compression on 
MRI 
52.4 (45.3 to 59.4) 50.3 (42.4 to 58.1) 57.7 (46.1 to 69.2) 60.3 (47.4 to 73.3) 
Abbreviations: HADS, Hospital Anxiety and Depression scale. MRI, magnetic resonance imaging. PSEQ, Pain Self-Efficacy Questionnaire. RMDQ, Roland Morris Disability 
Questionnaire (RMDQ) leg version. s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and signs neuropathic pain scale 
† Sub-groups: Non-neuropathic pain, s-LANSS < 12 at baseline and each follow-up point thereafter. Developing neuropathic pain, s-LANSS < 12 at baseline and ≥ 12 at one 
or more follow-up points. Non-persistent neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at one (at most) of the three follow-up points. Longstanding persistent 
neuropathic pain, s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of the three follow-up points. 
*Confidence intervals are for certainty around a point estimate for imputed data 
‡Higher scores on PSEQ reflect stronger self-efficacy belief  
§ Muscle strength was tested according to the oxford scale and muscle weakness was categorised as 0-4 on this scale: 
0. No visible flicker of movement or contraction 
1. Flicker of movement 
2. Full active movement with gravity counterbalanced 
3. Full active movement against gravity but not applied resistance 
4. Full active movement against gravity and some applied resistance 
5. Full active movement against gravity and strong resistance  
Muscle strength is reported as either normal (5/5) or reduced (0/5 to 4/5) as there were no observations for some categories and imputation was not possible 
|| Hyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful stimuli (for example, strokes) 
** Neural tension tests; straight leg raise, crossover straight leg raise, femoral stretch and slump test 
††LBLP patients with a clinical diagnosis of sciatica are described as having “possible” neuropathic pain 
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Appendix C Supplementary data for Chapter Nine: analysis based 
on imputed data 
Proportion of patients with improvement by neuropathic pain definition in those who 
were prescribed one or more neuropathic pain medications compared to those who 
were not. 
Neuropathic 
pain 
medication‡ 
Neuropathic pain definition  Patients with improvement* at four 
months 
Proportion 
(%) 
95% Confidence 
Interval† 
None S-LANSS  68.3 60.5 to 76.0 
Clinical diagnosis of sciatica  71.5 65.7 to 77.2 
Clinical diagnosis of sciatica with 
evidence of nerve root 
compression  
72.0 64.3 to 79.7 
Persistent neuropathic pain at four 
months†  
40.0 24.4 to 55.6 
One  S-LANSS  60.6 47.6 to 73.7 
Clinical diagnosis of sciatica  65.2 54.5 to 75.8 
Clinical diagnosis of sciatica with 
evidence of nerve root 
compression  
66.0 52.5 to 79.6 
Persistent neuropathic pain at four 
months  
47.6 25.3 to 69.9 
Two or 
more 
S-LANSS  50.8 31.0 to 70.6 
Clinical diagnosis of sciatica  53.5 38.8 to 68.3 
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Neuropathic 
pain 
medication‡ 
Neuropathic pain definition  Patients with improvement* at four 
months 
Proportion 
(%) 
95% Confidence 
Interval† 
Clinical diagnosis of sciatica with 
evidence of nerve root 
compression  
51.4 33.5 to 69.4 
Persistent neuropathic pain at four 
months  
36.3 6.0 to 66.7 
Abbreviations:  s-LANSS, self-report version of the Leeds Assessment of Neuropathic Symptoms and 
signs neuropathic pain scale 
*Improvement: Leg pain intensity < 5 (0-10 NRS) or ≥ 30% reduction in LBLP-related disability (RMDQ 0-
23) at 4 months 
† Confidence intervals are for certainty around a point estimate for imputed data 
‡ Neuropathic pain medications prescribed up to four months before and after an index consultation in 
the ATLAS research clinic 
Persistent neuropathic pain: s-LANSS ≥ 12 at baseline and ≥ 12 at two or more of the three follow-up 
points 
Definitions based on a clinical diagnosis of sciatica with evidence of nerve root compression are 
described as having “probable” neuropathic pain, those based on s-LANSS and sciatica (with or without 
evidence of nerve root compression) are described as having “possible” neuropathic pain. 
 
 
 
 
